US20110190364A1 - Benzimidazole modulators of vr1 - Google Patents

Benzimidazole modulators of vr1 Download PDF

Info

Publication number
US20110190364A1
US20110190364A1 US13/084,718 US201113084718A US2011190364A1 US 20110190364 A1 US20110190364 A1 US 20110190364A1 US 201113084718 A US201113084718 A US 201113084718A US 2011190364 A1 US2011190364 A1 US 2011190364A1
Authority
US
United States
Prior art keywords
phenyl
benzimidazol
vinyl
alkyl
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/084,718
Inventor
Mark R. Player
Scott L. Dax
William H. Parsons
Michael Richard Brandt
Raul R. Calvo
Sharmila Patel
Jian Liu
Wing S. Cheung
Michele C. Jetter
Yu-Kai Lee
Mark A. Youngman
Wenxi Pan
Kenneth M. Wells
Derek A. Beauchamp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Priority to US13/084,718 priority Critical patent/US20110190364A1/en
Assigned to JANSSEN PHARMACEUTICA N.V. reassignment JANSSEN PHARMACEUTICA N.V. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BEAUCHAMP, DEREK A., CHEUNG, WING S., BRANDT, MICHAEL, DAX, SCOTT L., JETTER, MICHELE C., YOUNGMAN, MARK A., CALVO, RAUL R., LEE, YU-KAI, LIU, JIAN, PAN, WENXI, PARSONS, WILLIAM H., PATEL, SHARMILA, PLAYER, MARK R., WELLS, KENNETH M.
Publication of US20110190364A1 publication Critical patent/US20110190364A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • Noxious chemical, thermal and mechanical stimuli excite peripheral nerve endings of small diameter sensory neurons (nociceptors) deriving from sensory ganglia (e.g., dorsal root, nodose and trigeminal ganglia) and initiate signals that are perceived as pain.
  • Such nociceptive neurons i.e., nociceptors
  • are crucial for the detection of harmful or potentially harmful stimuli e.g., noxious thermal, chemical, and/or mechanical
  • harmful or potentially harmful stimuli e.g., noxious thermal, chemical, and/or mechanical
  • Nociceptors transduce noxious stimuli into membrane depolarization that leads to an action potential, its subsequent conduction to the CNS, and ultimately to the perception of pain, discomfort, etc. as well as to certain responses thereto.
  • nociception is carried out by ion channels and/or receptors.
  • Plant-derived vanilloid compounds e.g., capsaicin and resiniferatoxin
  • capsaicin mimics the action of physiological/endogenous stimuli that activate the “nociceptive pathway”.
  • VR1 a.k.a. capsaicin receptor or TRPV1
  • TRPV1 capsaicin receptor
  • VR1 agonists have been demonstrated in inflammatory, neuropathic, and visceral pain states.
  • dermal capsaicin pretreatment reduced the pain caused by intradermal injection of an acidic solution (Bianco, E. D.; Geppetti, P.; Zippi, P.; (solani, D.; Magini, B.; Cappugi, P. Brit J of Clin Pharmacol 1996, 41, 1-6), suggesting the benefit of VR1 agonists in the treatment of inflammatory pain.
  • a particular role for VR1 agonists has been shown in inflammation and inflammatory pain: for example, resiniferatoxin prevented inflammatory hypersensitivity and edema induction by carrageenan (Kissin, I.; Bright, C. A.; Bradley, E. L., Jr. Anesth Analg 2002, 94, 1253-1258).
  • capsaicin-containing creams for example, Axcain® and Lidocare®
  • capsaicin-containing creams are marketed for dermal relief of pain related to diabetic neuropathy and postherpetic neuralgia, indicative of the usefulness of VR1 agonists in the treatment of neuropathic pain states.
  • such creams have been shown to reduce postsurgical neuropathic pain (Ellison, N., Loblui, C. L., Kugler, J., Hatfield, A. K., Miser, A., Sloan, J. A., Wender, D. B., Rowland, K. M., Molina, R., Cascino, T. L., Vukov, A. M., Dhaliwal, H. S, and Ghosh, C.
  • capsaicin contained in a taffy vehicle was shown to substantially reduce oral mucositis pain caused by chemotherapy and radiation therapy (Berger, A., Henderson, M., Naadoolman, W., Duffy, V., Cooper, D., Saberski, L. and Bartoshuk, L. J. Pain Sympt. Mgmt 10:243-248, 1995.
  • VR1 also plays a role in the physiology of bladder emptying.
  • VR1 is expressed by bladder sensory neurons, where it modulates bladder responsivity to liquid filling.
  • the VR1 agonist resiniferatoxin desensitized bladder afferents in a dose-dependent manner (Avelino, A.; Cruz, F.; Coimbra, A. Eur. J. Pharmacol. 1999, 378, 17-22), supporting its usefulness for the treatment of overactive bladder (Chancellor, M. B.; De Groat, W. C. J. Urol. (Baltimore) 1999, 162, 3-11).
  • VR1 antagonists also may be useful in the treatment of inflammatory, neuropathic and visceral pain.
  • the therapeutic utility of VR1 antagonists has been demonstrated in visceral inflammatory conditions.
  • VR1 is elevated in colonic nerve fibers in patients with inflammatory bowel disease, and VR1 antagonists relieved pain and dysmotility (Yiangou, Y.; Facer, P.; Dyer, N. H.; Chan, C. L.; Knowles, C.; Williams, N. S.; Anand, P. Lancet 2001, 357, 1338-1339).
  • Intestinal inflammation induced by toxin A or dextran sulfate sodium in rodents was attenuated by VR1 antagonists (McVey, D. C.; Schmid, P.
  • a synthetic VR1 antagonist reduced colitis disease scores at several important endpoints, including macroscopic damage, microscopic epithelial damage, myeloperoxidase levels, and diarrhea scores, strongly supporting the therapeutic use of VR1 antagonists in inflammatory bowel diseases (Kimball, E. S.; Wallace, N. H.; Schneider, C. R.; D'Andrea, M. R.; Hornby, P. J. Neurogasteroenterology 2004, 16, 811-818).
  • the VR1 antagonists capsazepine and BCTC reversed mechanical hyperalgesia in models of inflammatory and neuropathic pain in guinea pigs (Walker, K. M.; Urban, L.; Medhurst, S. J.; Patel, S.; Panesar, M.; Fox, A. J.; McIntyre, P. J. Pharmacol. Exp. Ther. 2003, 304, 56-62) and rats (Pomonis, J. D.; Harrison, J. E.; Mark, L.; Bristol, D. R.; Valenzano, K. J.; Walker, K. J. Pharmacol. Exp. Ther. 2003, 306, 387-393).
  • VR1 agonists also modulate body temperature and fever.
  • administration of resiniferatoxin-induced hypothermia (Woods, A. J.; Stock, M. J.; Gupta, A. N.; Wong, T. T. L.; Andrews, P. L. R. Eur. J. Pharmacol. 1994, 264, 125-133).
  • phase I of LPS (lipopolysaccharide)-induced fever did not occur in animals desensitized with low intraperitoneal doses of capsaicin (Romanovsky, A. A. Frontiers in Bioscience 2004, 9, 494-504).
  • VR1 antagonists in inflammatory bronchial conditions are demonstrated by the finding that they antagonize capsaicin- and acid-induced bronchoconstriction (Nault, M. A.; Vincent, S. G.; Fisher, J. T. J. Physiol. 1999, 515, 567-578).
  • Related findings demonstrate that the VR1 antagonist capsazepine attenuates anandamide-induced cough in guinea pigs (Jia, Y.; McLeod, R. L.; Wang, X.; Parra, L. E.; Egan, R. W.; Hey, J. A. Brit. J. Pharmacol. 2002, 137, 831-836).
  • VR1 antagonist capsazepine was demonstrated to significantly reduce anxiety-like behaviors in rats using the elevated plus maze (Kasckow, J. W.; Mulchahey, J. J.; Geracioti, T. D. Jr. Progress in Neuro-Psychopharmacol. and Biological Psychiatry 2004, 28, 291-295).
  • VR1 antagonists may have utility in the treatment of anxiety, panic disorders, phobias or other non-adaptive stress responses.
  • the present invention is directed to a compound of Formula (I):
  • R 1 , R 2 , R 3a , R 3b , R 4 , p, q, r, L and A 1 are as defined herein, and their use as potent modulators of VR 1 .
  • the present invention is also directed to a method for treating a VR 1 ion channel mediated disease in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I).
  • the present invention is further directed to a process for making a compound of Formula (I) and salts thereof.
  • the present invention is directed to compounds of Formula (I):
  • An example of the present invention includes a compound of Formula (I) or a form thereof, wherein q is 0.
  • An example of the present invention includes a compound of Formula (I) or a form thereof, wherein A 1 is selected from the group consisting of phenyl, biphenyl, naphthyl, quinolinyl and indole.
  • An example of the present invention includes a compound of Formula (I) or a form thereof, wherein
  • An example of the present invention includes a compound of Formula (I) or a form thereof, wherein R 2 is selected from the group consisting of halogen and C 1-4 alkyl, wherein alkyl is optionally perfluorinated.
  • An example of the present invention includes a compound of Formula (I) or a form thereof, wherein R 3a and R 3b are each selected from the group consisting of hydrogen and C 1-4 alkyl.
  • An example of the present invention includes a compound of Formula (I) or a form thereof, wherein R 4 is each selected from the group consisting of halogen, carboxy, C 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkyl, haloC 1-6 alkoxy, C 1-6 alkylcarbonyl, haloC 1-6 alkylthio, C 1-6 alkylsulfonyl, haloC 1-6 alkylsulfonyl, (C 1-6 alkyl) 1-2 -amino, (C 1-6 alkyl) 1-2 -aminocarbonyl, C 1-6 alkylcarbonylamino, C 1-6 alkylsulfonylamino and haloC 1-6 alkylsulfonylamino, wherein alkyl and alkoxy are optionally perfluorinated.
  • An example of the present invention includes a compound of Formula (I) or a form thereof, wherein
  • the present invention is further directed to compounds of Formula Ia or Ib:
  • An example of the present invention includes compounds and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof selected from the group consisting of:
  • the compounds of Formula (I) are useful in methods for treating a VR1 ion channel mediated disease in a subject which disease is affected by the modulation of one or more vanilloid receptors.
  • the present invention is directed to a method of treating a VR1 ion channel mediated disease in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I) or a salt or solvate thereof.
  • form means, in reference to compounds of the present invention, such may exist as, without limitation, a salt, stereoisomer, tautomer, crystalline, polymorph, amorphous, solvate, hydrate, ester, prodrug or metabolite form.
  • the present invention encompasses all such compound forms and mixtures thereof.
  • isolated form means, in reference to compounds of the present invention, that such may exist in an essentially pure state such as, without limitation, an enantiomer, a racemic mixture, a geometric isomer (such as a cis or trans stereoisomer), a mixture of geometric isomers, and the like.
  • the present invention encompasses all such isolated forms and mixtures thereof.
  • Certain compounds of Formula (I) may exist in various stereoisomeric or tautomeric forms and mixtures thereof.
  • the invention encompasses all such compounds and mixtures thereof.
  • the compounds of the present invention may be present in the form of pharmaceutically acceptable salts.
  • pharmaceutically acceptable salts for use in medicines, refer to non-toxic acidic/anionic or basic/cationic salt forms.
  • Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
  • a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
  • suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic ligands, e.g. quaternary ammonium salts.
  • representative pharmaceutically acceptable salts include the following: acetate, adipate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium, camsylate (or camphorsulphonate), carbonate, chloride, choline, clavulanate, citrate, dihydrochloride, disodium, edetate, fumarate, gluconate, glutamate, hydrabamine, hydrobromine, hydrochloride, iodide, isothionate, lactate, malate, maleate, mandelate, mesylate, nitrate, oleate, pamoate, palmitate, phosphate/diphosphate, salicylate, sodium, stearate, sulfate, succinate, tartrate, tromethane, tosylate, trichloroacetate, trifluoroacetate and the like.
  • An example of the present invention includes compounds of Formula (I) and a salt form thereof wherein the salt is selected from the group consisting of disodium, hydrochloride and sodium.
  • the invention includes compounds of various isomers and mixtures thereof.
  • the term “isomer” refers to compounds that have the same composition and molecular weight but differ in physical and/or chemical properties. Such substances have the same number and kind of atoms but differ in structure. The structural difference may be in constitution (geometric isomers) or in an ability to rotate the plane of polarized light (stereoisomers).
  • optical isomer means isomers of identical constitution that differ only in the spatial arrangement of their groups. Optical isomers rotate the plane of polarized light in different directions.
  • optical activity means the degree to which an optical isomer rotates the plane of polarized light.
  • racemate or “racemic mixture” means an equimolar mixture of two enantiomeric species, wherein each of the isolated species rotates the plane of polarized light in the opposite direction such that the mixture is devoid of optical activity.
  • enantiomer means an isomer having a nonsuperimposable mirror image.
  • diastereomer means stereoisomers that are not enantiomers.
  • chiral means a molecule, which in a given configuration, cannot be superimposed on its mirror image. This is in contrast to achiral molecules, which can be superimposed on their mirror images.
  • the invention is considered to include the tautomeric forms of all compounds of Formula (I).
  • the invention is considered to include pure enantiomers, racemic mixtures, as well as mixtures of enantiomers having 0.001% to 99.99% enantiomeric excess.
  • some of the compounds represented by Formula (I) may be prodrugs, i.e., derivatives of a drug that possess superior delivery capabilities and therapeutic value as compared to the active drug. Prodrugs are transformed into active drugs by in vivo enzymatic or chemical processes.
  • the two distinct mirror image versions of the chiral molecule are also known as levo (left-handed), abbreviated L, or dextro (right handed), abbreviated D, depending on which way they rotate polarized light.
  • L left-handed
  • D dextro
  • R and S represent the configuration of groups around a stereogenic carbon atom(s).
  • An example of an enantiomerically enriched form isolated from a racemic mixture includes a dextrorotatory enantiomer, wherein the mixture is substantially free of the levorotatory isomer.
  • substantially free means the levorotatory isomer may, in a range, comprise less than 25% of the mixture, less than 10%, less than 5%, less than 2% or less than 1% of the mixture according to the formula:
  • an example of an enantiomerically enriched form isolated from a racemic mixture includes a levorotatory enantiomer, wherein the mixture is substantially free of the dextrorotatory isomer.
  • substantially free means the dextrorotatory isomer may, in a range, comprise less than 25% of the mixture, less than 10%, less than 5%, less than 2% or less than 1% of the mixture according to the formula:
  • “Geometric isomer” means isomers that differ in the orientation of substituent atoms in relationship to a carbon-carbon double bond, to a cycloalkyl ring, or to a bridged bicyclic system. Substituent atoms (other than hydrogen) on each side of a carbon-carbon double bond may be in an E or Z configuration. In the “E” configuration, the substituents are on opposite sides in relationship to the carbon-carbon double bond. In the “Z” configuration, the substituents are oriented on the same side in relationship to the carbon-carbon double bond. The scope of the present invention is intended to include all such “E” and “Z” isomers.
  • Substituent atoms (other than hydrogen) attached to a ring system may be in a cis or trans configuration.
  • the substituents are on the same side in relationship to the plane of the ring; in the “trans” configuration, the substituents are on opposite sides in relationship to the plane of the ring.
  • Compounds having a mixture of “cis” and “trans” species are designated “cis/trans”. The scope of the present invention is intended to include all such “cis” and “trans” isomers.
  • compounds of the present invention may have at least one crystalline, polymorph or amorphous form.
  • the plurality of such forms is included in the scope of the invention.
  • some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents (e.g., organic esters such as ethanolate and the like). The plurality of such solvates is also intended to be encompassed within the scope of this invention.
  • Bond lines drawn into a ring system from a substituent variable indicate that the substituent may be attached to any of the substitutable ring atoms.
  • C 1-6 alkyl or “alkyl” means a straight or branched chain hydrocarbon alkyl radical, comprising from 1 to 6 carbon atoms.
  • Non-limiting examples include methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, tertiary butyl (also referred to as t-butyl or tert-butyl), 1-pentyl, 2-pentyl, 3-pentyl, 1-hexyl, 2-hexyl, 3-hexyl and the like.
  • the term further includes alkyl groups in any combination thereof (e.g. C 1-2 , C 1-3 , C 1-4 and the like).
  • An alkyl radical may be attached to a core molecule where allowed by available valences.
  • C 2-3 alkenyl and C 2-3 alkynyl mean straight or branched carbon chains having 2 to 3 carbon atoms, wherein a C 2-3 alkenyl chain has at least one double bond in the chain and a C 2-3 alkynyl chain has at least one triple bond in the chain.
  • An alkenyl and alkynyl radical may be attached to a core molecule where allowed by available valences.
  • C 1-6 alkoxy or “alkoxy” means a straight or branched chain hydrocarbon alkyl radical or alkyldiyl linking group of the formula —O—C 1-6 alkyl, comprising from 1 to 6 carbon atoms. Examples include methoxy, ethoxy, propoxy, isopropoxy, butoxy and the like. The term further includes alkoxy groups in any combination thereof (e.g. C 1-2 , C 1-3 , C 1-4 and the like). An alkoxy radical may be attached to a core molecule where allowed by available valences.
  • cycloalkyl refers to a saturated or partially unsaturated, monocyclic, polycyclic or benzofused hydrocarbon ring system composed of from 3 to 14 carbon atoms. Except when specified, the term includes a C 3-8 cycloalkyl, C 3-10 cycloalkyl, C 5-6 cycloalkyl, C 5-8 cycloalkyl, C 5-12 cycloalkyl, C 8-10 cycloalkyl, C 9-13 cycloalkyl, C 3-14 cycloalkyl or benzofused C 3-14 cycloalkyl ring system.
  • Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, 1H-indenyl, indanyl, adamantanyl, 9H-fluorenyl, 1,2,3,4-tetrahydro-naphthalenyl, acenaphthenyl, bicyclo[2.2.1]heptenyl and the like.
  • C 3-14 cycloalkyl radicals may be attached to a core molecule and further substituted on any atom when allowed by available valences.
  • benzofused used as a prefix for a ring system, means a radical formed by any ring system radical fused with a benzene ring.
  • the benzofused radical may be attached to a core molecule via either ring of the bicyclic system and further substituted on any atom where allowed by available valences.
  • aryl refers to monocyclic or bicyclic aromatic ring systems containing from 6 to 12 carbons in the ring. Examples include phenyl, biphenyl, naphthalene, azulenyl, anthracenyl and the like. Aryl radicals may be attached to a core molecule and further substituted on any atom when allowed by available valences.
  • aromatic refers to a cycloalkylic hydrocarbon ring system having an unsaturated, conjugated ⁇ electron system.
  • hetero refers to the replacement of at least one ring carbon atom with one or more heteroatoms independently selected from a nitrogen, oxygen or sulfur atom, wherein the nitrogen and sulfur atoms can exist in any allowed oxidation state. Examples include rings wherein 1, 2, 3 or 4 ring members are a nitrogen atom; or, 0, 1, 2 or 3 ring members are nitrogen atoms and 1 member is an oxygen or sulfur atom. When allowed by available valences, up to two adjacent ring members may be heteroatoms; wherein one heteroatom is nitrogen and the other is one heteroatom selected from N, S or O.
  • heterocyclyl refers to a nonaromatic (i.e. saturated or partially unsaturated) monocyclic, polycyclic or benzofused ring system radical.
  • Heteroatom ring members are selected from at least one of N, O, S, S(O) or SO 2 , wherein the nitrogen and sulfur atoms can exist in any allowed oxidation state.
  • Examples include 2H-pyrrole, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, 2-imidazolinyl (also referred to as 4,5-dihydro-1H-imidazolyl), imidazolidinyl, 2-pyrazolinyl, pyrazolidinyl, oxazolidinyl, tetrazolinyl, tetrazolidinyl, piperidinyl, morpholinyl, 1,4-dithianyl, thiomorpholinyl, piperazinyl, azetidinyl, azepanyl, dihydro-pyranyl, tetrahydro-furanyl, tetrahydro-thienyl, tetrahydro-pyranyl, tetrahydro-pyridazinyl, hexahydro-1,4-diazepinyl, hexahydro-1,4-oxazepan
  • heteroaryl means an aromatic monocyclic, polycyclic or benzofused ring system radical.
  • Heteroatom ring members are selected from at least one of N, O, S, S(O) or SO 2 , wherein the nitrogen and sulfur atoms can exist in any allowed oxidation state.
  • Examples include furanyl, thienyl, pyrrolyl, pyrazolyl, 1H-imidazolyl, isothiazolyl, isoxazolyl, oxazolyl, thiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, 1H-tetrazolyl, 2H-tetrazolyl, 1H-[1,2,3]triazolyl, 2H-[1,2,3]triazolyl, 4H-[1,2,4]triazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, indolyl, azaindolyl, indazolyl, azaindazolyl, isoindolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, benzoisoxazoly
  • C 1-6 alkoxy-C 1-6 alkyl means a radical of the formula: —C 1-6 alkyl-O—C 1-6 alkyl.
  • C 1-6 alkoxycarbonyl means a radical of the formula: —C(O)—O—C 1-6 alkyl. Examples include C 1-4 alkoxycarbonyl.
  • C 1-6 alkoxycarbonylamino means a radical of the formula: —NH—C(O)—O—C 1-6 alkyl. Examples include C 1-4 alkylcarbonylamino.
  • (C 1-6 alkyl) 1-2 -amino means a radical of the formula: —NH—C 1-6 alkyl or —N(C 1-6 alkyl) 2 . Examples include (C 1-4 alkyl) 1-2 -amino.
  • (C 1-6 alkyl) 1-2 -amino-C 1-6 alkyl means a radical of the formula: —C 1-6 alkyl-NH—C 1-6 alkyl or —C 1-6 alkyl-N(C 1-6 alkyl) 2 . Examples include (C 1-4 alkyl) 1-2 -amino-C 1-6 alkyl.
  • (C 1-6 alkyl) 1-2 -aminocarbonyl means a radical of the formula: —C(O)—NH—C 1-6 alkyl or —C(O)—N(C 1-6 alkyl) 2 . Examples include (C 1-4 alkyl) 1-2 -aminocarbonyl.
  • (C 1-6 alkyl) 1-2 -aminocarbonylamino means a radical of the formula: —NH—C(O)—NH—C 1-6 alkyl or —NH—C(O)—N(C 1-6 alkyl) 2 .
  • Examples include (C 1-4 alkyl) 1-2 -aminocarbonylamino.
  • (C 1-4 alkyl) 1-2 -aminosulfonyl means a radical of the formula: —SO 2 —NH—C 1-4 alkyl or —SO 2 —N(C 1-4 alkyl) 2 .
  • C 1-6 alkylcarbonyl means a radical of the formula: —C(O)—C 1-6 alkyl. Examples include C 1-4 alkylcarbonyl.
  • C 1-6 alkylcarbonylamino means a radical of the formula: —NH—C(O)—C 1-6 alkyl. Examples include C 1-4 alkylcarbonylamino.
  • C 1-6 alkylsulfonyl means a radical of the formula: —SO 2 —C 1-6 alkyl. Examples include C 1-4 alkylsulfonyl.
  • C 1-6 alkylsulfinylamino means a radical of the formula: —NH—S(O)—C 1-6 alkyl.
  • C 1-6 alkylsulfonylamino means a radical of the formula: —NH—SO 2 —C 1-6 alkyl.
  • C 1-6 alkylthio means a radical of the formula: —S—C 1-6 alkyl. Examples include C 1-4 alkylthio.
  • amino means a radical of the formula: —NH 2 .
  • amino-C 1-6 alkyl means a radical of the formula: —C 1-6 alkyl-NH 2 .
  • aminocarbonyl means a radical of the formula: —C(O)—NH 2 .
  • aminocarbonylamino means a radical of the formula: —NH—C(O)—NH 2 .
  • aminosulfonyl means a radical of the formula: —SO 2 —NH 2 .
  • aminosulfonylamino means a radical of the formula: —NH—SO 2 —NH 2 .
  • (C 1-6 alkyl) 1-2 -aminosulfonylamino means a radical of the formula: —NH—SO 2 —NH—C 1-6 alkyl or —NH—SO 2 —N(C 1-6 alkyl) 2 .
  • Examples include (C 1-4 alkyl) 1-2 -aminosulfonylamino.
  • aminosulfonylamino-C 1-6 alkyl means a radical of the formula: —C 1-6 alkyl-NH—SO 2 —NH 2 .
  • (C 1-6 alkyl) 1-2 -aminosulfonylamino-C 1-6 alkyl means a radical of the formula: —C 1-6 alkyl-NH—SO 2 —NH—C 1-6 alkyl or —C 1-6 alkyl-NH—SO 2 —N(C 1-6 alkyl) 2 .
  • C 3-8 cycloalkyl-C 1-6 alkyl means a radical of the formula: —C 1-6 alkyl-C 3-8 cycloalkyl. Examples include C 3-8 cycloalkyl-C 1-4 alkyl.
  • C 3-8 cycloalkyl-C 1-6 alkoxy means a radical of the formula: —O—C 1-6 alkyl-C 3-8 cycloalkyl. Examples include C 3-8 cycloalkyl-C 1-4 alkoxy.
  • C 3-8 cycloalkyl-oxy means a radical of the formula: —O—C 3-8 cycloalkyl.
  • (C 3-8 cycloalkyl) 1-2 -amino means a radical of the formula: —NH—(C 3-8 cycloalkyl) or —N(C 3-8 cycloalkyl) 2 .
  • (C 3-8 cycloalkyl-C 1-4 alkyl) 1-2 -amino means a radical of the formula: —NH—C 1-4 alkyl-C 3-8 cycloalkyl or —N(C 1-4 alkyl-C 3-8 cycloalkyl) 2 .
  • oxo means a radical of the formula: ⁇ O.
  • halogen or “halo” means the group chloro, bromo, fluoro or iodo.
  • haloC 1-6 alkyl means a radical of the formula: —C 1-6 alkyl(halo) n , wherein “n” represents that amount of available valences on C 1-6 alkyl, which may be substituted with one or more halogen atoms while remaining stable. Examples include difluoromethyl, trifluoromethyl, trifluoroethyl, chloromethyl and the like.
  • haloC 1-6 alkoxy means a radical of the formula: —O—C 1-6 alkyl(halo) n , wherein “n” represents that amount of available valences on C 1-6 alkoxy, which may be substituted with one or more halogen atoms while remaining stable. Examples include difluoromethoxy, trifluoromethoxy, trifluoroethoxy, chloromethoxy and the like.
  • haloC 1-6 alkylsulfonyl means a radical of the formula: —SO 2 —C 1-6 alkyl(halo) n , wherein “n” represents that amount of available valences on C 1-6 alkyl, which may be substituted with one or more halogen atoms while remaining stable. Examples include trifluoromethylsulfonyl and the like.
  • haloC 1-6 alkylsulfonylamino means a radical of the formula: —NH—SO 2 —C 1-6 alkyl(halo) n , wherein “n” represents that amount of available valences on C 1-6 alkyl, which may be substituted with one or more halogen atoms while remaining stable. Examples include trifluoromethylsulfonyl and the like.
  • haloC 1-6 alkylthio means a radical of the formula: —S—C 1-6 alkyl(halo) n , wherein “n” represents that amount of available valences on C 1-6 alkyl, which may be substituted with one or more halogen atoms while remaining stable. Examples include trifluoromethylsulfonyl and the like.
  • perfluorinated means a radical that is substituted with fluoro atoms to the extent allowed by available valences while remaining stable.
  • substituted refers to a core molecule on which one or more hydrogen atoms have been replaced with one or more functional radical moieties.
  • the number that is allowed by available valences limits the amount of substituents. Substitution is not limited to the core molecule, but may also occur on a substituent radical, whereby the substituent radical becomes a linking group.
  • the compounds of Formula (I) are useful in methods for treating a VR1 ion channel mediated disease in a subject which disease is affected by the modulation of one or more vanilloid receptors.
  • the present invention is directed to a method of treating a VR1 ion channel mediated disease in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I) or a salt or solvate thereof.
  • VR1 ion channel mediated disease refers to chronic or acute pain due to disease that causes inflammatory pain, burning pain or post-operative pain.
  • An example of a use of the compound of Formula (I) or a salt or solvate thereof includes use in the manufacture of a medicament for treating a VR1 ion channel mediated disease, wherein the VR1 ion channel mediated disease is chronic or acute pain due to disease that causes inflammatory pain, burning pain or post-operative pain.
  • An example of a use of the compound of Formula (I) or a salt or solvate thereof includes use as a medicine for treating a VR1 ion channel mediated disease, wherein the VR1 ion channel mediated disease is chronic or acute pain due to disease that causes inflammatory pain, burning pain or post-operative pain.
  • prodrug means a compound of Formula (I) or a form thereof that is converted in vivo into a functional derivative form that may contribute to therapeutic biological activity, wherein the converted form may be: 1) a relatively active form; 2) a relatively inactive form; 3) a relatively less active form; or, 4) any form which results, directly or indirectly, from such in vivo conversions.
  • Prodrugs are useful when said compound may be either too toxic to administer systemically, absorbed poorly by the digestive tract or broken down by the body before it reaches its target.
  • Conventional procedures for the selection and preparation of suitable prodrug derivatives are described in, for example, “ Design of Prodrugs ”, ed. H. Bundgaard, Elsevier, 1985.
  • metabolite means a form of a compound of Formula (I) or a form thereof converted by in vivo metabolism or a metabolic process to a derivative of said compound.
  • subject refers to a patient, such as an animal, a mammal or a human, who has been the object of treatment, observation or experiment and is at risk of (or susceptible to) developing a disease that has or will result in VR1 ion channel mediated chronic or acute pain, wherein the pain caused by the disease is inflammatory pain, burning pain or post-operative pain.
  • the term “effective amount” refers to that amount of a compound of Formula (I) or a form, pharmaceutical composition, medicine or medicament thereof that elicits the biological or medicinal response (such as inhibiting, preventing or ameliorating VR1 ion channel mediated chronic or acute pain) in a tissue system, animal or human, that is being sought by a researcher, veterinarian, medical doctor, or other clinician, which includes alleviation of the symptoms of the inflammatory pain, burning pain or post-operative pain being treated.
  • the effective amount of a compound of Formula (I) or a form thereof is from about 0.001 mg/kg/day to about 300 mg/kg/day.
  • composition refers to a product containing a compound of Formula (I) or a form thereof, such as a product comprising the specified ingredients in the specified amounts, as well as any product that results, directly or indirectly, from such combinations of the specified ingredients in the specified amounts.
  • the term “medicament” or “medicine” refers to a product containing a compound of Formula (I) or a form thereof.
  • the present invention includes use of such a medicament for treating VR1 ion channel mediated chronic or acute pain.
  • pharmaceutically acceptable refers to molecular entities and compositions that are of sufficient purity and quality for use in the formulation of a pharmaceutical composition, medicine or medicament of the present invention. Since both human use (clinical and over-the-counter) and veterinary use are equally included within the scope of the present invention, a pharmaceutically acceptable formulation would include a pharmaceutical composition, medicine or medicament for either human or veterinary use.
  • treating refers, without limitation, inhibiting, ameliorating, facilitating the eradication of, inhibiting the progression of or promoting the stasis of VR1 ion channel mediated chronic or acute pain.
  • the pharmaceutical composition, medicine or medicament is preferably in the form of a tablet containing, e.g., 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 150, 200, 250 and 500 milligrams of a compound of formula (I) or a form thereof for the symptomatic adjustment of the dosage to the patient to be treated.
  • Optimal dosages will vary depending on factors associated with the particular patient being treated (e.g., age, weight, diet and time of administration), the severity of the condition being treated, the particular compound being used, the mode of administration and the strength of the preparation. The use of either daily administration or post-periodic dosing may be employed.
  • a representative compound of Formula (I) or a form thereof includes a compound selected from the group consisting of:
  • a representative compound of Formula (I) or a form thereof includes a compound selected from the group consisting of:
  • a representative compound of Formula (I) or a form thereof includes a compound selected from the group consisting of:
  • a representative compound of Formula (I) or a form thereof includes a compound selected from the group consisting of:
  • a representative compound of Formula (I) or a form thereof includes a compound selected from the group consisting of:
  • a representative prophetic compound of Formula (I) or a form thereof includes a compound selected from the group consisting of:
  • Representative compounds of the present invention can be synthesized in accordance with the general synthetic methods described below and are illustrated in the schemes that follows. Since the schemes are an illustration, the invention should not be construed as being limited by the chemical reactions and conditions expressed. The preparation of the various starting materials used in the schemes is well within the skill of persons versed in the art.
  • Scheme AA illustrates a general synthesis of benzimidazoles of formula AA5, representative of a compound of Formula (I).
  • the acid can be converted to an acid chloride using oxalyl chloride and a catalytic amount of DMF in a solvent such as methylene chloride.
  • the acid chloride AA2 is heated with 4-bromobenzene-1,2-diamine AA1 in acetic acid to give AA3.
  • a suitably substituted phenyl group can be appended to AA3 by a variety of coupling reactions (Suzuki, Stille) that are well known to those versed in the art.
  • a particularly useful substitution method employs a palladium catalyzed cross-coupling Suzuki reaction (Huff, B. et. al. Org. Syn. 1997, 75: 53-60; and, Goodson, F. E. et. al. Org. Synth. 1997, 75: 61-68).
  • a mixture of bromobenzimidazole AA3 is reacted with a suitable phenyl boronic acid AA4 in the presence of a reagent such as cesium carbonate and a catalytic amount of a palladium catalyst such as PdCl 2 dppf in a solvent such as a mixture of dioxane and ethanol at elevated temperatures to give AA5.
  • a reagent such as cesium carbonate
  • a palladium catalyst such as PdCl 2 dppf
  • a solvent such as a mixture of dioxane and ethanol
  • the reaction times can be reduced by carrying out this procedure at similar (about 100° C.) or lower temperatures in a microwave synthesizer.
  • Other palladium catalysts suitable for this type of reaction include Pd(PPh 3 ) 4 .
  • Cinnamic acids as required, can be synthesized via procedures described in reaction Scheme BB.
  • Phenylpropionic acid BB3 can be synthesized from cinnamic acid BB2 by hydrogenation using a variety of standard procedures. As shown above, a mixture of BB2 in ethanol with a catalytic amount of palladium on carbon (10%) is stirred at room temperature in an atmosphere of hydrogen (50 psi) to provide acid BB3.
  • Reaction Scheme BB′ is a variation of Reaction Scheme BB.
  • Acid BB2 is converted to the acid chloride by reaction with oxalyl chloride and a catalytic amount of DMF in a solvent such as methylene chloride.
  • the acid chloride is then heated with AA1 in acetic acid to give BB′1, which is further elaborated in place of AA3 as described in reaction Scheme AA.
  • Reaction Scheme CC provides a method to prepare substituted 4-bromobenzene-1,2-diamine intermediates.
  • reaction Scheme DD An alternative synthetic sequence to produce compounds of the present invention is described in reaction Scheme DD.
  • a substituted bromobenzimidazole DD1 (representative of AA3 in Scheme AA) is protected (using a protecting group such as Boc), then converted to a pinicolboronate ester DD2 under standard Suzuki coupling conditions (Prieto, M. et. al., J. Org. Chem. 2004, 69: 6812-6820; McDonald, D. et. al., Bioorg. Med. Chem. Lett. 2005, 15: 5241-5246; and, Poon, S. F. et. al. Bioorg. Med. Chem. Lett. 2004, 14, 5477-5480).
  • a protecting group such as Boc
  • Boronate ester DD2 can be converted to compounds of the present invention (Boc protected DD3) by Suzuki coupling with a phenyl halide, mesylate or triflate (R 1 ) p Ph-X.
  • borane DD2 is reacted with a suitable aryl halide, tetrakis (triphenylphosphine) palladium (0) and tri-tert-butylphosphonium tetrafluoroborate in 2M aqueous potassium carbonate in toluene at 100° C. to give the protected form of DD3.
  • Deprotection with an acid such as TFA gives DD3.
  • Reaction Scheme EE describes methods to prepare representative compounds of the present invention.
  • Aniline EE1 can be converted to a variety of amides, carbamates or ureas EE2 by utilizing any number of acylation methods that are commonly used by persons versed in the art.
  • reaction of EE1 in a solvent such as THF with a substituted acid chloride and a base such as triethylamine gives the corresponding amide of EE2.
  • reaction of EE1 in THF with a substituted chloroformate and triethylamine gives the corresponding substituted carbamate of EE2.
  • EE1 can be converted to sulfonamides by utilizing various sulfonylation conditions. For instance, reaction of EE1 in a solvent such as THF with an alkylsulfonyl chloride and triethylamine gives the alkylsulfonamide EE3. EE1 can be selectively, and successively substituted to give EE3. An efficient method of achieving this is via reductive alkylation with aldehydes or ketones (see Mattson, R. J. et. al. J. Org. Chem. 1990, 55, 2552-2554) and references cited therein]. In this procedure, equal amounts of EE1 and an aldehyde or ketone are stirred with titanium (IV) isopropoxide, followed the addition of sodium cyanoborohydride in a solvent such as ethanol to give substituted amine EE3.
  • a solvent such as THF
  • Reaction Scheme GG describes an alternative method to prepare cyclopropyl acid intermediates.
  • Cinnamic acids are converted to the corresponding Weinreb amide, by conversion to the acid chloride as described in Reaction Scheme AA and BB′.
  • the acid chloride is reacted with N,N-dimethylhydroxylamine hydrochloride and a base such as triethylamine in methylene chloride to give amide GG2.
  • Amide GG2 is converted to cyclopropyl amide GG3 as described in Scheme FF.
  • the amide GG3 is then hydrolyzed to give acid GG4, typically by reaction with potassium tertiary butoxide in THF.
  • An ester of commercially available 4-hydroxycinnamic acid II1 can be converted to ether analogs by a number of routes including the Williamson reaction.
  • II1 and an alkyl halide is reacted with a base such as cesium carbonate in a solvent such as acetonitrile to give the product II2.
  • More effective electrophiles can be derivatives of alcohols such as mesylates, p-toluene sulfonates or trifluoromethanesulfonates (triflates).
  • An effective alternative method is the conversion of II1 to ether analogs II2 via the Mitsunobu reaction (as reviewed by Mitsunobu, O., Synthesis, 1981, 1-28).
  • Ether analogs II2 can be further reduced to acid II3 using standard techniques.
  • Reaction Scheme JJ describes methods to prepare cinnamic acids that contain substituted amino groups.
  • Cinnamate ester JJ1 can be converted to a variety of amides, carbamates or ureas JJ2 by utilizing any number of acylation methods that are commonly used by persons versed in the art.
  • reaction of JJ1 in a solvent such as THF with a substituted acid chloride and a base such as triethylamine gives the corresponding amide of JJ2.
  • reaction of JJ1 in THF with a substituted chloroformate and triethylamine gives the corresponding substituted carbamate of JJ2.
  • JJ1 can be converted to sulfonamides by utilizing various sulfonylation conditions.
  • reaction of JJ1 in a solvent such as THF with an alkylsulfonyl chloride and triethylamine gives the alkylsulfonamide JJ3.
  • JJ1 can be selectively, and successively substituted to give JJ4.
  • An efficient method of substitution is via reductive alkylation with aldehydes or ketones (see Mattson, R. J. et. al. J. Org. Chem., 1990, 55, 2552-2554 and references cited therein).
  • equal amounts of JJ1 and an aldehyde or ketone are stirred with titanium (IV) isopropoxide, followed the addition of sodium cyanoborohydride in a solvent such as ethanol to give substituted amine JJ4.
  • propiolic acids KK2 are prepared by reaction of acetylenes KK1 with n-butyl lithium in THF at ⁇ 78° C. warming to 0° C. for 30 min. The mixture is cooled to ⁇ 78° C., and transferred to a saturated solution of carbon dioxide in THF at ⁇ 78° C. The reaction is slowly warmed to rt to give the corresponding propiolic acid KK2.
  • reaction Scheme LL An alternative synthetic sequence to produce compounds of the present invention is described in reaction Scheme LL.
  • LL2 is then reacted with an acid or acid chloride to give LL3 (as described in reaction Schemes AA or BB′).
  • reaction Scheme NN An alternative synthetic sequence to produce compounds of the present invention is described in reaction Scheme NN.
  • the biaryldiamine LL2 is reacted with dichloroimine MM1 as described in reaction Scheme MM to give NN1.
  • NN1 is carried forward to give NN2.
  • olefin PP1 Reaction of olefin PP1 with an alkyl diazoacetate, such as ethyl diazoacetate, in the presence of a catalyst, such as copper(I) trifluoromethane sulfonate and Evans' chiral ligand (Evans, D. A.; Woerpel, K. A.; Hinman, M. M.; Faul, M. M. J. Am. Chem. Soc. 1991, 113, 726-728) in a solvent such as chloroform, gives a cyclopropyl ester enantiomer PP2.
  • a catalyst such as copper(I) trifluoromethane sulfonate and Evans' chiral ligand
  • the (R,R)-cyclopropyl ester PP2 enantiomer is obtained when a chiral ligand such as 2,2-bis-[2-((4S)-(1,1-dimethylethyl)-1,3-oxazolinyl)]propane Compound 38b is used.
  • the (S,S)-cyclopropyl ester enantiomer is obtained when the chiral ligand 2,2-bis-[2-((4R)-(1,1-dimethylethyl)-1,3-oxazolinyl)]propane Compound 38a is used.
  • the configurations of the cyclopropyl moiety were predicted based on Evans' J. Am. Chem. Soc. 1991 report. Hydrolysis of the ester PP2 gives acid PP3, which is further elaborated into the benzimidazoles of Scheme AA.
  • acid PP3 is reacted with N,O-dimethylhydroxylamine in the presence of a base such as diisopropylethylamine, and an amide coupling reagent such as BOP, in a solvent such as DMF to produce the methoxy methyl amide PP4.
  • a base such as diisopropylethylamine
  • an amide coupling reagent such as BOP
  • the aldehyde QQ1 is reacted with malonic acid and a catalytic amount of piperidine in pyridine at elevated temperatures to provide an acid QQ2.
  • Acid QQ2 is converted to an acid chloride QQ3 by reaction with oxalyl chloride and a catalytic amount of DMF in a solvent such as methylene chloride.
  • a suitably substituted phenyl boronic acid is reacted with benzimidazole QQ4 in the presence of a reagent and a catalytic amount of a palladium catalyst in a solvent to give an alcohol substituted benzimidazole QQ5, representative of a compound of Formula (I).
  • Step B (E)-1-(2- ⁇ 2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl ⁇ -phenyl)-ethanone
  • Step B 2- ⁇ 2-[3-(4-tert-butyl-phenyl)-propyl]-1H-benzimidazol-5-yl ⁇ -phenol
  • reaction mixture was partitioned between 20 mL EtOAc, 20 mL water, and 2 mL brine. The organic fraction was evaporated, and the residue was purified by chromatography. (reverse-phase, acetonitrile:water+0.1% TFA, 25:75-95:5). The relevant fractions were frozen and lyophilized to give the product Compound 32 (0.013 g, 0.04 mmol) as a tan powder.
  • Step B (E)-5-bromo-2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazole
  • the filter cake was rinsed with acetonitrile, ethyl acetate, and methanol.
  • the filtrate was stirred with aqueous NaHCO 3 /EtOAc.
  • the organic fraction was evaporated, and partitioned between 100 mL EtOAc and 100 mL saturated NaHCO 3 .
  • the organic fraction was dried with Na 2 SO 4 , filtered, and the filtrate was evaporated.
  • the residue was purified by chromatography (silica gel, EtOAc:heptane, 1:4-1:1)) to yield the title Compound 8b (1.595 g, 3.70 mmol) as a tan powder.
  • the mixture was then stirred at room temperature for 1 h.
  • the pH of the mixture was checked and adjusted to acidic using additional 2N HCl if prophetic.
  • the two layers were separated, and the aqueous layer was extracted twice with ether.
  • the organic layers were combined, and dried with magnesium sulfate and filtered.
  • the filtrate was concentrated under reduced pressure to yield a pale yellow oil.
  • the residue was then diluted with ethyl acetate (400 mL) and, washed with 1N sodium hydroxide solution (150 mL ⁇ 3).
  • the basic aqueous layers were combined and acidified with 2N HCl.
  • the clear solution turned cloudy when the acid was added.
  • the mixture was extracted with ether (150 mL ⁇ 3).
  • Step E (E)-2-(2- ⁇ 2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl ⁇ -phenyl)-propan-2-ol
  • the aqueous layers were combined and extracted with ethyl acetate once (about 300 mL).
  • the organic layers were combined, dried with sodium sulfate, and filtered.
  • the volume of the filtrate was reduced to about 170 mL under reduced pressure.
  • the mixture was then filtered through a pad of silica gel and the pad was washed with ethyl acetate until the filtrate did not contain any product. After concentration, a light pink/beige solid was obtained.
  • the solid was triturated with 50 mL ethyl acetate, and the mixture was heated to 85° C. for 5 min. The mixture was slowly cooled to r.t., then cooled at 0° C. for 0.5 h.
  • the slurry was acidified to pH 2.0-3.0 with concentrated hydrochloric acid (about 675-700 mL).
  • the material was stirred for 30 min., and a white solid was collected by filtration.
  • the filter cake was washed with water until the filtrate was neutral (pH about 5.5-6, 2.5 L), air-dried in a Buchner funnel for 2 h, and then further dried in a vacuum oven at 60° C. overnight to provide 300.5 g (96%) of the title Compound 10a as a white solid.
  • the 2-(2-bromophenyl)propan-2-ol solution was slowly added to the n-BuLi solution. The addition took 90 min in order to maintain a reaction temperature below ⁇ 70° C. After the addition was complete, the reaction mixture was stirred at ⁇ 70 to ⁇ 75° C. for 30 min. The triethylborate (230 mL, 1.35 mol) was quickly added in 3 portions at ⁇ 70° C. An exotherm was observed, the batch temperature rose from ⁇ 70 to ⁇ 64° C. The reaction was stirred at ⁇ 70° C. and slowly warmed to room temperature over night.
  • reaction was slowly quenched with 2 M HCl (1 L, 2.00 mol) added via the addition funnel while maintaining the batch temperature 0-5° C.
  • the reaction mixture was stirred for 1 h.
  • the aqueous phase pH was 9-10.
  • the pH was then adjusted to acidic (4-5) with 2 M HCl (200 mL).
  • the two phases were separated and the aqueous layer was extracted with MTBE (2 ⁇ 500 mL).
  • the combined organic phases were dried with anhydrous magnesium sulfate.
  • the solution was filtered and concentrated to yield a yellow oil.
  • the yellow oil was diluted with MTBE (1.5 L) and washed with 1M NaOH (3 ⁇ 500 mL).
  • Step E (E)-2-(2- ⁇ 2-[2-(4-Trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl ⁇ -phenyl)-propan-2-ol
  • a 5-L 4-neck flask equipped with a thermocouple controller, condenser, overhead mechanical stirrer, Firestone valve® and a nitrogen inlet/outlet was charged with dimethoxyethane (2 L), DI water (1 L) and sodium carbonate (230.9 g, 2.18 mol).
  • the solution was degassed and purged with N 2 three times.
  • Compound 10e (71.7 g, 0.35 mol) and Compound 10c (100.0 g, 0.27 mol) were added to the degassed solution.
  • the solution was degassed and purged with N 2 three times.
  • PdCl 2 (dppf) 44.48 g, 54.4 mmol
  • the resulting two-phase suspension was heated to reflux for 18 h, and then cooled to room temperature.
  • the reaction mixture was transferred to a 12-L separatory funnel, and the layers were separated.
  • the organic layer was washed with brine (1 L).
  • the two aqueous layers were combined and extracted with EtOAc (1 L).
  • the combined organic layers were dried (Na 2 SO 4 ), filtered, and the filtrate was concentrated to an oil.
  • Two separate 100 g coupling reactions were combined and purified by chromatography in 10 successive chromatography runs on an ISCO preparative chromatography system (10 ⁇ 1.5 Kg SiO 2 , 5 column volumes of EtOAc, 250 mL/min flow rate).
  • Step D 4-trifluoromethyl acrylic acid (1.19 g, 0.0055, 1.1 eq) was dissolved in 30 mL of POCl 3 . To this solution was added Compound 11c (1.27 g, 0.005 mol), and the reaction mixture was heated at reflux for 6 h (The reaction mixture was quite dark). The reaction mixture was cooled to room temperature and then concentrated in vacuo. The residue was taken up in 50 mL of ethyl acetate, washed with 50 mL of brine, dried over Na 2 SO 4 , filtered, and the filtrate was concentrated in vacuo.
  • Step B (E)-N-(2- ⁇ 6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl ⁇ -phenyl)-acetamide
  • the reaction mixture was diluted with ice water (150 mL) and the solid was collected by vacuum filtration. The solid was washed with water (50 mL) and dried in vacuo to provide the title Compound 14a as a pale yellow solid (5.55 g).
  • Step E (E)-(2- ⁇ 6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl ⁇ -phenyl)-methanol
  • Step B (E)-2- ⁇ 2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl ⁇ -benzenesulfonamide
  • Step A (5-bromo-2-tert-butoxycarbonylamino-phenyl)-carbamic acid tert-butyl ester
  • Step B (3-tert-butoxycarbonylamino-2′-tert-butylsulfamoyl-biphenyl-4-yl)-carbamic acid tert-butyl ester
  • Step C 3′,4′-diamino-biphenyl-2-sulfonic acid tert-butylamide
  • N-methylbenzenesulfonamide (2.00 g, 0.0117 mmol) in 20 mL THF at 0° C. was added dropwise n-butyl lithium (1.6 M in hexanes, 14.6 mL, 0.0234 mmol). After 30 min., triisopropyl borate (3.1 mL, 0.0164 mmol) was added, and the mixture was stirred at 0° C. for 2 hours. The reaction was quenched by addition of 20 mL of 1M HCl (aq).
  • Step B (3-tert-butoxycarbonylamino-2′-methylsulfamoyl-biphenyl-4-yl)-carbamic acid tert-butyl ester
  • Step A (3-tert-butoxycarbonylamino-2′-methanesulfonylamino-biphenyl-4-yl)-carbamic acid tert-butyl ester
  • Step B N-(3′,4′-diamino-biphenyl-2-yl)-methanesulfonamide
  • Example 19 Using the procedures described in Example 19, or using the procedures in Example 1 and the corresponding bromobenzimidazole and boronic acid or boronate ester, and reagents, starting materials and conditions known to those skilled in the art, the following prophetic compounds representative of the present invention may be prepared:
  • Example 1 Using the procedures described in Example 1 or Example 19 and reagents, starting materials and conditions known to those skilled in the art, the following prophetic compounds representative of the present invention may be prepared:
  • Step B 2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid methoxy-methyl-amide
  • Step E 2-(2- ⁇ 2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl ⁇ -phenyl)-propan-2-ol
  • Step B 2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol
  • Step B 2- ⁇ 2-[2-(4-Trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl ⁇ -benzylamine
  • Step A (E)-5-bromo-1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole and (E)-6-bromo-1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole
  • Step B (E)-N-(2- ⁇ 3-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-3H-benzimidazol-5-yl ⁇ -phenyl)-methanesulfonamide and (E)-N-(2- ⁇ 1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl ⁇ -phenyl)-methanesulfonamide
  • Example 1 Using the procedure of Example 1, Step B, the title compounds were prepared from a mixture of (E)-5-bromo-1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole and (E)-6-bromo-1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole and 2-methylsulfonylaminophenyl boronic acid.
  • Step A (E)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-5-[2-(1-trimethylsilanyloxy-vinyl)-phenyl]-1H-benzimidazole
  • Step B (E)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-5-[2-(2-trimethylsilanyloxy-oxiranyl)-phenyl]-1H-benzimidazole
  • Step B (1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid
  • Step C 2-(2- ⁇ 2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl ⁇ -phenyl)-propan-2-ol
  • Step D (1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid methoxy-methyl-amide
  • Step E Determination of ee
  • HEK293 cells were transfected with hVR1 vanilloid receptors and washed with Hank's balanced Salt Solution, dissociated with cell dissociation buffer (Sigma), and then centrifuged at 1000 ⁇ g for 5 min.
  • the pelleted membranes were stored in a freezer at ⁇ 80° C.
  • % inhibition 100% ⁇ [(total binding-binding)/(total binding-non specific binding)]
  • K i values were calculated using a Prism program.
  • the functional activity of the test compounds was determined by measuring changes in intracellular calcium concentration using a Ca ++ -sensitive fluorescent dye and FLIPRTM technology. Increases in Ca ++ concentration were readily detected upon challenge with capsaicin.
  • HEK293 cells expressing hVR1 were grown on poly-D-lysine coated 384 well black-walled plates (BD 354663) and 1 day later loaded with Calcium 3 Dye for 35 min at 37° C., 5% CO 2 and then for 25 min at room temperature, and subsequently tested for agonist-induced increases in intracellular Ca 2+ levels using FLIPRTM technology.
  • Cells were challenged with test compounds (at varying concentrations) and intracellular Ca 2+ was measured for 5 min prior to the addition of capsaicin to all wells to achieve a final concentration of 0.030 ⁇ M eliciting about 80% maximal response.
  • IC 50 values were determined from concentration-response studies, which were generated using the average of quadruplicate wells for each data point.
  • IC 50 (nM) value and percent inhibition value is shown in Table 2. Except where indicated, the percent inhibition values were obtained at a test concentration of 1 ⁇ M; otherwise: (1) the test concentration was 5 ⁇ M. The percent inhibition value is provided for those compounds where an IC 50 value was not obtained.
  • NA means that the data is “not available” because it was not obtained for a particular compound.
  • rats were orally dosed (2.5 mL/kg) with test compound (10 mg/kg) or vehicle (20% hydroxypropyl beta cyclodextran). To determine the time of peak effect, latencies were redetermined 30, 60, 100, 180 and 300 min after compound administration.

Abstract

The invention is directed to compounds of Formula (I):
Figure US20110190364A1-20110804-C00001
to pharmaceutical compositions containing such compounds and to methods of treatment using them.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • The present application claims the benefits of the filing of U.S. application Ser. No. 11/734,984 filed Apr. 13, 2007, and U.S. Provisional Application No. 60/797,504 filed May 3, 2006. The complete disclosures of the aforementioned related patent applications are hereby incorporated herein by reference for all purposes.
    • BACKGROUND OF THE INVENTION
  • Noxious chemical, thermal and mechanical stimuli excite peripheral nerve endings of small diameter sensory neurons (nociceptors) deriving from sensory ganglia (e.g., dorsal root, nodose and trigeminal ganglia) and initiate signals that are perceived as pain. Such nociceptive neurons (i.e., nociceptors) are crucial for the detection of harmful or potentially harmful stimuli (e.g., noxious thermal, chemical, and/or mechanical) that arise from changes in the extracellular environment during inflammatory, ischemic or otherwise traumatic conditions and that cause or have the potential to cause tissue damage (Wall, P. D., and Melzack, R., Textbook of Pain, 1994, New York: Churchill Livingstone).
  • Nociceptors transduce noxious stimuli into membrane depolarization that leads to an action potential, its subsequent conduction to the CNS, and ultimately to the perception of pain, discomfort, etc. as well as to certain responses thereto. At the molecular level, nociception is carried out by ion channels and/or receptors. Plant-derived vanilloid compounds (e.g., capsaicin and resiniferatoxin) are known to selectively depolarize nociceptors and elicit sensations of burning pain: the sensation that is typically evoked by capsaicin-containing hot chili peppers. Therefore, capsaicin mimics the action of physiological/endogenous stimuli that activate the “nociceptive pathway”. Recent advances in pain biology have identified a receptor, called VR1 (a.k.a. capsaicin receptor or TRPV1) for vanilloids, protons and noxious heat. Because nociceptors are drivers of unwanted pain and inflammatory conditions in human beings and animals, modulation of their function is a validated strategy for palliative and other analgesic therapies.
  • Compounds that are modulators (competitive and non-competitive agonists or antagonists [with respect to capsaicin and/or its recognition site] and allosteric modulators) at VR1 have broad therapeutic potential, as demonstrated by the clinical usefulness of marketed, VR1-targeted pharmaceutical agents or the efficacy of VR1 modulators in animal models of disease. Furthermore, it is recognized that agonist modulators of VR1 may possess clinical utility deriving from their agonist properties, per se, and/or from their ability to produce an agonist-mediated desensitization, which would indirectly manifest as a functional antagonism. Similarly, antagonist modulators could exhibit direct antagonist (competitive or non-competitive) properties and/or indirect antagonist properties via the aforementioned desensitization mechanism. It is further recognized that positive and negative allosteric modulators may produce any or all of the aforementioned functional consequences and, as such, may also have clinical utility. Accordingly, this invention is directed to each of these types of modulators.
  • The effective use of VR1 agonists has been demonstrated in inflammatory, neuropathic, and visceral pain states. In an experimental human pain model, dermal capsaicin pretreatment reduced the pain caused by intradermal injection of an acidic solution (Bianco, E. D.; Geppetti, P.; Zippi, P.; (solani, D.; Magini, B.; Cappugi, P. Brit J of Clin Pharmacol 1996, 41, 1-6), suggesting the benefit of VR1 agonists in the treatment of inflammatory pain. A particular role for VR1 agonists has been shown in inflammation and inflammatory pain: for example, resiniferatoxin prevented inflammatory hypersensitivity and edema induction by carrageenan (Kissin, I.; Bright, C. A.; Bradley, E. L., Jr. Anesth Analg 2002, 94, 1253-1258).
  • Additionally, capsaicin-containing creams (for example, Axcain® and Lidocare®) are marketed for dermal relief of pain related to diabetic neuropathy and postherpetic neuralgia, indicative of the usefulness of VR1 agonists in the treatment of neuropathic pain states. Furthermore, such creams have been shown to reduce postsurgical neuropathic pain (Ellison, N., Loprinzi, C. L., Kugler, J., Hatfield, A. K., Miser, A., Sloan, J. A., Wender, D. B., Rowland, K. M., Molina, R., Cascino, T. L., Vukov, A. M., Dhaliwal, H. S, and Ghosh, C. J. Clin. Oncol. 15:2974-2980, 1997). In cancer patients, capsaicin contained in a taffy vehicle, was shown to substantially reduce oral mucositis pain caused by chemotherapy and radiation therapy (Berger, A., Henderson, M., Naadoolman, W., Duffy, V., Cooper, D., Saberski, L. and Bartoshuk, L. J. Pain Sympt. Mgmt 10:243-248, 1995.
  • VR1 also plays a role in the physiology of bladder emptying. VR1 is expressed by bladder sensory neurons, where it modulates bladder responsivity to liquid filling. The VR1 agonist resiniferatoxin desensitized bladder afferents in a dose-dependent manner (Avelino, A.; Cruz, F.; Coimbra, A. Eur. J. Pharmacol. 1999, 378, 17-22), supporting its usefulness for the treatment of overactive bladder (Chancellor, M. B.; De Groat, W. C. J. Urol. (Baltimore) 1999, 162, 3-11). Indeed, intravesicular administration of capsaicin or resiniferatoxin inhibited bladder contraction in both normal and spinal cord injured rats (Komiyama, I.; Igawa, Y.; Ishizuka, O.; Nishizawa, O.; Andersson, K.-E. J. Urol. (Baltimore) 1999, 161, 314-319), indicative of the usefulness of VR1 agonists in nerve-injured incontinent patients. The effectiveness of capsaicin or resiniferatoxin treatment on incontinence in spinal cord injured patients was confirmed in a clinical study (de Seze, M.; Wiart, L.; de Seze, M.-P.; Soyeur, L.; Dosque, J.-P.; Blajezewski, S.; Moore, N.; Brochet, B.; Mazaux, J.-M.; Barat, M.; Joseph, P.-A. Journal of Urology (Hagerstown, Md., United States) 2003, 171, 251-255).
  • The effectiveness of VR1 agonists in the reduction of elevated blood pressure is suggested by capsaicin reduction in blood pressure in SHR and WKY rats (Li, J.; Kaminski, N. E.; Wang, D. H. Hypertension 2003, 41, 757-762.). Capsaicin was also gastroprotective with respect to gastric antral ulcers (Yamamoto, H.; Horie, S.; Uchida, M.; Tsuchiya, S.; Murayama, T.; Watanabe, K. Eur. J. Pharmacol. 2001, 432, 203-210).
  • VR1 antagonists also may be useful in the treatment of inflammatory, neuropathic and visceral pain. For example, the therapeutic utility of VR1 antagonists has been demonstrated in visceral inflammatory conditions. VR1 is elevated in colonic nerve fibers in patients with inflammatory bowel disease, and VR1 antagonists relieved pain and dysmotility (Yiangou, Y.; Facer, P.; Dyer, N. H.; Chan, C. L.; Knowles, C.; Williams, N. S.; Anand, P. Lancet 2001, 357, 1338-1339). Intestinal inflammation induced by toxin A or dextran sulfate sodium in rodents was attenuated by VR1 antagonists (McVey, D. C.; Schmid, P. C.; Schmid, H. H. O.; Vigna, S. R. J. Pharmacol. Exp. Ther. 2003, 304, 713-722). In addition, a synthetic VR1 antagonist reduced colitis disease scores at several important endpoints, including macroscopic damage, microscopic epithelial damage, myeloperoxidase levels, and diarrhea scores, strongly supporting the therapeutic use of VR1 antagonists in inflammatory bowel diseases (Kimball, E. S.; Wallace, N. H.; Schneider, C. R.; D'Andrea, M. R.; Hornby, P. J. Neurogasteroenterology 2004, 16, 811-818). The VR1 antagonists capsazepine and BCTC reversed mechanical hyperalgesia in models of inflammatory and neuropathic pain in guinea pigs (Walker, K. M.; Urban, L.; Medhurst, S. J.; Patel, S.; Panesar, M.; Fox, A. J.; McIntyre, P. J. Pharmacol. Exp. Ther. 2003, 304, 56-62) and rats (Pomonis, J. D.; Harrison, J. E.; Mark, L.; Bristol, D. R.; Valenzano, K. J.; Walker, K. J. Pharmacol. Exp. Ther. 2003, 306, 387-393).
  • LPS-induced fever was attenuated in VR1 knock out mice (Lida, T.; Shimizu, I.; Nealen, M. L.; Campbell, A.; Caterina, M. Neurosci. Lett. 2005, 378, 28-33). VR1 agonist-induced rises in core body temperature were suppressed by capsazepine, indicative of the usefulness of VR1 antagonists in the treatment of pyresis (Ohnluki, K.; Haramizu, S.; Watanabe, T.; Yazawa, S.; Fushiki, T. J. Nutr. Sci. Vitaminol. (Tokyo) 2001, 47, 295-298).
  • VR1 agonists also modulate body temperature and fever. In ferret, rat and mouse, administration of resiniferatoxin-induced hypothermia (Woods, A. J.; Stock, M. J.; Gupta, A. N.; Wong, T. T. L.; Andrews, P. L. R. Eur. J. Pharmacol. 1994, 264, 125-133). Additionally, phase I of LPS (lipopolysaccharide)-induced fever did not occur in animals desensitized with low intraperitoneal doses of capsaicin (Romanovsky, A. A. Frontiers in Bioscience 2004, 9, 494-504).
  • The therapeutic potential of VR1 antagonists in inflammatory bronchial conditions is demonstrated by the finding that they antagonize capsaicin- and acid-induced bronchoconstriction (Nault, M. A.; Vincent, S. G.; Fisher, J. T. J. Physiol. 1999, 515, 567-578). Related findings demonstrate that the VR1 antagonist capsazepine attenuates anandamide-induced cough in guinea pigs (Jia, Y.; McLeod, R. L.; Wang, X.; Parra, L. E.; Egan, R. W.; Hey, J. A. Brit. J. Pharmacol. 2002, 137, 831-836).
  • The VR1 antagonist capsazepine was demonstrated to significantly reduce anxiety-like behaviors in rats using the elevated plus maze (Kasckow, J. W.; Mulchahey, J. J.; Geracioti, T. D. Jr. Progress in Neuro-Psychopharmacol. and Biological Psychiatry 2004, 28, 291-295). Thus, VR1 antagonists may have utility in the treatment of anxiety, panic disorders, phobias or other non-adaptive stress responses.
  • U.S. Pat. No. 6,299,796B1 discloses electroluminescent elements comprising units of the formula:
  • Figure US20110190364A1-20110804-C00002
  • Thus, there is a need for potent modulators of VR1, and in particular, for novel benzimidazole compounds that exhibit potent binding affinity for the human and rat VR1 ion channel. There is also a need for novel benzimidazole compounds that act as potent functional antagonists and/or agonists of the human and rat VR1 ion channel. Finally, there is a need for novel benzimidazoles that bind with high affinity to VR1 and also act as potent functional antagonists of the human and rat VR1 ion channel.
    • SUMMARY OF THE INVENTION
  • The present invention is directed to a compound of Formula (I):
  • Figure US20110190364A1-20110804-C00003
  • and a form thereof, wherein R1, R2, R3a, R3b, R4, p, q, r, L and A1 are as defined herein, and their use as potent modulators of VR1.
  • The present invention is also directed to a method for treating a VR1 ion channel mediated disease in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I). The present invention is further directed to a process for making a compound of Formula (I) and salts thereof.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention is directed to compounds of Formula (I):
  • Figure US20110190364A1-20110804-C00004
  • and a form thereof, wherein:
    • the dashed lines between positions 1, 2 and 3 in Formula (I) indicate the positions of a tautomeric double bond,
    • wherein when a double bond is formed between positions 1 and 2, then R3b is present, and
    • wherein, when a double bond is formed between positions 2 and 3, then R3a is present;
    • p is 1 or 2;
    • q is 0 or 1;
    • r is 0, 1, 2 or 3;
    • L is C1-3alkyl, C2-3alkenyl, C2-3alkynyl or cyclopropyl;
    • A1 is selected from the group consisting of phenyl, biphenyl, naphthyl, pyridinyl, quinolinyl and indole;
    • R1 is each selected from the group consisting of hydroxy, cyano, halogen, formyl, carboxy, C1-6alkyl, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, C1-6alkylcarbonyl, C1-6alkoxycarbonyl, C1-6alkylthio, C1-6alkylsulfonyl, C3-8cycloalkyl, C3-8cycloalkyl-C1-4alkyl, C3-8cycloalkyl-C1-4alkoxy, C3-8cycloalkyl-oxy, amino, (C1-6alkyl)1-2-amino, (C3-8cycloalkyl)1-2-amino, (C3-8cycloalkyl-C1-4alkyl)1-2-amino, aminocarbonyl, (C1-6alkyl)1-2-aminocarbonyl, C1-6alkylcarbonylamino, C1-6alkoxycarbonylamino, aminocarbonylamino, (C1-6alkyl)1-2-aminocarbonylamino, C1-6alkylsulfonylamino, C1-6alkylsulfinylamino, aminosulfonyl, (C1-4alkyl)1-2-aminosulfonyl, aminosulfonylamino and (C1-6alkyl)1-2-aminosulfonylamino,
    • wherein alkyl is optionally substituted with C1-8alkoxy, amino, (C1-4alkyl)1-2-amino, C1-6alkylcarbonylamino, C1-6alkoxycarbonylamino, aminocarbonylamino, (C1-6alkyl)1-2-aminocarbonylamino, C1-6alkylsulfonylamino, aminosulfonylamino, (C1-6alkyl)1-2-aminosulfonylamino hydroxy and phenyl,
    • wherein phenyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halogen, cyano, nitro, C1-6alkyl, C1-6alkoxy, C1-6alkylthio and C1-6alkylsulfonyl, and
    • wherein, each instance of alkyl and alkoxy is optionally perfluorinated;
    • R2 is selected from the group consisting of halogen, C1-4alkyl, C1-4alkoxy, C1-4alkylsulfonyl, nitro, amino, (C1-4alkyl)1-2-amino and cyano, wherein each instance of alkyl and alkoxy is optionally perfluorinated;
    • R3a and R3b are each selected from the group consisting of hydrogen and optionally perfluorinated C1-4alkyl; and
    • R4 is each selected from the group consisting of halogen, nitro, cyano, carboxy, C1-6alkyl, C1-6alkoxy, haloC1-6alkyl, haloC1-6alkoxy, C1-6alkoxy-C1-6alkyl, C1-6alkylcarbonyl, C1-6alkylthio, haloC1-6alkylthio, C1-6alkylsulfonyl, haloC1-6alkylsulfonyl, C3-8cycloalkyl, C3-8cycloalkyl-C1-4alkyl, C3-8cycloalkyl-C1-4alkoxy, C3-8cycloalkyl-oxy, amino, (C1-6alkyl)1-2-amino, (C3-8cycloalkyl)1-2-amino, (C3-8cycloalkyl-C1-4alkyl)1-2-amino, aminocarbonyl, (C1-6alkyl)1-2-aminocarbonyl, C1-6alkylcarbonylamino, C1-6alkoxycarbonylamino, aminocarbonylamino, (C1-6alkyl)1-2-aminocarbonylamino, C1-6alkylsulfonylamino, haloC1-6alkylsulfonylamino, C1-6alkylsulfinylamino, aminosulfonyl and (C1-4alkyl)1-2-aminosulfonyl,
    • wherein each instance of alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of C1-8alkoxy, amino, (C1-4alkyl)1-2-amino, C1-6alkylcarbonylamino, C1-6alkoxycarbonylamino, aminocarbonylamino, (C1-6alkyl)1-2-aminocarbonylamino, C1-6alkylsulfonylamino, oxo and hydroxy, and
    • wherein, each instance of alkyl and alkoxy is optionally perfluorinated.
  • An example of the present invention includes a compound of Formula (I) or a form thereof, wherein q is 0.
  • An example of the present invention includes a compound of Formula (I) or a form thereof, wherein A1 is selected from the group consisting of phenyl, biphenyl, naphthyl, quinolinyl and indole.
  • An example of the present invention includes a compound of Formula (I) or a form thereof, wherein
    • R1 is each selected from the group consisting of hydroxy, halogen, formyl, C1-6alkyl, haloC1-6alkyl, haloC1-6alkoxy, C1-6alkylcarbonyl, C1-6alkoxycarbonyl, C1-6alkylthio, C1-6alkylsulfonyl, amino, aminocarbonyl, C1-6alkylcarbonylamino, C1-6alkoxycarbonylamino, C1-6alkylsulfonylamino, aminosulfonyl, (C1-4alkyl)1-2-aminosulfonyl and aminosulfonylamino,
    • wherein alkyl is optionally substituted with amino, (C1-4alkyl)1-2-amino, aminosulfonylamino or hydroxy, and wherein, alkyl is optionally perfluorinated.
  • An example of the present invention includes a compound of Formula (I) or a form thereof, wherein R2 is selected from the group consisting of halogen and C1-4alkyl, wherein alkyl is optionally perfluorinated.
  • An example of the present invention includes a compound of Formula (I) or a form thereof, wherein R3a and R3b are each selected from the group consisting of hydrogen and C1-4alkyl.
  • An example of the present invention includes a compound of Formula (I) or a form thereof, wherein R4 is each selected from the group consisting of halogen, carboxy, C1-6alkyl, C1-6alkoxy, haloC1-6alkyl, haloC1-6alkoxy, C1-6alkylcarbonyl, haloC1-6alkylthio, C1-6alkylsulfonyl, haloC1-6alkylsulfonyl, (C1-6alkyl)1-2-amino, (C1-6alkyl)1-2-aminocarbonyl, C1-6alkylcarbonylamino, C1-6alkylsulfonylamino and haloC1-6alkylsulfonylamino, wherein alkyl and alkoxy are optionally perfluorinated.
  • An example of the present invention includes a compound of Formula (I) or a form thereof, wherein
    • p is 1 or 2;
    • q is 0;
    • r is 0, 1, 2 or 3;
    • L is C1-3alkyl, C2-3alkenyl, C2-3alkynyl or cyclopropyl;
    • A1 is selected from the group consisting of phenyl, biphenyl, naphthyl, quinolinyl and indole;
    • R1 is each selected from the group consisting of hydroxy, halogen, formyl, C1-6alkyl, haloC1-6alkyl, haloC1-6alkoxy, C1-6alkylcarbonyl, C1-6alkoxycarbonyl, C1-6alkylthio, C1-6alkylsulfonyl, amino, aminocarbonyl, C1-6alkylcarbonylamino, C1-6alkoxycarbonylamino, C1-6alkylsulfonylamino, aminosulfonyl, (C1-4alkyl)1-2-aminosulfonyl and aminosulfonylamino,
    • wherein alkyl is optionally substituted with amino, (C1-4alkyl)1-2-amino, aminosulfonylamino or hydroxy, and wherein, alkyl is optionally perfluorinated;
    • R2 is selected from the group consisting of halogen and C1-4alkyl, wherein alkyl is optionally perfluorinated;
    • R3a and R3b are each selected from the group consisting of hydrogen and C1-4alkyl; and
    • R4 is each selected from the group consisting of halogen, carboxy, C1-6alkyl, C1-6alkoxy, haloC1-6alkyl, haloC1-6alkoxy, C1-6alkylcarbonyl, haloC1-6alkylthio, C1-6alkylsulfonyl, haloC1-6alkylsulfonyl, (C1-6alkyl)1-2-amino, (C1-6alkyl)1-2-aminocarbonyl, C1-6alkylcarbonylamino, C1-6alkylsulfonylamino and haloC1-6alkylsulfonylamino, wherein alkyl and alkoxy are optionally perfluorinated.
  • The present invention is further directed to compounds of Formula Ia or Ib:
  • Figure US20110190364A1-20110804-C00005
  • wherein:
    • R1 is independently hydroxyl; halogen, C1-6alkanyl; fluorinated C1-6alkanyl; C1-6alkanyloxy; fluorinated C1-6alkanyloxy; C1-6alkanylthio; fluorinated C1-6alkanylthio; C1-6alkanylsulfonyl; fluorinated C1-6alkanylsulfonyl; C3-8cycloalkanyl; C3-8cycloalkanyl; C1-4alkanyl; C3-8cycloalkanyloxy; C3-8cycloalkanyl; C1-4alkanyloxy; amino; (C1-6alkanyl)1-2-amino; (C3-8cycloalkanyl)1-2-amino; (C3-8cycloalkanyl; C1-4alkanyl)1-2-amino; cyano; aminocarbonyl; (C1-6alkanyl)1-2-aminocarbonyl; C1-6alkanylcarbonylamino; fluorinated C1-6alkanylcarbonylamino; C1-6alkanyloxycarbonylamino; C0-6alkanylaminocarbonylamino; C1-6alkanylsulfonylamino; fluorinated C1-6alkanylsulfonylamino; aminosulfonyl; (C1-8alkanyl)1-2-aminosulfonyl; fluorinated (C1-8alkanyl)1-2-aminosulfonyl; wherein the alkanyl in any alkanyl-containing substituent of R1 is optionally substituted with 1 to 3 substituents independently selected from the group consisting of amino, (C1-8alkanyl)1-2-amino, C1-6alkanylcarbonylamino; fluorinated C1-6alkanylcarbonylamino; C1-6alkanyloxycarbonylamino; C0-6alkanylaminocarbonylamino; C1-6alkanylsulfonylamino; fluorinated C1-6alkanylsulfonylamino; halogen, oxo, hydroxyl, fluorinated alkanyl, and C1-8alkanyloxy;
    • p is 1 or 2;
    • R2 is independently selected from the group consisting of halogen; C1-4alkanyl; fluorinated C1-4alkanyl; C1-4alkanyloxy; fluorinated C1-6alkanyloxy; C1-4alkanylsulfonyl; fluorinated C1-4alkanylsulfonyl; nitro; (C1-4alkanyl)1-2-amino; cyano;
    • n is 0, or 1;
    • R3 is independently selected from the group consisting of hydrogen, C1-4alkanyl, and fluorinated C1-4alkanyl;
    • L is C2-3alkyldiyl,
    • A1 is selected from the group consisting of phenyl and naphthyl;
    • R4 is independently halogen, C1-6alkanyl; fluorinated C1-6alkanyl; C1-6alkanyloxy; fluorinated C1-6alkanyloxy; C1-6alkanylthio; fluorinated C1-6alkanylthio; C1-6alkanylsulfonyl; fluorinated C1-6alkanylsulfonyl; C3-8cycloalkanyl; C3-8cycloalkanyl; C1-4alkanyl; C3-8cycloalkanyloxy; C3-8cycloalkanyl; C1-4alkanyloxy; amino; (C1-6alkanyl)1-2-amino; (C3-8cycloalkanyl)1-2-amino; (C3-8cycloalkanyl; C1-4alkanyl)1-2-amino; cyano; aminocarbonyl; (C1-6alkanyl)1-2-aminocarbonyl; C0-6alkanylcarbonylamino; fluorinated C1-6alkanylcarbonylamino; C1-6alkanyloxycarbonylamino; C0-6alkanylaminocarbonylamino; C1-6alkanylsulfonylamino; fluorinated C1-6alkanylsulfonylamino; aminosulfonyl; (C1-8alkanyl)1-2-aminosulfonyl; fluorinated (C1-8alkanyl)1-2-aminosulfonyl; wherein the alkanyl in any alkanyl-containing substituent of R1 is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, oxo, hydroxyl, fluorinated alkanyl, and C1-8alkanyloxy; phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen; C1-4alkanyl; fluorinated C1-4alkanyl; C1-4alkanyloxy; fluorinated C1-4alkanyloxy; C1-4alkanylsulfonyl; fluorinated C1-4alkanylsulfonyl; nitro; cyano;
    • r is 0, 1 or 2; and
    • enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.
  • An example of the present invention includes compounds and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof selected from the group consisting of:
  • Figure US20110190364A1-20110804-C00006
    Figure US20110190364A1-20110804-C00007
    Figure US20110190364A1-20110804-C00008
    Figure US20110190364A1-20110804-C00009
    Figure US20110190364A1-20110804-C00010
    Figure US20110190364A1-20110804-C00011
    Figure US20110190364A1-20110804-C00012
    Figure US20110190364A1-20110804-C00013
    Figure US20110190364A1-20110804-C00014
    Figure US20110190364A1-20110804-C00015
    Figure US20110190364A1-20110804-C00016
    Figure US20110190364A1-20110804-C00017
    Figure US20110190364A1-20110804-C00018
    Figure US20110190364A1-20110804-C00019
    Figure US20110190364A1-20110804-C00020
    Figure US20110190364A1-20110804-C00021
    Figure US20110190364A1-20110804-C00022
    Figure US20110190364A1-20110804-C00023
    Figure US20110190364A1-20110804-C00024
    Figure US20110190364A1-20110804-C00025
    Figure US20110190364A1-20110804-C00026
    Figure US20110190364A1-20110804-C00027
    Figure US20110190364A1-20110804-C00028
    Figure US20110190364A1-20110804-C00029
    Figure US20110190364A1-20110804-C00030
    Figure US20110190364A1-20110804-C00031
    Figure US20110190364A1-20110804-C00032
    Figure US20110190364A1-20110804-C00033
    Figure US20110190364A1-20110804-C00034
    Figure US20110190364A1-20110804-C00035
    Figure US20110190364A1-20110804-C00036
    Figure US20110190364A1-20110804-C00037
    Figure US20110190364A1-20110804-C00038
    Figure US20110190364A1-20110804-C00039
    Figure US20110190364A1-20110804-C00040
    Figure US20110190364A1-20110804-C00041
    Figure US20110190364A1-20110804-C00042
    Figure US20110190364A1-20110804-C00043
    Figure US20110190364A1-20110804-C00044
    Figure US20110190364A1-20110804-C00045
    Figure US20110190364A1-20110804-C00046
    Figure US20110190364A1-20110804-C00047
    Figure US20110190364A1-20110804-C00048
    Figure US20110190364A1-20110804-C00049
    Figure US20110190364A1-20110804-C00050
    Figure US20110190364A1-20110804-C00051
    Figure US20110190364A1-20110804-C00052
    Figure US20110190364A1-20110804-C00053
    Figure US20110190364A1-20110804-C00054
    Figure US20110190364A1-20110804-C00055
    Figure US20110190364A1-20110804-C00056
    Figure US20110190364A1-20110804-C00057
    Figure US20110190364A1-20110804-C00058
    Figure US20110190364A1-20110804-C00059
    Figure US20110190364A1-20110804-C00060
    Figure US20110190364A1-20110804-C00061
    Figure US20110190364A1-20110804-C00062
    Figure US20110190364A1-20110804-C00063
    Figure US20110190364A1-20110804-C00064
    Figure US20110190364A1-20110804-C00065
    Figure US20110190364A1-20110804-C00066
    Figure US20110190364A1-20110804-C00067
    Figure US20110190364A1-20110804-C00068
    Figure US20110190364A1-20110804-C00069
    Figure US20110190364A1-20110804-C00070
    Figure US20110190364A1-20110804-C00071
    Figure US20110190364A1-20110804-C00072
    Figure US20110190364A1-20110804-C00073
    Figure US20110190364A1-20110804-C00074
    Figure US20110190364A1-20110804-C00075
    Figure US20110190364A1-20110804-C00076
    Figure US20110190364A1-20110804-C00077
    Figure US20110190364A1-20110804-C00078
    Figure US20110190364A1-20110804-C00079
    Figure US20110190364A1-20110804-C00080
    Figure US20110190364A1-20110804-C00081
    Figure US20110190364A1-20110804-C00082
    Figure US20110190364A1-20110804-C00083
    Figure US20110190364A1-20110804-C00084
    Figure US20110190364A1-20110804-C00085
    Figure US20110190364A1-20110804-C00086
    Figure US20110190364A1-20110804-C00087
    Figure US20110190364A1-20110804-C00088
    Figure US20110190364A1-20110804-C00089
    Figure US20110190364A1-20110804-C00090
    Figure US20110190364A1-20110804-C00091
    Figure US20110190364A1-20110804-C00092
    Figure US20110190364A1-20110804-C00093
    Figure US20110190364A1-20110804-C00094
    Figure US20110190364A1-20110804-C00095
    Figure US20110190364A1-20110804-C00096
    Figure US20110190364A1-20110804-C00097
    Figure US20110190364A1-20110804-C00098
    Figure US20110190364A1-20110804-C00099
    Figure US20110190364A1-20110804-C00100
    Figure US20110190364A1-20110804-C00101
    Figure US20110190364A1-20110804-C00102
    Figure US20110190364A1-20110804-C00103
    Figure US20110190364A1-20110804-C00104
    Figure US20110190364A1-20110804-C00105
    Figure US20110190364A1-20110804-C00106
    Figure US20110190364A1-20110804-C00107
    Figure US20110190364A1-20110804-C00108
    Figure US20110190364A1-20110804-C00109
    Figure US20110190364A1-20110804-C00110
    Figure US20110190364A1-20110804-C00111
    Figure US20110190364A1-20110804-C00112
    Figure US20110190364A1-20110804-C00113
    Figure US20110190364A1-20110804-C00114
    Figure US20110190364A1-20110804-C00115
    Figure US20110190364A1-20110804-C00116
    Figure US20110190364A1-20110804-C00117
    Figure US20110190364A1-20110804-C00118
    Figure US20110190364A1-20110804-C00119
    Figure US20110190364A1-20110804-C00120
    Figure US20110190364A1-20110804-C00121
    Figure US20110190364A1-20110804-C00122
    Figure US20110190364A1-20110804-C00123
    Figure US20110190364A1-20110804-C00124
    Figure US20110190364A1-20110804-C00125
    Figure US20110190364A1-20110804-C00126
    Figure US20110190364A1-20110804-C00127
    Figure US20110190364A1-20110804-C00128
    Figure US20110190364A1-20110804-C00129
    Figure US20110190364A1-20110804-C00130
    Figure US20110190364A1-20110804-C00131
    Figure US20110190364A1-20110804-C00132
    Figure US20110190364A1-20110804-C00133
    Figure US20110190364A1-20110804-C00134
    Figure US20110190364A1-20110804-C00135
    Figure US20110190364A1-20110804-C00136
    Figure US20110190364A1-20110804-C00137
    Figure US20110190364A1-20110804-C00138
    Figure US20110190364A1-20110804-C00139
    Figure US20110190364A1-20110804-C00140
    Figure US20110190364A1-20110804-C00141
    Figure US20110190364A1-20110804-C00142
    Figure US20110190364A1-20110804-C00143
    Figure US20110190364A1-20110804-C00144
    Figure US20110190364A1-20110804-C00145
    Figure US20110190364A1-20110804-C00146
    Figure US20110190364A1-20110804-C00147
    Figure US20110190364A1-20110804-C00148
    Figure US20110190364A1-20110804-C00149
    Figure US20110190364A1-20110804-C00150
    Figure US20110190364A1-20110804-C00151
    Figure US20110190364A1-20110804-C00152
    Figure US20110190364A1-20110804-C00153
    Figure US20110190364A1-20110804-C00154
    Figure US20110190364A1-20110804-C00155
    Figure US20110190364A1-20110804-C00156
    Figure US20110190364A1-20110804-C00157
    Figure US20110190364A1-20110804-C00158
    Figure US20110190364A1-20110804-C00159
    Figure US20110190364A1-20110804-C00160
    Figure US20110190364A1-20110804-C00161
    Figure US20110190364A1-20110804-C00162
    Figure US20110190364A1-20110804-C00163
    Figure US20110190364A1-20110804-C00164
    Figure US20110190364A1-20110804-C00165
    Figure US20110190364A1-20110804-C00166
    Figure US20110190364A1-20110804-C00167
    Figure US20110190364A1-20110804-C00168
    Figure US20110190364A1-20110804-C00169
    Figure US20110190364A1-20110804-C00170
    Figure US20110190364A1-20110804-C00171
  • As modulators of the vanilloid VR1 ion channel, the compounds of Formula (I) are useful in methods for treating a VR1 ion channel mediated disease in a subject which disease is affected by the modulation of one or more vanilloid receptors.
  • Accordingly, the present invention is directed to a method of treating a VR1 ion channel mediated disease in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I) or a salt or solvate thereof.
    • Compound Forms
  • The term “form” means, in reference to compounds of the present invention, such may exist as, without limitation, a salt, stereoisomer, tautomer, crystalline, polymorph, amorphous, solvate, hydrate, ester, prodrug or metabolite form. The present invention encompasses all such compound forms and mixtures thereof.
  • The term “isolated form” means, in reference to compounds of the present invention, that such may exist in an essentially pure state such as, without limitation, an enantiomer, a racemic mixture, a geometric isomer (such as a cis or trans stereoisomer), a mixture of geometric isomers, and the like. The present invention encompasses all such isolated forms and mixtures thereof.
  • Certain compounds of Formula (I) may exist in various stereoisomeric or tautomeric forms and mixtures thereof. The invention encompasses all such compounds and mixtures thereof.
  • The compounds of the present invention may be present in the form of pharmaceutically acceptable salts. For use in medicines, the “pharmaceutically acceptable salts” of the compounds of this invention refer to non-toxic acidic/anionic or basic/cationic salt forms.
  • Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
  • Furthermore when the compounds of the present invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic ligands, e.g. quaternary ammonium salts.
  • Thus, representative pharmaceutically acceptable salts include the following: acetate, adipate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium, camsylate (or camphorsulphonate), carbonate, chloride, choline, clavulanate, citrate, dihydrochloride, disodium, edetate, fumarate, gluconate, glutamate, hydrabamine, hydrobromine, hydrochloride, iodide, isothionate, lactate, malate, maleate, mandelate, mesylate, nitrate, oleate, pamoate, palmitate, phosphate/diphosphate, salicylate, sodium, stearate, sulfate, succinate, tartrate, tromethane, tosylate, trichloroacetate, trifluoroacetate and the like.
  • An example of the present invention includes compounds of Formula (I) and a salt form thereof wherein the salt is selected from the group consisting of disodium, hydrochloride and sodium.
  • The invention includes compounds of various isomers and mixtures thereof. The term “isomer” refers to compounds that have the same composition and molecular weight but differ in physical and/or chemical properties. Such substances have the same number and kind of atoms but differ in structure. The structural difference may be in constitution (geometric isomers) or in an ability to rotate the plane of polarized light (stereoisomers).
  • The term “optical isomer” means isomers of identical constitution that differ only in the spatial arrangement of their groups. Optical isomers rotate the plane of polarized light in different directions. The term “optical activity” means the degree to which an optical isomer rotates the plane of polarized light.
  • The term “racemate” or “racemic mixture” means an equimolar mixture of two enantiomeric species, wherein each of the isolated species rotates the plane of polarized light in the opposite direction such that the mixture is devoid of optical activity.
  • The term “enantiomer” means an isomer having a nonsuperimposable mirror image. The term “diastereomer” means stereoisomers that are not enantiomers.
  • The term “chiral” means a molecule, which in a given configuration, cannot be superimposed on its mirror image. This is in contrast to achiral molecules, which can be superimposed on their mirror images.
  • The invention is considered to include the tautomeric forms of all compounds of Formula (I). In addition, for chiral embodiments of the invention, the invention is considered to include pure enantiomers, racemic mixtures, as well as mixtures of enantiomers having 0.001% to 99.99% enantiomeric excess. In addition, some of the compounds represented by Formula (I) may be prodrugs, i.e., derivatives of a drug that possess superior delivery capabilities and therapeutic value as compared to the active drug. Prodrugs are transformed into active drugs by in vivo enzymatic or chemical processes.
  • The two distinct mirror image versions of the chiral molecule are also known as levo (left-handed), abbreviated L, or dextro (right handed), abbreviated D, depending on which way they rotate polarized light. The symbols “R” and “S” represent the configuration of groups around a stereogenic carbon atom(s).
  • An example of an enantiomerically enriched form isolated from a racemic mixture includes a dextrorotatory enantiomer, wherein the mixture is substantially free of the levorotatory isomer. In this context, substantially free means the levorotatory isomer may, in a range, comprise less than 25% of the mixture, less than 10%, less than 5%, less than 2% or less than 1% of the mixture according to the formula:
  • % levorotatory = ( mass levorotatory ) ( mass dextrorotatory ) + ( mass levorotatory ) × 100
  • Similarly, an example of an enantiomerically enriched form isolated from a racemic mixture includes a levorotatory enantiomer, wherein the mixture is substantially free of the dextrorotatory isomer. In this context, substantially free means the dextrorotatory isomer may, in a range, comprise less than 25% of the mixture, less than 10%, less than 5%, less than 2% or less than 1% of the mixture according to the formula:
  • % dextrorotatory = ( mass dextrorotatory ) ( mass dextrorotatory ) + ( mass levorotatory ) × 100
  • “Geometric isomer” means isomers that differ in the orientation of substituent atoms in relationship to a carbon-carbon double bond, to a cycloalkyl ring, or to a bridged bicyclic system. Substituent atoms (other than hydrogen) on each side of a carbon-carbon double bond may be in an E or Z configuration. In the “E” configuration, the substituents are on opposite sides in relationship to the carbon-carbon double bond. In the “Z” configuration, the substituents are oriented on the same side in relationship to the carbon-carbon double bond. The scope of the present invention is intended to include all such “E” and “Z” isomers.
  • Substituent atoms (other than hydrogen) attached to a ring system may be in a cis or trans configuration. In the “cis” configuration, the substituents are on the same side in relationship to the plane of the ring; in the “trans” configuration, the substituents are on opposite sides in relationship to the plane of the ring. Compounds having a mixture of “cis” and “trans” species are designated “cis/trans”. The scope of the present invention is intended to include all such “cis” and “trans” isomers.
  • The isomeric descriptors (“R,” “S,” “E,” and “Z”) indicate atom configurations relative to a core molecule and are intended to be used as defined in the literature.
  • Furthermore, compounds of the present invention may have at least one crystalline, polymorph or amorphous form. The plurality of such forms is included in the scope of the invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents (e.g., organic esters such as ethanolate and the like). The plurality of such solvates is also intended to be encompassed within the scope of this invention.
    • Chemical Nomenclature and Definitions
  • Bond lines drawn into a ring system from a substituent variable indicate that the substituent may be attached to any of the substitutable ring atoms.
  • As used herein, the following terms are intended to have the following meanings (additional definitions are provided where prophetic throughout the Specification). The definitions herein may specify that a chemical term has an indicated formula. The particular formula provided is not intended to limit the scope of the invention, but is provided as an illustration of the term and is intended to include the plurality of variations expected to be included by one of ordinary skill in the art.
    • Definitions
  • The term “C1-6alkyl” or “alkyl” means a straight or branched chain hydrocarbon alkyl radical, comprising from 1 to 6 carbon atoms. Non-limiting examples include methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, tertiary butyl (also referred to as t-butyl or tert-butyl), 1-pentyl, 2-pentyl, 3-pentyl, 1-hexyl, 2-hexyl, 3-hexyl and the like. The term further includes alkyl groups in any combination thereof (e.g. C1-2, C1-3, C1-4 and the like). An alkyl radical may be attached to a core molecule where allowed by available valences.
  • The terms “C2-3alkenyl” and “C2-3alkynyl” mean straight or branched carbon chains having 2 to 3 carbon atoms, wherein a C2-3alkenyl chain has at least one double bond in the chain and a C2-3alkynyl chain has at least one triple bond in the chain. An alkenyl and alkynyl radical may be attached to a core molecule where allowed by available valences.
  • The term “C1-6alkoxy” or “alkoxy” means a straight or branched chain hydrocarbon alkyl radical or alkyldiyl linking group of the formula —O—C1-6alkyl, comprising from 1 to 6 carbon atoms. Examples include methoxy, ethoxy, propoxy, isopropoxy, butoxy and the like. The term further includes alkoxy groups in any combination thereof (e.g. C1-2, C1-3, C1-4 and the like). An alkoxy radical may be attached to a core molecule where allowed by available valences.
  • The term “cycloalkyl” refers to a saturated or partially unsaturated, monocyclic, polycyclic or benzofused hydrocarbon ring system composed of from 3 to 14 carbon atoms. Except when specified, the term includes a C3-8cycloalkyl, C3-10cycloalkyl, C5-6cycloalkyl, C5-8cycloalkyl, C5-12cycloalkyl, C8-10cycloalkyl, C9-13cycloalkyl, C3-14cycloalkyl or benzofused C3-14cycloalkyl ring system. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, 1H-indenyl, indanyl, adamantanyl, 9H-fluorenyl, 1,2,3,4-tetrahydro-naphthalenyl, acenaphthenyl, bicyclo[2.2.1]heptenyl and the like. C3-14cycloalkyl radicals may be attached to a core molecule and further substituted on any atom when allowed by available valences.
  • The term “benzofused,” used as a prefix for a ring system, means a radical formed by any ring system radical fused with a benzene ring. The benzofused radical may be attached to a core molecule via either ring of the bicyclic system and further substituted on any atom where allowed by available valences.
  • The term “aryl” refers to monocyclic or bicyclic aromatic ring systems containing from 6 to 12 carbons in the ring. Examples include phenyl, biphenyl, naphthalene, azulenyl, anthracenyl and the like. Aryl radicals may be attached to a core molecule and further substituted on any atom when allowed by available valences.
  • The term “aromatic” refers to a cycloalkylic hydrocarbon ring system having an unsaturated, conjugated π electron system.
  • The term “hetero,” used as a prefix for a ring system, refers to the replacement of at least one ring carbon atom with one or more heteroatoms independently selected from a nitrogen, oxygen or sulfur atom, wherein the nitrogen and sulfur atoms can exist in any allowed oxidation state. Examples include rings wherein 1, 2, 3 or 4 ring members are a nitrogen atom; or, 0, 1, 2 or 3 ring members are nitrogen atoms and 1 member is an oxygen or sulfur atom. When allowed by available valences, up to two adjacent ring members may be heteroatoms; wherein one heteroatom is nitrogen and the other is one heteroatom selected from N, S or O.
  • The term “heterocyclyl” refers to a nonaromatic (i.e. saturated or partially unsaturated) monocyclic, polycyclic or benzofused ring system radical. Heteroatom ring members are selected from at least one of N, O, S, S(O) or SO2, wherein the nitrogen and sulfur atoms can exist in any allowed oxidation state. Examples include 2H-pyrrole, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, 2-imidazolinyl (also referred to as 4,5-dihydro-1H-imidazolyl), imidazolidinyl, 2-pyrazolinyl, pyrazolidinyl, oxazolidinyl, tetrazolinyl, tetrazolidinyl, piperidinyl, morpholinyl, 1,4-dithianyl, thiomorpholinyl, piperazinyl, azetidinyl, azepanyl, dihydro-pyranyl, tetrahydro-furanyl, tetrahydro-thienyl, tetrahydro-pyranyl, tetrahydro-pyridazinyl, hexahydro-1,4-diazepinyl, hexahydro-1,4-oxazepanyl, 1,3-dioxolanyl, 1,4-dioxanyl, 1,3-benzodioxolyl (also referred to as benzo[1,3]dioxolyl), 2,3-dihydro-1,4-benzodioxinyl (also referred to as 2,3-dihydro-benzo[1,4]dioxinyl) and the like. Heterocyclyl radicals may be attached to a core molecule and further substituted on any atom when allowed by available valences.
  • The term “heteroaryl” means an aromatic monocyclic, polycyclic or benzofused ring system radical. Heteroatom ring members are selected from at least one of N, O, S, S(O) or SO2, wherein the nitrogen and sulfur atoms can exist in any allowed oxidation state.
  • Examples include furanyl, thienyl, pyrrolyl, pyrazolyl, 1H-imidazolyl, isothiazolyl, isoxazolyl, oxazolyl, thiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, 1H-tetrazolyl, 2H-tetrazolyl, 1H-[1,2,3]triazolyl, 2H-[1,2,3]triazolyl, 4H-[1,2,4]triazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, indolyl, azaindolyl, indazolyl, azaindazolyl, isoindolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, benzoisoxazolyl, benzothiadiazolyl, benzotriazolyl, purinyl, 4H-quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalzinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl and the like. Heteroaryl radicals may be attached to a core molecule and further substituted on any atom when allowed by available valences.
  • The term “C1-6alkoxy-C1-6alkyl” means a radical of the formula: —C1-6alkyl-O—C1-6alkyl.
  • The term “C1-6alkoxycarbonyl” means a radical of the formula: —C(O)—O—C1-6alkyl. Examples include C1-4alkoxycarbonyl.
  • The term “C1-6alkoxycarbonylamino” means a radical of the formula: —NH—C(O)—O—C1-6alkyl. Examples include C1-4alkylcarbonylamino.
  • The term “(C1-6alkyl)1-2-amino” means a radical of the formula: —NH—C1-6alkyl or —N(C1-6alkyl)2. Examples include (C1-4alkyl)1-2-amino.
  • The term “(C1-6alkyl)1-2-amino-C1-6alkyl” means a radical of the formula: —C1-6alkyl-NH—C1-6alkyl or —C1-6alkyl-N(C1-6alkyl)2. Examples include (C1-4alkyl)1-2-amino-C1-6alkyl.
  • The term “(C1-6alkyl)1-2-aminocarbonyl” means a radical of the formula: —C(O)—NH—C1-6alkyl or —C(O)—N(C1-6alkyl)2. Examples include (C1-4alkyl)1-2-aminocarbonyl.
  • The term “(C1-6alkyl)1-2-aminocarbonylamino” means a radical of the formula: —NH—C(O)—NH—C1-6alkyl or —NH—C(O)—N(C1-6alkyl)2. Examples include (C1-4alkyl)1-2-aminocarbonylamino.
  • The term “(C1-4alkyl)1-2-aminosulfonyl” means a radical of the formula: —SO2—NH—C1-4alkyl or —SO2—N(C1-4alkyl)2.
  • The term “C1-6alkylcarbonyl” means a radical of the formula: —C(O)—C1-6alkyl. Examples include C1-4alkylcarbonyl.
  • The term “C1-6alkylcarbonylamino” means a radical of the formula: —NH—C(O)—C1-6alkyl. Examples include C1-4alkylcarbonylamino.
  • The term “C1-6alkylsulfonyl” means a radical of the formula: —SO2—C1-6alkyl. Examples include C1-4alkylsulfonyl.
  • The term “C1-6alkylsulfinylamino” means a radical of the formula: —NH—S(O)—C1-6alkyl.
  • The term “C1-6alkylsulfonylamino” means a radical of the formula: —NH—SO2—C1-6alkyl.
  • The term “C1-6alkylthio” means a radical of the formula: —S—C1-6alkyl. Examples include C1-4alkylthio.
  • The term “amino” means a radical of the formula: —NH2.
  • The term “amino-C1-6alkyl” means a radical of the formula: —C1-6alkyl-NH2.
  • The term “aminocarbonyl” means a radical of the formula: —C(O)—NH2.
  • The term “aminocarbonylamino” means a radical of the formula: —NH—C(O)—NH2.
  • The term “aminosulfonyl” means a radical of the formula: —SO2—NH2.
  • The term “aminosulfonylamino” means a radical of the formula: —NH—SO2—NH2.
  • The term “(C1-6alkyl)1-2-aminosulfonylamino” means a radical of the formula: —NH—SO2—NH—C1-6alkyl or —NH—SO2—N(C1-6alkyl)2. Examples include (C1-4alkyl)1-2-aminosulfonylamino.
  • The term “aminosulfonylamino-C1-6alkyl” means a radical of the formula: —C1-6alkyl-NH—SO2—NH2.
  • The term “(C1-6alkyl)1-2-aminosulfonylamino-C1-6alkyl” means a radical of the formula: —C1-6alkyl-NH—SO2—NH—C1-6alkyl or —C1-6alkyl-NH—SO2—N(C1-6alkyl)2.
  • The term “carboxy” means a radical of the formula: —C(O)OH.
  • The term “C3-8cycloalkyl-C1-6alkyl” means a radical of the formula: —C1-6alkyl-C3-8cycloalkyl. Examples include C3-8cycloalkyl-C1-4alkyl.
  • The term “C3-8cycloalkyl-C1-6alkoxy” means a radical of the formula: —O—C1-6alkyl-C3-8cycloalkyl. Examples include C3-8cycloalkyl-C1-4alkoxy.
  • The term “C3-8cycloalkyl-oxy” means a radical of the formula: —O—C3-8cycloalkyl.
  • The term “(C3-8cycloalkyl)1-2-amino” means a radical of the formula: —NH—(C3-8cycloalkyl) or —N(C3-8cycloalkyl)2.
  • The term “(C3-8cycloalkyl-C1-4alkyl)1-2-amino” means a radical of the formula: —NH—C1-4alkyl-C3-8cycloalkyl or —N(C1-4alkyl-C3-8cycloalkyl)2.
  • The term “formyl” means a radical of the formula: —C(O)H.
  • The term “oxo” means a radical of the formula: ═O.
  • The term “halogen” or “halo” means the group chloro, bromo, fluoro or iodo.
  • The term “haloC1-6alkyl” means a radical of the formula: —C1-6alkyl(halo)n, wherein “n” represents that amount of available valences on C1-6alkyl, which may be substituted with one or more halogen atoms while remaining stable. Examples include difluoromethyl, trifluoromethyl, trifluoroethyl, chloromethyl and the like.
  • The term “haloC1-6alkoxy” means a radical of the formula: —O—C1-6alkyl(halo)n, wherein “n” represents that amount of available valences on C1-6alkoxy, which may be substituted with one or more halogen atoms while remaining stable. Examples include difluoromethoxy, trifluoromethoxy, trifluoroethoxy, chloromethoxy and the like.
  • The term “haloC1-6alkylsulfonyl” means a radical of the formula: —SO2—C1-6alkyl(halo)n, wherein “n” represents that amount of available valences on C1-6alkyl, which may be substituted with one or more halogen atoms while remaining stable. Examples include trifluoromethylsulfonyl and the like.
  • The term “haloC1-6alkylsulfonylamino” means a radical of the formula: —NH—SO2—C1-6alkyl(halo)n, wherein “n” represents that amount of available valences on C1-6alkyl, which may be substituted with one or more halogen atoms while remaining stable. Examples include trifluoromethylsulfonyl and the like.
  • The term “haloC1-6alkylthio” means a radical of the formula: —S—C1-6alkyl(halo)n, wherein “n” represents that amount of available valences on C1-6alkyl, which may be substituted with one or more halogen atoms while remaining stable. Examples include trifluoromethylsulfonyl and the like.
  • The term “perfluorinated” means a radical that is substituted with fluoro atoms to the extent allowed by available valences while remaining stable.
  • The term “substituted,” refers to a core molecule on which one or more hydrogen atoms have been replaced with one or more functional radical moieties. The number that is allowed by available valences limits the amount of substituents. Substitution is not limited to the core molecule, but may also occur on a substituent radical, whereby the substituent radical becomes a linking group.
    • Therapeutic Use
  • As modulators of the vanilloid VR1 ion channel, the compounds of Formula (I) are useful in methods for treating a VR1 ion channel mediated disease in a subject which disease is affected by the modulation of one or more vanilloid receptors.
  • Accordingly, the present invention is directed to a method of treating a VR1 ion channel mediated disease in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I) or a salt or solvate thereof.
  • The term “VR1 ion channel mediated disease” refers to chronic or acute pain due to disease that causes inflammatory pain, burning pain or post-operative pain.
  • An example of a use of the compound of Formula (I) or a salt or solvate thereof includes use in the manufacture of a medicament for treating a VR1 ion channel mediated disease, wherein the VR1 ion channel mediated disease is chronic or acute pain due to disease that causes inflammatory pain, burning pain or post-operative pain.
  • An example of a use of the compound of Formula (I) or a salt or solvate thereof includes use as a medicine for treating a VR1 ion channel mediated disease, wherein the VR1 ion channel mediated disease is chronic or acute pain due to disease that causes inflammatory pain, burning pain or post-operative pain.
  • The term “prodrug” means a compound of Formula (I) or a form thereof that is converted in vivo into a functional derivative form that may contribute to therapeutic biological activity, wherein the converted form may be: 1) a relatively active form; 2) a relatively inactive form; 3) a relatively less active form; or, 4) any form which results, directly or indirectly, from such in vivo conversions.
  • Prodrugs are useful when said compound may be either too toxic to administer systemically, absorbed poorly by the digestive tract or broken down by the body before it reaches its target. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described in, for example, “Design of Prodrugs”, ed. H. Bundgaard, Elsevier, 1985.
  • The term “metabolite” means a form of a compound of Formula (I) or a form thereof converted by in vivo metabolism or a metabolic process to a derivative of said compound.
  • The term “subject” as used herein, refers to a patient, such as an animal, a mammal or a human, who has been the object of treatment, observation or experiment and is at risk of (or susceptible to) developing a disease that has or will result in VR1 ion channel mediated chronic or acute pain, wherein the pain caused by the disease is inflammatory pain, burning pain or post-operative pain.
  • The term “effective amount” refers to that amount of a compound of Formula (I) or a form, pharmaceutical composition, medicine or medicament thereof that elicits the biological or medicinal response (such as inhibiting, preventing or ameliorating VR1 ion channel mediated chronic or acute pain) in a tissue system, animal or human, that is being sought by a researcher, veterinarian, medical doctor, or other clinician, which includes alleviation of the symptoms of the inflammatory pain, burning pain or post-operative pain being treated.
  • The effective amount of a compound of Formula (I) or a form thereof is from about 0.001 mg/kg/day to about 300 mg/kg/day.
  • The term “pharmaceutical composition” refers to a product containing a compound of Formula (I) or a form thereof, such as a product comprising the specified ingredients in the specified amounts, as well as any product that results, directly or indirectly, from such combinations of the specified ingredients in the specified amounts.
  • The term “medicament” or “medicine” refers to a product containing a compound of Formula (I) or a form thereof. The present invention includes use of such a medicament for treating VR1 ion channel mediated chronic or acute pain.
  • The term “pharmaceutically acceptable” refers to molecular entities and compositions that are of sufficient purity and quality for use in the formulation of a pharmaceutical composition, medicine or medicament of the present invention. Since both human use (clinical and over-the-counter) and veterinary use are equally included within the scope of the present invention, a pharmaceutically acceptable formulation would include a pharmaceutical composition, medicine or medicament for either human or veterinary use.
  • The term “treating” refers, without limitation, inhibiting, ameliorating, facilitating the eradication of, inhibiting the progression of or promoting the stasis of VR1 ion channel mediated chronic or acute pain.
  • For oral administration, the pharmaceutical composition, medicine or medicament is preferably in the form of a tablet containing, e.g., 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 150, 200, 250 and 500 milligrams of a compound of formula (I) or a form thereof for the symptomatic adjustment of the dosage to the patient to be treated. Optimal dosages will vary depending on factors associated with the particular patient being treated (e.g., age, weight, diet and time of administration), the severity of the condition being treated, the particular compound being used, the mode of administration and the strength of the preparation. The use of either daily administration or post-periodic dosing may be employed.
  • A representative compound of Formula (I) or a form thereof includes a compound selected from the group consisting of:
  • Cpd Name
    1 (E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
    2 (E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanol,
    3 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,
    4 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,
    5 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,
    6 (E)-3-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,
    7 (E)-4-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,
    8 (E)-N-(4-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,
    9 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    10 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    carbamic acid tert-butyl ester,
    11 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenylamine,
    12 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanol,
    13 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzamide,
    14 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,
    15 (E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanone,
    16 (E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanol,
    17 (E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    18 (E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    19 (E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,
    20 (E)-1-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanone,
    21 (E)-1-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanol,
    22 (E)-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    23 (E)-2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    24 (E)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    acetamide,
    25 (E)-N-(3-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,
    26 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,
    27 (E)-1-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
    28 (E)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    29 2-{2-[3-(4-tert-butyl-phenyl)-propyl]-1H-benzimidazol-5-yl}-phenol,
    30 2-[3-(4-tert-butyl-phenyl)-propyl]-5-m-tolyl-1H-benzimidazole,
    31 N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    32 2-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol,
    33 3-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol,
    34 4-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol,
    35 (E)-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanol,
    36 (E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,
    37 (E)-N-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-acetamide,
    38 (E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzamide,
    39 (E)-1-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-ethanone,
    40 (E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-
    5-yl}-phenyl)-ethanone,
    41 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenol,
    42 (E)-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-methanol,
    43 (E)-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-
    5-yl}-phenyl)-acetamide,
    44 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzamide,
    45 (E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-
    5-yl}-phenyl)-ethanol,
    46 1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-
    yl}-phenyl)-ethanol,
    47 (E)-2-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-
    5-yl}-phenyl)-propan-2-ol,
    48 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-
    yl}-phenol,
    49 (E)-3-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-
    yl}-phenol,
    50 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-
    benzimidazol-5-yl}-phenyl)-acetamide,
    51 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-
    5-yl}-phenyl)-methanol,
    52 (E)-2-[2-(4-tert-butyl-phenyl)-vinyl]-5-(2-fluoro-phenyl)-6-trifluoromethyl-
    1H-benzimidazole,
    53 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-
    yl}-benzamide,
    54 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-
    5-yl}-phenyl)-carbamic acid tert-butyl ester,
    55 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    56 (E)-N-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-acetamide,
    57 (E)-1-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-ethanone,
    58 (E)-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanol,
    59 (E)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenol,
    60 (E)-3-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenol,
    61 (E)-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-methanol,
    62 (E)-1-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-ethanone,
    63 (E)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzamide,
    64 (E)-N-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-acetamide,
    65 (E)-N-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-methanesulfonamide,
    66 (E)-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-methanol,
    67 (E)-1-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-ethanone,
    68 (E)-2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenol,
    69 (E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    70 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    71 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    72 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    73 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    74 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-
    1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    75 (E)-1-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanone,
    76 (E)-1-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanol,
    77 (E)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    78 (E)-2-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    propan-2-ol,
    79 (E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    80 (E)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    C,C,C-trifluoro-methanesulfonamide,
    81 (E)-1-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanone,
    82 (E)-1-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanol,
    83 (E)-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    84 (E)-2-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    85 (E)-2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    86 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    87 (E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-
    benzimidazol-5-yl)-phenyl]-ethanone,
    88 (E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-
    benzimidazol-5-yl)-phenyl]-ethanol,
    89 (E)-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-
    1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    90 (E)-2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-
    benzimidazol-5-yl)-phenyl]-propan-2-ol,
    91 (E)-2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-
    benzimidazol-5-yl)-benzenesulfonamide,
    92 (E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-
    phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    93 (E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-
    yl)-phenyl]-ethanone,
    94 (E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-
    yl)-phenyl]-ethanol,
    95 (E)-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-
    yl)-phenyl]-methanesulfonamide,
    96 (E)-2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-
    yl)-phenyl]-propan-2-ol,
    97 (E)-2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-
    benzenesulfonamide,
    98 (E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-
    benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    99 (E)-1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-
    benzimidazol-5-yl)-phenyl]-ethanone,
    100 (E)-1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-
    benzimidazol-5-yl)-phenyl]-ethanol,
    101 (E)-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-
    benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    102 (E)-2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-
    benzimidazol-5-yl)-phenyl]-propan-2-ol,
    103 (E)-2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-
    benzimidazol-5-yl)-benzenesulfonamide,
    104 (E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-
    vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    105 (E)-1-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanone,
    106 (E)-1-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanol,
    107 (E)-N-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    108 (E)-2-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    propan-2-ol,
    109 (E)-2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    110 (E)-N-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    C,C,C-trifluoro-methanesulfonamide,
    111 (E)-1-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanone,
    112 (E)-1-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanol,
    113 (E)-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    114 (E)-2-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    115 (E)-2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    116 (E)-C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    117 (E)-N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-
    methanesulfonamide,
    118 (E)-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-
    phenyl]-methanesulfonamide,
    119 (E)-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-methanesulfonamide,
    120 (E)-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-
    yl}-vinyl)-phenyl]-methanesulfonamide,
    121 (E)-2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    122 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    123 (E)-N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-
    C,C,C-trifluoro-methanesulfonamide,
    124 (E)-C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-
    benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide,
    125 (E)-C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H-
    benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide,
    126 (E)-C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-
    benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide,
    127 (E)-2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-benzenesulfonamide,
    128 (E)-C,C,C-trifluoro-N-(4-{2-[5-(2-trifluoromethanesulfonylamino-phenyl)-
    1H-benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide,
    129 2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    130 2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    131 2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    132 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    133 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    134 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    135 1-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanone,
    136 1-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
    137 N-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    138 2-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-
    2-ol,
    139 2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    140 N-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-
    trifluoro-methanesulfonamide,
    141 1-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanone,
    142 1-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanol,
    143 N-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    144 2-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    145 2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    146 C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    147 1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-
    benzimidazol-5-yl)-phenyl]-ethanone,
    148 1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-
    benzimidazol-5-yl)-phenyl]-ethanol,
    149 N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-
    benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    150 2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-
    benzimidazol-5-yl)-phenyl]-propan-2-ol,
    151 2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-
    benzimidazol-5-yl)-benzenesulfonamide,
    152 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-
    phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    153 1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-
    phenyl]-ethanone,
    154 1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-
    phenyl]-ethanol,
    155 N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-
    phenyl]-methanesulfonamide,
    156 2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-
    phenyl]-propan-2-ol,
    157 2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-
    benzenesulfonamide,
    158 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-
    benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    159 1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-
    benzimidazol-5-yl)-phenyl]-ethanone,
    160 1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-
    benzimidazol-5-yl)-phenyl]-ethanol,
    161 N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-
    benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    162 2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-
    benzimidazol-5-yl)-phenyl]-propan-2-ol,
    163 2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-benzimidazol-
    5-yl)-benzenesulfonamide,
    164 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-
    ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    165 1-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanone,
    166 1-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
    167 N-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    168 2-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-
    2-ol,
    169 2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    170 N-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-
    trifluoro-methanesulfonamide,
    171 1-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanone,
    172 1-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanol,
    173 N-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    174 2-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-
    propan-2-ol,
    175 2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    176 C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    177 N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)-
    methanesulfonamide,
    178 N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-ethyl)-
    phenyl]-methanesulfonamide,
    179 N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    180 N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-
    ethyl)-phenyl]-methanesulfonamide,
    181 2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    182 C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    183 N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)-C,C,C-
    trifluoro-methanesulfonamide,
    184 C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-
    yl}-ethyl)-phenyl]-methanesulfonamide,
    185 C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H-
    benzimidazol-2-yl]-ethyl}-phenyl)-methanesulfonamide,
    186 C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-
    benzimidazol-2-yl}-ethyl)-phenyl]-methanesulfonamide,
    187 2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-
    5-yl}-benzenesulfonamide,
    188 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-ethyl]-
    1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    189 2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    190 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    191 2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-
    5-yl}-benzenesulfonamide,
    192 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    193 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    194 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-cyclopropyl]-
    1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    195 1-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanone,
    196 1-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanol,
    197 N-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    198 2-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-
    propan-2-ol,
    199 2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    200 N-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-
    C,C,C-trifluoro-methanesulfonamide,
    201 1-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanone,
    202 1-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanol,
    203 N-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    204 2-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    205 2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    206 C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    207 1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-
    1H-benzimidazol-5-yl)-phenyl]-ethanone,
    208 1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-
    1H-benzimidazol-5-yl)-phenyl]-ethanol,
    209 N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-
    1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    210 2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-
    1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
    211 2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-
    1H-benzimidazol-5-yl)-benzenesulfonamide,
    212 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-
    phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    213 1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-
    5-yl)-phenyl]-ethanone,
    214 1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-
    5-yl)-phenyl]-ethanol,
    215 N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-
    benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    216 2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-
    5-yl)-phenyl]-propan-2-ol,
    217 2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-
    yl)-benzenesulfonamide,
    218 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-
    1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    219 1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-
    benzimidazol-5-yl)-phenyl]-ethanone,
    220 1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-
    benzimidazol-5-yl)-phenyl]-ethanol,
    221 N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-
    benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    222 2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-
    benzimidazol-5-yl)-phenyl]-propan-2-ol,
    223 2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-
    benzimidazol-5-yl)-benzenesulfonamide,
    224 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-
    cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    225 1-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanone,
    226 1-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanol,
    227 N-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    228 2-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-
    propan-2-ol,
    229 2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    230 N-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-
    C,C,C-trifluoro-methanesulfonamide,
    231 1-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanone,
    232 1-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanol,
    233 N-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    234 2-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    235 2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    236 C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    237 N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)-
    methanesulfonamide,
    238 N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-cyclopropyl)-
    phenyl]-methanesulfonamide,
    239 N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    240 N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-
    cyclopropyl)-phenyl]-methanesulfonamide,
    241 2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    242 C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-
    1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    243 N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)-
    C,C,C-trifluoro-methanesulfonamide,
    244 C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-
    yl}-cyclopropyl)-phenyl]-methanesulfonamide,
    245 C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H-
    benzimidazol-2-yl]-cyclopropyl}-phenyl)-methanesulfonamide,
    246 C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-
    benzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide,
    247 2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-cyclopropyl]-1H-
    benzimidazol-5-yl}-benzenesulfonamide,
    248 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-
    cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    249 2-[2-(4-trifluoromethoxy-phenylethynyl)-1H-benzimidazol-5-yl]-
    benzenesulfonamide,
    250 2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-
    benzenesulfonamide,
    251 2-[2-(4-trifluoromethanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-
    benzenesulfonamide,
    252 C,C,C-trifluoro-N-{2-[2-(4-trifluoromethoxy-phenylethynyl)-1H-
    benzimidazol-5-yl]-phenyl}-methanesulfonamide,
    253 C,C,C-trifluoro-N-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-
    5-yl]-phenyl}-methanesulfonamide,
    254 C,C,C-trifluoro-N-{2-[2-(4-trifluoromethanesulfonyl-phenylethynyl)-1H-
    benzimidazol-5-yl]-phenyl}-methanesulfonamide,
    255 1-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone,
    256 1-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol,
    257 N-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-
    methanesulfonamide,
    258 2-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-
    ol,
    259 2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
    260 N-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-C,C,C-
    trifluoro-methanesulfonamide,
    261 1-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-
    ethanone,
    262 1-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-
    ethanol,
    263 N-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-
    methanesulfonamide,
    264 2-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-
    propan-2-ol,
    265 2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-
    benzenesulfonamide,
    266 C,C,C-trifluoro-N-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-
    benzimidazol-5-yl]-phenyl}-methanesulfonamide,
    267 1-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-
    benzimidazol-5-yl}-phenyl)-ethanone,
    268 1-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-
    benzimidazol-5-yl}-phenyl)-ethanol,
    269 N-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    270 2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-
    benzimidazol-5-yl}-phenyl)-propan-2-ol,
    271 2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-
    benzimidazol-5-yl}-benzenesulfonamide,
    272 C,C,C-trifluoro-N-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-
    phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    273 1-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanone,
    274 1-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanol,
    275 N-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    276 2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    277 2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    278 C,C,C-trifluoro-N-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    279 1-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-
    benzimidazol-5-yl}-phenyl)-ethanone,
    280 1-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-
    benzimidazol-5-yl}-phenyl)-ethanol,
    281 N-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    282 2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-
    benzimidazol-5-yl}-phenyl)-propan-2-ol,
    283 2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    284 C,C,C-trifluoro-N-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-
    1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    285 1-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone,
    286 2-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-
    ol,
    287 N-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-
    methanesulfonamide,
    288 1-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol,
    289 2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
    290 N-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-C,C,C-
    trifluoro-methanesulfonamide,
    291 1-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-
    ethanone,
    292 1-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-
    ethanol,
    293 N-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-
    methanesulfonamide,
    294 2-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-
    propan-2-ol,
    295 2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-
    benzenesulfonamide,
    296 C,C,C-trifluoro-N-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-
    5-yl]-phenyl}-methanesulfonamide,
    297 N-{4-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}-
    methanesulfonamide,
    298 N-(4-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl}-
    phenyl)-methanesulfonamide,
    299 N-{2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-
    phenyl}-methanesulfonamide,
    300 N-(4-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl-
    ethynyl}-phenyl)-methanesulfonamide,
    301 2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-
    benzenesulfonamide,
    302 C,C,C-trifluoro-N-{2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-
    benzimidazol-5-yl]-phenyl}-methanesulfonamide,
    303 N-{4-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}-C,C,C-
    trifluoro-methanesulfonamide,
    304 C,C,C-trifluoro-N-(4-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl-
    ethynyl}-phenyl)-methanesulfonamide,
    305 C,C,C-trifluoro-N-{4-[5-(2-methanesulfonylamino-phenyl)-1H-
    benzimidazol-2-yl-ethynyl]-phenyl}-methanesulfonamide,
    306 C,C,C-trifluoro-N-(4-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-
    benzimidazol-2-yl-ethynyl}-phenyl)-methanesulfonamide,
    307 2-[2-(4-trifluoromethanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-
    yl]-benzenesulfonamide,
    308 C,C,C-trifluoro-N-{2-[2-(4-trifluoromethanesulfonylamino-phenylethynyl)-
    1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,
    309 (E)-N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    310 (E)-N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    311 (E)-2-hydroxy-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-
    5-yl}-phenyl)-ethanone,
    312 (E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    314 (E)-N-methyl-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-
    benzenesulfonamide,
    315 (E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    316 (E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    317 (E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide,
    318 (E)-2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide,
    319 (E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    N-methyl-benzenesulfonamide,
    320 (E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    N-methyl-benzenesulfonamide,
    321 (E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide,
    322 (E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    N-methyl-benzenesulfonamide,
    323 (E)-N-methyl-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    324 (E)-N-methyl-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    325 (E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    326 (E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    327 (E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    328 (E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    329 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    330 (E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    N-methyl-benzenesulfonamide,
    331 (E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    N-methyl-benzenesulfonamide,
    332 (E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    N-methyl-benzenesulfonamide,
    333 (E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide,
    334 (E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide,
    335 (E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide,
    336 (E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide,
    337 (E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    338 (E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    339 (E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide,
    340 (E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-N-methyl-benzenesulfonamide,
    341 (E)-N-methyl-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-benzenesulfonamide,
    342 (E)-N-methyl-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-benzenesulfonamide,
    343 (E)-N-methyl-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    344 (E)-N-methyl-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    345 (E)-N-methyl-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    346 (E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    347 (E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    348 (E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    349 (E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    350 N-methyl-2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    351 (E)-2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide,
    357 (E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    358 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    359 (E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    360 (E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    361 (E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    362 (E)-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    363 (E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    364 (E)-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    365 (E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    366 (E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    367 (E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    368 (E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    369 (E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    370 (E)-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    371 (E)-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    372 (E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    373 (E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    374 (E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    375 (E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    376 (E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    378 (E)-2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    379 (E)-2-{2-[2-(5-bromo-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    380 (E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    383 2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    384 2-{2-[2-(2,3,4-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    385 2-{2-[2-(2,4,5-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    386 2-{2-[2-(2,6-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    387 2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    388 2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    389 2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    390 2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    391 2-{2-[2-(3-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    392 2-{2-[2-(2,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    393 2-{2-[2-(3,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    394 2-{2-[2-(2,3-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    395 2-{2-[2-(2,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    396 2-{2-[2-(3,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    397 2-(2-phenethyl-1H-benzimidazol-5-yl)-benzenesulfonamide,
    398 (E)-N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-
    5-yl}-benzenesulfonamide,
    399 N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    400 N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    402 2-{2-[2-(2-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    404 2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    405 2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    406 (E)-N-(2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    407 (E)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    408 (E)-N-(2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    409 (E)-N-(2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    410 (E)-N-(2-{2-[2-(4-difluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    411 (E)-N-(2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-methanesulfonamide,
    412 (E)-N-{2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-
    methanesulfonamide,
    413 (E)-N-(2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    414 (E)-N-(2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    415 (E)-N-{2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-
    methanesulfonamide,
    416 (E)-N-(2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    417 (E)-N-(2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-methanesulfonamide,
    418 (E)-N-(2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-methanesulfonamide,
    419 2-{2-[2-(2-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    420 2-{2-[2-(4-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    421 2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    422 (E)-5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazole,
    423 (E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    424 (E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    425 (E)-2-{2-[2-(3-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    426 (E)-2-(2-styryl-1H-benzimidazol-5-yl)-benzenesulfonamide,
    427 (E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    428 (E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    429 (E)-2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    430 (E)-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
    431 (E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    432 (E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    433 (E)-2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-
    benzenesulfonamide,
    434 (E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    435 (E)-2-{2-[2-(4-difluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    436 (E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    437 (E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    438 (E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    439 (E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    440 (E)-2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    441 (E)-4-fluoro-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    442 2-{2-[2-(4-isopropyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    443 (E)-N-(2-{3-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-3H-benzimidazol-
    5-yl}-phenyl)-methanesulfonamide,
    444 (E)-4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-benzenesulfonamide,
    445 4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-
    5-yl}-benzenesulfonamide,
    446 (E)-5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-benzenesulfonamide,
    447 5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-
    5-yl}-benzenesulfonamide,
    448 (E)-1-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-
    vinyl)-phenyl]-ethanone,
    449 (E)-2-{2-[2-(2-quinolin-6-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-
    ol,
    450 (E)-N-isopropyl-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-
    vinyl}-benzamide,
    451 (E)-2-{2-[2-(4-cyano-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    452 (E)-N-(4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-
    phenyl)-acetamide,
    453 (E)-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-
    benzoic acid,
    454 (E)-2-{2-[2-(1H-indol-6-yl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    455 (E)-2-{2-[2-(2,4-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide,
    456 (E)-2-{2-[2-(4-acetyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    457 N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-
    acetamide,
    458 (E)-2,2,2-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-acetamide,
    459 (E)-2,2,2-trifluoro-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-
    vinyl]-1H-benzimidazol-5-yl}-phenyl)-amide,
    460 (E)-2,2-dimethyl-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-propionamide,
    461 (E)-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-amide,
    462 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-carbamic acid methyl ester,
    463 (E)-2-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    propan-2-ol,
    464 2-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-
    propan-2-ol,
    465 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenylamine,
    466 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzoic
    acid ethyl ester,
    467 N-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    468 (E)-2-[2-(2-styryl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
    469 (Z)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    470 (E)-5-(2-aminosulfonylamino-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-
    1H-benzimidazole,
    471 2-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    472 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenol,
    473 (2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenyl)-carbamic acid tert-butyl ester,
    474 (2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanol,
    475 (E)-N-{2-[2-(2-biphenyl-4-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-
    methanesulfonamide,
    476 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanol,
    477 (E)-N-(2-{1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-
    5-yl}-phenyl)-methanesulfonamide,
    478 (E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-acetamide,
    479 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-carbamic acid tert-butyl ester,
    480 (E)-5-(2-methylsulfanyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazole,
    481 (E)-2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-5-(2-trifluoromethyl-
    phenyl)-1H-benzimidazole,
    482 (E)-2-(2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    483 (E)-dimethyl-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzyl)-amine,
    484 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzaldehyde,
    485 (E)-methyl-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzyl)-amine,
    486 2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzylamine,
    487 (E)-5-(2-trifluoromethyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazole,
    488 (E)-5-(2-trifluoromethoxy-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazole,
    489 2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
    490 2-(2-phenylethynyl-1H-benzimidazol-5-yl)-benzenesulfonamide,
    491 (E)-5-(2-aminosulfonylamino-methylphenyl)-2-[2-(4-trifluoromethyl-
    phenyl)-vinyl]-1H-benzimidazole,
    492 2-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-
    propan-2-ol,
    494 2-(2-{2-[2-(4-methoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-
    propan-2-ol,
    497 2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    498 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    benzamide,
    499 N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-
    benzimidazol-5-yl}-benzenesulfonamide,
    500 5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-
    1H-benzimidazole,
    501 2-(2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-
    benzimidazol-5-yl}-phenyl)-propan-2-ol,
    502 2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    503 2-(2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-
    benzimidazol-5-yl}-phenyl)-propan-2-ol,
    504 2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    505 2-(2-{2-[(1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-
    benzimidazol-5-yl}-phenyl)-propan-2-ol,
    506 2-{2-[(1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    507 2-(2-{2-[(1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-
    benzimidazol-5-yl}-phenyl)-propan-2-ol, and
    508 2-{2-[(1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide.
  • A representative compound of Formula (I) or a form thereof includes a compound selected from the group consisting of:
  • Cpd Name
    1 (E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanone,
    2 (E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanol,
    3 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,
    4 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    acetamide,
    5 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,
    6 (E)-3-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,
    7 (E)-4-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,
    8 (E)-N-(4-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    acetamide,
    9 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    10 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    carbamic acid tert-butyl ester,
    11 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenylamine,
    12 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanol,
    13 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzamide,
    14 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,
    15 (E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanone,
    16 (E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanol,
    17 (E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    18 (E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    19 (E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzamide,
    20 (E)-1-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanone,
    21 (E)-1-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanol,
    22 (E)-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    23 (E)-2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    24 (E)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    acetamide,
    25 (E)-N-(3-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    acetamide,
    26 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,
    27 (E)-1-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanone,
    28 (E)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    29 2-{2-[3-(4-tert-butyl-phenyl)-propyl]-1H-benzimidazol-5-yl}-phenol,
    30 2-[3-(4-tert-butyl-phenyl)-propyl]-5-m-tolyl-1H-benzimidazole,
    31 N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    32 2-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol,
    33 3-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol,
    34 4-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol,
    35 (E)-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanol,
    36 (E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenol,
    37 (E)-N-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-acetamide,
    38 (E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzamide,
    39 (E)-1-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-ethanone,
    40 (E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-
    5-yl}-phenyl)-ethanone,
    41 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenol,
    42 (E)-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-methanol,
    43 (E)-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-
    5-yl}-phenyl)-acetamide,
    44 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzamide,
    45 (E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-
    5-yl}-phenyl)-ethanol,
    46 1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-
    yl}-phenyl)-ethanol,
    47 (E)-2-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-
    5-yl}-phenyl)-propan-2-ol,
    48 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-
    yl}-phenol,
    49 (E)-3-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-
    yl}-phenol,
    50 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-
    benzimidazol-5-yl}-phenyl)-acetamide,
    51 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-
    5-yl}-phenyl)-methanol,
    52 (E)-2-[2-(4-tert-butyl-phenyl)-vinyl]-5-(2-fluoro-phenyl)-6-trifluoromethyl-
    1H-benzimidazole,
    53 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-
    yl}-benzamide,
    54 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-
    5-yl}-phenyl)-carbamic acid tert-butyl ester,
    55 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    56 (E)-N-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-acetamide,
    57 (E)-1-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-ethanone,
    58 (E)-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanol,
    59 (E)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenol,
    60 (E)-3-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenol,
    61 (E)-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-methanol,
    62 (E)-1-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-ethanone,
    63 (E)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzamide,
    64 (E)-N-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-acetamide,
    65 (E)-N-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-methanesulfonamide,
    66 (E)-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-methanol,
    67 (E)-1-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-ethanone,
    68 (E)-2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenol,
    69 (E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    70 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    71 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    77 (E)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    78 (E)-2-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    propan-2-ol,
    79 (E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    83 (E)-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    84 (E)-2-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    85 (E)-2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    95 (E)-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-
    yl)-phenyl]-methanesulfonamide,
    101 (E)-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-
    benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    113 (E)-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    114 (E)-2-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    129 2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    130 2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    131 2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    139 2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    145 2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    175 2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    190 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    198 2-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-
    propan-2-ol,
    234 2-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    250 2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-
    benzenesulfonamide,
    294 2-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-
    propan-2-ol,
    295 2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-
    benzenesulfonamide,
    309 (E)-N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    310 (E)-N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    311 (E)-2-hydroxy-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-
    5-yl}-phenyl)-ethanone,
    312 (E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    314 (E)-N-methyl-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-
    benzenesulfonamide,
    315 (E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    316 (E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    317 (E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide,
    318 (E)-2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide,
    319 (E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    N-methyl-benzenesulfonamide,
    320 (E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    N-methyl-benzenesulfonamide,
    321 (E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide,
    322 (E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    N-methyl-benzenesulfonamide,
    323 (E)-N-methyl-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    324 (E)-N-methyl-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    325 (E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    326 (E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    327 (E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    328 (E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    329 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    330 (E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    N-methyl-benzenesulfonamide,
    331 (E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    N-methyl-benzenesulfonamide,
    332 (E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    N-methyl-benzenesulfonamide,
    333 (E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide,
    334 (E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide,
    335 (E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide,
    336 (E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide,
    337 (E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    338 (E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    339 (E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide,
    340 (E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-N-methyl-benzenesulfonamide,
    341 (E)-N-methyl-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-benzenesulfonamide,
    342 (E)-N-methyl-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-benzenesulfonamide,
    343 (E)-N-methyl-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    344 (E)-N-methyl-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    345 (E)-N-methyl-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    346 (E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    347 (E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    348 (E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    349 (E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    350 N-methyl-2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    351 (E)-2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide,
    357 (E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    358 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    359 (E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    360 (E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    361 (E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    362 (E)-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    363 (E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    364 (E)-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    365 (E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    366 (E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    367 (E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    368 (E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    369 (E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    370 (E)-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    371 (E)-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    372 (E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    373 (E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    374 (E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    375 (E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    376 (E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    378 (E)-2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    379 (E)-2-{2-[2-(5-bromo-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    380 (E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    383 2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    384 2-{2-[2-(2,3,4-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    385 2-{2-[2-(2,4,5-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    386 2-{2-[2-(2,6-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    387 2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    388 2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    389 2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    390 2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    391 2-{2-[2-(3-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    392 2-{2-[2-(2,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    393 2-{2-[2-(3,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    394 2-{2-[2-(2,3-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    395 2-{2-[2-(2,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    396 2-{2-[2-(3,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    397 2-(2-phenethyl-1H-benzimidazol-5-yl)-benzenesulfonamide,
    398 (E)-N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-
    5-yl}-benzenesulfonamide,
    399 N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    400 N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    402 2-{2-[2-(2-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    404 2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    405 2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    406 (E)-N-(2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    407 (E)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    408 (E)-N-(2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    409 (E)-N-(2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    410 (E)-N-(2-{2-[2-(4-difluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    411 (E)-N-(2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-methanesulfonamide,
    412 (E)-N-{2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-
    methanesulfonamide,
    413 (E)-N-(2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    414 (E)-N-(2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    415 (E)-N-{2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-
    methanesulfonamide,
    416 (E)-N-(2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    417 (E)-N-(2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-methanesulfonamide,
    418 (E)-N-(2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-methanesulfonamide,
    419 2-{2-[2-(2-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    420 2-{2-[2-(4-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    421 2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    422 (E)-5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazole,
    423 (E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    424 (E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    425 (E)-2-{2-[2-(3-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    426 (E)-2-(2-styryl-1H-benzimidazol-5-yl)-benzenesulfonamide,
    427 (E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    428 (E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    429 (E)-2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    430 (E)-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
    431 (E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    432 (E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    433 (E)-2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-
    benzenesulfonamide,
    434 (E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    435 (E)-2-{2-[2-(4-difluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    436 (E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    437 (E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    438 (E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    439 (E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    440 (E)-2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    441 (E)-4-fluoro-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    442 2-{2-[2-(4-isopropyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    443 (E)-N-(2-{3-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-3H-benzimidazol-
    5-yl}-phenyl)-methanesulfonamide,
    444 (E)-4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-benzenesulfonamide,
    445 4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-
    5-yl}-benzenesulfonamide,
    446 (E)-5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-benzenesulfonamide,
    447 5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-
    5-yl}-benzenesulfonamide,
    448 (E)-1-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-
    vinyl)-phenyl]-ethanone,
    449 (E)-2-{2-[2-(2-quinolin-6-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-
    ol,
    450 (E)-N-isopropyl-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-
    vinyl}-benzamide,
    451 (E)-2-{2-[2-(4-cyano-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    452 (E)-N-(4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-
    phenyl)-acetamide,
    453 (E)-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-
    benzoic acid,
    454 (E)-2-{2-[2-(1H-indol-6-yl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    455 (E)-2-{2-[2-(2,4-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide,
    456 (E)-2-{2-[2-(4-acetyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    457 N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-
    acetamide,
    458 (E)-2,2,2-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-acetamide,
    459 (E)-2,2,2-trifluoro-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-
    vinyl]-1H-benzimidazol-5-yl}-phenyl)-amide,
    460 (E)-2,2-dimethyl-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-propionamide,
    461 (E)-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-amide,
    462 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-carbamic acid methyl ester,
    463 (E)-2-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    propan-2-ol,
    464 2-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-
    propan-2-ol,
    465 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenylamine,
    466 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzoic
    acid ethyl ester,
    467 N-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    468 (E)-2-[2-(2-styryl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
    469 (Z)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    470 (E)-5-(2-aminosulfonylamino-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-
    1H-benzimidazole,
    471 2-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    472 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenol,
    473 (2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenyl)-carbamic acid tert-butyl ester,
    474 (2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanol,
    475 (E)-N-{2-[2-(2-biphenyl-4-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-
    methanesulfonamide,
    476 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanol,
    477 (E)-N-(2-{1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-
    5-yl}-phenyl)-methanesulfonamide,
    478 (E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-acetamide,
    479 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-carbamic acid tert-butyl ester,
    480 (E)-5-(2-methylsulfanyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazole,
    481 (E)-2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-5-(2-trifluoromethyl-
    phenyl)-1H-benzimidazole,
    482 (E)-2-(2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    483 (E)-dimethyl-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzyl)-amine,
    484 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzaldehyde,
    485 (E)-methyl-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzyl)-amine,
    486 2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzylamine,
    487 (E)-5-(2-trifluoromethyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazole,
    488 (E)-5-(2-trifluoromethoxy-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazole,
    489 2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
    490 2-(2-phenylethynyl-1H-benzimidazol-5-yl)-benzenesulfonamide,
    491 (E)-5-(2-aminosulfonylamino-methylphenyl)-2-[2-(4-trifluoromethyl-
    phenyl)-vinyl]-1H-benzimidazole,
    492 2-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-
    propan-2-ol,
    494 2-(2-{2-[2-(4-methoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-
    propan-2-ol,
    497 2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    498 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    benzamide,
    499 N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-
    benzimidazol-5-yl}-benzenesulfonamide,
    500 5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-
    1H-benzimidazole,
    40333774 501 2-(2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-
    benzimidazol-5-yl}-phenyl)-propan-2-ol,
    40334255 502 2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    503 2-(2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-
    benzimidazol-5-yl}-phenyl)-propan-2-ol,
    504 2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    505 2-(2-{2-[(1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-
    benzimidazol-5-yl}-phenyl)-propan-2-ol,
    506 2-{2-[(1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    507 2-(2-{2-[(1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-
    benzimidazol-5-yl}-phenyl)-propan-2-ol, and
    508 2-{2-[(1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide.
  • A representative compound of Formula (I) or a form thereof includes a compound selected from the group consisting of:
  • Cpd Name
    1 (E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanone,
    2 (E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanol,
    3 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,
    4 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    acetamide,
    5 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,
    9 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    10 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    carbamic acid tert-butyl ester,
    11 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenylamine,
    12 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanol,
    13 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzamide,
    15 (E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanone,
    16 (E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanol,
    17 (E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    18 (E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    22 (E)-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    27 (E)-1-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanone,
    28 (E)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    31 N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    32 2-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol,
    34 4-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol,
    35 (E)-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanol,
    38 (E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzamide,
    39 (E)-1-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-ethanone,
    40 (E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-
    5-yl}-phenyl)-ethanone,
    41 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenol,
    42 (E)-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-methanol,
    44 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzamide,
    45 (E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-
    5-yl}-phenyl)-ethanol,
    46 1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-
    yl}-phenyl)-ethanol,
    47 (E)-2-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-
    5-yl}-phenyl)-propan-2-ol,
    50 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-
    benzimidazol-5-yl}-phenyl)-acetamide,
    51 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-
    5-yl}-phenyl)-methanol,
    53 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-
    yl}-benzamide,
    56 (E)-N-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-acetamide,
    58 (E)-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanol,
    59 (E)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenol,
    61 (E)-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-methanol,
    62 (E)-1-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-ethanone,
    63 (E)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzamide,
    66 (E)-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-methanol,
    67 (E)-1-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-ethanone,
    68 (E)-2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenol,
    69 (E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    70 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    71 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    77 (E)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    78 (E)-2-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    propan-2-ol,
    79 (E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    84 (E)-2-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    95 (E)-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-
    yl)-phenyl]-methanesulfonamide,
    114 (E)-2-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    129 2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    130 2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    131 2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    139 2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    175 2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    190 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    198 2-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-
    propan-2-ol,
    250 2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-
    benzenesulfonamide,
    294 2-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-
    propan-2-ol,
    295 2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-
    benzenesulfonamide,
    309 (E)-N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    310 (E)-N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    311 (E)-2-hydroxy-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-
    5-yl}-phenyl)-ethanone,
    312 (E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    314 (E)-N-methyl-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-
    benzenesulfonamide,
    315 (E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    316 (E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    317 (E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide,
    318 (E)-2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide,
    319 (E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    N-methyl-benzenesulfonamide,
    320 (E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    N-methyl-benzenesulfonamide,
    321 (E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide,
    322 (E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    N-methyl-benzenesulfonamide,
    323 (E)-N-methyl-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    324 (E)-N-methyl-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    325 (E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    326 (E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    327 (E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    328 (E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    329 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    330 (E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    N-methyl-benzenesulfonamide,
    331 (E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    N-methyl-benzenesulfonamide,
    332 (E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    N-methyl-benzenesulfonamide,
    333 (E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide,
    334 (E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide,
    335 (E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide,
    336 (E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide,
    337 (E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    338 (E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    339 (E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide,
    340 (E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-N-methyl-benzenesulfonamide,
    341 (E)-N-methyl-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-benzenesulfonamide,
    342 (E)-N-methyl-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-benzenesulfonamide,
    343 (E)-N-methyl-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    344 (E)-N-methyl-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    345 (E)-N-methyl-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    346 (E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    347 (E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    348 (E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    349 (E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    350 N-methyl-2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    357 (E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    358 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    359 (E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    360 (E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    361 (E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    362 (E)-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    363 (E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    364 (E)-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    365 (E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    366 (E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    367 (E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    368 (E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    369 (E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    370 (E)-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    371 (E)-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    372 (E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    373 (E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    374 (E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    375 (E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    376 (E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    378 (E)-2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    379 (E)-2-{2-[2-(5-bromo-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    380 (E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    383 2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    384 2-{2-[2-(2,3,4-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    385 2-{2-[2-(2,4,5-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    386 2-{2-[2-(2,6-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    387 2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    388 2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    390 2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    391 2-{2-[2-(3-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    392 2-{2-[2-(2,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    393 2-{2-[2-(3,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    394 2-{2-[2-(2,3-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    395 2-{2-[2-(2,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    396 2-{2-[2-(3,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    397 2-(2-phenethyl-1H-benzimidazol-5-yl)-benzenesulfonamide,
    398 (E)-N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-
    5-yl}-benzenesulfonamide,
    399 N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    402 2-{2-[2-(2-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    404 2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    405 2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    406 (E)-N-(2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    407 (E)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    410 (E)-N-(2-{2-[2-(4-difluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    411 (E)-N-(2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-methanesulfonamide,
    412 (E)-N-{2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-
    methanesulfonamide,
    413 (E)-N-(2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    414 (E)-N-(2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    415 (E)-N-{2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-
    methanesulfonamide,
    416 (E)-N-(2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    417 (E)-N-(2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-methanesulfonamide,
    418 (E)-N-(2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-methanesulfonamide,
    419 2-{2-[2-(2-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    420 2-{2-[2-(4-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    421 2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    422 (E)-5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazole,
    423 (E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    424 (E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    426 (E)-2-(2-styryl-1H-benzimidazol-5-yl)-benzenesulfonamide,
    427 (E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    428 (E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    429 (E)-2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    430 (E)-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
    431 (E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    432 (E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    433 (E)-2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-
    benzenesulfonamide,
    434 (E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    435 (E)-2-{2-[2-(4-difluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    436 (E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    437 (E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    438 (E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    439 (E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    440 (E)-2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    442 2-{2-[2-(4-isopropyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    444 (E)-4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-benzenesulfonamide,
    445 4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-
    5-yl}-benzenesulfonamide,
    446 (E)-5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-benzenesulfonamide,
    447 5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-
    5-yl}-benzenesulfonamide,
    448 (E)-1-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-
    vinyl)-phenyl]-ethanone,
    449 (E)-2-{2-[2-(2-quinolin-6-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-
    ol,
    451 (E)-2-{2-[2-(4-cyano-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    455 (E)-2-{2-[2-(2,4-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide,
    456 (E)-2-{2-[2-(4-acetyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    461 (E)-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-amide,
    462 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-carbamic acid methyl ester,
    463 (E)-2-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    propan-2-ol,
    464 2-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-
    propan-2-ol,
    465 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenylamine,
    466 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzoic
    acid ethyl ester,
    467 N-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    468 (E)-2-[2-(2-styryl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
    469 (Z)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    470 (E)-5-(2-aminosulfonylamino-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-
    1H-benzimidazole,
    471 2-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    475 (E)-N-{2-[2-(2-biphenyl-4-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-
    methanesulfonamide,
    476 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanol,
    482 (E)-2-(2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    489 2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
    490 2-(2-phenylethynyl-1H-benzimidazol-5-yl)-benzenesulfonamide,
    491 (E)-5-(2-aminosulfonylamino-methylphenyl)-2-[2-(4-trifluoromethyl-
    phenyl)-vinyl]-1H-benzimidazole,
    492 2-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-
    propan-2-ol,
    494 2-(2-{2-[2-(4-methoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-
    propan-2-ol,
    497 2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    498 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    benzamide,
    500 5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-
    1H-benzimidazole,
    501 2-(2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-
    benzimidazol-5-yl}-phenyl)-propan-2-ol,
    502 2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    503 2-(2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-
    benzimidazol-5-yl}-phenyl)-propan-2-ol, and
    504 2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide.
  • A representative compound of Formula (I) or a form thereof includes a compound selected from the group consisting of:
  • Cpd Name
    1 (E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanone,
    2 (E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanol,
    5 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,
    9 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    12 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanol,
    16 (E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanol,
    17 (E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    18 (E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    22 (E)-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    31 N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    35 (E)-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanol,
    40 (E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-
    5-yl}-phenyl)-ethanone,
    42 (E)-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-methanol,
    45 (E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-
    5-yl}-phenyl)-ethanol,
    46 1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-
    yl}-phenyl)-ethanol,
    47 (E)-2-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-
    5-yl}-phenyl)-propan-2-ol,
    51 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-
    5-yl}-phenyl)-methanol,
    53 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-
    yl}-benzamide,
    58 (E)-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanol,
    61 (E)-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-methanol,
    66 (E)-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-methanol,
    69 (E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    70 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    71 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    77 (E)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    78 (E)-2-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    propan-2-ol,
    79 (E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    84 (E)-2-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    114 (E)-2-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    129 2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    130 2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    131 2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    139 2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    175 2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    190 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    198 2-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-
    propan-2-ol,
    250 2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-
    benzenesulfonamide,
    294 2-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-
    propan-2-ol,
    295 2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-
    benzenesulfonamide,
    310 (E)-N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    311 (E)-2-hydroxy-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-
    5-yl}-phenyl)-ethanone,
    312 (E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    314 (E)-N-methyl-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-
    benzenesulfonamide,
    315 (E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    316 (E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    317 (E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide,
    318 (E)-2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide,
    319 (E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    N-methyl-benzenesulfonamide,
    320 (E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    N-methyl-benzenesulfonamide,
    321 (E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide,
    322 (E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    N-methyl-benzenesulfonamide,
    323 (E)-N-methyl-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    324 (E)-N-methyl-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    328 (E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    329 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    331 (E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    N-methyl-benzenesulfonamide,
    332 (E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    N-methyl-benzenesulfonamide,
    333 (E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide,
    335 (E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide,
    337 (E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    339 (E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide,
    340 (E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-N-methyl-benzenesulfonamide,
    341 (E)-N-methyl-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-benzenesulfonamide,
    342 (E)-N-methyl-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-benzenesulfonamide,
    344 (E)-N-methyl-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    345 (E)-N-methyl-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    347 (E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    349 (E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    350 N-methyl-2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    357 (E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    358 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    359 (E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    360 (E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    361 (E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    362 (E)-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    363 (E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    364 (E)-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    365 (E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    366 (E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    367 (E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    368 (E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    369 (E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    370 (E)-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    371 (E)-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    372 (E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    373 (E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    374 (E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    376 (E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    378 (E)-2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    379 (E)-2-{2-[2-(5-bromo-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    380 (E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    383 2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    384 2-{2-[2-(2,3,4-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    385 2-{2-[2-(2,4,5-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    386 2-{2-[2-(2,6-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    387 2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    388 2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    390 2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    391 2-{2-[2-(3-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    392 2-{2-[2-(2,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    393 2-{2-[2-(3,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    394 2-{2-[2-(2,3-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    395 2-{2-[2-(2,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    396 2-{2-[2-(3,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    397 2-(2-phenethyl-1H-benzimidazol-5-yl)-benzenesulfonamide,
    398 (E)-N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-
    5-yl}-benzenesulfonamide,
    399 N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    402 2-{2-[2-(2-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    404 2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    405 2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    407 (E)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    417 (E)-N-(2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-methanesulfonamide,
    418 (E)-N-(2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-methanesulfonamide,
    419 2-{2-[2-(2-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    420 2-{2-[2-(4-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    421 2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    422 (E)-5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazole,
    423 (E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    424 (E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    426 (E)-2-(2-styryl-1H-benzimidazol-5-yl)-benzenesulfonamide,
    427 (E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    428 (E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    429 (E)-2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    430 (E)-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
    431 (E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    432 (E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    433 (E)-2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-
    benzenesulfonamide,
    434 (E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    435 (E)-2-{2-[2-(4-difluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    436 (E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    437 (E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    438 (E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    439 (E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    440 (E)-2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    442 2-{2-[2-(4-isopropyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    444 (E)-4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-benzenesulfonamide,
    445 4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-
    5-yl}-benzenesulfonamide,
    446 (E)-5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-benzenesulfonamide,
    447 5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-
    5-yl}-benzenesulfonamide,
    448 (E)-1-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-
    vinyl)-phenyl]-ethanone,
    449 (E)-2-{2-[2-(2-quinolin-6-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-
    ol,
    451 (E)-2-{2-[2-(4-cyano-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    455 (E)-2-{2-[2-(2,4-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide,
    456 (E)-2-{2-[2-(4-acetyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    461 (E)-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-amide,
    462 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-carbamic acid methyl ester,
    463 (E)-2-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    propan-2-ol,
    464 2-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-
    propan-2-ol,
    466 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzoic
    acid ethyl ester,
    468 (E)-2-[2-(2-styryl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
    469 (Z)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    470 (E)-5-(2-aminosulfonylamino-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-
    1H-benzimidazole,
    471 2-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    475 (E)-N-{2-[2-(2-biphenyl-4-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-
    methanesulfonamide,
    476 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanol,
    482 (E)-2-(2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    489 2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
    490 2-(2-phenylethynyl-1H-benzimidazol-5-yl)-benzenesulfonamide,
    491 (E)-5-(2-aminosulfonylamino-methylphenyl)-2-[2-(4-trifluoromethyl-
    phenyl)-vinyl]-1H-benzimidazole,
    492 2-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-
    propan-2-ol,
    494 2-(2-{2-[2-(4-methoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-
    propan-2-ol,
    497 2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    498 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    benzamide,
    500 5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-
    1H-benzimidazole,
    501 2-(2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-
    benzimidazol-5-yl}-phenyl)-propan-2-ol,
    503 2-(2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-
    benzimidazol-5-yl}-phenyl)-propan-2-ol, and
    504 2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide.
  • A representative compound of Formula (I) or a form thereof includes a compound selected from the group consisting of:
  • Cpd Name
    9 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    12 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanol,
    17 (E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    18 (E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    69 (E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    70 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    78 (E)-2-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    propan-2-ol,
    79 (E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    114 (E)-2-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    130 2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    310 (E)-N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    312 (E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide,
    319 (E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    N-methyl-benzenesulfonamide,
    341 (E)-N-methyl-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-benzenesulfonamide,
    357 (E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    358 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    362 (E)-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    369 (E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    384 2-{2-[2-(2,3,4-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    390 2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    391 2-{2-[2-(3-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    394 2-{2-[2-(2,3-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    398 (E)-N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-
    5-yl}-benzenesulfonamide,
    399 N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    407 (E)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    421 2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    422 (E)-5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazole,
    428 (E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    429 (E)-2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    430 (E)-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
    434 (E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    442 2-{2-[2-(4-isopropyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    449 (E)-2-{2-[2-(2-quinolin-6-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-
    ol,
    461 (E)-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-amide,
    464 2-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-
    propan-2-ol,
    468 (E)-2-[2-(2-styryl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
    469 (Z)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    471 2-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    489 2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
    492 2-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-
    propan-2-ol, and
    503 2-(2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-
    benzimidazol-5-yl}-phenyl)-propan-2-ol.
  • A representative prophetic compound of Formula (I) or a form thereof includes a compound selected from the group consisting of:
  • Cpd Name
    72 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    73 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    74 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-
    1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    75 (E)-1-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanone,
    76 (E)-1-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanol,
    80 (E)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    C,C,C-trifluoro-methanesulfonamide,
    81 (E)-1-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanone,
    82 (E)-1-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanol,
    86 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    87 (E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-
    benzimidazol-5-yl)-phenyl]-ethanone,
    88 (E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-
    benzimidazol-5-yl)-phenyl]-ethanol,
    89 (E)-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-
    1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    90 (E)-2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-
    benzimidazol-5-yl)-phenyl]-propan-2-ol,
    91 (E)-2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-
    benzimidazol-5-yl)-benzenesulfonamide,
    92 (E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-
    phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    93 (E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-
    yl)-phenyl]-ethanone,
    94 (E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-
    yl)-phenyl]-ethanol,
    96 (E)-2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-
    yl)-phenyl]-propan-2-ol,
    97 (E)-2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-
    benzenesulfonamide,
    98 (E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-
    benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    99 (E)-1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-
    benzimidazol-5-yl)-phenyl]-ethanone,
    100 (E)-1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-
    benzimidazol-5-yl)-phenyl]-ethanol,
    102 (E)-2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-
    benzimidazol-5-yl)-phenyl]-propan-2-ol,
    103 (E)-2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-
    benzimidazol-5-yl)-benzenesulfonamide,
    104 (E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-
    vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    105 (E)-1-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanone,
    106 (E)-1-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanol,
    107 (E)-N-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    108 (E)-2-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    propan-2-ol,
    109 (E)-2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    110 (E)-N-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    C,C,C-trifluoro-methanesulfonamide,
    111 (E)-1-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanone,
    112 (E)-1-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanol,
    115 (E)-2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    116 (E)-C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    117 (E)-N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-
    methanesulfonamide,
    118 (E)-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-
    phenyl]-methanesulfonamide,
    119 (E)-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-methanesulfonamide,
    120 (E)-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-
    yl}-vinyl)-phenyl]-methanesulfonamide,
    121 (E)-2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    122 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    123 (E)-N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-
    C,C,C-trifluoro-methanesulfonamide,
    124 (E)-C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-
    benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide,
    125 (E)-C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H-
    benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide,
    126 (E)-C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-
    benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide,
    127 (E)-2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-benzenesulfonamide,
    128 (E)-C,C,C-trifluoro-N-(4-{2-[5-(2-trifluoromethanesulfonylamino-phenyl)-
    1H-benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide,
    132 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    133 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    134 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    135 1-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanone,
    136 1-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
    137 N-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    138 2-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-
    2-ol,
    140 N-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-
    trifluoro-methanesulfonamide,
    141 1-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanone,
    142 1-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanol,
    143 N-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    144 2-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    146 C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    147 1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-
    benzimidazol-5-yl)-phenyl]-ethanone,
    148 1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-
    benzimidazol-5-yl)-phenyl]-ethanol,
    149 N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-
    benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    150 2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-
    benzimidazol-5-yl)-phenyl]-propan-2-ol,
    151 2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-
    benzimidazol-5-yl)-benzenesulfonamide,
    152 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-
    phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    153 1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-
    phenyl]-ethanone,
    154 1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-
    phenyl]-ethanol,
    155 N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-
    phenyl]-methanesulfonamide,
    156 2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-
    phenyl]-propan-2-ol,
    157 2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-
    benzenesulfonamide,
    158 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-
    benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    159 1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-
    benzimidazol-5-yl)-phenyl]-ethanone,
    160 1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-
    benzimidazol-5-yl)-phenyl]-ethanol,
    161 N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-
    benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    162 2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-
    benzimidazol-5-yl)-phenyl]-propan-2-ol,
    163 2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-benzimidazol-
    5-yl)-benzenesulfonamide,
    164 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-
    ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    165 1-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanone,
    166 1-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
    167 N-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    168 2-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-
    2-ol,
    169 2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    170 N-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-
    trifluoro-methanesulfonamide,
    171 1-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanone,
    172 1-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanol,
    173 N-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    174 2-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-
    propan-2-ol,
    176 C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    177 N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)-
    methanesulfonamide,
    178 N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-ethyl)-
    phenyl]-methanesulfonamide,
    179 N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    180 N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-
    ethyl)-phenyl]-methanesulfonamide,
    181 2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    182 C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    183 N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)-C,C,C-
    trifluoro-methanesulfonamide,
    184 C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-
    yl}-ethyl)-phenyl]-methanesulfonamide,
    185 C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H-
    benzimidazol-2-yl]-ethyl}-phenyl)-methanesulfonamide,
    186 C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-
    benzimidazol-2-yl}-ethyl)-phenyl]-methanesulfonamide,
    187 2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-
    5-yl}-benzenesulfonamide,
    188 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-ethyl]-
    1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    189 2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    191 2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-
    5-yl}-benzenesulfonamide,
    192 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    193 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    194 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-cyclopropyl]-
    1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    195 1-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanone,
    196 1-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanol,
    197 N-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    199 2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    200 N-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-
    C,C,C-trifluoro-methanesulfonamide,
    201 1-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanone,
    202 1-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanol,
    203 N-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    204 2-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    205 2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    206 C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    207 1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-
    1H-benzimidazol-5-yl)-phenyl]-ethanone,
    208 1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-
    1H-benzimidazol-5-yl)-phenyl]-ethanol,
    209 N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-
    1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    210 2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-
    1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
    211 2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-
    1H-benzimidazol-5-yl)-benzenesulfonamide,
    212 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-
    phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    213 1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-
    5-yl)-phenyl]-ethanone,
    214 1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-
    5-yl)-phenyl]-ethanol,
    215 N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-
    benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    216 2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-
    5-yl)-phenyl]-propan-2-ol,
    217 2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-
    yl)-benzenesulfonamide,
    218 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-
    1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    219 1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-
    benzimidazol-5-yl)-phenyl]-ethanone,
    220 1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-
    benzimidazol-5-yl)-phenyl]-ethanol,
    221 N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-
    benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    222 2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-
    benzimidazol-5-yl)-phenyl]-propan-2-ol,
    223 2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-
    benzimidazol-5-yl)-benzenesulfonamide,
    224 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-
    cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    225 1-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanone,
    226 1-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanol,
    227 N-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    228 2-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-
    propan-2-ol,
    229 2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    230 N-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-
    C,C,C-trifluoro-methanesulfonamide,
    231 1-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanone,
    232 1-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanol,
    233 N-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    235 2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    236 C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    237 N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)-
    methanesulfonamide,
    238 N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-cyclopropyl)-
    phenyl]-methanesulfonamide,
    239 N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    240 N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-
    cyclopropyl)-phenyl]-methanesulfonamide,
    241 2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    242 C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-
    1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    243 N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)-
    C,C,C-trifluoro-methanesulfonamide,
    244 C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-
    yl}-cyclopropyl)-phenyl]-methanesulfonamide,
    245 C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H-
    benzimidazol-2-yl]-cyclopropyl}-phenyl)-methanesulfonamide,
    246 C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-
    benzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide,
    247 2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-cyclopropyl]-1H-
    benzimidazol-5-yl}-benzenesulfonamide,
    248 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-
    cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    249 2-[2-(4-trifluoromethoxy-phenylethynyl)-1H-benzimidazol-5-yl]-
    benzenesulfonamide,
    251 2-[2-(4-trifluoromethanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-
    benzenesulfonamide,
    252 C,C,C-trifluoro-N-{2-[2-(4-trifluoromethoxy-phenylethynyl)-1H-
    benzimidazol-5-yl]-phenyl}-methanesulfonamide,
    253 C,C,C-trifluoro-N-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-
    5-yl]-phenyl}-methanesulfonamide,
    254 C,C,C-trifluoro-N-{2-[2-(4-trifluoromethanesulfonyl-phenylethynyl)-1H-
    benzimidazol-5-yl]-phenyl}-methanesulfonamide,
    255 1-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone,
    256 1-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol,
    257 N-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-
    methanesulfonamide,
    258 2-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-
    ol,
    259 2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
    260 N-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-C,C,C-
    trifluoro-methanesulfonamide,
    261 1-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-
    ethanone,
    262 1-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-
    ethanol,
    263 N-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-
    methanesulfonamide,
    264 2-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-
    propan-2-ol,
    265 2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-
    benzenesulfonamide,
    266 C,C,C-trifluoro-N-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-
    benzimidazol-5-yl]-phenyl}-methanesulfonamide,
    267 1-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-
    benzimidazol-5-yl}-phenyl)-ethanone,
    268 1-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-
    benzimidazol-5-yl}-phenyl)-ethanol,
    269 N-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    270 2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-
    benzimidazol-5-yl}-phenyl)-propan-2-ol,
    271 2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-
    benzimidazol-5-yl}-benzenesulfonamide,
    272 C,C,C-trifluoro-N-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-
    phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    273 1-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanone,
    274 1-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanol,
    275 N-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    276 2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    277 2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    278 C,C,C-trifluoro-N-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    279 1-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-
    benzimidazol-5-yl}-phenyl)-ethanone,
    280 1-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-
    benzimidazol-5-yl}-phenyl)-ethanol,
    281 N-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    282 2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-
    benzimidazol-5-yl}-phenyl)-propan-2-ol,
    283 2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    284 C,C,C-trifluoro-N-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-
    1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    285 1-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone,
    286 2-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-
    ol,
    287 N-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-
    methanesulfonamide,
    288 1-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol,
    289 2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,
    290 N-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-C,C,C-
    trifluoro-methanesulfonamide,
    291 1-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-
    ethanone,
    292 1-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-
    ethanol,
    293 N-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-
    methanesulfonamide,
    296 C,C,C-trifluoro-N-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-
    5-yl]-phenyl}-methanesulfonamide,
    297 N-{4-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}-
    methanesulfonamide,
    298 N-(4-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl}-
    phenyl)-methanesulfonamide,
    299 N-{2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-
    phenyl}-methanesulfonamide,
    300 N-(4-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl-
    ethynyl}-phenyl)-methanesulfonamide,
    301 2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-
    benzenesulfonamide,
    302 C,C,C-trifluoro-N-{2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-
    benzimidazol-5-yl]-phenyl}-methanesulfonamide,
    303 N-{4-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}-C,C,C-
    trifluoro-methanesulfonamide,
    304 C,C,C-trifluoro-N-(4-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl-
    ethynyl}-phenyl)-methanesulfonamide,
    305 C,C,C-trifluoro-N-{4-[5-(2-methanesulfonylamino-phenyl)-1H-
    benzimidazol-2-yl-ethynyl]-phenyl}-methanesulfonamide,
    306 C,C,C-trifluoro-N-(4-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-
    benzimidazol-2-yl-ethynyl}-phenyl)-methanesulfonamide,
    307 2-[2-(4-trifluoromethanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-
    yl]-benzenesulfonamide, and
    308 C,C,C-trifluoro-N-{2-[2-(4-trifluoromethanesulfonylamino-phenylethynyl)-
    1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide.
    • General Synthetic Methods
  • Representative compounds of the present invention can be synthesized in accordance with the general synthetic methods described below and are illustrated in the schemes that follows. Since the schemes are an illustration, the invention should not be construed as being limited by the chemical reactions and conditions expressed. The preparation of the various starting materials used in the schemes is well within the skill of persons versed in the art.
  • Compounds of the present invention can be synthesized using the methods described in the schemes that follow.
  • The terms used in describing the invention are commonly used and known to those skilled in the art. As used herein, the following abbreviations and formulas have the indicated meanings:
  • Abbreviation Meaning
    Boc tert-butoxycarbonyl
    BOP benzotriazol-1-yloxy-
    tris(dimethylamino)phosphonium
    hexafluorophosphate
    AcOH acetic acid
    Cpd compound
    DBU 1,8-diazabicyclo[5.4.0]undec-7-ene
    DCM dichloromethane
    DIEA N,N-diisopropyl ethyl amine
    DME ethylene glycol dimethyl ether
    DMF N,N-dimethylformamide
    DMSO dimethyl sulfoxide
    EtOAc ethyl acetate
    EtOH ethanol
    HPLC high performance liquid chromatography
    LiOH lithium hydroxide
    min minute(s)
    n-BuLi n-butyl lithium
    h/hr/hrs hour(s)
    mCPBA m-chloroperbenzoic acid
    MeOH methanol
    MTBE methyl-t-butyl ether
    PdCl2(dppf) or [1,1′-bis-(diphenylphosphino)ferroceno]
    Pd(dppf)Cl2CH2Cl2 dichloropalladium (II) dichloromethane complex
    Pd(PPh3)4 palladium tetrakistriphenylphosphine
    RT or rt room temperature
    TBAB tetrabutylammonium bromide
    TBSOTf t-butyldimethylsilyl trifluoromethane sulfonate
    Et3N triethylamine
    TFA trifluoroacetic acid
    THF tetrahydrofuran
    TLC thin layer chromatography
    • Reaction Scheme AA
  • Scheme AA illustrates a general synthesis of benzimidazoles of formula AA5, representative of a compound of Formula (I).
  • Figure US20110190364A1-20110804-C00172
  • Typically, a solution of 4-bromobenzene-1,2-diamine AA1 and a suitable carboxylic acid AA2 in phosphorous oxychloride (POCl3) is heated at reflux to obtain bromobenzimidazole AA3.
  • Alternatively, the acid can be converted to an acid chloride using oxalyl chloride and a catalytic amount of DMF in a solvent such as methylene chloride.
  • The acid chloride AA2 is heated with 4-bromobenzene-1,2-diamine AA1 in acetic acid to give AA3. A suitably substituted phenyl group can be appended to AA3 by a variety of coupling reactions (Suzuki, Stille) that are well known to those versed in the art. A particularly useful substitution method employs a palladium catalyzed cross-coupling Suzuki reaction (Huff, B. et. al. Org. Syn. 1997, 75: 53-60; and, Goodson, F. E. et. al. Org. Synth. 1997, 75: 61-68).
  • Figure US20110190364A1-20110804-C00173
  • As an example, a mixture of bromobenzimidazole AA3 is reacted with a suitable phenyl boronic acid AA4 in the presence of a reagent such as cesium carbonate and a catalytic amount of a palladium catalyst such as PdCl2dppf in a solvent such as a mixture of dioxane and ethanol at elevated temperatures to give AA5. The reaction times can be reduced by carrying out this procedure at similar (about 100° C.) or lower temperatures in a microwave synthesizer. Other palladium catalysts suitable for this type of reaction include Pd(PPh3)4.
    • Reaction Scheme BB
  • Cinnamic acids, as required, can be synthesized via procedures described in reaction Scheme BB.
  • Figure US20110190364A1-20110804-C00174
  • A solution of arylaldehyde BB1 and (carbethoxymethylene)triphenyl phosphorane in a solvent such as toluene or benzene in the presence of a base such as NaOH is stirred usually at elevated temperatures to give the corresponding cinnamate ester. The ester is hydrolyzed under standard conditions to provide the corresponding cinnamic acid BB2.
  • Figure US20110190364A1-20110804-C00175
  • Phenylpropionic acid BB3, as required, can be synthesized from cinnamic acid BB2 by hydrogenation using a variety of standard procedures. As shown above, a mixture of BB2 in ethanol with a catalytic amount of palladium on carbon (10%) is stirred at room temperature in an atmosphere of hydrogen (50 psi) to provide acid BB3.
    • Reaction Scheme BB′
  • Reaction Scheme BB′ is a variation of Reaction Scheme BB.
  • Figure US20110190364A1-20110804-C00176
  • Reaction of aldehyde BB1 with malonic acid and a catalytic amount of piperidine in pyridine at elevated temperatures produces cinnamic acid BB2 in high yield.
  • Figure US20110190364A1-20110804-C00177
  • Acid BB2 is converted to the acid chloride by reaction with oxalyl chloride and a catalytic amount of DMF in a solvent such as methylene chloride. The acid chloride is then heated with AA1 in acetic acid to give BB′1, which is further elaborated in place of AA3 as described in reaction Scheme AA.
    • Reaction Scheme CC
  • Reaction Scheme CC provides a method to prepare substituted 4-bromobenzene-1,2-diamine intermediates.
  • Figure US20110190364A1-20110804-C00178
  • As an example, to a solution of a suitably substituted 4-bromoaniline CC1 in trifluoroacetic anhydride is added KNO3 portionwise at a suitable temperature. The reaction mixture may then be warmed to room temperature for optimal conversion to nitroamide CC2.
  • Figure US20110190364A1-20110804-C00179
  • Sequentially, using standard procedures, the amide is hydrolyzed and the nitro group is reduced to give bromodiamine CC3. Intermediate CC3 is further elaborated as described in reaction Scheme AA.
    • Reaction Scheme DD
  • An alternative synthetic sequence to produce compounds of the present invention is described in reaction Scheme DD.
  • Figure US20110190364A1-20110804-C00180
  • A substituted bromobenzimidazole DD1 (representative of AA3 in Scheme AA) is protected (using a protecting group such as Boc), then converted to a pinicolboronate ester DD2 under standard Suzuki coupling conditions (Prieto, M. et. al., J. Org. Chem. 2004, 69: 6812-6820; McDonald, D. et. al., Bioorg. Med. Chem. Lett. 2005, 15: 5241-5246; and, Poon, S. F. et. al. Bioorg. Med. Chem. Lett. 2004, 14, 5477-5480).
  • In a typical procedure, a mixture of bromo-benzimidazole DD1, bis-(pinacolato)diboron, potassium carbonate and a catalytic amount of a palladium catalyst such as PdCl2dppf in DMF is heated at elevated temperatures to give boronate ester DD2. Frequently, the reaction durations can be reduced by carrying out this procedure at similar or lower temperatures in a microwave irradiation apparatus.
  • Figure US20110190364A1-20110804-C00181
  • Boronate ester DD2 can be converted to compounds of the present invention (Boc protected DD3) by Suzuki coupling with a phenyl halide, mesylate or triflate (R1)pPh-X. In this instance, borane DD2 is reacted with a suitable aryl halide, tetrakis (triphenylphosphine) palladium (0) and tri-tert-butylphosphonium tetrafluoroborate in 2M aqueous potassium carbonate in toluene at 100° C. to give the protected form of DD3. Deprotection with an acid such as TFA gives DD3.
    • Reaction Scheme EE
  • Reaction Scheme EE describes methods to prepare representative compounds of the present invention.
  • Figure US20110190364A1-20110804-C00182
  • Aniline EE1 can be converted to a variety of amides, carbamates or ureas EE2 by utilizing any number of acylation methods that are commonly used by persons versed in the art. As an example, reaction of EE1 in a solvent such as THF with a substituted acid chloride and a base such as triethylamine gives the corresponding amide of EE2. As a further example, reaction of EE1 in THF with a substituted chloroformate and triethylamine gives the corresponding substituted carbamate of EE2.
  • EE1 can be converted to sulfonamides by utilizing various sulfonylation conditions. For instance, reaction of EE1 in a solvent such as THF with an alkylsulfonyl chloride and triethylamine gives the alkylsulfonamide EE3. EE1 can be selectively, and successively substituted to give EE3. An efficient method of achieving this is via reductive alkylation with aldehydes or ketones (see Mattson, R. J. et. al. J. Org. Chem. 1990, 55, 2552-2554) and references cited therein]. In this procedure, equal amounts of EE1 and an aldehyde or ketone are stirred with titanium (IV) isopropoxide, followed the addition of sodium cyanoborohydride in a solvent such as ethanol to give substituted amine EE3.
    • Reaction Scheme FF
  • A synthetic sequence to produce compounds of the present invention wherein L is cyclopropyl is described in reaction Scheme FF.
  • Figure US20110190364A1-20110804-C00183
  • Reaction of cinnamate ester FF1, in this case a methyl ester, with trimethylsulfonium iodide methylide in a solvent such as DMSO and sodium hydride (as exemplified by Burger, A. et. al. J. Med. Chem. 1970, 13, 33-35), gives cyclopropyl ester FF2. Hydrolysis of FF2 gives acid FF3, which is further elaborated into the benzimidazoles described in Scheme AA.
    • Reaction Scheme GG
  • Reaction Scheme GG describes an alternative method to prepare cyclopropyl acid intermediates.
  • Figure US20110190364A1-20110804-C00184
  • Cinnamic acids are converted to the corresponding Weinreb amide, by conversion to the acid chloride as described in Reaction Scheme AA and BB′. The acid chloride is reacted with N,N-dimethylhydroxylamine hydrochloride and a base such as triethylamine in methylene chloride to give amide GG2.
  • Amide GG2 is converted to cyclopropyl amide GG3 as described in Scheme FF. The amide GG3 is then hydrolyzed to give acid GG4, typically by reaction with potassium tertiary butoxide in THF.
    • Reaction Scheme HH
  • A synthetic sequence to produce compounds of the present invention wherein R1Ar is benzenesulfonamide is described in reaction Scheme HH.
  • Figure US20110190364A1-20110804-C00185
  • Coupling by Suzuki reaction of boronate ester DD2 from reaction Scheme DD and bromobenzene-t-butylsulfonamide HH1 followed by deprotection with TFA gives the product HH2.
    • Reaction Scheme II
  • A synthetic sequence to produce compounds of the present invention wherein R is an ether group is described in reaction Scheme II.
  • Figure US20110190364A1-20110804-C00186
  • An ester of commercially available 4-hydroxycinnamic acid II1 can be converted to ether analogs by a number of routes including the Williamson reaction. In this well-known procedure, II1 and an alkyl halide is reacted with a base such as cesium carbonate in a solvent such as acetonitrile to give the product II2.
  • More effective electrophiles can be derivatives of alcohols such as mesylates, p-toluene sulfonates or trifluoromethanesulfonates (triflates). An effective alternative method is the conversion of II1 to ether analogs II2 via the Mitsunobu reaction (as reviewed by Mitsunobu, O., Synthesis, 1981, 1-28).
  • Figure US20110190364A1-20110804-C00187
  • Ether analogs II2 can be further reduced to acid II3 using standard techniques.
    • Reaction Scheme JJ
  • Reaction Scheme JJ describes methods to prepare cinnamic acids that contain substituted amino groups.
  • Figure US20110190364A1-20110804-C00188
  • Cinnamate ester JJ1 can be converted to a variety of amides, carbamates or ureas JJ2 by utilizing any number of acylation methods that are commonly used by persons versed in the art. As an example, reaction of JJ1 in a solvent such as THF with a substituted acid chloride and a base such as triethylamine gives the corresponding amide of JJ2. As a further example, reaction of JJ1 in THF with a substituted chloroformate and triethylamine gives the corresponding substituted carbamate of JJ2. JJ1 can be converted to sulfonamides by utilizing various sulfonylation conditions.
  • For instance, reaction of JJ1 in a solvent such as THF with an alkylsulfonyl chloride and triethylamine gives the alkylsulfonamide JJ3. JJ1 can be selectively, and successively substituted to give JJ4. An efficient method of substitution is via reductive alkylation with aldehydes or ketones (see Mattson, R. J. et. al. J. Org. Chem., 1990, 55, 2552-2554 and references cited therein). In this procedure, equal amounts of JJ1 and an aldehyde or ketone are stirred with titanium (IV) isopropoxide, followed the addition of sodium cyanoborohydride in a solvent such as ethanol to give substituted amine JJ4.
    • Reaction Scheme KK
  • A synthetic sequence to prepare compounds of the present invention wherein L is acetylene is described in Reaction Scheme KK.
  • Figure US20110190364A1-20110804-C00189
  • When not commercially available, propiolic acids KK2 are prepared by reaction of acetylenes KK1 with n-butyl lithium in THF at −78° C. warming to 0° C. for 30 min. The mixture is cooled to −78° C., and transferred to a saturated solution of carbon dioxide in THF at −78° C. The reaction is slowly warmed to rt to give the corresponding propiolic acid KK2.
  • Figure US20110190364A1-20110804-C00190
  • Reaction of the propiolic acid KK2 with 4-bromobenzene-1,2-diamine dihydrochloride KK3 in refluxing ethylene glycol gives chlorovinylbenzimidazole KK4.
  • Figure US20110190364A1-20110804-C00191
  • Reaction of KK3 with a phenyl boronic acid under Suzuki conditions in a microwave synthesizer and thermal conditions as described in Reaction Scheme AA gives acetylene compounds KK4.
    • Reaction Scheme LL
  • An alternative synthetic sequence to produce compounds of the present invention is described in reaction Scheme LL.
  • Figure US20110190364A1-20110804-C00192
  • Protected bromodiamine LL1 is coupled with a suitable boronic acid via Suzuki coupling as described in previous reaction schemes to give the diamine LL2.
  • Figure US20110190364A1-20110804-C00193
  • LL2 is then reacted with an acid or acid chloride to give LL3 (as described in reaction Schemes AA or BB′).
    • Reaction Scheme MM
  • A synthetic sequence to produce compounds of the present invention wherein L is vinyl or ethyl that may be used as an alternative to Scheme BB′ is described in reaction Scheme MM.
  • Figure US20110190364A1-20110804-C00194
  • A solution of AA1 and dichloroimine MM1 (as described in McElvain, S. M. et. al. J. Am. Chem. Soc. 1942, 64, 1825) in ethanol is heated to give chloromethyl benzimidazole MM2 (as described in Komoriya et. al. Bioorg. Med. Chem., 2004, 12, 2099-2114).
  • Figure US20110190364A1-20110804-C00195
  • Heating in dichloroethane with triphenylphosphine converts MM2 to the phosphonium salt MM3.
  • Figure US20110190364A1-20110804-C00196
  • Reaction of MM3 with various aldehydes or ketones in a solution of anhydrous THF and EtOH with a base such as DBU (1,8-diazabicyclo[4.5.0]undec-7-ene) gives bromobenzimidazole BB′1, which is further elaborated as described in reaction Scheme AA.
    • Reaction Scheme NN
  • An alternative synthetic sequence to produce compounds of the present invention is described in reaction Scheme NN.
  • Figure US20110190364A1-20110804-C00197
  • The biaryldiamine LL2 is reacted with dichloroimine MM1 as described in reaction Scheme MM to give NN1.
  • Figure US20110190364A1-20110804-C00198
  • As described in reaction Scheme MM, NN1 is carried forward to give NN2.
    • Reaction Scheme OO
  • Compounds of the present invention wherein L is ethylene can be prepared by the alternate route described in Reaction Scheme OO.
  • Figure US20110190364A1-20110804-C00199
  • Compounds of the present invention such as NN3, wherein L is vinyl, are dissolved in a solvent such as methanol, and are hydrogenated using a catalyst such as 10% Pd on carbon to give 001.
    • Reaction Scheme PP
  • A synthetic sequence to produce compounds of the present invention wherein L is cyclopropyl is described in reaction Scheme PP.
  • Figure US20110190364A1-20110804-C00200
  • Reaction of olefin PP1 with an alkyl diazoacetate, such as ethyl diazoacetate, in the presence of a catalyst, such as copper(I) trifluoromethane sulfonate and Evans' chiral ligand (Evans, D. A.; Woerpel, K. A.; Hinman, M. M.; Faul, M. M. J. Am. Chem. Soc. 1991, 113, 726-728) in a solvent such as chloroform, gives a cyclopropyl ester enantiomer PP2.
  • The (R,R)-cyclopropyl ester PP2 enantiomer is obtained when a chiral ligand such as 2,2-bis-[2-((4S)-(1,1-dimethylethyl)-1,3-oxazolinyl)]propane Compound 38b is used. The (S,S)-cyclopropyl ester enantiomer is obtained when the chiral ligand 2,2-bis-[2-((4R)-(1,1-dimethylethyl)-1,3-oxazolinyl)]propane Compound 38a is used. The configurations of the cyclopropyl moiety were predicted based on Evans' J. Am. Chem. Soc. 1991 report. Hydrolysis of the ester PP2 gives acid PP3, which is further elaborated into the benzimidazoles of Scheme AA.
  • Figure US20110190364A1-20110804-C00201
  • To determine the enantiomeric excess of the asymmetric cyclopropanation products PP2, acid PP3 is reacted with N,O-dimethylhydroxylamine in the presence of a base such as diisopropylethylamine, and an amide coupling reagent such as BOP, in a solvent such as DMF to produce the methoxy methyl amide PP4.
  • The resulting 1H NMR of amide PP4 in the presence of an appropriate amount of chiral shifting agent, such as (R)-(−)-2,2,2-trifluoro-1-(9-anthryl)ethanol, gives base line resolution of the resulting methoxy singlets. The ratio of the integration of the methoxy singlets gives the ee value. Thus, the NMR showed methoxy singlets around 3.47 and 3.45 ppm. The integration of the singlets was 1 and 99, respectively; thus providing an ee value of 99%.
    • Reaction Scheme QQ
  • A synthetic sequence to produce compounds of the present invention wherein R1 is an alcohol is described in reaction Scheme QQ.
  • Figure US20110190364A1-20110804-C00202
  • As elaborated in Scheme BB′, the aldehyde QQ1 is reacted with malonic acid and a catalytic amount of piperidine in pyridine at elevated temperatures to provide an acid QQ2. Acid QQ2 is converted to an acid chloride QQ3 by reaction with oxalyl chloride and a catalytic amount of DMF in a solvent such as methylene chloride.
  • Figure US20110190364A1-20110804-C00203
  • As elaborated in Scheme AA, the acid chloride QQ3 is heated with 4-bromobenzene-1,2-diamine AA1 in acetic acid to give a bromobenzimidazole QQ4.
  • Figure US20110190364A1-20110804-C00204
  • As elaborated in Scheme AA, a suitably substituted phenyl boronic acid is reacted with benzimidazole QQ4 in the presence of a reagent and a catalytic amount of a palladium catalyst in a solvent to give an alcohol substituted benzimidazole QQ5, representative of a compound of Formula (I).
    • Example 1 (E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone (Cpd 1) Step A. (E)-5-bromo-2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazole
  • To a solution of 3-(4-tert-butyl-phenyl)-acrylic acid (12 g, 58.7 mmol) in POCl3 (200 mL), was slowly added 4-bromo-benzene-1,2-diamine (10 g, 53.4 mmol). The solution was heated at reflux for 18 h. The solution was concentrated, and the residual POCl3 was azeotropically removed with toluene. The residue was partitioned between EtOAc and 10% Na2CO3. The organic layer was washed with brine, dried over Na2SO4, filtered, and the filtrate was concentrated. The residue was purified by chromatography (silica, EtOAc: hexanes, 3:7) to give the title Compound Ia (7.1 g, 31% yield). 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.64 (d, 1H, J=13.9 Hz) 7.62 (s, 1H) 7.41 (d, 2H, J=8.4 Hz) 7.36 (d, 1H, J=8.5 Hz) 7.33 (d, 2H, J=8.4 Hz) 7.28 (s, 1H) 7.22 (dd, 1H, J=1.8 Hz, J=8.5 Hz) 7.02 (d, 1H, J=16.5 Hz) 1.25 (s, 9H).
    • Step B. (E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone
  • A solution of Compound 1a (0.106 g, 0.30 mmol), 2-acetylbenzeneboronic acid (136 mg; 0.76 mmol), PdCl2dppf (0.06 mmol) and Cs2CO3 (0.244 g, 0.75 mmol) in 1,4-dioxane:EtOH 5:1 was heated to 115° C. After 18 h, the solution was cooled and concentrated. The residue was purified using preparative TLC plates (silica gel, 20×20 cm, 2000 microns, EtOAc:hexanes 3:7) to give the title Compound 1 (0.0146 g). 1H-NMR (400 MHz, CD3OD) δ (ppm): 7.54 (m, 11H) 7.23 (dd, 1H, J=1.6 Hz, J=8.3 Hz) 7.15 (d, 1H, J=16.5 Hz) 2.02 (s, 3H) 1.36 (s, 9H). MS (ESI, pos. ion) m/z: 395.3 (M+1).
  • Using the procedures described in Example 1 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:
  • Cpd Name and Data
    3 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol
    The title compound (0.0048 g) was prepared from 2-hydroxybenzeneboronic
    acid (0.0345 g, 0.25 mmol) and Compound 1a (0.029 g, 0.1 mmol). 1H-NMR
    (400 MHz, CDCl3) δ (ppm): 7.56 (s, 1H) 7.31 (dd, 2H, J = 12.2 Hz, J = 24.1 Hz)
    7.10 (m, 8H) 6.86 (t, 1H, J = 7.3 Hz) 6.78 (d, 1H, J = 16.4 Hz) 1.19 (s, 9H). MS
    (ESI, pos. ion) m/z: 368.3 (M + 1).
    4 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    acetamide
    The title compound (0.001 g) was prepared from 2-N-acetyl-benzeneboronic
    acid (0.136 g, 0.76 mmol) and Compound 1a (0.106 g, 0.3 mmol). 1H-NMR
    (400 MHz, CD3OD) δ (ppm) 7.44 (m, 4H) 7.24 (m, 6H) 6.91 (d, 1H, J = 12.4 Hz)
    6.47 (d, 1H, J = 12.4 Hz) 1.86 (s, 1H) 1.20 (s, 9H). MS (ESI, pos. ion) m/z:
    410.2 (M + 1).
    5 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide
    The title compound (0.001 g) was prepared from 2-aminocarbonyl
    benzeneboronic acid (0.136 g, 0.76 mmol) and Compound 1a (0.106 g, 0.3 mmol).
    1H-NMR (400 MHz, CD3OD) δ (ppm) 7.48 (m, 6H) 7.37 (m, 5H)
    7.26 (dd, 1H, J = 1.6 Hz, J = 8.3 Hz) 7.04 (d, 1H, J = 16.5 Hz) 1.26 (s, 9H). MS (ESI,
    pos. ion) m/z: 396.1 (M + 1).
    6 (E)-3-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide
    The title compound (0.001 g) was prepared from 3-aminocarbonylbenzene
    boronic acid (0.136 g, 0.76 mmol) and Compound 1a (0.106 g, 0.3 mmol). 1H-
    NMR (400 MHz, CD3OD) δ (ppm) 8.22 (t, 1H, J = 1.7 Hz) 7.88 (m, 3H) 7.62 (m,
    6H) 7.51 (m, 2H) 7.17 (d, 1H, J = 16.5 Hz) 1.38 (s, 9H). MS (ESI, pos. ion) m/z:
    396.1 (M + 1).
    7 (E)-4-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide
    The title compound (0.002 g) was prepared from 4-aminocarbonylbenzene
    boronic acid (0.136 g, 0.76 mmol) and Compound 1a (0.106 g, 0.3 mmol). 1H-
    NMR (400 MHz, CD3OD) δ (ppm) 7.97 (m, 2H) 7.77 (m, 4H) 7.60 (m, 4H)
    7.47 (d, 2H, J = 8.4 Hz) 7.13 (d, 1H, J = 16.5 Hz) 1.36 (s, 9H). MS (ESI, pos. ion) m/z:
    410.2 (M + 1).
    8 (E)-N-(4-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    acetamide
    The title compound 0.0038 g) was prepared from 4-N-acetylbenzeneboronic
    acid (0.136 g, 0.76 mmol) and Compound 1a (0.106 g, 0.3 mmol) to give the title
    compound (0.0038 g). 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.73 (m, 2H)
    7.61 (m, 7H) 7.49 (m, 3H) 7.12 (d, 1H, J = 16.5 Hz) 2.17 (s, 3H) 1.36 (s, 9H). MS
    (ESI, pos. ion) m/z: 410.2 (M + 1).
    9 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide
    The title compound (0.0045 g) was prepared from 2-methanesulfonamide
    benzeneboronic acid (0.163 g, 0.76 mmol) and Compound 1a (0.106 g, 0.3 mmol).
    1H-NMR (400 MHz, CD3OD) δ (ppm) 7.62 (m, 6H) 7.50 (d, 2H, J = 8.5 Hz)
    7.41 (m, 2H) 7.34 (m, 2H) 7.17 (d, 1H, J = 16.5 Hz) 2.75 (s, 3H) 1.37 (s, 9H). MS
    (ESI, pos. ion) m/z: 446.2 (M + 1).
    10 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    carbamic acid tert-butyl ester
    The title compound (0.0016 g) was prepared from 2-N-Boc-benzeneboronic acid
    (0.180 g, 0.76 mmol) and (E)-5-bromo-2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-
    aminobenzimidazole Compound 1b (0.106 g, 0.3 mmol). 1H-NMR (400 MHz,
    CD3OD) δ (ppm) 7.62 (m, 5H) 7.50 (m, 2H) 7.33 (dd, 1H, J = 1.6 Hz, J = 8.3 Hz)
    7.14 (m, 3H) 6.83 (m, 2H) 3.37 (s, 9H) 1.37 (s, 9H). MS (ESI, pos. ion) m/z:
    468.1 (M + 1).
    11 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenylamine
    A solution of (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-carbamic acid tert-butyl ester (0.005 g, 0.01 mmol) in methylene
    chloride (1 mL) was treated with trifluoroacetic acid (0.5 mL). The solution was
    stirred at room temperature for 4 h, then concentrated to give the title compound
    (0.003 g). 1H-NMR (400 MHz, CD3OD) δ (ppm) 8.03 (d, 1H, J = 16.5 Hz) 7.90 (d,
    1H, J = 8.5 Hz) 7.85 (s, 1H) 7.74 (d, 2H, J = 8.4 Hz) 7.65 (dd, 1H, J = 1.5 Hz, J = 8.5 Hz)
    7.59 (d, 2H, J = 8.4 Hz) 7.43 (m, 5H) 1.39 (s, 9H). MS (ESI, pos. ion) m/z:
    368.1 (M + 1).
    12 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanol
    The title compound (0.0046 g) was prepared from 2-hydroxymethylbenzene
    boronic acid (0.102 g, 0.76 mmol) and Compound 1a (0.106 g, 0.3 mmol). 1H-
    NMR (400 MHz, CD3OD) δ (ppm) 7.59 (m, 5H) 7.49 (d, 2H, J = 8.4 Hz) 7.40 (m,
    2H) 7.34 (m, 2H) 7.27 (dd, 1H, J = 1.6 Hz, J = 8.3 Hz) 7.16 (d, 1H, J = 16.6 Hz)
    4.58 (s, 2H) 1.37 (s, 9H). MS (ESI, pos. ion) m/z: 383.2 (M + 1).
    24 (E)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    acetamide
    Using the procedure of Example 1, Step B, the title compound (0.001 g) was
    prepared from 2-N-acetylbenzeneboronic acid (0.136 g, 0.76 mmol) and (E)-5-
    bromo-2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazole Compound 1c (0.10 g,
    0.30 mmol). 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.61 (m, 5H) 7.39 (m, 6H)
    7.18 (d, 1H, J = 16.5 Hz) 1.99 (s, 3H). MS (ESI, pos. ion) m/z: 390.2 (M + 1).
    25 (E)-N-(3-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    acetamide
    The title compound (0.0102 g) was prepared from 3-N-acetylbenzeneboronic
    acid (0.136 g, 0.76 mmol) and Compound 1c (0.10 g, 0.30 mmol). 1H-NMR (400 MHz,
    CD3OD) δ (ppm) 7.78 (d, 1H, J = 0.9 Hz) 7.63 (s, 1H) 7.44 (m, 5H) 7.26 (m,
    4H) 7.01 (d, 1H, J = 16.5 Hz) 2.06 (s, 3H). MS (ESI, pos. ion) m/z: 390.1 (M + 1).
    26 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide
    The title compound (0.0031 g) was prepared from 2-aminocarbonylbenzene
    boronic acid (0.125 g, 0.76 mmol) and Compound 1c (0.10 g, 0.30 mmol). 1H-
    NMR (400 MHz, CDCl3 + CD3OD) δ (ppm) 7.62 (s, 1H) 7.40 (m, 9H) 7.18 (td,
    1H, J = 8.4 Hz, J = 10.1 Hz) 7.01 (d, 1H, J = 16.5 Hz). MS (ESI, pos. ion) m/z:
    376.2 (M + 1).
    27 (E)-1-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanone
    The title compound (0.001 g) was prepared from 2-acetylbenzeneboronic acid
    (0.125 g, 0.76 mmol) and Compound 1c (0.10 g, 0.30 mmol). 1H-NMR (400 MHz,
    CD3OD) δ (ppm) 7.49 (m, 5H) 7.37 (m, 4H) 7.23 (td, 1H, J = 8.4 Hz, J = 10.3 Hz)
    7.14 (dd, 1H, J = 1.7 Hz, J = 8.3 Hz) 7.06 (d, 1H, J = 16.5 Hz) 1.91 (s, 3H). MS
    (ESI, pos. ion) m/z: 375.2 (M + 1).
    28 (E)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide
    The title compound (0.0021 g) was prepared from 2-methylsulfonylamino
    benzeneboronic acid (0.163 g, 0.76 mmol) and Compound 1c (0.10 g, 0.30 mmol).
    1H-NMR (400 MHz, CD3OD) δ (ppm) 7.50 (m, 5H) 7.36 (m, 1H) 7.26 (m,
    5H) 7.07 (d, 1H, J = 16.5 Hz) 2.64 (s, 3H). MS (ESI, pos. ion) m/z: 426.1 (M + 1).
    30 (E)-2-[3-(4-tert-butyl-phenyl)-propyl]-5-m-tolyl-1H-benzimidazole
    The title compound (0.0182 g) was prepared from 3-methylphenylbenzene
    boronic acid (0.052 g, 0.38 mmol) and 5-bromo-2-[3-(4-tert-butyl-phenyl)-
    propyl]-1H-benzimidazole Compound 5a (0.055 g, 0.15 mmol). 1H-NMR (400 MHz,
    CDCl3) δ (ppm) 7.33 (m, 3H) 7.18 (m, 5H) 7.03 (d, 1H, J = 7.4 Hz) 6.95 (d,
    2H, J = 8.3 Hz) 2.85 (m, 2H) 2.57 (t, 2H, J = 7.5 Hz) 2.30 (s, 3H) 2.06 (m, 2H)
    1.17 (s, 9H). MS (ESI, pos. ion) m/z: 383.2 (M + 1).
    • Example 2 (E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol (Cpd 2)
  • A solution of (E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone Cpd 1 (0.005 g, 0.01 mmol) in ethanol (0.5 mL) was treated with NaBH4 (0.003 g, 0.08 mmol). After 3 h, the reaction mixture was applied to a preparative TLC plate (2000 microns, silica gel, 20×20) and developed using EtOAc: hexanes, 1:1. The desired band was extracted and concentrated to give the title compound (0.002 g). 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.69 (m, 1H) 7.62 (m, 3H) 7.50 (m, 3H) 7.41 (ddd, 2H, J=2.5 Hz, J=10.1 Hz, J=14.1 Hz) 7.32 (dt, 1H, J=1.4 Hz, J=7.5 Hz) 7.23 (m, 2H) 7.17 (d, 1H, J=16.5 Hz) 4.99 (q, 1H, J=6.3 Hz) 1.38 (s, 9H) 1.35 (d, 1.5H, J=6.1 Hz) 1.33 (d, 1.5H, J=6.1 Hz). MS (ESI, pos. ion) m/z: 397.2 (M+1).
    • Example 3 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide (Cpd 13) Step A. (E)-5-bromo-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole
  • Using the procedure of Example 1, Step A, the title Compound 10c (0.910 g) was prepared from 3-(4-trifluoromethyl-phenyl)-acrylic acid Compound 10a (1.5 g, 6.9 mmol) and 4-bromo-benzene-1,2-diamine (1.3 g, 6.9 mmol). 1H-NMR (400 MHz, CDCl3+DMSO(d6)) δ (ppm) 7.78 (d, 1H, J=16.5 Hz) 7.73 (d, 1H, J=1.7 Hz) 7.66 (m, 4H) 7.48 (d, 2H, J=8.0 Hz) 7.33 (dd, 1H, J=1.8 Hz, J=8.5 Hz) 7.23 (d, 1H, J=16.5 Hz).
    • Step B. (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide
  • Using the procedure of Example 1, Step B, the title compound (0.001 g) was prepared from 2-carboxamidophenylbenzeneboronic acid (0.120 g, 0.76 mmol) and Compound 10c (0.110 g, 0.30 mmol). 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.74 (d, 2H, J=8.2 Hz) 7.63 (m, 3H) 7.57 (s, 1H) 7.40 (m, 6H) 7.22 (d, 1H, J=16.5 Hz). MS (ESI, pos. ion) m/z: 408.1 (M+1).
  • Using the procedures described in Example 3 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:
  • Cpd Name and Data
    14 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol
    The title compound (0.001 g) was prepared from 2-hydroxybenzeneboronic acid
    (0.105 g, 0.38 mmol) and Compound 10c (0.110 g, 0.30 mmol). 1H-NMR (400 MHz,
    CD3OD) δ (ppm) 7.74 (d, 2H, J = 8.3 Hz) 7.63 (dd, 3H, J = 8.7 Hz, J = 17.1 Hz)
    7.56 (s, 1H) 7.50 (d, 1H, J = 8.3 Hz) 7.38 (dd, 1H, J = 1.5 Hz, J = 8.4 Hz)
    7.22 (m, 2H) 7.06 (m, 1H) 6.82 (m, 2H). MS (ESI, pos. ion) m/z: 381.3 (M + 1).
    15 (E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanone
    The title compound (0.001 g) was prepared from 2-acetylbenzeneboronic acid
    (0.125 g, 0.76 mmol) and Compound 10c (0.110 g, 0.30 mmol). 1H-NMR (400 MHz,
    CD3OD) δ (ppm) 7.75 (d, 2H, J = 8.2 Hz) 7.60 (m, 4H) 7.48 (m, 2H)
    7.38 (m, 3H) 7.23 (d, 1H, J = 16.6 Hz) 7.16 (dd, 1H, J = 1.7 Hz, J = 8.3 Hz) 1.92 (s, 3H).
    MS (ESI, pos. ion) m/z: 407.3 (M + 1).
    16 (E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanol
    A solution of (E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-ethanone Compound 15 (0.005 g, 0.01 mmol) in ethanol (0.5 mL)
    was treated with NaBH4 (0.003 g, 0.08 mmol). After 3 h, the solution was
    applied to a preparative TLC plate (2000 microns, silica gel, 20 × 20) and
    developed using EtOAc: hexanes, 1:1. The desired band was extracted and
    concentrated to give the title compound (0.001 g). 1H-NMR (400 MHz, CD3OD)
    δ (ppm) 7.87 (d, 1H, J = 8.2 Hz) 7.76 (d, 1H, J = 8.0 Hz) 7.67 (m, 1H) 7.51 (s, 1H)
    7.42 (m, 1H) 7.32 (m, 1H) 7.25 (m, 1H) 4.98 (q, 1H, J = 6.4 Hz) 1.35 (d, 1H,
    J = 6.4 Hz). MS (ESI, pos. ion) m/z: 409.2 (M + 1).
    17 (E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide
    The title compound (0094 g) was prepared from 2-methylsulfonyl
    aminobenzeneboronic acid (0.163 g, 0.76 mmol) and Compound 10c (0.110 g,
    0.30 mmol). 1H-NMR (400 MHz, DMSO(d6)) δ (ppm) 12.82 (s, 1H) 8.89 (s, 1H)
    7.91 (d, 2H, J = 8.1 Hz) 7.80 (m, 2H) 7.75 (s, 1H) 7.70 (m, 1H) 7.58 (d, 1H, J = 6.9 Hz)
    7.37 (m, 6H) 2.73 (d, 3H, J = 28.8 Hz). MS (ESI, pos. ion) m/z: 458.2 (M + 1).
    31 N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide
    Using the procedure of Example 1, Step A., 5-bromo-2-[2-(4-trifluoroethyl-
    phenyl)-ethyl]-1H-benzimidazole Compound 3b was prepared from 3-(4-
    trifluoromethyl-phenyl)-propionic acid (1.04 g, 5.04 mmol) and 4-bromo-
    benzene-1,2-diamine (0.946 g, 5.06 mmol).
    Using the procedure of Example 1, Step B., the title compound was prepared
    from 2-methylsulfonylaminobenzeneboronic acid (0.367 g, 1.7 mmol) and
    Compound 3b (0.188 g, 0.51 mmol). 1H-NMR (400 MHz, (CD3OD) δ (ppm)
    7.64-7.50 (m, 5H), 7.47-7.34 (m, 4H), 7.34-7.27 (m, 2H), 3.27 (s, 4H), 2.71 (s,
    3H). MS (ESI, pos. ion) m/z: 460.16 (M + 1).
    • Example 4 (E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide (Cpd 19) Step A. 3-(4-trifluoromethoxy-phenyl)-acrylic acid
  • A solution of 4-trifluoromethoxybenzaldehyde (26.3 mmol), malonic acid (5.6 g, 53.8 mmol) and piperidine (0.265 mL, 2.7 mmol) in pyridine (15 mL) was heated to 70° C. for 18 h. Water (200 mL) was added to the reaction solution. The mixture was acidified to pH 4 using concentrated hydrochloric acid. The solution was filtered. The solid was washed with water. The solid was dried in vacuo to give the title Compound 4a (1.2 g). 1H-NMR (d6-DMSO) δ (ppm): 6.80 (d, J=16.02 Hz, 1H), 6.72 (m, 2H), 6.38 (m, 2H), 5.55 (d, J=16.00 Hz, 1H).
    • Step B. 3-(4-trifluoromethoxy-phenyl)-acryloyl chloride
  • A solution of Compound 4a (1.2 g, 5.2 mmol) in methylene chloride (20 mL) was treated with oxalyl chloride (7.8 mL, 3.6 mmol). To the solution was added DMF (0.02 mL). The reaction solution was stirred at room temperature for 2 h. The reaction solution was concentrated. The residue was dried in vacuo to provide Compound 4b, which was used without further purification in the next step.
    • Step C. (E)-5-bromo-2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazole
  • A solution of Compound 4b (1 g, 4 mmol) in acetic acid (10 mL) was added slowly to a solution of 4-bromo-benzene-1,2-diamine (0.744 g, 4 mmol) in acetic acid (10 mL). The solution was heated to 100° C. for 18 h. The solution was cooled to room temperature. To the solution was added ethyl acetate:hexanes 3:7 (100 mL). The solution was filtered. The solid was dried in vacuo to give the title Compound 4c (1.1 g). 1H-NMR (400 MHz, DMSO d6) ppm 8.12 (d, J=16.60 Hz, 1H), 7.98 (m, 1H), 7.87 (m, 2H), 7.82-7.68 (m, 1H), 7.67-7.37 (m, 4H), 7.34 (d, J=16.58 Hz, 1H). MS (ESI pos. ion) m/z: 383.2 and 385.2.
    • Step D. (E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide
  • Using the procedure of Example 1, Step B, the title Compound 19 was prepared from 2-carboxamido-phenylbenzene boronic acid and Compound 4c.
  • Using the procedures described in Example 4 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:
  • Cpd Name and Data
    20 (E)-1-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanone
    The title compound (0.001 g) was prepared from 2-acetylbenzeneboronic acid
    (0.280 g, 1.7 mmol) and Compound 4c (0.195 g, 0.51 mmol). 1H-NMR (400 MHz,
    CD3OD) δ (ppm) 7.66 (d, J = 8.72 Hz, 2H), 7.61-7.43 (m, 4H),
    7.43-7.32 (m, 3H), 7.24 (d, J = 8.19 Hz, 2H), 7.19-7.06 (m, 2H), 1.96-1.86 (m, 3H). MS
    (ESI, pos. ion) m/z: 423.14 (M + 1).
    21 (E)-1-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanol
    Using the procedure of Example 2, the title compound was prepared from
    Compound 20. 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.76-7.80 (d,
    J = 8.84 Hz, 2H) 7.60-7.70 (m, 3H) 7.50 (bs, 1H) 7.40-7.44 (ddd, J = 1.26,
    7.32 Hz, 1H) 7.29-7.37 (m, 3H) 7.20-7.25 (m, 3H) 4.96-5.02 (q, J = 6.57 Hz,
    1H) 1.34-1.36 (d, J = 6.32 Hz, 3H). MS (ESI, pos. ion) m/z:
    425.2 (M + 1).
    22 (E)-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide
    The title compound (0.05 g) was prepared from 2-methylsulfonyl
    aminobenzeneboronic acid (0.521 g, 2.4 mmol) and Compound 4c (0.463 g,
    1.2 mmol). 1H-NMR (400 MHz, DMSO(d6)) δ (ppm) 12.76 (d, J = 5.43 Hz, 1H),
    8.90 (d, J = 4.68 Hz, 1H), 7.83 (d, J = 8.72 Hz, 2H), 7.65 (m, 1H), 7.50-7.22 (m,
    8H), 2.76 (s, 1.5H), 2.69 (s, 1.5H). MS (ESI, pos. ion) m/z: 474.2 (M + 1).
    • Example 5 2-{2-[3-(4-tert-butyl-phenyl)-propyl]-1H-benzimidazol-5-yl}-phenol (Cpd 29) Step A. 5-bromo-2-[3-(4-tert-butyl-phenyl)-propyl]-1H-benzimidazole
  • Using the procedure of Example 1, Step A, the title Compound 5a (0.512 g) was prepared from 4-(4-tert-butyl-phenyl)-butyric acid (2.0 g, 10.7 mmol) and 4-bromo-benzene-1,2-diamine (2.0 g, 10.7 mmol). 1H-NMR (400 MHz, CDCl3) δ (ppm) 7.73 (d, 1H, J=1.6 Hz) 7.45 (d, 1H, J=8.5 Hz) 7.38 (dd, 1H, J=1.8 Hz, J=8.5 Hz) 7.32 (m, 3H) 7.12 (d, 2H, J=8.3 Hz) 2.97 (m, 2H) 2.73 (t, 2H, J=7.4 Hz) 2.23 (m, 2H) 1.33 (s, 9H).
    • Step B. 2-{2-[3-(4-tert-butyl-phenyl)-propyl]-1H-benzimidazol-5-yl}-phenol
  • Using the procedure outlined in Example 1, Step B, the title Compound 29 (0.0083 g) was prepared from 2-hydroxybenzeneboronic acid (0.07 g, 0.5 mmol) and Compound 5a (0.074 g, 0.2 mmol). 1H-NMR (400 MHz, CDCl3) δ (ppm) 7.51 (s, 1H) 7.39 (d, 1H, J=8.1 Hz) 7.16 (m, 6H) 6.95 (d, 3H, J=8.2 Hz) 6.88 (t, 1H, J=7.4 Hz) 2.73 (t, 2H, J=7.5 Hz) 2.52 (t, 2H, J=7.3 Hz) 2.00 (m, 2H) 1.20 (s, 9H). MS (ESI, pos. ion) m/z: 385.3 (M+1).
    • Example 6 2-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol (Cpd 32) Step A. 3-(4-tert-butyl-phenyl)-propionic acid
  • A mixture of 3-(4-tert-butyl-phenyl)-acrylic acid (12.28 g, 60.1 mmol) and 10% palladium on carbon (0.6 g) in ethanol was hydrogenated at 50 psi hydrogen for 2 hours. The reaction mixture was filtered over a pad of celite, a nylon disk, and the solvents were removed in vacuo to yield the title Compound 6a (12.36 g, 59.9 mmol) as a white crystalline powder. 1H-NMR (d6-DMSO) δ (ppm): 12.10 (s, 1H), 7.29 (d, 2H), 7.12 (d, 2H), 2.88 (t, 2H), 2.50 (t, 2H), 1.25 (s, 9H). MS (ESI pos. ion) m/z: 228.9 (M+Na+)
    • Step B. 5-bromo-2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazole
  • To a solution of Compound 6a (1.04 g, 5.04 mmol), in 25 mL of POCl3 was added 4-bromo-benzene-1,2-diamine (0.946 g, 5.06 mmol). The reaction mixture was refluxed under a nitrogen atmosphere for 2.5 h then concentrated in vacuo. The residue was treated with 25 mL benzene and evaporated in vacuo. The residue was partitioned between 50 mL EtOAc and 50 mL saturated NaHCO3. The organic fractions were washed with 50 mL of saturated NaHCO3 and with 50 mL brine. The organic fraction was dried with Na2SO4, filtered and the filtrate was concentrated in vacuo. The residue was purified by chromatography (silica gel, EtOAc:Heptane, 2:8-4:6)) to yield the title Compound 6b (0.726 g, 2.03 mmol) as a tan powder. 1H-NMR (d6-DMSO) δ (ppm): 12.48-12.32 (m, 1H), 7.74-7.58 (m, 1H), 7.51-7.38 (m, 1H), 7.33-7.22 (m, 3H), 7.17 (d, 2H), 3.10 (m, 4H), 1.27 (s, 9H).
  • MS (ESI pos. ion) m/z: 357.1/359.1 (M+H+).
    • Step C. 2-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol
  • A mixture of Compound 6b, (0.036 g, 0.10 mmol), 2-hydroxy phenyl boronic acid (0.022 g, 0.16 mmol), Cs2CO3 (0.074 g, 0.23 mmol), and PdCl2(dppf) (0.008 g, 0.01 mmol) in 2 mL 5:1 dioxane/EtOH in a sealed tube was heated at 100° C. for 15 minutes in a microwave synthesizer. More 2-hydroxy phenyl boronic acid (0.024 g, 0.17 mmol) and more PdCl2(dppf) (0.010 g, 0.01 mmol) were added and the reaction was heated at 120° C. for 20 minutes. The reaction mixture was partitioned between 20 mL EtOAc, 20 mL water, and 2 mL brine. The organic fraction was evaporated, and the residue was purified by chromatography. (reverse-phase, acetonitrile:water+0.1% TFA, 25:75-95:5). The relevant fractions were frozen and lyophilized to give the product Compound 32 (0.013 g, 0.04 mmol) as a tan powder. 1H-NMR (d6-DMSO) δ (ppm): 14.55 (br s, 1H), 9.69 (s, 1H), 7.87 (s, 1H), 7.77 (d, 1H), 7.65 (d, 1H), 7.36-7.30 (m, 3H), 7.24-7.15 (m, 3H), 6.98 (d, 1H), 6.92 (t, 1H), 3.40 (t, 2H), 3.17 (t, 2H), 1.25 (s, 9H). MS (ESI pos. ion) m/z: 371.2 (M+H+).
  • Using the procedures described in Example 6 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:
  • Cpd Name and Data
    33 3-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol
    The title compound (0.016 g) was prepared from 3-hydroxy phenyl boronic acid
    (0.037 g) and Compound 6b (0.036 g). 1H-NMR (d6-DMSO) δ (ppm): 14.62 (br
    s, 1H), 9.62 (s, 1H), 7.88 (s, 1H), 7.81 (d, 1H), 7.71 (dd, 1H), 7.36-7.27 (m, 3H),
    7.18 (d, 2H), 7.13 (d, 1H), 7.08 (t, 1H), 6.82 (dd, 1H), 3.40 (t, 2H), 3.16 (t, 2H),
    1.25 (s, 9H). MS (ESI pos. ion): 371.2 (M + H+).
    34 4-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol
    The title compound (0.022 g) was prepared from 4-hydroxy phenyl boronic acid
    (0.032 g) and Compound 6b (0.036 g). 1H-NMR (d6-DMSO) δ (ppm): 14.61 (br
    s, 1H), 9.65 (s, 1H), 7.85 (s, 1H), 7.78 (d, 1H), 7.71 (dd, 1H), 7.56 (d, 2H),
    7.33 (d, 2H), 7.18 (d, 2H), 6.89 (d, 2H), 3.39 (t, 2H), 3.16 (t, 2H), 1.25 (s, 9H). MS
    (ESI pos. ion) m/z: 371.2 (M + H+).
    • Example 7 (E)-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol (Cpd 35) Step A. (E)-3-(4-trifluoromethylsulfanyl-phenyl)-acrylic acid ethyl ester
  • To a solution of 4-trifluoromethylsulfanyl-benzaldehyde (15.46 g, 75.0 mmol) in 350 mL of benzene was added (carbethoxymethylene)triphenyl-phosphorane (26.14 g, 75.0 mmol). The reaction mixture was refluxed under a nitrogen atmosphere for 6 hours. The solvents were removed in vacuo and the resulting material was triturated with 350 mL of diethyl ether and filtered. The filtrate was concentrated in vacuo and triturated once more with 50 mL diethyl ether and filtered. The filtrate was evaporated in vacuo and purified by chromatography (silica, EtOAc:heptane, 0:10-1:9) to obtain the title Compound 7a (15.8 g, 57.3 mmol) as a white solid. 1H-NMR (400 MHz, d6-DMSO) δ (ppm): 7.89 (d, 2H), 7.75 (d, 2H), 7.70 (d, 1H), 6.77 (d, 1H), 4.21 (q, 2H), 1.27 (t, 3H). MS (ESI pos. ion) m/z: 277.0 (M+H+).
    • Step B. (E)-3-(4-trifluoromethylsulfanyl-phenyl)-acrylic acid
  • To a solution of Compound 7a (10.31 g, 37.3 mmol), in 300 mL of ethanol was added 3N aqueous NaOH solution (13.0 mL, 39.0 mmol). The reaction mixture was stirred for 21 hours, then evaporated in vacuo. The residue was dissolved in 250 mL water, and to it was added 1N aqueous HCl (45 mL, 45 mmol). The resulting precipitate was filtered, rinsed with water and dried under a stream of air to yield the title Compound 7b (8.967 g, 36.1 mmol) as a white powder. 1H-NMR (400M Hz, d6-DMSO) δ (ppm): 12.58 (s, 1H), 7.85 (d, 2H), 7.74 (d, 2H), 7.63 (d, 1H), 6.66 (d, 1H).
    • Step C. (E)-5-bromo-2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazole
  • To a suspension of Compound 7b (1.240 g, 5.00 mmol) in 100 mL of CH3CN was added POCl3 (2.3 mL, 25.1 mmol) and 4-bromo-benzene-1,2-diamine (0.938 g, 5.01 mmol). The reaction mixture was heated at reflux under a nitrogen atmosphere for 18 hours, cooled slightly then additional 4-bromo-benzene-1,2-diamine (0.468 g, 2.50 mmol) was added. Refluxing was continued for 6 hours, then a final amount of 4-bromo-benzene-1,2-diamine (0.468 g, 2.50 mmol) was added. After heating for an additional 15 hours, the reaction mixture was concentrated in vacuo. The residue was purified by chromatography (silica, NH3 in MeOH (2M):CH2Cl2, 1:99-5:95) then a second time (EtOAc:heptane, 1:9-1:1)) to afford the title Compound 7c (1.255 g, 3.14 mmol) as a tan powder. 1H-NMR (400 MHz, d6-DMSO) δ (ppm): 12.96-12.83 (br d, 1H), 7.87-7.68 (m, 6H), 7.60-7.45 (m, 1H), 7.39-7.29 (m, 2H). MS (ESI pos. ion) m/z: 398.9/400.9 (M+H+).
    • Step D. (E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol
  • To a solution of Compound 7c (0.040 g, 0.10 mmol) and 2-hydroxymethyl phenyl boronic acid (0.029 g, 0.19 mmol) in 3 mL dioxane in a small pressure tube was added aqueous Na2CO3 solution (0.13 mL, 2M, 0.26 mmol) followed by PdCl2(dppf) (0.008 g, 0.01 mmol). The vessel was flushed with argon, capped and heated in an oil bath at 120° C. for 1 hour. The reaction mixture was partitioned between 20 mL EtOAc, 20 mL water, and 2 mL brine. The organic fractions were dried with Na2SO4, filtered and the filtrate was evaporated. The residue was purified by chromatography (reverse-phase, acetonitrile:water+0.1% TFA, 1:3-95:5). The relevant fractions were mixed with poly(vinylpyridine), filtered, frozen and lyophilized to give the title Compound 35 (0.027 g, 0.063 mmol) as a yellow powder. 1H-NMR (400 MHz, d6-DMSO) δ (ppm): 7.89-7.78 (m, 5H), 7.71-7.57 (m, 3H), 7.44-7.28 (m, 5H), 4.44 (s, 2H). MS (ESI pos. ion) m/z: 426.7 (M+H+).
  • Using the procedures described in Example 7 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:
  • Cpd Name and Data
    36 (E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenol
    The title compound (0.029 g) was prepared from 2-hydroxy phenyl boronic acid
    (0.028 g) and Compound 7c (0.040 g). 1H-NMR (400 MHz, d6-DMSO) δ (ppm):
    9.61 (s, 1H), 7.90-7.79 (m, 6H), 7.70 (d, 1H), 7.54 (d, 1H), 7.42 (d, 1H),
    7.33 (dd, 1H), 7.19 (dt, 1H), 6.98 (d, 1H), 6.91 (dt, 1H). MS (ESI pos. ion) m/z:
    412.8 (M + H+).
    37 (E)-N-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-acetamide
    The title compound (0.016 g) was prepared from N-[2-(4,4,5,5-tetramethyl-
    [1,3,2]dioxaborolan-2-yl)-phenyl]-acetamide (0.052 g) and Compound 7c (0.040 g).
    1H-NMR (400 MHz, d6-DMSO) δ (ppm): 9.24 (s, 1H), 7.86 (d, 2H),
    7.82-7.75 (m, 3H), 7.67 (d, 1H), 7.57 (s, 1H), 7.51 (d, 1H), 7.44-7.24 (m, 5H), 1.89 (s, 3H).
    MS (ESI pos. ion) m/z: 453.8 (M + H+).
    38 (E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzamide
    The title compound (0.031 g) was prepared from 2-benzamido boronic acid
    (0.034 g) and Compound 7c (0.040 g). 1H-NMR (400 MHz, d6-DMSO) δ (ppm):
    7.91-7.79 (m, 5H), 7.73-7.66 (m, 3H), 7.54-7.38 (m, 6H), 7.31 (s, 1H). MS (ESI
    pos. ion) m/z: 439.8 (M + H+).
    39 (E)-1-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-ethanone
    The title compound (0.027 g) was prepared from 2-acetyl phenyl boronic acid
    (0.034 g) and Compound 7c (0.040 g). 1H-NMR (400 MHz, d6-DMSO) δ (ppm):
    7.87 (d, 2H), 7.84-7.77 (m, 3H), 7.69 (d, 1H), 7.55-7.47 (m, 2H), 7.64-7.58 (m,
    3H), 7.40 (d, 1H), 7.21 (dd, 1H), 2.09 (s, 3H). MS (ESI pos. ion) m/z:
    438.7 (M + H+).
    • Example 8 (E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone (Cpd 40) Step A. (E)-3-(4-trifluoromethanesulfonyl-phenyl)-acrylic acid
  • To a suspension of Compound 7b (2.483 g, 10.01 mmol), in 50 mL of TFA was added 30% H2O2 solution (8 mL, 83 mmol). The reaction mixture was stirred for 21 h, then poured into 250 mL of ice water. The resulting precipitate was filtered off, rinsed with water and dried under vacuum at 50° C. to yield the title Compound 8a (2.281 g, 8.14 mmol) as a white powder. 1H-NMR (400 MHz, d6-DMSO) δ (ppm): 12.80 (s, 1H), 8.15 (s, 4H), 7.73 (d, 1H), 6.83 (d, 1H). MS (ESI pos. ion) m/z: 278.9 (M−H+).
    • Step B. (E)-5-bromo-2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazole
  • To a suspension of Compound 8a (1.405 g, 5.01 mmol) in 100 mL of acetonitrile was added POCl3 (2.3 mL, 25.1 mmol). The reaction mixture was refluxed under a nitrogen atmosphere for 30 minutes, then cooled slightly. To this reaction mixture was added 4-bromo-benzene-1,2-diamine (0.946 g, 5.06 mmol) and the reaction was refluxed for 2 h before additional 4-bromo-benzene-1,2-diamine (0.942 g, 5.04 mmol) was added. After an hour of heating, the reaction mixture was cooled and filtered over a pad of celite. The filter cake was rinsed with acetonitrile, ethyl acetate, and methanol. The filtrate was stirred with aqueous NaHCO3/EtOAc. The organic fraction was evaporated, and partitioned between 100 mL EtOAc and 100 mL saturated NaHCO3. The organic fraction was dried with Na2SO4, filtered, and the filtrate was evaporated. The residue was purified by chromatography (silica gel, EtOAc:heptane, 1:4-1:1)) to yield the title Compound 8b (1.595 g, 3.70 mmol) as a tan powder. 1H-NMR (400 MHz, d6-DMSO) δ (ppm): 13.00 (d, 1H), 8.14 (q, 4H), 7.87-7.73 (m, 2H), 7.63-7.50 (m, 2H), 7.40-7.33 (m, 1H). MS (ESI pos. ion) m/z: 430.8/432.8 (M+H+).
    • Step C. (E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone
  • A solution of Compound 8b (0.043 g, 0.10 mmol), and 2-acetyl phenyl boronic acid (0.035 g, 0.21 mmol) in 3 mL dioxane was stirred in a small pressure tube. Aqueous Na2CO3 solution (0.13 mL, 2M, 0.26 mmol) was added followed by PdCl2(dppf) (0.007 g, 0.01 mmol). The vessel was flushed with argon, capped and heated in an oil bath at 120° C. for 1 h. The reaction mixture was partitioned between 20 mL EtOAc, 20 mL water, and 2 mL brine. The organic fraction was dried with Na2SO4, filtered, and the filtrate was evaporated. The residue was flushed over a plug of silica gel with 100% EtOAc then evaporated. The crude material was purified by chromatography (reverse-phase, acetonitrile/water+0.1% TFA, 1:3-95:5). The appropriate fractions were mixed with poly(vinylpyridine), filtered, frozen and lyophilized to give the title Compound 40 (0.022 g, 0.047 mmol) as a yellow powder. 1H-NMR (400 MHz, d6-DMSO) δ (ppm): 8.16 (q, 4H), 7.87 (d, 1H), 7.70 (d, 1H), 7.64-7.56 (m, 3H), 7.55-7.47 (m, 3H), 7.21 (d, 1H), 2.09 (s, 3H). MS (ESI pos. ion): 471.0 (M+H+).
  • Using the procedures described in Example 8 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:
  • Cpd Name and Data
    41 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenol
    The title compound (0.024 g) was prepared from 2-hydroxy phenyl boronic acid
    (0.029 g) and Compound 8b (0.043 g). 1H-NMR (400 MHz, d6-DMSO) δ (ppm):
    9.53 (s, 1H), 8.16 (q, 4H), 7.85 (d, 1H), 7.77 (s, 1H), 7.65 (d, 1H), 7.58 (d, 1H),
    7.47 (d, 1H), 7.33 (d, 1H), 7.17 (dt, 1H), 6.97 (d, 1H), 6.90 (dt, 1H). MS (ESI
    pos. ion) m/z: 445.0 (M + H+).
    42 (E)-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-methanol
    The title compound (0.030 g) was prepared from 2-hydroxymethyl phenyl
    boronic acid (0.027 g) and Compound 8b (0.043 g). 1H-NMR (400 MHz, d6-
    DMSO) δ (ppm): 8.16 (q, 4H), 7.89 (d, 1H), 7.69 (d, 1H), 7.62 (d, 2H), 7.58 (d,
    1H), 7.43-7.33 (m, 2H), 7.30 (dd, 2H), 4.44 (s, 2H). MS (ESI pos. ion) m/z:
    459.0 (M + H+).
    43 (E)-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-
    5-yl}-phenyl)-acetamide
    The title compound (0.011 g) was prepared from N-[2-(4,4,5,5-tetramethyl-
    [1,3,2]dioxaborolan-2-yl)-phenyl]-acetamide (0.053 g) and Compound 8b (0.043 g).
    1H-NMR (400 MHz, d6-DMSO) δ (ppm): 9.23 (s, 1H), 8.15 (q, 4H), 7.85 (d,
    1H), 7.67 (d, 1H), 7.62-7.55 (m, 2H), 7.51 (d, 1H), 7.42-7.23 (m, 4H), 1.89 (s,
    3H). MS (ESI pos. ion) m/z: 486.1 (M + H+).
    44 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzamide
    The title compound (0.018 g) was prepared from 2-benzamido boronic acid
    (0.034 g) and Compound 8b (0.043 g). 1H-NMR (400 MHz, d6-DMSO) δ (ppm):
    8.16 (q, 4H), 7.88 (d, 1H), 7.70-7.64 (m, 3H), 7.59 (d, 1H), 7.54-7.39 (m, 4H),
    7.36 (dd, 1H), 7.30 (s, 1H). MS (ESI pos. ion) m/z: 472.0 (M + H+).
    • Example 9 (E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol (Cpd 45) 1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol (Cpd 46)
  • To a solution of Compound 40 (0.047 g, 0.10 mmol) in 5 mL EtOH was added NaBH4 (0.028 g, 0.74 mmol). After 1 h, an additional amount of NaBH4 (0.024 g, 0.63 mmol) was added. After an additional 4.5 h, the reaction was diluted into 25 mL EtOAc and washed twice with 25 mL water/brine. The organic fractions were dried with Na2SO4, filtered and the filtrate was evaporated. The residue was purified by chromatography (reverse-phase (acetonitrile/water with 0.1% TFA, 1:3-95:5). The two products were isolated, frozen and lyophilized to give the products Compound 45 (0.024 g, 0.051 mmol) as a yellow powder and Compound 46 (0.020 g, 0.042 mmol) as a white powder.
  • Compound 45: 1H-NMR (400 MHz, d6-DMSO) δ (ppm): 8.18 (dd, 4H), 7.93 (d, 1H), 7.74 (d, 1H), 7.67 (d, 1H), 7.64-7.57 (m, 2H), 7.43 (dt, 1H), 7.35-7.27 (m, 2H), 7.21 (dd, 1H), 4.80 (q, 1H), 1.22 (d, 3H). MS (ESI pos. ion) m/z: 472.8 (M+H+).
  • Compound 46: 1H-NMR (400 MHz, d6-DMSO) δ (ppm): 8.12 (d, 2H), 7.82-7.74 (m, 3H), 7.70-7.63 (m, 2H), 7.47-7.37 (m, 2H), 7.32 (dt, 1H), 7.18 (dd, 1H), 4.72 (q, 1H), 3.47 (t, 2H), 3.40 (t, 2H), 1.19 (d, 3H). MS (ESI pos. ion) m/z: 474.8 (M+H+).
    • Example 10 (E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol(Cpd 18)
  • Figure US20110190364A1-20110804-C00205
    • Step A. 3-(4-trifluoromethyl-phenyl)-acrylic acid
  • A solution of 4-trifluoromethylbenzaldehyde (7.7 mL, 57.7 mmol), malonic acid (12.0 g, 115.4 mmol), 0.567 μL piperidine (5.75 mmol) in 30 mL of pyridine was stirred at 70° C. for 18 h. The reaction solution was cooled to room temperature. Water (300 mL) was added and the resulting mixture was acidified to pH 4 (litmus) using concentrated hydrochloric acid to give a precipitate. The solid was filtered, and washed with water until the filtrate was neutral. The solid product was dried in vacuo to give the title Compound 10a as a white powder (11.2 g, 90%). 1HNMR (400 MHz, DMSO-d6) δ (ppm): 12.60 (bs, 1H), 7.92 (d, 2H, J=8.2 Hz), 7.77 (d, 2H, J=8.2 Hz), 7.66 (d, 1H, J=16.0 Hz), 6.70 (d, 1H, J=16.0 Hz).
  • Figure US20110190364A1-20110804-C00206
    • Step B. (E)-5-bromo-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole
  • A solution of Compound 10a (20.6 g, 95.4 mmol) in anhydrous methylene chloride (200 mL) was treated with oxalyl chloride (16.6 mL, 190 mmol) and “3 drops” of anhydrous dimethylformamide. The resulting solution was stirred at room temperature under an argon atmosphere for 18 h. The solvent was concentrated to give 3-(4-trifluoromethyl-phenyl)-acryloyl chloride Compound 10b as a solid, which was used without further purification in the next step.
  • To a solution of 4-bromo-benzene-1,2-diamine (16.1 g, 86.7 mmol) in acetic acid (100 mL) was added dropwise a solution of Compound 10b (assumed 95.4 mmol) in acetic acid (100 mL). The reaction mixture was stirred at 100° C. for 18 h. The reaction mixture was cooled to room temperature, and a mixture of ethyl acetate and hexanes 3:7 (500 mL) was added. The mixture was triturated at room temperature for 3 h to give a precipitate. The solid was filtered, and dried in vacuo to give the title Compound 10c (23.2 g, 73%). 1H NMR (400 MHz, DMSO-d6/CDCl3) δ (ppm): 8.45 (d, 1H, J=16.7 Hz), 7.84-7.90 (m, 1H), 7.74 (d, 2H, J=8.3 Hz), 7.56-7.62 (m, 3H), 7.50-7.52 (m, 1H), 7.34 (d, 1H, 16.7 Hz).
  • Figure US20110190364A1-20110804-C00207
    • Step C. 2-(2-bromo-phenyl)-propan-2-ol
  • To a solution of methyl 2-bromobenzoate (20.76 g, 96 mmol) in 120 mL of anhydrous ether under Argon at 0° C. was slowly added methylmagnesium bromide (77 mL, 3.26 M) at a rate that the internal temperature of the mixture was below 20° C. A white suspension resulted, and the mixture was stirred at room temperature for 2 h. The mixture was cooled in an ice-water bath. To the reaction mixture was very slowly added hydrochloric acid (400 mL, 0.5 M). The pH of the final mixture was adjusted to less than about 6 with few drops of 2M hydrochloric acid. The layers were separated, and the aqueous layer was extracted twice with ether. The organic layers were combined and dried over magnesium sulfate. The organic fraction was filtered, and the filtrate was concentrated to yield the title compound as a pale yellow liquid, which was distilled under vacuum to afford the title Compound 10d as a colorless liquid (16.9 g, 82%, b.p. about 65-70° C./0.3 mmHg). 1H NMR (400 MHz, CDCl3) δ (ppm): 7.67 (dd, 1H, J=1.7, 7.9 Hz), 7.58 (dd, 1H, J=1.3, 7.9 Hz), 7.30 (ddd, 1H, J=1.4, 7.4, 7.9 Hz), 7.10 (ddd, 1H, J=1.7, 7.4, 7.8 Hz), 2.77 (br s, 1H), 1.76 (s, 6H).
  • Figure US20110190364A1-20110804-C00208
    • Step D. 3,3-dimethyl-3H-benzo[c][1,2]oxaborol-1-ol
  • To a solution of n-BuLi (166 mL, 2.6 M, 432 mmol) in 200 mL of THF at −78° C. under argon was slowly added a solution of Compound 10d (42.2 g, 196 mmol) in 60 mL of THF at a rate that the internal temperature remained below −70° C. The mixture was stirred at −75° C. for 2 h. To the reaction mixture was then added triisopropylborate (59 mL, 255 mmol) in three portions. The mixture was allowed to warm slowly to room temperature overnight. The mixture was then cooled to 0° C., and was carefully quenched with dilute hydrochloric acid (250 mL, 2N). The mixture was then stirred at room temperature for 1 h. The pH of the mixture was checked and adjusted to acidic using additional 2N HCl if prophetic. The two layers were separated, and the aqueous layer was extracted twice with ether. The organic layers were combined, and dried with magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to yield a pale yellow oil. The residue was then diluted with ethyl acetate (400 mL) and, washed with 1N sodium hydroxide solution (150 mL×3). The basic aqueous layers were combined and acidified with 2N HCl. The clear solution turned cloudy when the acid was added. The mixture was extracted with ether (150 mL×3). The organic layers were combined and dried with magnesium sulfate. The solution was filtered, and the filtrate was concentrated under reduced pressure to yield the title Compound 10e as a colorless oil (26.2 g, 82%) which was used without further purification in the next step. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 9.00 (s, 1H), 7.66 (dm, 1H, J=7.3 Hz), 7.45 (dt, 1H, J=1.1, 7.7 Hz), 7.40 (dm, 1H, J=7.6 Hz), 7.31 (dt, 1H, J=1.2, 7.1 Hz), 1.44 (s, 6H).
  • Figure US20110190364A1-20110804-C00209
    • Step E. (E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol
  • To a mixture of Compound 10e (11.7 g, 71 mmol), Compound 10c (19.9 g, 54 mmol), sodium carbonate (46 g, 435 mmol) and PdCl2(dppf).CH2Cl2 (8.9 g, 11 mmol) in a 1 L round bottom flask equipped with water condenser was added 400 mL of anhydrous DME and 200 mL of water. The mixture was evacuated and filled with Argon three times. The mixture was heated to 100° C. for 20 h. The mixture was then cooled to room temperature. The biphasic system was transferred to a 1 L separatory funnel and the two layers were separated. The organic layer was washed with brine (2×300 mL). The aqueous layers were combined and extracted with ethyl acetate once (about 300 mL). The organic layers were combined, dried with sodium sulfate, and filtered. The volume of the filtrate was reduced to about 170 mL under reduced pressure. The mixture was then filtered through a pad of silica gel and the pad was washed with ethyl acetate until the filtrate did not contain any product. After concentration, a light pink/beige solid was obtained. The solid was triturated with 50 mL ethyl acetate, and the mixture was heated to 85° C. for 5 min. The mixture was slowly cooled to r.t., then cooled at 0° C. for 0.5 h. The mixture was filtered, and the solid was washed with cold ethyl acetate twice, and dried under vacuum at 40° C. to yield the title Compound 18 as a light beige solid (7.58 g, 33%). RP-HPLC 95% pure. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 12.73 (m, 1H,), 7.90 (d, 2H, J=8.2 Hz), 7.85 (dd, 1H, J=8.0, 0.6 Hz), 7.78 (d, 2H, J=8.4 Hz), 7.74 (d, 1H, J=16.8 Hz), 7.59-7.47 (m, 1H), 7.41 (s, 1H), 7.37-7.32 (m, 2H), 7.21 (dt, 1H, J=1.2, 7.4 Hz), 7.06 (s, 1H), 7.02 (d, 1H, J=7.4 Hz), 4.85 (s, 1H), 1.21 (s, 6H). Mass Spectrum (LCMS, APCI pos.) Calcd. For C25H21F3N2O: 423.2 (M+H), Found 423.3. m.p. (uncorr.) 250-251° C.
  • Using the procedures described in Example 10 and corresponding reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:
  • Cpd Name and Data
    23 (E)-2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol
    1H-NMR (400 MHz, DMSO d6) δ (ppm) 7.84 (dd, J = 1.26, 8.084 Hz, 1H)
    7.75-7.85 (m, 2H) 7.66 (d, J = 16.4 Hz) 7.53-7.58 (m, 1H) 7.45 (bs, 1H) 7.34-7.38 (m,
    3H) 7.17-7.26 (m, 3H) 7.09 (dd, J = 1.58, 7.58 Hz, 1H) 1.36 (s, 6H). MS (ESI,
    pos. ion) m/z: 439.2 (M + 1).
    47 (E)-2-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-
    5-yl}-phenyl)-propan-2-ol
    1H NMR (400 MHz, CD3OD) δ (ppm): 8.07 (d, 2H, J = 8.6 Hz), 7.98 (d, 2H, J = 8.6 Hz),
    7.78 (dd, 1H, J = 1.1, 8.1 Hz), 7.69 (d, 1H, J = 16.5 Hz), 7.54 (d, 1H, J = 8.2 Hz),
    7.44 (d, 1H, J = 16.5 Hz), 7.42 (br s, 1H), 7.31 (ddd, 1H, J = 1.5, 7.8, 8.1 Hz),
    7.18 (dt, 1H, J = 1.3, 7.4 Hz), 7.16 (dd, 1H, J = 1.5, 8.3 Hz), 7.03 (dd, 1H, J = 1.4,
    7.5 Hz), 1.31 (s, 6H). Mass Spectrum (LCMS, APCI pos.) Calcd. For
    C25H21F3N2O3S: 487.1 (M + H), Found 487.1.
    78 (E)-2-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    propan-2-ol
    1H NMR (400 MHz, CD3OD) δ (ppm): 7.79 (dd, 1H, J = 8.1, 1.1 Hz),
    7.63-7.54 (m, 3H), 7.51 (br d, 1H, J = 9.7, 7.4 Hz), 7.40-7.38 (m, 3H), 7.31 (m, 1H),
    7.19 (dt, 1H, J = 1.4, 7.4 Hz), 7.15 (d, 1H, J = 16.5 Hz), 7.13 (dd, 1H, J = 7.9, 1.8 Hz),
    7.04 (dd, 1H, J = 7.5, 1.4 Hz), 1.30 (s, 6H). Mass Spectrum (LCMS, APCI pos.)
    Calcd. For C24H21ClN2O: 389.1 (M + H), Found 389.3.
    84 (E)-2-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.00 (d, J = 8 Hz, 2H), 7.91 (d, J = 8 Hz, 2H),
    7.82 (dd, J = 1.6, 8 Hz, 1H), 7.70 (d, J = 16.4 Hz, 2H), 7.41 (s, 1H), 7.36 (dt, J = 1.6,
    8 Hz, 1H), 7.34 (s, 1H), 7.23 (dt, J = 1.6, 8 Hz, 1H), 7.19 (dd, J = 1.6, 8 Hz, 1H),
    7.07 (dd, J = 1.6, 8 Hz, 1H), 3.16 (s, 3H), 1.26 (s, 6H). Mass Spectrum (LCMS,
    ESI pos.) Calcd. For C25H24N2O3S: 433.1 (M + H), Found 433.4.
    114 (E)-2-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol
    1H NMR (400 MHz, CD3OD) δ (ppm): 7.89-7.87 (m, 2H), 7.79 (dd, 1H, J = 8.1,
    1.1 Hz), 7.67-7.56 (m, 3H), 7.52 (m, 1H), 7.40 (br s, 1H), 7.31 (m, 1H), 7.27 (d,
    1H, J = 16.6 Hz), 7.18 (dt, 1H, J = 1.3, 7.4 Hz), 7.14 (dd, 1H, J = 8.3, 1.4 Hz, 1H),
    7.04 (dd, 1H, J = 7.52, 1.38 Hz), 1.31 (s, 6H). Mass Spectrum (LCMS, APCI
    pos.) Calcd. For C25H21F3N2O: 423.2 (M + H), Found 423.3.
    458 (E)-2,2,2-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-acetamide.
    The title compound (0.0195 g) was prepared from Compound 465 (0.10 g, 0.26 mmol)
    and trifluoroacetylimidazolide (0.047 g, 0.29 mmol). 1H-NMR (400 MHz,
    DMSO d6) δ (ppm): 12.7-12.9 (bs, 1H) 11.0 (s, 1H) 7.90-7.94 (d, J = 8.59 Hz, 2H))
    7.78-7.81 (d, J = 8.59 Hz, 2H) 7.37-7.76 (m, 7H) 7.20 (d, J = 9.34 Hz, 1H) MS (ESI,
    pos. ion) m/z: 476.2 (M + 1).
    459 (E)-2,2,2-trifluoro-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-
    vinyl]-1H-benzimidazol-5-yl}-phenyl)-amide
    The title compound (0.0015 g) was prepared from Compound 465 (0.034 g, 0.09 mmol)
    and trifluoromethylsulfonylchloride (0.018 g, 0.10 mmol). 1H-NMR (400 MHz,
    DMSO d6) δ (ppm) 12.75-12.82 (bs, 1H) 9.70-9.80 (bs, 1H) 7.90-7.96 (d,
    J = 8.08 Hz, 2H) 7.78-7.84 (m, 3H) 7.54-7.77 (m, 2H) 7.40-7.50 (m, 2H)
    7.24-7.40 (m, 6H) 4.0 (bs, 2H)MS (ESI, pos. ion) m/z: 526.1 (M + 1).
    460 (E)-2,2-dimethyl-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-propionamide
    The title compound (0.0014 g) was prepared from Compound 465 (0.034 g, 0.09 mmol)
    and trimethylacetylchloride (0.012 mL, 0.036 mmol). 1H-NMR (400 MHz,
    CD3OD) δ (ppm) 7.80-7.84 (m, 3H) 7.58-7.78 (m, 6H) 7.38-7.42 (m, 2H)
    7.24-7.35 (m, 3H) 1.20 (s, 9H) MS (ESI, pos. ion) m/z: 464.3 (M + 1).
    461 (E)-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-amide
    The title compound (0.0018 g) was prepared from Compound 465 (0.10 g, 0.26 mmol)
    and ethylsulfonyl chloride (0.027 mL, 0.29 mmol). 1H-NMR (400 MHz,
    DMSO d6) δ (ppm) 12.88 (d, J = 9.1 Hz, 1H) 8.92 (d, J = 7.3 Hz, 1H) 7.78 (d,
    J = 8.08 Hz, 2H)) 7.85 (d, J = 8.08 Hz, 2H) 7.72-7.82 (m, 3H) 7.63-7.68 (m, 1H)
    7.30-7.53 (m, 6H) 2.78-2.92 (qq, J = 7.33 Hz, 2H) 1.00 (tt, J = 7.33 Hz, 3H). MS
    (ESI, pos. ion) m/z: 472.1 (M + 1).
    462 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-carbamic acid methyl ester
    The title compound (0.0056 g) was prepared from Compound 465 (0.10 g, 0.26 mmol)
    and chloromethylformate (0.022 mL, 0.29 mmol). 1H-NMR (400 MHz,
    DMSO d6) δ (ppm) 7.82-7.84 (d, J = 8.59 Hz, 2H) 7.76-7.78 (d, J = 8.59 Hz, 2H)
    7.62-7.70 (m, 3H) 7.59 (bs, 1H) 7.36-7.41 (m, 3H) 7.24-7.34 (m, 3H). MS (ESI,
    pos. ion) m/z: 438.4 (M + 1).
    463 (E)-2-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    propan-2-ol
    1H-NMR (400 MHz, DMSO d6) δ (ppm) 7.82-7.84 (m, 1H) 7.35-7.64 (m, 8H)
    7.10-7.30 (m, 4H) 1.38 (s, 15H). MS (ESI, pos. ion) m/z: 411.3 (M + 1).
    465 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenylamine
    The title compound was prepared from Compound 479 by stirring in TFA with
    heating.
    1H-NMR (400 MHz, DMSO d6) δ (ppm) 12.78 (s, 0.5H) 12.75 (s, 0.5H) 7.91 (d,
    J = 8.08 Hz, 2H) 7.78-7.81 (m, 3H) 7.74 (d, J = 4.55 Hz, 1H) 7.68 (d, J = 8.08 Hz, 1H)
    7.56-7.62 (m, 1H) 7.52 (bs, 1H) 7.41 (d, J = 16.4 Hz, 1H) 7.20-7.29 (m, 1H)
    7.05 (t, J = 7.6 Hz, 2H) 6.78 (d, J = 8.34 Hz, 1H) 6.65 (t, J = 6.8 Hz, 1H) 4.81 (s, 1H)
    4.74 (s, 1H)MS (ESI, pos. ion) m/z: 526.1 (M + 1).
    466 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzoic
    acid ethyl ester
    1H-NMR (400 MHz, DMSO d6) δ (ppm) 7.82-7.84 (d, J = 8.59 Hz, 2H)
    7.76-7.78 (d, J = 8.59 Hz, 2H) 7.62-7.70 (m, 3H) 7.59 (bs, 1H) 7.36-7.41 (m, 3H)
    7.24-7.34 (m, 3H). MS (ESI, pos. ion) m/z: 438.4 (M + 1).
    468 (E)-2-[2-(2-styryl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol
    1H-NMR (400 MHz, CD3OD) δ (ppm) 8.18 (bs, 2H) 7.70 (m, 3H) 7.44 (m, 3H)
    7.30 (m, 3H) 7.22 (m, 2H) 7.19 (m, 1H) 1.28 (s, 9H). MS (ESI, pos. ion) m/z:
    412.2 (M + 1).
    470 (E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)sulfamide
    The title compound (0.0023 g) was prepared from Compound 465 (0.0175 g,
    0.046 mmol) and sulfamide (0.5 g, 5.2 mmol). 1H-NMR (400 MHz, DMSO d6) δ
    (ppm) 7.86 (d, J = 8.61 Hz, 2H) 7.62-7.78 (m, 6H) 7.31-7.41 (m, 4H) 7.21-7.25 (m,
    1H). MS (ESI, pos. ion) m/z: 459.2 (M + 1).
    476 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanol
    1H-NMR (400 MHz, CD3OD) δ (ppm) 7.83 (d, J = 8.59 Hz, 2H) 7.77 (d, J = 8.34 Hz,
    2H)7.56-7.74 (m, 5H)7.24-7.42 (m, 5H) 4.56 (s, 2H)MS (ESI, pos. ion) m/z:
    395.1 (M + 1).
    478 (E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-acetamide
    1H-NMR (400 MHz, CD3OD) δ (ppm) 7.80-7.84 (m, 3H) 7.56-7.78 (m, 5H)
    7.30-7.44 (m, 5H) 1.97 (s, 3H). MS (ESI, pos. ion) m/z: 422.3 (M + 1).
    479 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-carbamic acid tert-butyl ester
    1H-NMR (400 MHz, CD3OD) δ (ppm) 7.76-8.00 (d, J = 8.1 Hz, 2H) 7.82-7.90 (d,
    J = 8.8 Hz, 2H) 7.68-7.79 (m, 4H) 7.36-7.48 (5H) 1.44 (s, 9H). MS (ESI, pos. ion)
    m/z: 480.2 (M + 1).
    480 (E)-5-(2-methylsulfanyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazole
    1H-NMR (400 MHz, CD3OD) δ (ppm) 7.84-7.87 (d, J = 8.1 Hz, 2H) 7.56-7.78 (m,
    5H) 7.20-7.40 (m, 6H). MS (ESI, pos. ion) m/z: 411.2 (M + 1).
    481 (E)-2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-5-(2-trifluoromethyl-
    phenyl)-1H-benzimidazole
    1H NMR (400 MHz, CD3OD) δ (ppm): 8.10 (d, 2H, J = 8.5 Hz, 1H), 8.02 (d, 2H,
    J = 8.5 Hz), 7.77 (d, 1H, J = 7.8 Hz, 1H), 7.73 (d, 1H, J = 16.5 Hz), 7.64 (d, 1H, J = 7.4 Hz),
    7.60 (d, 1H, J = 8.4 Hz), 7.54 (d, 1H, J = 7.7 Hz), 7.50 (s, 1H), 7.46 (d,
    1H, J = 16.5 Hz), 7.42 (d, 1H, J = 7.6 Hz), 7.22 (dd, 1H, J = 8.4, 1.0 Hz). Mass
    Spectrum (LCMS, APCI pos.) Calcd. For C23H14F6N2O2S: 497.1 (M + H), Found
    497.1.
    482 (E)-2-(2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol
    1H NMR (400 MHz, CD3OD) δ (ppm): 8.00-7.94 (m, 2H), 7.79 (dd, 1H, J = 8.1,
    1.1 Hz), 7.73 (d, 1H, J = 7.9 Hz), 7.66 (t, 1H, J = 7.7 Hz), 7.53 (br s, 1H), 7.50 (t,
    1H, J = 7.67, 7.67 Hz), 7.41 (br s, 1H), 7.31 (m, 1H), 7.21-7.13 (m, 3H), 7.04 (dd,
    1H, J = 7.5, 1.4 Hz), 1.31 (s, 6H). Mass Spectrum (LCMS, APCI pos.) Calcd. For
    C25H21F3N2O: 423.2 (M + H), Found 423.3.
    483 (E)-dimethyl-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzyl)-amine
    To a solution of Compound 484 (20.7 mg, 0.053 mmol) in DMF (10 mL) was
    added dimethylamine 2.0 M in THF (66 μL, 0.132 mmol). The mixture was
    stirred for 45 min and sodium triacetoxyborohydride (17 mg, 0.080 mmol) was
    added. The mixture was stirred at rt for 2.5 d and then concentrated under
    reduced pressure. The residue was purified using preparative TLC plates (silica
    gel, 20 × 20 cm, 2000 microns, EtOAc:hexanes:methanol 5:5:1) to give the
    title compound (18.2 mg, 81%). 1H NMR (400 MHz, CD3OD) δ (ppm): 7.81 (d,
    2H, J = 8.2 Hz), 7.70 (d, 2H, J = 8.0 Hz), 7.67 (d, 1H, J = 16.3 Hz), 7.60 (d, 1H, J = 8.2 Hz),
    7.55-7.47 (m, 2H), 7.40-7.26 (m, 4H), 7.19 (dd, 1H, J = 8.3, 1.5 Hz),
    3.58 (s, 2H), 2.14 (s, 6H). Mass Spectrum (LCMS, APCI pos.) Calcd. For
    C25H22F3N3: 422.2 (M + H), Found 422.1.
    484 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzaldehyde
    1H NMR (400 MHz, DMSO-d6) δ (ppm): 12.93 (d, 1H, J = 12.5 Hz), 9.93 (s, 1H),
    7.93 (d, 3H, J = 8.4 Hz), 7.82-7.56 (m, 8H), 7.44 (d, 1H, J = 16.5 Hz), 7.28 (dd,
    1H, J = 10.1, 9.3 Hz). Mass Spectrum (LCMS, APCI pos.) Calcd. For
    C23H15F3N2O: 393.1 (M + H), Found 393.3.
    485 (E)-methyl-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzyl)-amine
    The title compound was prepared according to the procedure used for
    Compound 483, with the exception that methylamine was used. 1H NMR (400 MHz,
    CD3OD) δ (ppm): 7.82 (d, 2H, J = 8.3 Hz, 1H), 7.71 (d, 2H, J = 8.3 Hz),
    7.69 (d, 1H, J = 16.6 Hz), 7.63 (d, 1H, J = 8.1 Hz), 7.52-7.47 (m, 2H), 7.39 (tdd, 2H, J = 9.1,
    7.2, 3.6, 3.6 Hz), 7.35-7.29 (m, 2H), 7.23 (dd, 1H, J = 8.3, 1.6 Hz), 3.86 (s,
    2H), 2.30 (s, 3H). Mass Spectrum (LCMS, APCI pos.) Calcd. For C24H20F3N3:
    408.2 (M + H), Found 408.1.
    487 (E)-5-(2-trifluoromethyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazole
    1H NMR (400 MHz, CD3OD) δ (ppm): 7.80 (d, 2H, J = 8.2 Hz), 7.76 (d, 1H, J = 7.9 Hz),
    7.70-7.60 (m, 4H), 7.57 (d, 1H, J = 8.3 Hz), 7.52 (t, 1H, J = 7.7 Hz),
    7.47 (s, 1H), 7.40 (d, 1H, J = 7.6 Hz), 7.29 (d, 1H, J = 16.6 Hz), 7.19 (dd, 1H, J = 8.3,
    1.0 Hz). Mass Spectrum (LCMS, APCI pos.) Calcd. For C23H14F6N2: 433.1 (M + H),
    Found 433.3.
    488 (E)-5-(2-trifluoromethoxy-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazole
    1H NMR (400 MHz, CD3OD) δ (ppm): 7.78 (d, 2H, J = 8.3 Hz), 7.68-7.66 (m, 3H),
    7.63-7.58 (m, 2H), 7.50 (m, 1H), 7.43-7.35 (m, 3H), 7.33 (dd, 1H, J = 8.4, 1.6 Hz),
    7.27 (d, 1H, J = 16.6 Hz). Mass Spectrum (LCMS, APCI pos.) Calcd. For
    C23H14F6N2O: 449.1 (M + H), Found 449.3.
    • Example 10.1 Scale Up Preparation of (E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Cpd 18) Step A. 3-(4-trifluoromethyl-phenyl)-acrylic acid
  • A 2-L 4-neck round bottom flask equipped with an air condenser/argon inlet, mechanical stirrer, thermocouple and a stopper was charged with 4-(trifluoromethyl)benzaldehyde (250 g, 196.2 mL, 1.44 mol), malonic acid (302.6 g, 2.87 mol), and pyridine (750 mL). An exotherm developed (about 38-40° C.), which was maintained for 30 min. Piperidine (14.202 mL, 143.58 mmol) was then added to the reaction and a second exotherm developed (Tmax about 42° C. after about 10 min.). The reaction was stirred for 30 min and then heated to 60° C. for 18 h (overnight). The reaction appeared to be complete by TLC, and was cooled to about 40° C., diluted into water (2 L; done to prevent reaction freezing), cooled to room temperature, and further diluted with water (4 L, 6 L total). The slurry was acidified to pH=2.0-3.0 with concentrated hydrochloric acid (about 675-700 mL). The material was stirred for 30 min., and a white solid was collected by filtration. The filter cake was washed with water until the filtrate was neutral (pH about 5.5-6, 2.5 L), air-dried in a Buchner funnel for 2 h, and then further dried in a vacuum oven at 60° C. overnight to provide 300.5 g (96%) of the title Compound 10a as a white solid.
    • Step B. (E)-5-bromo-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole
  • To a 5-L 4-neck round bottom flask equipped with a magnetic stirrer, argon inlet-argon outlet to a carbonate scrub, two stoppers, and a room temperature water bath was charged with 4-(trifluoromethyl)cinnamic acid (315 g, 1.46 mol) and dichloromethane (3.15 L) to give a slurry. To the slurry was added oxalyl chloride (151.71 mL, 1.75 mol) and DMF (1.13 mL, 14.57 mmol). Upon addition of DMF, gas evolution commenced, and the reaction was continued for about 3 h during which time a solution developed. When the reaction was complete (LC-MS), it was concentrated to dryness to give 342.4 g of 3-(4-trifluoromethyl-phenyl)-acryloyl chloride Compound 10b (>100%) as a yellow oily solid.
  • A 5-L 4-neck round bottom flask equipped with mechanical stirrer, thermocouple, air condenser with argon inlet, and a stopper was charged with 4-bromo-benzene-1,2-diamine (244 g, 1.27 mol) and acetic acid (2.13 L). To this solution was added a solution of Compound 10b (327 g, 1.39 mol) in toluene (237 mL). After this addition, the temperature spiked to 45° C. in about 30 seconds and then subsided. The reaction was then heated to 90° C. for 16 h (overnight). The reaction was cooled to 40° C., and poured into a mixed solution of EtOAc and heptane (about 1:3, 5.75 L) and a precipitate occurred. The resulting slurry was stirred for 3 h, and the solid was collected by filtration, washed with EtOAc: heptane (1:3, 3 L), and then dried in a vacuum oven (60° C.) to give 324.3 g (65%) of the title Compound 10c as a partial acetate salt.
    • Step C. 2-(2-bromo-phenyl)-propan-2-ol
  • A 12-Liter 4-neck flask equipped with a thermocouple, condenser, septum, addition funnel and overhead mechanical stirrer under argon was charged with methyl-2-bromobenzoate (226.5 g, 1.05 mol) and THF (1.6 L, 19.66 mol). The mixture was cooled to a temperature between 2 and 5° C. with stirring and held for 30 min. To the solution was slowly added methyl magnesium bromide in diethyl ether (3M, 1.05 L; 3.15 mol) via the addition funnel at a rate to maintain the reaction temperature below 15° C. An exotherm was observed during the addition, the reaction temperature warmed from 3 to 15° C. The addition of 1.05 L Grignard was complete in 4 h (approximate feed rate was 4.17 mL/min). The reaction mixture appeared to be off-white/yellow slurry. The reaction was allowed to warm to room temperature and stirred overnight (15 h). The reaction was sampled by HPLC/TLC and showed no starting material present. The ice bath was again applied to the reaction flask and a 0.5 M HCl solution (4.5 L; 2.25 mol) was slowly added over a period of 2 h. The temperature increased dramatically from 0 to 15° C. After the quench was complete, the reaction was stirred at room temperature for 30 min. Additional 2 N HCl (500 mL; 1.00 mol) was slowly added to maintain a pH less than 6. MTBE (1 L) was added to help with the phase split. The reaction was stirred at room temperature for 1 to 2 h to dissolve the solid material into the aqueous phase (most likely Mg(OH)2 which is very basic). The pH must be checked and adjusted with additional acid when necessary. The phases were separated and the aqueous layer was washed with an additional 1 L MTBE (2×500 mL). The organic phases were combined, washed with NaHCO3 solution (2×300 mL), dried over MgSO4, filtered and the filtrate was concentrated under vacuum to yield the title Compound 10d (220.83 g, 97.48% yield) as a clear yellow oil.
    • Step D. 3,3-dimethyl-3H-benzo[c][1,2]oxaborol-1-ol
  • A 12-Liter 4-neck round bottom flask equipped with a thermocouple, condenser, addition funnel and overhead mechanical stirrer under dry Argon was charged with anhydrous THF, (3 L) and chilled to −70 to −78° C. via a dry ice/acetone bath. n-Butyl lithium (2.5N in hexanes, 860 mL, 2.15 mol) was slowly added via addition funnel. An exotherm was observed as the temperature rose from −78 to −70° C. To the addition funnel was added a solution of Compound 10d (220 g, 979.97 mmol) in anhydrous THF (1 L). The 2-(2-bromophenyl)propan-2-ol solution was slowly added to the n-BuLi solution. The addition took 90 min in order to maintain a reaction temperature below −70° C. After the addition was complete, the reaction mixture was stirred at −70 to −75° C. for 30 min. The triethylborate (230 mL, 1.35 mol) was quickly added in 3 portions at −70° C. An exotherm was observed, the batch temperature rose from −70 to −64° C. The reaction was stirred at −70° C. and slowly warmed to room temperature over night. After the reaction was cooled to 0-5° C., the reaction was slowly quenched with 2 M HCl (1 L, 2.00 mol) added via the addition funnel while maintaining the batch temperature 0-5° C. The reaction mixture was stirred for 1 h. The aqueous phase pH was 9-10. The pH was then adjusted to acidic (4-5) with 2 M HCl (200 mL). The two phases were separated and the aqueous layer was extracted with MTBE (2×500 mL). The combined organic phases were dried with anhydrous magnesium sulfate. The solution was filtered and concentrated to yield a yellow oil. The yellow oil was diluted with MTBE (1.5 L) and washed with 1M NaOH (3×500 mL). The product containing basic aqueous phases were combined and acidified with 2 M HCl (800 mL) (the clear solution turns turbid with the addition of acid). After stirring the turbid solution for 15 min (pH=4-5) (Note 1), it was extracted with MTBE (2×500 mL). The organic phases were combined and dried over MgSO4. The solution was filtered and the filtrate was concentrated to yield the title Compound 10e as a clear yellow oil (121.78 grams, 77% yield).
    • Step E. (E)-2-(2-{2-[2-(4-Trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol
  • A 5-L 4-neck flask equipped with a thermocouple controller, condenser, overhead mechanical stirrer, Firestone valve® and a nitrogen inlet/outlet was charged with dimethoxyethane (2 L), DI water (1 L) and sodium carbonate (230.9 g, 2.18 mol). The solution was degassed and purged with N2 three times. Compound 10e (71.7 g, 0.35 mol) and Compound 10c (100.0 g, 0.27 mol) were added to the degassed solution. The solution was degassed and purged with N2 three times. PdCl 2(dppf) (44.48 g, 54.4 mmol) was added to the solution, and the solution was degassed and purged with N2 three times. The resulting two-phase suspension was heated to reflux for 18 h, and then cooled to room temperature. The reaction mixture was transferred to a 12-L separatory funnel, and the layers were separated. The organic layer was washed with brine (1 L). The two aqueous layers were combined and extracted with EtOAc (1 L). The combined organic layers were dried (Na2SO4), filtered, and the filtrate was concentrated to an oil. Two separate 100 g coupling reactions were combined and purified by chromatography in 10 successive chromatography runs on an ISCO preparative chromatography system (10×1.5 Kg SiO2, 5 column volumes of EtOAc, 250 mL/min flow rate). The combined fractions were transferred to two 22 L 4-neck round bottom flasks, and Silicycle Si-thiol functionalized silica gel (2 g) was added to each solution. The solutions were warmed to 40° C. and aged for 1 h. The solutions were filtered thru a medium glass funnel and washed with EtOAc (4 L) and combined. The filtrate was evaporated to a semi solid, which was transferred to a 2 L round bottom flask, to which EtOAc (0.4 L) was added. The resulting white precipitate slurry was cooled to −5° C. and stirred for 1 h. The slurry was filtered and washed twice with cold EtOAc (100 mL). The solids were dried in a vacuum oven at 40° C. for 40 h to afford 84.0 g (36.5% yield, 98.8 area % purity) of the title Compound 18 as a white solid. Anal. Calcd for C25H21N2OF3 0.04% H2O 0.15 mol MeOH: C, 70.48; H, 5.14: N, 6.42; F, 13.06 Found: C, 70.54; H, 4.83: N, 6.18; F, 13.33
    • Example 10.2 (E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol monosodium salt (Cpd 18)
  • A 5-L 4-neck flask equipped with a thermocouple controller, an overhead mechanical stirrer, and a nitrogen inlet/outlet was charged with (E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol. Compound 18 (125.0 g, 0.510 mol) and MeOH (1.25 L). A solution of sodium methoxide in methanol (0.5 M, 592 mL, 0.3 mol) was added. The reaction was heated to 65° C. for 30 min and all solids dissolved. The solution was cooled and evaporated to dryness. The foam was collected by scraping it out of the flask. The solids were placed in vacuum oven for 24 h at 40° C. to afford 139 g (about 100% isolated yield) of the title Compound 18 monosodium salt as a yellowish solid. 1H NMR (400 MHz, DMSO-d6) δ 7.80-7.84 (m, 3H), 7.74 (d, 2H, J=8.59 Hz), 7.65 (d, 1H, J=16.4 Hz), 7.40-7.44 (m, 2H), 7.25-7.37 (m, 2H), 7.16-7.20 (m, 1H), 7.01-7.05 (m, 1H), 6.84-6.87 (m, 1H), 1.23 (s, 6H). Mass Spectrum (LCMS, APCI pos.) Calcd. For C25H21F3N2O: 423.2 (M+H), Found 423.3. m.p. (uncorr.) 258-259° C.
    • Example 10.3 (E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol hydrochloride salt (Cpd 18)
  • A 250-mL separatory funnel was charged with (E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol. Compound 18 (1.0 g, 2.4 mmol) and EtOAc (20 mL). Aqueous HCl (1M, 20 mL) was added to the white slurry, and the separatory funnel was shaken. The solid product quickly dissolved, and a white precipitate started to form. The organic layer was transferred to a 100 mL round bottom flask equipped with a magnetic stir bar, and was stirred for 2 h. The thick slurry was filtered, rinsed with EtOAc (2×5 mL), and put into a vacuum oven at 40° C. for 36 h to afford 0.95 g (87.5%) of the title Compound 18 hydrochloride salt.
    • Example 11 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenol (Cpd 48) Step A. N-(4-bromo-2-nitro-5-trifluoromethyl-phenyl)-2,2,2-trifluoro-acetamide
  • 4-bromo-3-trifluoromethyl aniline (4.8 g, 0.02 mol) was added in portions to a stirred ice-cold trifluoroacetic anhydride (50 mL). To the resulting solution was added KNO3 (2.22 g, 0.022 mol, 1.1 eq) in portions. The reaction mixture was stirred at 0° C. for 1 h, and then allowed to warm to room temperature overnight. The reaction mixture was diluted with ice water (150 mL), and the solid was collected by vacuum filtration. The solid was washed with water (50 mL) and dried in vacuo to provide the title Compound 11 a as a bright yellow solid (6.4 g). 1H-NMR (400 MHz, CDCl3) δ (ppm): 9.19 (s, 1H) 8.64 (s, 1H) MS (ESI, pos. ion) m/z: 381.4 (M+1).
    • Step B. 4-bromo-2-nitro-5-trifluoromethyl-phenylamine
  • Compound 11a (5.7 g, 0.015 mol) was dissolved in a mixture of methanol (25 mL) and saturated aqueous K2CO3 (15 mL). The reaction mixture was then stirred at room temperature for 10 h. The reaction mixture was diluted with water (25 mL) and the product was collected by vacuum filtration to provide the title Compound 11b as a yellow solid (2.99 g). 1H-NMR (400 MHz, CDCl3) δ (ppm): 8.44 (s, 1H) 7.21 (s, 1H), 6.21 (bs, 2H). MS (ESI, pos. ion) m/z: 285.0 (M+1).
    • Step C. 4-bromo-5-trifluoromethyl-benzene-1,2-diamine
  • Compound 11b (2.85 g, 0.01 mol) was dissolved in 30 mL of ethanol. Zinc powder (5.9 g, 0.09 mol) was added in portions followed by the addition of ammonium chloride (1.07 g, 0.02 mol, 2 eq). The reaction mixture was stirred at room temperature overnight (16 h). The reaction mixture was filtered over a pad of celite and the solvent was evaporated in vacuo. The residue was taken up in ethyl acetate (40 mL), washed with 35 mL of brine, dried over Na2SO4, and evaporated in vacuo. The residue was purified by chromatography (silica gel, CH2Cl2: MeOH, 96:4-94:6)) to provide the title Compound 11c as a bright yellow solid (1.53 g), which was used without further purification in the next step. 1H-NMR (400 MHz, CD3OD) δ (ppm): 6.99 (s, 1H) 6.92 (s, 1H) MS (ESI, pos. ion) m/z: 254.7 (M+1).
    • Step D. (E)-5-bromo-2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazole
  • 4-t-butyl acrylic acid (1.02 g, 0.0055, 1.1 eq) was dissolved in 30 mL of POCl3. To this was added Compound 11c (1.27 g, 0.005 mol), and the reaction mixture was heated at reflux for 6 h. (The reaction mixture was quite dark). The reaction mixture was cooled to room temperature and concentrated in vacuo. The residue was taken up in 50 mL of ethyl acetate, washed with 50 mL of brine, dried over Na2SO4, filtered and the filtrate was concentrated in vacuo. The residue was purified by chromatography (silica gel, hexanes: EtOAc, 1:3-2:3) to provide the title Compound 11d as a light brown solid (0.84 g). 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.91 (d, 2H, J=18.5 Hz) 7.69 (d, 1H, J=16.4 Hz), 7.32 (m, 4H) 7.09 (d, 1H, J=16.5 Hz) 1.28 (s, 9H). MS (ESI, pos. ion) m/z: 423.7 (M+1).
    • Step E. (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenol
  • Compound 11d (0.00026 mol, 0.10 g) was dissolved in 5 mL of dioxane. 2-hydroxyphenyl boronic acid (0.00052 mol, 0.072 g, 2.0 equiv) was added followed by aqueous Na2CO3 (0.00055 mol, 0.28 mL of 2M solution) and dichlorobis(tricyclohexylphosphine)-palladium(II) (0.011 g, 6 mol %). The reaction mixture was heated in a microwave synthesizer at 110° C. for 20 minutes. The reaction mixture was cooled and the solvent was concentrated in vacuo. The residue was taken up in 10 mL of CH2Cl2, and washed sequentially with 10 mL of saturated aqueous NaHCO3 and 10 mL of brine. The organic fractions were dried over Na2SO4, filtered, and the filtrate was concentrated in vacuo. The residue purified by chromatography (silica gel, CH2Cl2: MeOH, 98:2-95:5) to provide the title Compound 48 as a white solid. 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.29-7.56 (m, 8H) 7.15 (d, 1H, J=6.7 Hz) 6.89-7.05 (m, 3H)) 1.34 (s, 9H). MS (ESI, pos. ion) m/z: 437.1 (M+1).
  • Using the procedures described in Example 11 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:
  • Cpd Name and Data
    49 (E)-3-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-
    5-yl}-phenol
    The title compound was prepared from 3-hydroxyphenyl boronic acid (0.00052 mol,
    0.072 g) and Compound 1a (0.00026 mol, 0.10 g). 1H-NMR (400 MHz,
    CDCl3) δ (ppm): 7.25-7.61 (m, 8H) 7.19 (d, 1H, J = 7.0 Hz) 6.90-7.11 (m, 3H))
    1.28 (s, 9H). MS (ESI, pos. ion) m/z: 437.1 (M + 1).
    50 (E)—N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-
    benzimidazol-5-yl}-phenyl)-acetamide
    The title compound was prepared from 2-acetamidophenyl boronic acid
    (0.00052 mol, 0.093 g) and Compound 1a (0.00026 mol, 0.10 g) to give the
    product as an off-white solid. 1H-NMR (400 MHz, CDCl3) δ (ppm): 8.15 (d, 2H,
    J = 8.1 Hz) 7.73-7.76 (m, 2H) 7.35-7.52 (m, 4H) 7.0-7.14 (m, 3H) 6.77 (s, 1 H)
    1.45 (s, 9H) 1.35 (s, 3H). MS (ESI, pos. ion) m/z: 478.2 (M + 1).
    51 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-
    5-yl}-phenyl)-methanol
    The title compound was prepared from 2-hydroxymethyl phenylboronic acid
    (0.00052 mol, 0.070 g) and Compound 1a (0.00026 mol, 0.10 g) to give the
    product as a white solid. 1H-NMR (400 MHz, CDCl3) δ (ppm): 6.9-7.5 (m, 12H)
    4.39 (m, 2H) MS (ESI, pos. ion) m/z: 451.2 (M + 1).
    52 (E)-2-[2-(4-tert-butyl-phenyl)-vinyl]-5-(2-fluoro-phenyl)-6-trifluoromethyl-
    1H-benzimidazole
    The title compound was prepared from 2-fluorophenylboronic acid (0.00052 mol,
    0.073 g) and Compound 1a (0.00026 mol, 0.10 g) to give the product as a beige
    solid. 1H-NMR (400 MHz, CDCl3) δ (ppm): 8.1 (m, 2H) 7.72 (d, 2H, J = 16 5 Hz)
    7.42-7.53 (m, 4H) 7.05-7.20 (m, 4H) 1.34 (s, 9H). MS (ESI, pos. ion) m/z:
    440.1 (M + 1).
    53 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-
    5-yl}-benzamide
    The title compound was prepared from 2-aminocarbonyl phenylboronic acid
    (0.00052 mol, 0.086 g) and Compound 1a (0.00026 mol, 0.10 g) to give the
    product as a yellow solid. 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.2-7.8 (m, 9H)
    6.91 (d, 2H, J = 5.4 Hz) 6.68 (d, 1H, J = 19.5 Hz) 1.32 (s, 9H). MS (ESI, pos. ion)
    m/z: 465.25 (M + 1).
    54 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-
    5-yl}-phenyl)-carbamic acid tert-butyl ester
    The title compound was prepared from t-butyl-N-[2-4,4,5,5-tetramethyl-1,3,2-
    dioxaborolan-2-yl) phenylcarbamate (0.00052 mol, 0.166 g) and Compound 1a
    (0.00026 mol, 0.10 g) to give the product as a beige solid. 1H-NMR (400 MHz,
    DMSO-d6) δ (ppm): 8.0 (s, 1H), 7.89 (s, 1H), 7.62-7.79 (m, 4H), 7.42-7.55 (m,
    3H), 7.36-7.41 (m, 2H), 7.15-7.30 (m, 2H))) 1.32 (s, 18H) MS (ESI, pos. ion)
    m/z: 536.2 (M + 1).
    55 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide
    The title compound was prepared from 2-methylsulfonylaminophenyl boronic
    acid (0.00052 mol, 0.111 g) and Compound 1a (0.00026 mol, 0.10 g) to give the
    product as a bright yellow solid. 1H-NMR (400 MHz, DMSO-d6) δ (ppm): 8.0 (s,
    1H) 7.79 (d, 1H, J = 16.5 Hz) 7.65 (d, 2H, J = 8.4 Hz) 7.5 (m, 3H) 7.41 (t, 1H, J = 7.7 Hz)
    7.23-7.28 (m, 3H) 7.10 (d, 1H, J = 12.1 Hz) 2.5 (s, 3H) 1.31 (s, 9H).
    MS (ESI, pos. ion) m/z: 514.2 (M + 1).
    • Example 12 (E)-N-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide (Cpd 56) Step A. (E)-5-bromo-6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole
  • Using the procedure of Example 11, Step D, 4-trifluoromethyl acrylic acid (1.19 g, 0.0055, 1.1 eq) was dissolved in 30 mL of POCl3. To this solution was added Compound 11c (1.27 g, 0.005 mol), and the reaction mixture was heated at reflux for 6 h (The reaction mixture was quite dark). The reaction mixture was cooled to room temperature and then concentrated in vacuo. The residue was taken up in 50 mL of ethyl acetate, washed with 50 mL of brine, dried over Na2SO4, filtered, and the filtrate was concentrated in vacuo. The residue was purified by chromatography (silica gel, hexanes: EtOAc, 3:1-3:2) to provide the title Compound 12a as a light yellow solid (1.02 g). 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.92 (d, 2H, J=14.1 Hz) 6.67-7.76 (m, 5H) 7.21 (d, 1H, J=16.5 Hz) MS (ESI, pos. ion) m/z: 368.3 (M+1).
    • Step B. (E)-N-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide
  • Compound 12a (0.00025 mol, 0.10 g) was dissolved in 5 mL of dioxane. 2-acetamidophenyl boronic acid (0.0005 mol, 0.089 g, 2.0 equiv) was added followed by aqueous Na2CO3 (0.00055 mol, 0.28 mL of 2M solution) and dichlorobis(tricyclohexylphosphine)-palladium(II) (0.011 g, 6 mol %). The reaction mixture was heated in a microwave synthesizer at 110° C. for 20 minutes. The reaction mixture was cooled and the reaction mixture was concentrated in vacuo. The residue was taken up in 10 mL of CH2Cl2, and washed sequentially with 10 mL of saturated aqueous NaHCO3 and 10 mL of brine. The organic fractions were dried over Na2SO4, filtered and the filtrate was concentrated in vacuo. The residue was purified by chromatography (silica gel CH2Cl2: MeOH, 98:2-95:5) to provide the title Compound 56 as a white solid. 1H-NMR (400M Hz, DMSO-d6) δ (ppm): 8.68 (s, 1H) 8.03 (s, 1H) 7.80-7.96 (m, 6H) 7.35-7.50 (m, 3H) 7.20 (d, 2H, J=4.1 Hz) 1.8 (s, 3H) MS (ESI, pos. ion) m/z: 490.0 (M+1).
  • Using the procedures described in Example 12 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:
  • Cpd Name and Data
    57 (E)-1-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-ethanone
    The title compound was prepared from 2-acetylphenyl boronic acid (0.0005 mol,
    0.082 g) and Compound 12a (0.00025 mol, 0.10 g) to give the product as a
    whitish-yellow solid. 1H-NMR (400 MHz, DMSO-d6) δ (ppm): 7.81-8.0 (m, 8H)
    7.42-7.62 (m, 3H) 7.30 (d, 1H, J = 6.8 Hz) 2.49 (s, 3H) MS (ESI, pos. ion) m/z:
    475.0 (M + 1).
    58 (E)-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanol
    The title compound was prepared from 2-hydroxymethyl phenylboronic acid
    (0.0005 mol, 0.067 g) and Compound 12a (0.00025 mol, 0.10 g) to give the
    product as a light yellow powder. 1H-NMR (400 MHz, CDCl3) δ (ppm): 8.0 (d,
    2H, J = 8.1 Hz) 7.8 (d, 2H, J = 8.2 Hz) 7.0-7.59 (m, 8H) 4.91-5.07 (m, 1H)
    4.09-4.22 (m, 2H) (s, 9H). MS (ESI, pos. ion) m/z: 463.0 (M + 1).
    • Example 13 (E)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol (Cpd 59) Step A. N-(4-bromo-5-fluoro-2-nitro-phenyl)-2,2,2-trifluoro-acetamide
  • 4-bromo-3-fluoromethyl aniline (3.8 g, 0.02 mol) was added in portions to a stirred ice-cold trifluoroacetic anhydride (50 mL). To the solution was added KNO3 (2.22 g, 0.022 mol, 1.1 eq) in portions. The reaction mixture was stirred at 0° C. for 1 h and then allowed to warm to room temperature overnight. The reaction mixture was diluted with ice water (150 mL) and the solid was collected by vacuum filtration. The solid was washed with water (50 mL) and dried in vacuo to provide the title Compound 13a as a bright yellow solid (5.42 g). 1H-NMR (400 MHz, CDCl3) δ (ppm): 8.66 (d, 1H, J=10.0 Hz) 8.60 (d, 1H, J=11.3 Hz). MS (ESI, pos. ion) m/z: 402.0 (M+Na).
    • Step B. 4-bromo-5-fluoro-2-nitro-phenylamine
  • Compound 13a (5.0 g, 0.015 mol) was dissolved in a mixture of methanol (25 mL) and saturated aqueous K2CO3 (15 mL) and the mixture was stirred at room temperature for 10 h. The reaction mixture was diluted with water (25 mL) and the product was collected by vacuum filtration to provide the title Compound 13b as a yellow solid (2.5 g). 1H-NMR (400 MHz, CDCl3) δ (ppm): 8.39 (d, 1H, J=7.1 Hz) 6.75 (d, 1H, J=9.6 Hz) 6.19 (bs, 2H). MS (ESI, pos. ion) m/z: 236.9 (M+1).
    • Step C. 4-bromo-5-fluoro-benzene-1,2-diamine
  • Compound 13b (1.88 g, 0.008 mol) was dissolved in 20 mL of ethanol. Zinc powder (4.71 g, 0.072 mol) was added in portions followed by the addition of the ammonium chloride (0.86 g, 0.016 mol). The reaction mixture was stirred at room temperature overnight (16 h). The reaction mixture was filtered over a pad of celite and the solvent was evaporated in vacuo. The residue was taken up in ethyl acetate (30 mL) and washed with 25 mL of brine. The organic fractions were dried over Na2SO4, filtered and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography (silica gel, CH2Cl2: MeOH, 96:4-94:6)) to provide the title Compound 13c as a dark yellow solid (1.02 g) that was used immediately in the next reaction. MS (ESI, pos. ion) m/z: 235.7 (M+1).
    • Step D. (E)-5-bromo-6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole
  • 4-trifluoromethyl cinnamic acid (1.2 g, 0.0055, 1.1 eq) was dissolved in 30 mL of POCl3. To the solution was added Compound 13c (1.02 g, 0.005 mol), and the reaction mixture was heated at reflux for 6 h. The reaction mixture was cooled to room temperature and then evaporated in vacuo. The residue was taken up in 50 mL of ethyl acetate, and washed with 50 mL of brine. The organic fractions were dried over Na2SO4 and concentrated in vacuo. The residue was purified by chromatography (silica gel, hexanes: EtOAc, 3:1-3:2) to provide the title
  • Compound 13d as a light brown solid (0.80 g). 1H-NMR (400 MHz, DMSO-d6) δ (ppm): 7.63-8.09 (m, 4H) 7.4 (d, 1H, J=20.7 Hz) 6.69 (d, 1H, J=20.7 Hz) MS (ESI, pos. ion) m/z: 386.0 (M+1).
    • Step E. (E)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol
  • Compound 13d (0.00025 mol, 0.096 g) was dissolved in 5 mL of dioxane. 2-hydroxyphenyl boronic acid (0.0005 mol, 0.069 g) was added followed by aqueous Na2CO3 (0.00055 mol, 0.28 mL of 2M solution) and dichlorobis(tricyclohexylphosphine)-palladium(II) (0.011 g, 6 mol %). The reaction mixture was heated in a microwave synthesizer at 110° C. for 20 minutes. The reaction mixture was cooled and the solvent was evaporated in vacuo. The residue was taken up in 10 mL of CH2Cl2, and washed sequentially with 10 mL of saturated aqueous NaHCO3 and 10 mL of brine. The organic fractions were dried over Na2SO4, filtered and the filtrate was concentrated in vacuo. The residue was purified by chromatography (silica gel (CH2Cl2: MeOH, 98:2-95:5) to provide the title Compound 59 as a tan solid. 1H-NMR (400 MHz, DMSO-d6) δ (ppm): 7.90 (d, 2H, J=8.0 Hz) 7.79 (d, 2H, J=7.8 Hz) 7.22-7.53 (m, 4H) 6.88-6.96 (m, 4H) MS (ESI, pos. ion) m/z: 399.1 (M+1).
  • Using the procedures described in Example 13 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:
  • Cpd Name and Data
    60 (E)-3-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenol
    The title compound was prepared from 3-hydroxyphenyl boronic acid (0.0005 mol,
    0.069 g) and Compound 13d (0.00025 mol, 0.096 g) to give the product as
    an off-white solid. 1H-NMR (400 MHz, DMSO-d6) δ (ppm): 7.76-8.0 (m, 4H)
    7.24-7.64 (m, 5H) 6.96-7.03 (m, 1H) 6.75-6.8 (m, 2H) MS (ESI, pos. ion) m/z:
    399.3 (M + 1).
    61 (E)-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenyl)-methanol
    The title compound was prepared from 2-hydroxymethyl phenylboronic acid
    (0.0005 mol, 0.067 g) and Compound 13d (0.00025 mol, 0.096 g) to give the
    product as a yellowish solid. 1H-NMR (400 MHz, CD3OD) δ (ppm): 7.83 (d, 2H,
    J = 8.2 Hz) 7.70-7.73 (m, 2H) 7.64 (t, 2H, J = 7.9, 7.5 Hz)) 7.55 (d, 1H, J = 7.2 Hz)
    7.25-7.46 (m, 4H) 7.10 (dd, 1H, J = 1.2 Hz) 4.29 (d, 2H, J = 0.85 Hz) MS
    (ESI, pos. ion) m/z: 413.1 (M + 1).
    62 (E)-1-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-
    5-yl}-phenyl)-ethanone
    The title compound was prepared from 2-acetylphenyl boronic acid (0.0005 mol,
    0.082 g) and Compound 13d (0.00025 mol, 0.096 g) to give the product as a
    bright yellow solid. 1H-NMR (400 MHz, CD3OD) δ (ppm): 7.75-7.91 (m, 5 H)
    7.55-7.68 (m, 4H) 7.41-7.47 (m, 3H) 2.46 (s, 3H) MS (ESI, pos. ion) m/z:
    425.1 (M + 1).
    63 (E)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzamide
    The title compound was prepared from 2-aminocarbonyl phenylboronic acid
    (0.0005 mol, 0.083 g) and Compound 13d (0.00025 mol, 0.096 g) to give the
    product as a sticky tan solid. 1H-NMR (400 MHz, DMSO-d6) δ (ppm): 7.93 (d,
    2H, J = 8.6 Hz) 7.83 (d, 2H, J = 8.6 Hz) 7.40-7.71 (m, 8H) MS (ESI, pos. ion)
    m/z: 426.0 (M + 1).
    64 (E)-N-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-
    5-yl}-phenyl)-acetamide
    The title compound was prepared from 2-acetamidophenyl boronic acid (0.0005 mol,
    0.089 g) and Compound 13d (0.00025 mol, 0.096 g) to give the product as
    an off-white solid. 1H-NMR (400 MHz, DMSO-d6) δ (ppm): 8.68 (s, 1H) 8.03 (s,
    1H) 7.80-7.96 (m, 6H) 7.35-7.50 (m, 3H) 7.20 (d, 2H, J = 4.1 Hz) 1.8 (s, 3H) MS
    (ESI, pos. ion) m/z: 440.1 (M + 1).
    65 (E)-N-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-
    5-yl}-phenyl)-methanesulfonamide
    The title compound was prepared from 2 methylsulfonylaminophenyl boronic
    acid (0.0005 mol, 0.108 g) and Compound 13d (0.00025 mol, 0.096 g) to give
    the product as an off-white solid. 1H-NMR (400 MHz, CD3OD) δ (ppm): 7.65 (s,
    1 H) 7.59 (d, 1H, J = 6.7 Hz) 7.26-7.48 (m, 10 H) 2.95 (s, 3H) MS (ESI, pos. ion)
    m/z: 476.1 (M + 1).
    • Example 14 (E)-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol (Cpd 66) Step A. N-(4-bromo-5-chloro-2-nitro-phenyl)-2,2,2-trifluoro-acetamide
  • 4-Bromo-3-chloromethyl aniline (4.1 g, 0.02 mol) was added in portions to a stirred ice cold trifluoroacetic anhydride (50 mL). To the resulting solution was added KNO3 (2.22 g, 0.022 mol, 1.1 eq) in portions. The reaction mixture was stirred at 0° C. for 1 hour and then allowed to warm to room temperature overnight.
  • The reaction mixture was diluted with ice water (150 mL) and the solid was collected by vacuum filtration. The solid was washed with water (50 mL) and dried in vacuo to provide the title Compound 14a as a pale yellow solid (5.55 g).
    • Step B. 4-bromo-5-chloro-2-nitro-phenylamine
  • Compound 14a (5.2 g, 0.015 mol) was dissolved in a mixture of methanol (25 mL) saturated aqueous K2CO3 (15 mL). The reaction mixture was stirred at room temperature for 10 hours. The reaction mixture was diluted with water (25 mL) and the product was collected by vacuum filtration to provide the title Compound 14b as a yellow solid (2.71 g). 1H-NMR (400 MHz, CDCl3) δ (ppm): 8.39 (s, 1H) 6.98 (s, 1H) 6.08 (bs, 2H). MS (ESI, pos. ion) m/z: 250.9 (Br, Cl pattern).
    • Step C. 4-bromo-5-chloro-benzene-1,2-diamine
  • Compound 14b (2.0 g, 0.008 mol) was dissolved in 20 mL of ethanol. Zinc powder (4.7 g, 0.072 mol) was added in portions followed by the addition of the ammonium chloride (0.88 g, 0.016 mol, 2 eq). The reaction mixture was stirred at room temperature overnight (16 hours). The reaction mixture was filtered over a pad of celite and the solvent was evaporated in vacuo. The residue was taken up in ethyl acetate (30 mL) and washed with 25 mL of brine. The organic fractions were dried over Na2SO4, filtered and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography (silica gel, CH2Cl2: MeOH, 96:4-94:6) to provide the title Compound 14c as a dark yellowish-brown solid (1.08 g) and was used immediately in the next reaction. MS (ESI, pos. ion) m/z: 220.9 (Br, Cl pattern).
    • Step D. (E)-5-bromo-6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole
  • 4-trifluoromethyl cinnamic acid (1.2 g, 0.0055, 1.1 eq) was dissolved in 30 mL of POCl3. To this solution was added Compound 14c (1.08 g, 0.005 mol), and the reaction mixture was heated to reflux for 6 hours (The reaction mixture was quite dark). The reaction mixture was cooled to room temperature and the evaporated in vacuo. The residue was taken up in 50 mL of ethyl acetate, and washed with 50 mL of brine. The organic fractions were dried over Na2SO4, filtered and the filtrate was evaporated in vacuo. The residue was purified by chromatography (silica gel hexanes: EtOAc, 3:1-3:2) to provide the title Compound 14d as a light brown solid (0.80 g). 1H-NMR (400 MHz, DMSO-d6) δ (ppm): 7.57-8.21 (m, 4H) 7.35 (d, 1H, J=19 Hz) 6.72 (d, 1H, J=18.5 Hz). MS (ESI, pos. ion) m/z: 401.0.
    • Step E. (E)-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol
  • Compound 14d (0.00025 mol, 0.100 g) was dissolved in 5 mL of dioxane. 2-hydroxymethyl phenylboronic acid (0.0005 mol, 0.067 g, 2.0 equiv) was added followed by aqueous Na2CO3 (0.00055 mol, 0.28 mL of 2M solution) and dichlorobis(tricyclohexylphosphine)-palladium(II) (0.011 g, 6 mol %). The reaction mixture was heated in a microwave at 110° C. for 20 minutes. The reaction mixture was cooled and the solvent was evaporated in vacuo. The residue was taken up in 10 mL of CH2Cl2, and washed sequentially with 10 mL of saturated aqueous NaHCO3 and 10 mL of brine. The organic fractions were dried over Na2SO4, filtered and the solvent was evaporated in vacuo. The residue was purified by chromatography (silica gel, CH2Cl2: MeOH, 98:2-95:5) to provide the title Compound 66 as a yellow sticky solid. 1H-NMR (400 MHz, CD3OD) δ (ppm): 7.82-7.85 (d, 2H, J=8.4 Hz) 7.72-7.74 (d, 2H, J=8.3 Hz) 7.56-7.66 (m, 3H) 7.26-7.43 (m, 5H) 5.05 (s, 1H) 4.58 (s, 2H). MS (ESI, pos. ion) m/z: 395.3 (—CH2OH).
  • Using the procedures described in Example 14 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:
  • Cpd Name and Data
    67 (E)-1-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-
    5-yl}-phenyl)-ethanone
    The title compound was prepared from 2-acetylphenyl boronic acid (0.0005 mol,
    0.082 g) and Compound 14d (0.00025 mol, 0.100 g) to give the product as a
    pale yellow solid. 1H-NMR (400 MHz, CD3OD) δ (ppm): 7.80-7.84 (m, 2H)
    7.70-7.74 (m, 2H) 7.67 (s, 1H), 7.50-7.7.64 (m, 2H) 7.27-7.43 (m, 5H), 1.36 (s, 9H).
    MS (ESI, pos. ion) m/z: 441.1 (M + 1).
    68 (E)-2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-phenol
    The title compound was prepared from 2-hydroxyphenyl boronic acid (0.0005 mol,
    0.108 g) and Compound 14d (0.00025 mol, 0.069 g) to give the product as
    a dark yellow solid. 1H-NMR (400 MHz, CD3OD) δ (ppm): 6.2-6.6 (m, 5H)
    5.99-6.05 (m, 5H) 5.59-5.66 (2H) 7.80-7.84 (m, 2H). MS (ESI, pos. ion) m/z:
    415.0 (M + 1).
    • Example 15 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide (Cpd 70) (E)-N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide (Cpd 309) Step A. (E)-N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide
  • A mixture of 2-(t-butylamino)sulfonylphenyl boronic acid (12.4 g, 0.048 mol), Compound 10c (13.6 g, 0.037 mol), Pd(dppf)Cl2CH2Cl2 (3.00 g, 3.70 mmol), TBAB (11.9 g, 0.037 mmol), and Na2CO3 (31.4, 0.296 mol) in 750 mL of mixed solvent (DME: water, 4:1) was heated at 90° C. for 12 hours. The reaction mixture was concentrated, and the residue was purified by chromatography (silica gel, hexanes: EtOAc, 1:1) to provide the title Compound 309 as a yellow oil. 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J=1.6 and 7.6 Hz) 7.84 (d, 2H, J=8.4 Hz) 7.73 (d, 2H, J=8.4 Hz) 7.70-7.62 (m, 4H) 7.54 (dt, 1H, J=1.6 and 8.6 Hz) 7.41 (dd, 1H, J=1.2 and 7.6 Hz) 7.37-7.31 (m, 2H) 1.00 (s, 9H) MS (ESI, pos. ion) m/z: 490.3 (M+1).
    • Step B. (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide
  • A solution of Compound 309 in 60 mL TFA was heated at 70° C. for 2 hours.
  • The reaction was concentrated, the residue was dissolved in EtOAc, and washed with sat'd NaHCO3. The organic layer was dried over Na2SO4, filtered, and the residue was concentrated. The residue was purified by chromatography (silica gel, hexanes: EtOAc, 1:2) to provide the title Compound 70 as a light brown solid. M.p. 168-170° C. 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.16 (dd, 1H, J=1.2 and 8.0 Hz) 7.95-7.91 (m, 3H) 7.82-7.76 (m, 4H) 7.70-7.56 (m, 3H) 7.44 (s, 1H) 7.16 (d, 1H, J=9.6 Hz) MS (ESI, pos. ion) m/z: 444.3 (M+1).
  • Using the procedures described in Example 15 and reagents, starting materials and conditions known to those skilled in the art, the following compound representative of the present invention was prepared:
  • Cpd Name and Data
    71 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 7.6 Hz) 8.10 (d,
    2H, J = 8.4 Hz) 8.01 (d, 2H, J = 8.4 Hz) 7.71-7.53 (m, 5H) 7.44 (d, 1H, J = 16.4 Hz)
    7.41 (dd, 1H, J = 1.2 and 7.6 Hz) 7.35 (dd, 1H, J = 1.2 and 8.4 Hz) MS (ESI,
    pos. ion) m/z: 508.3 (M + 1).
    398 (E)-N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-benzenesulfonamide
    The title compound was prepared from 2-N,N-dimethylaminosulfonylphenyl
    boronic acid and Compound 10c.
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.08 (dd, 1H, J = 1.2 and 8.4 Hz) 7.84 (d,
    2H, J = 8.4 Hz) 7.73 (d, 2H, J = 8.8 Hz) 7.69-7.56 (m, 5H) 7.43 (dd, 1H, J = 1.2
    and 7.2 Hz) 7.33 (d, 1H, J = 16.4 Hz) 7.28 (dd, 1H, J = 1.6 and 8.4 Hz) 2.34 (s,
    6H) MS (ESI, pos. ion) m/z: 472.5 (M + 1).
    441 (E)-4-fluoro-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    The title compound was prepared from 2-tert-butylaminosulfonyl-5-
    fluorophenylboronic acid and Compound 10c.
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.18 (dd, J = 5.6, 8 Hz, 1H), 7.94 (d, J = 5.6,
    8 Hz, 1H), 7.84 (d, J = 8 Hz, 2H), 7.73 (s, 1H), 7.71-7.69 (m, 2H), 7.63 (d, J = 8 Hz,
    1H), 7.35-7.32 (m, 1H), 7.28-7.22 (m, 2H), 7.14 (dd, J = 2, 9 Hz, 1H). Mass
    Spectrum (LCMS, ESI pos.) Calcd. For C22H15F4N3O2S: 462.4 (M + H), Found
    462.2.
    444 (E)-4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-benzenesulfonamide
    The title compound was prepared from 2-tert-butylaminosulfonyl-5-
    trifluoromethylphenyl boronic acid and Compound 10c.
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.33 (d, J = 8 Hz, 1H), 7.88 (s, 1H), 7.85 (d,
    J = 8 Hz, 2H), 7.74-7.68 (m, 6H), 7.36-7.32 (m, 1H), 7.34 (d, J = 16.4 Hz, 1H).
    Mass Spectrum (LCMS, ESI pos.) Calcd. For C23H15F6N3O2S: 512.5 (M + H),
    Found 512.3.
    446 (E)-5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-benzenesulfonamide
    The title compound was prepared from 2-tert-butylaminosulfonyl-4-
    trifluoromethylphenyl boronic acid and Compound 10c.
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.42 (s, 1H), 7.94 (d, J = 8 Hz, 1H), 7.85 (d,
    J = 8 Hz, 2H), 7.73 (d, J = 8 Hz, 2H), 7.71 (d, J = 8 Hz, 2H), 7.64 (d, J = 8 Hz, 2H),
    7.34 (d, J = 16.4 Hz, 2H). Mass Spectrum (LCMS, ESI pos.) Calcd. For
    C23H15F6N3O2S: 512.1 (M + H), Found 512.2.
    • Example 16 (E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide (Cpd 69) Step A. (5-bromo-2-tert-butoxycarbonylamino-phenyl)-carbamic acid tert-butyl ester
  • 4-bromo-phenylenediamine (25 g, 0.134 mol) was added portionwise to di-t-butyl dicarbonate (175 g, 0.802 mol) at 25° C., and the reaction mixture was stirred for 10 hours. The mixture was purified by chromatography (silica gel, hexanes to hexanes: EtOAc, 1:1) to provide the title Compound 16a as a light brown solid.
  • 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.76 (brs, 1H) 7.32 (brs, 1H) 7.22 (dd, 1H, J=2.0 and 8.8 Hz) 6.72 (brs, 1H) 6.53 (brs, 1H).
    • Step B. (3-tert-butoxycarbonylamino-2′-tert-butylsulfamoyl-biphenyl-4-yl)-carbamic acid tert-butyl ester
  • A mixture of 2-(t-butylamino)sulfonylphenyl boronic acid (4.7 g, 0.018 mmol), Compound 16a (4.7 g, 0.012 mmol), Pd(dppf)Cl2.CH2Cl2 (0.99 g, 0.0012 mmol), TBAB (3.90 g, 0.012 mmol), and 20 mL of 1M Na2CO3 (aq) in 100 mL of DME was heated at 100° C. for 12 hours. The reaction mixture was concentrated, and the residue was purified by chromatography (silica gel, hexanes: EtOAc, 2:1) to provide the title Compound 16b as a yellow oil.
    • Step C. 3′,4′-diamino-biphenyl-2-sulfonic acid tert-butylamide
  • A mixture of Compound 16b in 20 mL of 4M HCl in dioxane was stirred for 3 hours. The reaction mixture was concentrated, diluted with EtOAc and washed with sat'd NaHCO3 (aq), then dried over Na2SO4 and filtered. The filtrate was concentrated to provide the title Compound 16c as a brown oil. 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.04 (dd, 1H, J=1.2 and 7.6 Hz) 7.56 (dt, 1H, J=1.2 and 8.2 Hz) 7.44 (dt, 1H, J=1.2 and 8.4 Hz) 7.33 (dd, 1H, J=1.2 and 7.6 Hz) 6.86 (d, 1H, J=1.6 Hz) 6.77 (d, 1H, J=7.6 Hz) 6.73 (dd, 1H, J=2.0 and 8.0 Hz) 0.97 (s, 9H). MS (ESI, pos. ion) m/z: 319.9 (M+1).
    • Step D. (E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide
  • A mixture of Compound 16c (0.120 g, 0.376 mmol), trans 4-(trifluoromethoxy)-cinnamic acid (0.105 g, 0.451 mmol), and 0.4 mL of 4N HCl (aq) in 4 mL of ethylene glycol was heated at 180° C. for 1 hour. The reaction mixture was purified directly by HPLC (YMC ODS-A, H2O: MeCN, 90:10 to 40:60, over 10 min) to provide the title Compound 69 as an off-white solid. 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J=1.2 and 8.0 Hz) 7.75 (d, 2H, J=8.4 Hz) 7.68-7.53 (m, 5H) 7.41 (dd, 1H, J=1.2 and 7.6 Hz) 7.37-7.33 (m, 3H) 7.19 (d, 1H, J=16.8 Hz) MS (ESI, pos. ion) m/z: 460.3 (M+1).
  • Using the procedures described in Example 16 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:
  • Cpd Name and Data
    79 (E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzene
    sulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 7.6 Hz)
    7.68-7.54 (m, 7H) 7.46-7.40 (m, 3H) 7.38 (dd, 1H, J = 1.2 and 8.4 Hz) 7.19 (d, 1H, J = 16.8 Hz)
    MS (ESI, pos. ion) m/z: 410.4 (M + 1).
    85 (E)-2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 7.6 Hz) 7.99 (d,
    2H, J = 8.4 Hz) 7.89 (d, 2H, J = 8.4 Hz) 7.71-7.53 (m, 5H) 7.41 (dd, 1H, J = 1.6
    and 7.6 Hz) 7.36 (d, 1H, J = 16.4 Hz) 7.34 (dd, 1H, J = 1.6 and 8.4 Hz) MS (ESI,
    pos. ion) m/z: 453.4 (M + 1).
    357 (E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (d, 1H, J = 8.0 Hz) 7.83-7.75 (m, 2H)
    7.67-7.53 (m, 4H) 7.38 (t, 2H, J = 9.2 Hz) 7.22 (d, 1H, J = 16.8 Hz) 7.08-7.03 (m,
    2H) MS (ESI, pos. ion) m/z: 412.4 (M + 1).
    358 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 7.6 Hz)
    7.72-7.55 (m, 6H) 7.48-7.35 (m, 4H) 7.20 (d, 1H, J = 16.4 Hz) MS (ESI, pos. ion) m/z:
    412.4 (M + 1).
    359 (E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 8.0 Hz) 7.84 (d,
    1H, J = 16.8 Hz) 7.70-7.54 (m, 5H) 7.41 (dd, 2H, J = 1.6 and 8.4 Hz) 7.33 (d, 1H,
    J = 16.8 Hz) 7.29-7.23 (m, 2H) MS (ESI, pos. ion) m/z: 412.4 (M + 1).
    360 (E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 8.0 Hz) 7.81 (d,
    1H, J = 16.8 Hz) 7.69-7.54 (m, 5H) 7.46-7.38 (m, 2H) 7.33 (d, 1H, J = 16.8 Hz)
    7.26-7.14 (m, 2H) MS (ESI, pos. ion) m/z: 412.4 (M + 1).
    361 (E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J = 1.6 and 8.0 Hz)
    7.71-7.55 (m, 5H) 7.42 (td, 2H, J = 1.4 and 8.4 Hz) 7.34-7.28 (m, 3H) 7.04-6.99 (m, 1H)
    MS (ESI, pos. ion) m/z: 412.4 (M + 1).
    362 (E)-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 7.6 Hz)
    7.37-7.51 (m, 8H) 7.41 (dd, 1H, J = 1.2 and 8.0 Hz) 7.35 (dd, 1H, J = 1.6 and 8.0 Hz)
    7.29 (d, 1H, J = 8.8 Hz) 7.25 (d, 1H, J = 16.8 Hz) 7.34 (dd, 1H, J = 1.6 and 8.4 Hz)
    MS (ESI, pos. ion) m/z: 460.4 (M + 1).
    363 (E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (dd, 1H, J = 1.2 and 7.6 Hz) 7.93 (d,
    1H, J = 1.2 and 7.6 Hz) 7.65-7.47 (m, 6H) 7.42-7.29 (m, 4H) 7.22 (d, 1H, J = 16.8 Hz)
    MS (ESI, pos. ion) m/z: 454.3 (M + 1).
    364 (E)-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 8.0 Hz) 8.10 (dd,
    1H, J = 2.0 and 16.4 Hz) 8.01 (d, 1H, J = 7.6 Hz) 7.80 (d, 1H, J = 7.6 Hz)
    7.75-7.55 (m, 6H) 7.42 (dd, 2H, J = 1.2 and 8.4 Hz) 7.25 (d, 1H, J = 16.4 Hz) MS (ESI,
    pos. ion) m/z: 444.3 (M + 1).
    365 (E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.16 (d, 1H, J = 7.6 Hz) 8.13 (s, 1H)
    7.90 (d, 1H, J = 9.2 Hz) 7.68 (d, 1H, J = 14.4 Hz) 7.65-7.49 (m, 4H) 7.43-7.38 (m, 4H)
    7.25 (d, 1H, J = 16.4 Hz) MS (ESI, pos. ion) m/z: 410.3 (M + 1).
    366 (E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.35 (d, 1H, J = 16.4 Hz) 8.16 (dd, 1H, J = 1.6
    and 8.0 Hz) 7.97 (dd, 1H, J = 1.6 and 7.6 Hz) 7.84 (s, 1H) 7.80 (d, 1H, J = 9.2 Hz)
    7.76 (dd, 1H, J = 1.2 and 8.0 Hz) 7.70-7.60 (m, 3H) 7.52 (dt, 1H, J = 1.2
    and 8.2 Hz) 7.45-7.39 (m, 2H) 7.32 (d, 1H, J = 16.4 Hz) MS (ESI, pos. ion) m/z:
    454.3 (M + 1).
    367 (E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.15 (dd, 1H, J = 1.2 and 7.6 Hz)
    8.12-8.08 (m, 2H) 7.76-7.41 (m, 8H) 7.25 (d, 1H, J = 16.4 Hz) MS (ESI, pos. ion) m/z:
    461.4 (M + 1).
    368 (E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 7.6 Hz) 8.10 (t,
    1H, 7.0 Hz) 7.91 (d, 1H, J = 16.4 Hz) 7.75-7.54 (m, 5H) 7.46-7.34 (m, 4H) MS
    (ESI, pos. ion) m/z: 461.4 (M + 1).
    369 (E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.16 (dd, 1H, J = 1.6 and 8.0 Hz)
    8.12-8.10 (m, 2H) 7.94 (d, 1H, J = 16.8 Hz) 7.85 (dd, 1H, J = 0.8 and 1.6 Hz) 7.80 (dd, 1H,
    J = 0.8 and 8.8 Hz) 7.70-7.59 (m, 3H) 7.52 (t, 1H, J = 9.8 Hz) 7.43 (dd, 1H, J = 1.6
    and 7.6 Hz) 7.39 (d, 1H, J = 16.8 Hz) MS (ESI, pos. ion) m/z: 462.3 (M + 1).
    370 (E)-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (d, 1H, J = 8.0 Hz) 7.79 (d, 1H, J = 16.8 Hz)
    7.68 (d, 1H, J = 16.0 Hz) 7.64-7.55 (m, 4H) 7.43-7.40 (m, 2H) 7.31 (d,
    1H, J = 16.8 Hz) 7.23 (q, 1H, J = 8.1 Hz) MS (ESI, pos. ion) m/z: 430.4 (M + 1).
    371 (E)-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 8.0 Hz)
    7.84-7.79 (m, 1H) 7.75 (d, 1H, J = 15.6 Hz) 7.68-7.53 (m, 4H) 7.41 (dd, 1H, J = 1.2 and 7.6 Hz)
    7.37 (dd, 1H, J = 1.6 and 8.4 Hz) 7.33-7.25 (m, 2H) MS (ESI, pos. ion) m/z:
    430.3 (M + 1).
    372 (E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J = 0.8 and 7.6 Hz) 7.85 (d,
    1H, J = 16.8 Hz) 7.70-7.54 (m, 4H) 7.49 (d, 1H, J = 16.8 Hz) 7.46-7.40 (m, 3H)
    7.10 (t, 2H, J = 8.8 Hz) MS (ESI, pos. ion) m/z: 412.3 (M + 1).
    373 (E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.25 (s, 2H) 8.14 (dd, 1H, J = 1.2 and 7.6 Hz)
    7.95 (s, 1H) 7.71 (d, 1H, J = 16.8 Hz) 7.68-7.53 (m, 4H) 7.44 (d, 1H, J = 16.8 Hz)
    7.42 (dd, 1H, J = 1.2 and 7.6 Hz) 7.35 (dd, 1H, J = 1.6 and 8.0 Hz) MS (ESI,
    pos. ion) m/z: 512.4 (M + 1).
    374 (E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.36 (s, 1H) 8.24 (dd, 1H, J = 2.0 and 16.4 Hz)
    8.16 (dd, 1H, J = 1.2 and 8.0 Hz) 8.06 (d, 1H, J = 8.4 Hz) 7.84 (d, 1H, J = 8.4 Hz)
    7.83 (s, 1H) 7.79 (d, 1H, J = 8.8 Hz) 7.69-7.57 (m, 3H) 7.48-7.42 (m, 2H) MS
    (ESI, pos. ion) m/z: 512.4 (M + 1).
    375 (E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.51 (d, 1H, J = 16.0 Hz) 8.16-8.10 (m, 2H)
    8.03 (d, 1H, J = 8.4 Hz) 7.82 (dd, 1H, J = 1.6 and 8.0 Hz) 7.75-7.55 (m, 4H)
    7.49-7.36 (m, 2H) 7.28 (d, 1H, J = 16.4 Hz) MS (ESI, pos. ion) m/z: 488.1 (M + 1).
    376 (E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.15 (d, 1H, J = 7.6 Hz) 7.89 (s, 1H)
    7.74-7.58 (m, 7H) 7.48-7.37 (m, 3H) 7.27 (d, 1H, J = 16.4 Hz) MS (ESI, pos. ion) m/z:
    454.3 (M).
    378 (E)-2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J = 1.6 and 8.0 Hz) 8.04 (d,
    1H, J = 2.0 Hz) 7.93 (dd, 1H, J = 2.0 and 8.4 Hz) 7.71-7.54 (m, 6H) 7.43-7.38 (m,
    2H) 7.32 (d, 1H, J = 16.8 Hz) MS (ESI, pos. ion) m/z: 478.4 (M + 1).
    379 (E)-2-{2-[2-(5-bromo-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.15 (dd, 1H, J = 1.2 and 8.0 Hz) 8.00 (dd,
    1H, J = 2.4 and 6.4 Hz) 7.88 (d, 1H, J = 16.4 Hz) 7.76-7.57 (m, 5H) 7.51 (dd, 1H,
    J = 1.6 and 8.8 Hz) 7.42 (dd, 1H, J = 1.2 and 8.0 Hz) 7.38 (d, 1H, J = 16.4 Hz)
    7.20 (dd, 1H, J = 8.8 and 10.4 Hz) MS (ESI, pos. ion) m/z: 472.3 (M + 1).
    423 (E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, J = 1.2, 8.2 Hz, 1H), 7.74-7.62 (m,
    7H), 7.43-7.34 (m, 3H), 6.64 (d, J = 16.0 Hz, 1H). Mass Spectrum (LCMS, ESI
    pos.) Calcd. For C22H15F4N3O2S: 462.1 (M + H), Found 462.2.
    424 (E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (dd, J = 1.6, 8.0 Hz, 1H), 7.99 (t, J = 7.2 Hz,
    1H), 7.83 (d, J = 16.8 Hz, 1H), 7.67-7.52 (m, 4H), 7.45 (s, 1H), 7.43-7.40 (m,
    3H), 7.34 (dd, J = 1.6, 7.6 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For
    C22H15F4N3O2S: 462.1 (M + H), Found 462.2.
    425 (E)-2-{2-[2-(3-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzene
    sulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (dd, J = 1.6, 8.0 Hz, 1H), 7.99 (t, J = 7.2 Hz,
    1H), 7.57 (d, J = 16 Hz, 1H), 7.67-7.60 (m, 2H), 7.45 (s, 1H), 7.43-7.40 (m,
    2H), 7.25 (t, J = 4 Hz, 1H), 7.11 (d, J = 8 Hz, 1H), 7.07-7.08 (m, 1H), 6.92-6.89 (m,
    1H), 6.45 (d, J = 16 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For
    C23H21N3O3S: 420.1 (M + H), Found 420.2.
    426 (E)-2-(2-styryl-1H-benzimidazol-5-yl)-benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (dd, J = 1.6, 7.8 Hz, 1H), 7.66-7.58 (m,
    6H), 7.54 (dt, J = 1.6, 7.6 Hz, 1H), 7.44-7.40 (m, 3H), 7.38-7.34 (m, 1H), 7.31 (dd,
    J = 1.6, 8 Hz, 1H), 7.18 (d, J = 16.4 Hz, 1H). Mass Spectrum (LCMS, ESI pos.)
    Calcd. For C21H17N3O2S: 376.1 (M + H), Found 376.3.
    427 (E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzene
    sulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.82 (s, 1H),
    7.65-7.61 (m, 3H), 7.60-7.54 (m, 3H), 7.52 (s, 1H), 7.41 (dd, J = 1.6, 8 Hz, 1H),
    7.32 (dd, J = 1.6, 8 Hz, 1H), 7.22 (d, J = 16.4 Hz, 1H). Mass Spectrum (LCMS, ESI
    pos.) Calcd. For C21H15Cl2N3O2S: 444.0 (M + H), Found 444.1.
    428 (E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.78 (d, J = 8 Hz,
    1H), 7.75 (d, J = 8 Hz, 1H), 7.72 (s, 1H), 7.55-7.54 (m, 1H), 7.62 (dd, J = 1.6, 8 Hz,
    1H), 7.54 (dt, J = 1.6, 8 Hz, 1H), 7.41 (dd, J = 1.6, 8 Hz, 1H), 7.34-7.26 (m, 4H).
    Mass Spectrum (LCMS, ESI pos.) Calcd. For C21H15ClFN3O2S: 428.9 (M + H),
    Found 430.2.
    429 (E)-2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.65-7.60 (m,
    4H), 7.58-7.52 (m, 3H), 7.41 (dd, J = 1.6, 8 Hz, 1H), 7.32-7.29 (m, 3H), 7.13 (d,
    J = 16.8 Hz, 1H), 2.94 (h, J = 2.4 Hz, 1H), 1.27 (d, J = 8 Hz, 6H). Mass Spectrum
    (LCMS, ESI pos.) Calcd. For C24H23N3O2S: 418.1 (M + H), Found 418.4.
    430 (E)-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.65-7.58 (m,
    5H), 7.53 (d, J = 7.6 Hz, 2H), 7.41 (dd, J = 1.6, 8 Hz, 1H), 7.30 (dd, J = 1.6, 8 Hz,
    1H), 7.23 (d, J = 8 Hz, 2H), 7.11 (d, J = 16.8 Hz, 1H), 2.36 (s, 3H). Mass Spectrum
    (LCMS, ESI pos.) Calcd. For C22H19N3O2S: 390.1 (M + H), Found 390.5.
    431 (E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.80 (d, J = 16 Hz,
    1H), 7.73 (t, J = 7.2 Hz, 1H), 7.66-7.60 (m, 4H), 7.57-7.52 (m, 1H),
    7.51-7.46 (m, 1H), 7.42 (dd, J = 1.6, 8 Hz, 1H), 7.33 (dd, J = 1.6, 8 Hz, 1H), 7.22 (d, J = 16.8 Hz,
    1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C21H15ClFN3O2S:
    428.9 (M + H), Found 428.3.
    432 (E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.80 (dd, J = 2,
    7.2 Hz, 1H), 7.65-7.52 (m, 6H), 7.41 (dd, J = 1.6, 8 Hz, 1H), 7.33-7.28 (m, 2H),
    7.16 (d, J = 16.8 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For
    C21H15ClFN3O2S: 428.9 (M + H), Found 428.3.
    433 (E)-2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-benzene
    sulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 8.01 (s, 1H),
    7.91-7.82 (m, 4H), 7.80 (d, J = 16.8 Hz, 1H), 7.66-7.59 (m, 3H), 7.55 (dd, J = 1.6, 8 Hz,
    1H), 7.52-7.48 (m, 2H), 7.42 (dd, J = 2, 7.6 Hz, 1H), 7.32 (dd, J = 1.6, 8 Hz,
    1H), 7.30 (d, J = 16.8 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For
    C25H19N3O2S: 426.5 (M + H), Found 426.3.
    434 (E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzene
    sulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.69-7.66 (m,
    2H), 7.65-7.52 (m, 5H), 7.41 (dd, J = 1.6, 8 Hz, 1H), 7.31 (dd, J = 1.6, 8 Hz, 1H),
    7.18-7.10 (m, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C21H16FN3O2S:
    394.4 (M + H), Found 394.3.
    435 (E)-2-{2-[2-(4-difluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzene
    sulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.70 (d, J = 8 Hz,
    2H), 7.66-7.61 (m, 4H), 7.54 (dt, J = 1.6, 8 Hz, 1H), 7.42 (dd, J = 1.6, 8 Hz, 1H),
    7.32 (d, J = 8 Hz, 1H), 7.20 (d, J = 8 Hz, 2H), 7.15 (d, J = 16 Hz, 1H), 6.89 (s, 1H).
    Mass Spectrum (LCMS, ESI pos.) Calcd. For C22H17F2N3O2S: 426.5 (M + H),
    Found 426.3.
    436 (E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.78 (s, 1H),
    7.73 (dd, J = 1.6, 8 Hz, 1H), 7.66-7.61 (m, 4H), 7.54 (dt, J = 1.6, 8 Hz, 1H), 7.44 (d,
    J = 8 Hz, 1H), 7.41 (dd, J = 1.6, 8 Hz, 1H), 7.33 (d, J = 8 Hz, 1H), 7.34 (d, J = 16 Hz,
    1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C22H15F4N3O2S: 461.4 (M + H),
    Found 462.2.
    437 (E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzene
    sulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.97 (d, J = 16.8 Hz,
    1H), 7.84 (d, J = 8 Hz, 1H), 7.66-7.51 (m, 5H), 7.41-7.37 (m, 2H), 7.32 (dd,
    J = 1.6, 8 Hz, 1H), 7.20 (d, J = 16 Hz, 1H). Mass Spectrum (LCMS, ESI pos.)
    Calcd. For C21H15Cl2N3O2S: 445.3 (M + H), Found 446.1.
    438 (E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzene sulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.89 (d, J = 16.8 Hz,
    1H), 7.66-7.60 (m, 3H), 7.54 (dt, J = 1.6, 8 Hz, 1H), 7.45 (d, J = 16 Hz, 1H),
    7.43 (s, 1H), 7.41-7.32 (m, 3H), 7.24-7.18 (m, 1H). Mass Spectrum (LCMS, ESI
    pos.) Calcd. For C21H15ClFN3O2S: 428.9 (M + H), Found 428.3.
    439 (E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.94 (dd, J = 1.6,
    8 Hz, 1H), 7.68-7.62 (m, 6H), 7.41 (dd, J = 1.6, 8 Hz, 1H), 7.32 (d, J = 1.6, 8 Hz,
    1H), 7.28 (t, J = 8 Hz, 1H), 7.16 (d, J = 16.8 Hz, 1H). Mass Spectrum (LCMS, ESI
    pos.) Calcd. For C21H15BrFN3O2S: 473.3 (M + H), Found 473.2.
    440 (E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.94 (dd, J = 1.6,
    8 Hz, 1H), 7.68-7.62 (m, 6H), 7.41 (dd, J = 1.6, 8 Hz, 1H), 7.32 (d, J = 1.6, 8 Hz,
    1H), 7.28 (t, J = 8 Hz, 1H), 7.16 (d, J = 16.8 Hz, 1H). Mass Spectrum (LCMS, ESI
    pos.) Calcd. For C21H15BrFN3O2S: 473.3 (M + H), Found 473.2.
    • Prophetic Example 17
  • Using the procedures described in Example 15 or 16 and reagents, starting materials and conditions known to those skilled in the art, the following prophetic compounds representative of the present invention may be prepared:
  • Cpd Name and Data
    91 (E)-2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-
    vinyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,
    97 (E)-2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-
    benzimidazol-5-yl)-benzenesulfonamide,
    103 (E)-2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-
    benzimidazol-5-yl)-benzenesulfonamide,
    109 (E)-2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    115 (E)-2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide,
    121 (E)-2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-benzenesulfonamide, and
    127 (E)-2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-benzenesulfonamide.
    • Example 18 (E)-N-Methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide (Cpd 310) Step A. N-methylbenzenesulfonamide-2-boronic acid
  • To a solution of N-methylbenzenesulfonamide (2.00 g, 0.0117 mmol) in 20 mL THF at 0° C. was added dropwise n-butyl lithium (1.6 M in hexanes, 14.6 mL, 0.0234 mmol). After 30 min., triisopropyl borate (3.1 mL, 0.0164 mmol) was added, and the mixture was stirred at 0° C. for 2 hours. The reaction was quenched by addition of 20 mL of 1M HCl (aq). The mixture was extracted with EtOAc, and the organic fractions were washed with brine, dried over Na2SO4, filtered, and the filtrate was concentrated to provide the title Compound 18a as a yellow oil. 1H-NMR (400 MHz, CD3OD) δ (ppm): 7.81 (d, 1H) 7.62-7.56 (m, 2H) 2.52 (s, 3H).
    • Step B. (3-tert-butoxycarbonylamino-2′-methylsulfamoyl-biphenyl-4-yl)-carbamic acid tert-butyl ester
  • A mixture of the freshly prepared Compound 18a (9.3 g, 0.0434 mol), Compound 16a (11.2 g, 0.289 mol), Pd(dppf)Cl2CH2Cl2 (4.7 g, 6.42 mmol), TBAB (9.3 g, 0.0289 mol), in 120 mL of 1M Na2CO3 (aq) and 600 mL DME was heated at 85° C. for 10 hours. The reaction mixture was cooled, and concentrated. The residue was purified by chromatography (silica gel, hexanes: EtOAc, 2:1) to provide the title Compound 18b as a yellow oil. 1H-NMR (400 MHz, CDCl3) δ (ppm): 8.12 (d, 1H) 7.86 (d, 1H) 7.62-7.46 (m, 3H) 7.22 (d, 1H) 7.14 (d, 1H) 2.62 (d, 3H) 1.55 (s, 9H) 1.44 (s, 9H).
    • Step C. 3′,4′-diamino-biphenyl-2-sulfonic acid methylamide
  • A solution of Compound 18b (21.4 g, 0.0995 mol) in 210 mL of 4M HCl in dioxane was stirred for 4 hours. The reaction mixture was concentrated, made basic with 1M NaOH (aq), and extracted with EtOAc. The organic fraction was dried over Na2SO4, filtered, and the filtrate was concentrated to provide the title
  • Compound 18c as a brown oil. 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.00 (dd, 1H, J=1.6 and 8.0 Hz) 7.59 (dt, 1H, J=1.6 and 8.4 Hz) 7.48 (dt, 1H, J=1.2 and 8.4 Hz) 7.33 (dd, 1H, J=1.2 and 8.0 Hz) 6.79 (d, 1H, J=2.0 Hz) 6.75 (d, 1H, J=8.4 Hz) 6.68 (d, 1H, J=2.0 and 7.6 Hz) 2.93 (s, 3H) MS (ESI, pos. ion) m/z: 277.9 (M+1).
    • Step D. (E)-N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide
  • A mixture of Compound 18c (0.100 g, 0.361 mmol) and 4-trifluoromethyl cinnamic acid (0.324 mmol) in 2 mL of POCl3 was heated to 100° C. for 14 hours. Evaporation of the reaction mixture provided a residue, which was then purified by HPLC(H2O:MeCN, 90:10 to 30:70, over 15 min) to provide the title Compound 310 as a white solid. 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.07 (dd, 1H, J=1.2 and 8.4 Hz) 7.85 (d, 2H, J=8.4 Hz) 7.73 (d, 2H, J=8 Hz) 7.69-7.63 (m, 3H) 7.58 (dt, 2H, J=1.6 and 7.2 Hz) 7.44 (dd, 1H, J=1.2 and 7.2 Hz) 7.34 (d, J=16.4 Hz) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 499.2 (M+MeCN+1).
  • Using the procedures described in Example 18 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:
  • Cpd Name and Data
    312 (E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 8.0 Hz)
    7.68-7.60 (m, 3H) 7.59-7.55 (m, 6H) 7.43 (dd, 1H, J = 1.2 and 7.2 Hz) 7.30 (dd, 1H, J = 1.6
    and 8.0 Hz) 7.21 (d, 1H, J = 16.4 Hz) 2.38 (s, 3H) MS (ESI, pos. ion) m/z:
    509.2 (M + MeCN).
    314 (E)-N-methyl-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzene
    sulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.04 (dd, 1H, J = 1.2 and 8.0 Hz) 7.77 (d,
    1H, J = 16.4 Hz) 7.70 (d, 1H, J = 15.2 Hz) 7.66-7.64 (m, 2H) 7.61-7.55 (m, 3H)
    7.46 (dd, 1H, J = 1.6 and 8.4 Hz) 7.41 (dd, 1H, J = 1.2 and 7.6 Hz) 7.26 (d, 2H,
    J = 7.6 Hz) 7.15 (d, 1H, J = 16.8 Hz) 2.42 (s, 3H) 2.36 (s, 3H) MS (ESI, pos. ion)
    m/z: 404.2 (M + 1).
    315 (E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.05 (dd, 1H, J = 1.2 and 7.6 Hz)
    7.82-7.73 (m, 4H) 7.70-7.66 (m, 2H) 7.61 (dd, 1H, J = 1.2 and 7.6 Hz) 7.45 (dd, 1H, J = 1.2
    and 8.0 Hz) 7.43 (dd, 1H, J = 1.2 and 7.2 Hz) 7.22 (d, 1H, J = 8.4 Hz)
    7.21 (s, 2H) 7.18 (d, 1H, J = 7.6 Hz) 2.42 (s, 3H) MS (ESI, pos. ion) m/z:
    408.3 (M + 1).
    316 (E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.05 (dd, 1H, J = 1.2 and 7.6 Hz) 7.84 (s,
    1H) 7.70-7.66 (m, 2H) 7.64 (d, 1H) 7.60 (d, 2H, J = 7.6 Hz) 7.59 (s, 2H) 7.42 (dt,
    2H, J = 1.6 and 9.2 Hz) 7.25 (d, 1H, J = 16.4 Hz) 2.42 (s, 3H) MS (ESI, pos. ion)
    m/z: 408.3 (M + 1).
    317 (E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.05 (dd, 1H, J = 1.2 and 7.6 Hz) 7.96 (dd,
    1H, J = 2 and 5 Hz) 7.69-7.62 (m, 4H) 7.61-7.57 (m, 2H) 7.43 (dd, 1H, J = 1.2
    and 7.2 Hz) 7.39 (dd, 1H, J = 1.6 and 8.0 Hz) 7.29 (t, 1H, J = 8.4 Hz) 7.18 (d,
    1H, J = 16.4 Hz) 2.40 (s, 3H) MS (ESI, pos. ion) m/z: 486.2 (M).
    318 (E)-2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.05 (dd, 1H, J = 1.6 and 7.6 Hz) 7.96 (d,
    1H, J = 16.4 Hz) 7.73-7.67 (m, 3H) 7.63 (dd, 1H, J = 1.2 and 8.0 Hz) 7.59 (d,
    2H, J = 9.2 Hz) 7.52 (dd, 1H, J = 1.6 and 8.4 Hz) 7.44 (dd, 1H, J = 1.6 and 7.6 Hz)
    6.90 (d, 1H, J = 16 Hz) 6.81 (d, 2H, J = 8.8 Hz) 3.06 (s, 6H) 2.45 (s, 3H) MS
    (ESI, pos. ion) m/z: 433.4 (M + 1).
    319 (E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-N-methyl-benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.05 (dd, 1H, J = 1.6 and 6.4 Hz) 7.77 (q,
    1H, J = 5.3 Hz) 7.73-7.63 (m, 5H) 7.60 (dt, 1H, J = 1.6 and 8.4 Hz) 7.51 (dd, 1H,
    J = 1.6 and 6.4 Hz) 7.43 (d, 2H, J = 8.4 Hz) 7.39 (d, 1H, J = 16.8 Hz) 2.41 (s,
    3H) MS (ESI, pos. ion) m/z: 476.3 (M + 1).
    320 (E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-N-methyl-benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 6.4 Hz) 8.01 (t,
    1H, J = 7.8 Hz) 7.90 (d, 1H, J = 16.4 Hz) 7.70-7.65 (m, 3H) 7.61-7.56 (m, 3H)
    7.45 (d, 1H, J = 16.8 Hz) 7.28 (dd, 1H, J = 1.2 and 7.2 Hz) 7.40 (d, 1H, J = 1.2
    and 7.2 Hz) 2.40 (s, 3H) MS (ESI, pos. ion) m/z: 476.3 (M + 1).
    321 (E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.05 (dd, 1H, J = 1.6 and 6.0 Hz) 7.86 (t,
    1H, J = 2.0 and 6.2 Hz) 7.73-7.65 (m, 5H) 7.61 (dd, 1H, J = 1.6 and 7.6 Hz)
    7.46 (dd, 1H, J = 1.6 and 8.8 Hz) 7.43 (dd, 1H, J = 1.2 and 7.2 Hz) 7.34 (t, 1H, J = 8.8 Hz)
    7.22 (d, 1H, J = 16.4 Hz) 2.42 (s, 3H) MS (ESI, pos. ion) m/z:
    442.3 (M + 1).
    322 (E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-N-methyl-benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.05 (dd, 1H, J = 1.6 and 6.0 Hz) 7.86 (t,
    1H, J = 2.0 and 6.2 Hz) 7.73-7.65 (m, 5H) 7.61 (dd, 1H, J = 1.6 and 7.6 Hz)
    7.46 (dd, 1H, J = 1.6 and 8.8 Hz) 7.43 (dd, 1H, J = 1.2 and 7.2 Hz) 7.34 (t, 1H, J = 8.8 Hz)
    7.22 (d, 1H, J = 16.4 Hz) 2.42 (s, 3H) MS (ESI, pos. ion) m/z:
    442.3 (M + 1).
    323 (E)-N-methyl-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.06 (d, 1H, J = 7.6 Hz) 7.75 (d, 1H, J = 16.8 Hz)
    7.68-7.56 (m, 5H) 7.43 (d, 1H, J = 3.2 Hz) 7.34 (d, 1H, J = 1.2 and 8.0 Hz)
    7.33 (d, 1H, J = 4.0 Hz) 7.22 (q, 1H, J = 8.8 Hz) 2.38 (s, 3H) MS (ESI, pos.
    ion) m/z: 444.4 (M + 1).
    324 (E)-N-methyl-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.05 (dd, 1H, J = 1.2 and 8.0 Hz)
    7.87-7.82 (m, 2H) 7.72-7.58 (m, 5H) 7.46-7.42 (m, 2H) 7.31 (d, 1H, J = 16.4 Hz)
    2.41 (s, 3H) MS (ESI, pos. ion) m/z: 444.4 (M + 1).
    325 (E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 7.6 Hz) 7.95 (d,
    1H, J = 16.8 Hz) 7.74-7.66 (m, 3H) 7.63-7.59 (m, 2H) 7.47 (dd, 1H, J = 1.6 and
    8.0 Hz) 7.44 (dd, 1H, J = 1.6 and 8.0 Hz) 7.39 (d, 1H, J = 16.8 Hz) 7.34-7.70 (m,
    2H) 2.42 (s, 3H) MS (ESI, pos. ion) m/z: 426.4 (M + 1).
    326 (E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 7.6 Hz) 7.82 (d,
    1H, J = 16.4 Hz) 7.69-7.64 (m, 3H) 7.61-7.55 (m, 2H) 7.43 (dd, 1H, J = 1.6 and
    7.6 Hz) 7.37 (dd, 1H, J = 1.6 and 8.8 Hz) 7.33 (d, 1H, J = 16.8 Hz) 7.26-7.15 (m,
    2H) 2.39 (s, 3H) MS (ESI, pos. ion) m/z: 426.4 (M + 1).
    327 (E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 7.6 Hz) 7.90 (d,
    1H, J = 16.8 Hz) 7.71-7.58 (m, 4H) 7.51 (d, 1H, J = 16.8 Hz) 7.46-7.43 (m, 3H)
    7.12 (t, 2H, J = 9.0 Hz) 2.41 (s, 3H) MS (ESI, pos. ion) m/z: 426.4 (M + 1).
    328 (E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.05 (dd, 1H, J = 1.2 and 8.0 Hz)
    7.68-7.56 (m, 5H) 7.43 (dd, 1H, J = 1.2 and 7.2 Hz) 7.36 (dd, 1H, J = 1.6 and 8.8 Hz)
    7.31-7.25 (m, 3H) 6.99-6.96 (m, 1H) 2.39 (s, 3H) MS (ESI, pos. ion) m/z:
    426.3 (M + 1).
    329 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 7.6 Hz)
    7.66-7.56 (m, 6H) 7.48-7.42 (m, 2H) 7.36-7.32 (m, 2H) 7.17 (d, 1H, J = 16.8 Hz)
    2.38 (s, 3H) MS (ESI, pos. ion) m/z: 426.4 (M + 1).
    330 (E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-N-methyl-benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.25 (dd, 1H, J = 1.6 and 16.4 Hz)
    8.16 (dd, 1H, J = 1.2 and 9.2 Hz) 8.06 (dd, 1H, J = 1.2 and 7.6 Hz) 8.4 (d, 1H, J = 1.2 Hz)
    8.25 (dd, 1H, J = 0.8 and 8.0 Hz) 7.73-7.56 (m, 5H) 7.46 (dd, 1H, J = 1.6
    and 8.0 Hz) 7.65 (d, 1H, J = 16.4 Hz) 2.46 (s, 3H) MS (ESI, pos. ion) m/z:
    476.4 (M + 1).
    331 (E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-N-methyl-benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 8.0 Hz)
    8.02-7.98 (m, 2H) 7.18-7.56 (m, 4H) 7.45-7.40 (m, 2H) 7.38 (dd, 1H, J = 1.6 and 8.4 Hz)
    7.26 (d, 1H, J = 16.8 Hz) 2.39 (s, 3H) MS (ESI, pos. ion) m/z: 476.4 (M + 1).
    332 (E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-N-methyl-benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.10-8.05 (m, 2H) 7.84 (d, 1H, J = 16.8 Hz)
    7.71-7.55 (m, 5H) 7.43 (dd, 1H, J = 1.6 and 7.2 Hz) 7.37 (d, 1H, J = 16.8 Hz)
    7.32 (dd, 1H, J = 1.2 and 8.4 Hz) 2.37 (s, 3H) MS (ESI, pos. ion) m/z:
    476.5 (M + 1).
    333 (E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.24 (s, 2H) 7.06 (dd, 1H, J = 1.2 and 8.0 Hz)
    7.94 (s, 1H) 7.73-7.55 (m, 5H) 7.45-7.40 (m, 2H) 7.32 (dd, 1H, J = 1.6 and
    8.4 Hz) 2.38 (s, 3H) MS (ESI, pos. ion) m/z: 526.4 (M + 1).
    334 (E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.27 (s, 1H) 8.08-7.92 (m, 3H) 8.87 (d,
    1H, J = 8.4 Hz) 7.69-7.56 (m, 4H) 7.44 (dd, 1H, J = 1.6 and 8.0 Hz)
    7.36-7.32 (m, 2H) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 526.4 (M + 1).
    335 (E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.06 (d, 1H, J = 8.4 Hz) 7.93 (d, 1H, J = 8.0 Hz)
    7.81 (d, 1H, J = 16.4 Hz) 7.74-7.56 (m, 4H) 7.50-7.23 (m, 5H) 2.37 (s,
    3H) MS (ESI, pos. ion) m/z: 442.4 (M + 1).
    336 (E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 8.0 Hz) 7.89 (d,
    1H, J = 16.8 Hz) 7.68-7.55 (m, 4H) 7.45 (d, 1H, J = 16.8 Hz) 7.43 (dd, 1H, J = 1.2
    and 7.6 Hz) 7.38-7.31 (m, 3H) 7.23-7.18 (m, 1H) 2.37 (s, 3H) MS (ESI, pos.
    ion) m/z: 442.4 (M + 1).
    337 (E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.05 (dd, 1H, J = 1.2 and 8.0 Hz) 8.51 (d,
    1H, J = 16.8 Hz) 7.88 (d, 1H, J = 8.0 Hz) 7.68-7.56 (m, 5H) 7.45-7.41 (m, 2H)
    7.32 (dd, 1H, J = 1.6 and 8.4 Hz) 7.24 (d, 1H, J = 16.4 Hz) 2.37 (s, 3H) MS (ESI,
    pos. ion) m/z: 458.3 (M + 1).
    338 (E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 7.6 Hz) 7.82 (t,
    1H, J = 1.8 Hz) 7.68-7.49 (m, 7H) 7.43 (dd, 1H, J = 1.2 and 7.2 Hz) 7.35 (d, 1H,
    J = 7.6 Hz) 7.30 (dd, 1H, J = 0.8 and 8.0 Hz) 7.21 (d, 1H, J = 16.4 Hz) 2.37 (s,
    3H) MS (ESI, pos. ion) m/z: 468.3 (M + 1).
    339 (E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.40 (d, 1H, J = 16.4 Hz) 8.08-8.06 (m,
    2H) 8.01 (d, 1H, J = 8.4 Hz) 7.89 (dd, 1H, J = 2.4 and 8.4 Hz) 7.80-7.56 (m, 4H)
    7.44 (dd, 1H, J = 1.2 and 7.2 Hz) 7.33 (dd, 1H, J = 1.6 and 7.2 Hz) 7.26 (d, 1H,
    J = 16.4 Hz) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 442.3 (M + 1).
    340 (E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-
    5-yl}-N-methyl-benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 7.6 Hz)
    7.76-7.72 (m, 2H) 7.66-7.54 (m, 4H) 7.42 (dd, 1H, J = 0.8 and 7.2 Hz) 7.32-7.26 (m,
    4H) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 502.3 (M + 1).
    341 (E)-N-methyl-2-{2-[2-(4-trifluoromethylthio-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.12 (d, 2H, J = 8.8 Hz) 8.06 (dd, 1H, J = 1.2
    and 8.4 Hz) 8.06 (d, 2H, J = 8.8 Hz) 7.75-7.56 (m, 5H) 7.47 (d, 1H, J = 16.4 Hz)
    7.44 (dd, 1H, J = 1.2 and 7.2 Hz) 7.34 (dd, 1H, J = 1.2 and 8.4 Hz) 2.38 (s,
    3H) MS (ESI, pos. ion) m/z: 522.3 (M + 1).
    342 (E)-N-methyl-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 8.4 Hz) 7.75 (q,
    4H, J = 10.6 Hz) 7.44-7.55 (m, 5H) 7.43 (dd, 1H, J = 1.2 and 7.6 Hz)
    7.33-7.28 (m, 2H) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 490.3 (M + 1).
    343 (E)-N-methyl-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.07 (dd, 1H, J = 1.2 and 8.0 Hz) 8.02 (dd,
    1H, J = 12.0 and 16.0 Hz) 7.98 (d, 1H, J = 8.0 Hz) 7.77 (d, 1H, J = 8.4 Hz)
    7.72-7.62 (m, 4H) 7.57 (dt, 1H, J = 1.6 and 8.4 Hz) 7.54 (t, 1H, J = 7.6 Hz) 7.44 (dd,
    1H, J = 1.2 and 7.2 Hz) 7.32 (dd, 1H, J = 1.6 and 8.4 Hz) 7.21 (d, 1H, J = 16.4 Hz)
    2.37 (s, 3H) MS (ESI, pos. ion) m/z: 458.4 (M + 1).
    344 (E)-N-methyl-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-
    5-yl}-benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 8.0 Hz)
    7.66-7.62 (m, 4H) 7.60-7.54 (m, 3H) 7.51 (d, 1H, J = 8.0 Hz) 7.43 (dd, 1H, J = 1.2
    and 7.2 Hz) 7.31 (dd, 1H, J = 1.2 and 8.0 Hz) 7.28 (d, 1H, J = 8.4 Hz) 7.25 (d,
    1H, J = 16.8 Hz) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 474.4 (M + 1).
    345 (E)-N-methyl-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-
    5-yl}-benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 7.6 Hz) 7.75 (d,
    2H, J = 8.4 Hz) 7.69-7.64 (m, 3H) 7.61 (d, 1H, J = 8.0 Hz) 7.57 (dt, 1H, J = 1.2
    and 8.4 Hz) 7.42 (dd, 1H, J = 1.6 and 8.4 Hz) 7.33 (d, 3H, J = 10.0 Hz) 7.20 (d,
    1H, J = 16.4 Hz) 2.38 (s, 3H) MS (ESI, pos. ion) m/z: 474.4 (M + 1).
    346 (E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.03-8.05 (m, 2H) 7.87 (dd, 2H, J = 1.68
    and 7.6 Hz) 7.66-7.55 (m, 4H) 7.45 (dd, 1H, J = 1.6 and 7.6 Hz) 7.43 (dd, 1H, J = 1.2
    and 7.2 Hz) 7.38-7.30 (m, 3H) 7.22 (d, 1H, J = 16.4 Hz) 2.37 (s, 3H) MS
    (ESI, pos. ion) m/z: 425.3 (M + 1).
    347 (E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 8.0 Hz)
    7.36-7.63 (m, 4H) 7.62-7.55 (m, 3H) 7.44 (d, 3H, J = 8.0 Hz) 7.31 (dd, 1H, J = 1.6
    and 8.0 Hz) 7.19 (d, 1H, J = 16.4 Hz) 2.36 (s, 3H) MS (ESI, pos. ion) m/z:
    425.3 (M + 1).
    348 (E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.07 (dd, 1H, J = 1.2 and 8.0 Hz) 8.02 (d,
    1H, J = 16.4 Hz) 7.84 (dd, 1H, J = 1.6 and 8.4 Hz) 7.68-7.55 (m, 5H)
    7.44-7.40 (m, 2H) 7.31 (dd, 1H, J = 1.2 and 6.8 Hz) 7.02 (dt, 1H, J = 1.6 and 8.4 Hz)
    7.17 (d, 1H, J = 16.4 Hz) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 469.5 (M + 1).
    349 (E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 8.0 Hz) 7.80 (q,
    1H, J = 8.0 Hz) 7.74 (d, 1H, J = 16.8 Hz) 7.67-7.54 (m, 5H) 7.42 (dd, 1H, J = 1.2
    and 7.6 Hz) 7.30 (dd, 1H, J = 1.6 and 8.4 Hz) 7.23 (d, 1H, J = 16.8 Hz) 7.05 (t,
    1H, J = 8.8 Hz) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 426.4 (M + 1).
    351 (E)-2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.07 (dd, 1H, J = 1.2 and 8.0 Hz) 8.01 (d,
    2H, J = 8.4 Hz) 7.90 (d, 2H, J = 8.8 Hz) 7.72 (d, 1H, J = 16.4 Hz) 7.67-7.56 (m,
    4H) 7.44 (dd, 1H, J = 1.6 and 7.2 Hz) 7.38 (d, 1H, J = 16.4 Hz) 7.33 (dd, 1H, J = 1.6
    and 8.4 Hz) 3.15 (s, 3H) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 468.4 (M + 1).
    • Example 19 (E)-N-(2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide (Cpd 414) Step A. (3-tert-butoxycarbonylamino-2′-methanesulfonylamino-biphenyl-4-yl)-carbamic acid tert-butyl ester
  • To a solution of Compound 16a (2.0 g, 5.1 mmol), 2-methylsulfonylphenyl boronic acid (1.1 g, 5.1 mmol), and K2CO3 (2.1 g, 15.3 mmol) in 1,4-dioxane:water (4:1, 120 mL), was added Pd(dppf)Cl2CH2Cl2 (0.42 g, 0.51 mmol) under an argon atmosphere. The mixture was heated at 95° C. for 12 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by chromatography (silica, EtOAc: hexanes, 3:7) to provide the title Compound 19a as a yellow solid (1.7 g, 70% yield). 1H NMR (400 MHz, CDCl3) δ (ppm): 7.64 (d, J=8.4 Hz, 1H), 7.57 (d, J=14.4 Hz, 1H), 7.34 (t, J=8.4 Hz, 1H), 7.26-7.15 (m, 3H), 7.07 (s, 1H), 7.04 (d, J=8 Hz, 1H), 6.87 (s, 1H), 6.63 (s, 1H), 2.90 (s, 3H), 1.51 (s, 9H), 1.49 (s, 9H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C23H31N3O6S: 478.19 (M+H), Found 478.0.
    • Step B. N-(3′,4′-diamino-biphenyl-2-yl)-methanesulfonamide
  • A solution of Compound 19a (1.0 g, 2.1 mmol) in a mixture of 4M HCl in 1,4-dioxane (10 mL) was heated at 70° C. for 2 h. After concentration of the reaction, the residue was dissolved in dichloromethane (20 mL), and to the solution was added K2CO3 (0.5 g) and the mixture was stirred at room temperature for 20 min. After filtration and removal of solvents, the residue was dried to provide the title Compound 19b as a brown solid (0.58 g, quantitative yield). 1H NMR (400 MHz, CD3OD) δ (ppm): 7.47 (d, J=8.4 Hz, 1H), 7.40-7.35 (m, 1H), 7.32-7.29 (m, 2H), 7.16-7.09 (m, 3H), 2.80 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C13H15N3O2S: 278.09 (M+H), Found 278.1.
    • Step C. (E)-N-(2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide
  • A solution of Compound 19b (50 mg, 0.18 mmol) and commercially available 3-(4-ethoxy-phenyl)-acrylic acid (34.6 mg, 0.18 mmol) in POCl3 (1.5 mL) was heated to 100° C. for 12 h. The reaction was cooled, the excess POCl3 was removed under reduced pressure, and the residue was purified by HPLC (Gilson, C-18 column, CH3CN: H2O (gradient of CH3CN: 5%-80%)) to provide the title Compound 414 as an off-white solid (25 mg, 32% yield). 1H NMR (400 MHz, CD3OD) δ (ppm):7.62-7.59 (m, 4H), 7.54-7.52 (m, 1H), 7.41-7.37 (m, 2H), 7.35-7.30 (m, 2H), 7.03 (d, J=16.8 Hz, 2H), 6.97 (d, J=12 Hz, 2H), 4.09 (q, J=7.2 Hz, 2H), 2.72 (s, 3H), 1.41 (t, J=7.2 Hz, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C24H23N3O3S: 434.1 (M+H), Found 434.1.
  • Using the procedures described in Example 19 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:
  • Cpd Name and Data
    77 (E)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm) 7.40-7.56 (m, 6H) 7.24-7.33 (m, 4H)
    7.19-7.22 (m, 2H) 7.05 (d, J = 16.4 Hz, 1H) 2.61 (s, 3H). MS (ESI, pos. ion) m/z:
    424.1 (M + 1).,
    83 (E)-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 7.99-7.96 (m, 2H), 7.89-7.86 (m, 4H),
    7.78 (dd, J = 6.4, 15.8 Hz, 2H), 7.60 (dd, J = 1.2, 8.2 Hz, 1H), 7.46-7.39 (m, 2H),
    7.33 (dt, J = 1.6, 8.2 Hz, 2H), 6.99 (dd, J = 6.4, 15.8 Hz, 2H), 3.10 (s, 3H), 3.09 (s, 3H).
    Mass Spectrum (LCMS, ESI pos.) Calcd. For C23H21N3O4S2: 468.1 (M + H),
    Found 468.0.,
    95 (E)-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-
    yl)-phenyl]-methanesulfonamide
    1H NMR (400 MHz, CD3OD) δ (ppm): 7.67-7.62 (m, 5H), 7.54-7.52, (m, 1H),
    7.42-7.33 (m, 4H), 7.09 (d, J = 16.4 Hz, 2H), 7.08 (d, J = 12 Hz, 1H), 4.60 (q,
    J = 8.4 Hz, 2H), 2.74 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For
    C24H20F3N3O3S: 488.1 (M + H), Found 488.3,
    101 (E)-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-
    benzimidazol-5-yl)-phenyl]-methanesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 7.65-7.60 (m, 5H), 7.54-7.52 (m, 1H),
    7.41-7.37 (m, 2H), 7.34-7.30 (m, 2H), 7.10-7.06 (m, 3H), 4.68 (t, J = 12.8 Hz,
    2H), 2.74 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C25H20F5N3O3S:
    538.1 (M + H), Found 538.2.,
    113 (E)-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm) 7.90-7.96 (m, 2H) 7.54-7.76 (m, 6H)
    7.26-7.42 (m, 5H) 2.76 (s, 3H). MS (ESI, pos. ion) m/z: 458.1 (M + 1).,
    406 (E)-N-(2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 7.87-7.80 (m, 2H), 7.58-7.30 (m, 9H),
    2.85 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C22H18BrN3O2S: 468.0 (M + H),
    Found 469.1.,
    407 (E)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 7.67-7.52) (m, 6H), 7.14 (d, J = 16.4 Hz,
    1H), 3.13-3.12 (m, 1H), 2.72 (s, 3H), 1.27 (d, J = 6.8 Hz, 6H). Mass Spectrum
    (LCMS, ESI pos.) Calcd. For C25H25N3O2S: 432.2 (M + H), Found 432.2.,
    408 (E)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 7.82 (dd, J = 2.4, 7.2 Hz, 1H) 7.66-7.60 (m,
    4H), 7.56-7.52 (m, 2H), 7.41-7.39 (m, 6H), 7.18 (d, J = 16.4 Hz, 1H), 2.73 (s, 3H).
    Mass Spectrum (LCMS, ESI pos.) Calcd. For C22H17ClFN3O2S: 442.1 (M + H),
    Found 442.3.,
    409 (E)-N-(2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 7.95 (dd, J-2.4, 6.8 Hz, 1H), 7.69-7.68 (m,
    1H), 7.67-7.63 (m, 2H), 7.58 (d, J = 16.4 Hz, 1H), 7.53-7.51 (m, 1H),
    7.40-7.26 (m, 5H), 7.18 (d, J = 16.4 Hz, 1H), 2.72 (s, 3H). Mass Spectrum (LCMS, ESI
    pos.) Calcd. For C22H17BrFN3O2S: 486.0 (M + H), Found 486.3.,
    410 (E)-N-(2-{2-[2-(4-difluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 7.73 (d, J = 12.8 Hz, 2H), 7.54-7.52 (m,
    1H), 7.48-7.45 (m, 1H), 7.41-7.39 (m, 2H), 7.34-7.30 (m, 2H), 7.21 (d, J = 8.8 Hz,
    2H), 7.16 (d, J = 17.2 Hz, 1H), 6.90 (s, 1H), 2.73 (s, 3H). Mass Spectrum
    (LCMS, ESI pos.) Calcd. For C23H19F2N3O3S: 456.1 (M + H), Found 456.1.,
    411 (E)-N-(2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-
    5-yl}-phenyl)-methanesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 7.77 (s, 1H), 7.75 (d, J = 12 Hz, 1H),
    7.68 (s, 1H), 7.67-7.64 (m, 2H), 7.52 (d, J = 12 Hz, 1H), 7.46 (d, J = 12 Hz, 1H),
    7.40-7.25 (m, 5H), 2.74 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For
    C23H17F4N3O2S: 476.1 (M + H), Found 476.2,
    412 (E)-N-{2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-
    methanesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 7.65-7.60 (m, 3H), 7.41-7.36 (m, 3H),
    7.41-7.36 (m, 2H), 7.33-7.30 (m, 2H), 7.26 (d, J = 10 Hz, 2H), 7.18 (d, J = 20 Hz,
    1H), 2.74 (s, 3H), 2.39 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For
    C23H21N3O2S: 404.1 (M + H), Found 404.3,
    413 (E)-N-(2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 7.69-7.61 (m, 2H) 7.57-7.51 (m, 2H),
    7.46-7.39 (m, 3H), 7.29 (d, J = 16.2 Hz, 2H), 7.05 (d, J = 12 Hz, 1H),
    6.67 (d, J = 16.2 Hz, 2H), 6.33 (d, J = 12 Hz, 1H), 3.01 (s, 3H), 2.97 (s, 6H).
    Mass Spectrum (LCMS, ESI pos.) Calcd. For C24H24N4O2S: 433.2 (M + H),
    Found 433.3,
    415 (E)-N-{2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-
    methanesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.09 (s, 1H), 7.96-7.88, (m, 4H),
    7.74-7.72 (m, 2H), 7.57-7.52 (m, 3H), 7.51-7.33 (m, 6H), 2.80 (s, 3H). Mass Spectrum
    (LCMS, ESI pos.) Calcd. For C26H21N3O2S: 440.1 (M + H), Found 440.3,
    416 (E)-N-(2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.03-8.00 (m, 1H), 7.93 (s, 1H), 7.77 (s,
    1H), 7.74 (d, J = 11.2 Hz, 1H), 7.69 (s, 1H), 7.57-7.52 (m, 2H), 7.47 (d, J = 8 Hz,
    1H), 7.44 (d, J = 7.6 Hz, 2H), 7.40-7.36 (m, 1H), 7.32 (d, J = 17.2 Hz, 1H), 2.84 (s,
    3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C22H17Cl2N3O2S: 458.0 (M + H),
    Found 458.2.,
    417 (E)-N-(2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-
    5-yl}-phenyl)-methanesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.03-8.00 (m, 1H), 7.76 (t, J = 8.0 Hz, 1H),
    7.71-7.67 (m, 3H), 7.63 (d, J = 8.4 Hz, 1H), 7.54-7.52 (m, 1H), 7.78-7.44 (m, 1H),
    7.43-7.38 (m, 3H), 7.38-7.32 (m, 1H), 2.77 (s, 3H). Mass Spectrum (LCMS, ESI
    pos.) Calcd. For C23H17F4N3O2S: 476.1 (M + H), Found 476.2.,
    418 (E)-N-(2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-
    5-yl}-phenyl)-methanesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.00 (t, J = 8.4 Hz, 1H), 7.84 (d, J = 17.2 Hz,
    1H), 7.62-7.58 (m, 2H), 7.55-7.52 (m, 2H), 7.46 (s, 1H), 7.44-7.38 (m, 3H),
    7.38-7.32 (m, 2H), 2.74 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For
    C23H17F4N3O2S: 476.1 (M + H), Found 476.2,
    475 (E)-N-{2-[2-(2-biphenyl-4-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-
    methanesulfonamide
    1H-NMR (400 MHz, CDCl3) δ (ppm) 7.44-7.65 (m, 10H) 7.22-7.40 (m, 5H)
    7.10-7.20 (m, 3H) 2.76 (s, 3H). MS (ESI, pos. ion) m/z: 466.2 (M + 1).,
    • Prophetic Example 20
  • Using the procedures described in Example 19, or using the procedures in Example 1 and the corresponding bromobenzimidazole and boronic acid or boronate ester, and reagents, starting materials and conditions known to those skilled in the art, the following prophetic compounds representative of the present invention may be prepared:
  • Cpd Name and Data
    89 (E)-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-
    phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-
    methanesulfonamide,
    107 (E)-N-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    119 (E)-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    125 (E)-C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-
    phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-
    methanesulfonamide,
    • Prophetic Example 21
  • Using the procedures described in Example 1 or Example 19 and reagents, starting materials and conditions known to those skilled in the art, the following prophetic compounds representative of the present invention may be prepared:
  • Cpd Name and Data
    72 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    73 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    74 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide.
    75 (E)-1-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanone,
    76 (E)-1-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanol,
    80 (E)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    C,C,C-trifluoro-methanesulfonamide.
    81 (E)-1-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanone,
    82 (E)-1-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanol,
    87 (E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-
    1H-benzimidazol-5-yl)-phenyl]-ethanone,
    88 (E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-
    1H-benzimidazol-5-yl)-phenyl]-ethanol,
    90 (E)-2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-
    1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
    92 (E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-
    phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    93 (E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-
    phenyl]-ethanone,
    94 (E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-
    phenyl]-ethanol,
    96 (E)-2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-
    phenyl]-propan-2-ol,
    98 (E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-
    benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    99 (E)-1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-
    benzimidazol-5-yl)-phenyl]-ethanone,
    100 (E)-1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-
    benzimidazol-5-yl)-phenyl]-ethanol,
    102 (E)-2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-
    benzimidazol-5-yl)-phenyl]-propan-2-ol, and
    104 (E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-
    vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide.
    105 (E)-1-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanone,
    106 (E)-1-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanol,
    108 (E)-2-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    propan-2-ol,
    110 (E)-N-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-
    C,C,C-trifluoro-methanesulfonamide,
    111 (E)-1-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanone,
    112 (E)-1-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanol,
    116 (E)-C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide.
    117 (E)-N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-
    methanesulfonamide,
    118 (E)-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-
    phenyl]-methanesulfonamide,
    120 (E)-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-
    yl}-vinyl)-phenyl]-methanesulfonamide,
    122 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    123 (E)-N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-
    C,C,C-trifluoro-methanesulfonamide,
    124 (E)-C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-
    benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide,
    126 (E)-C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-
    benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide, and
    128 (E)-C,C,C-trifluoro-N-(4-{2-[5-(2-trifluoromethanesulfonylamino-phenyl)-
    1H-benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide.
    • Example 22 2-{2-[2-(2-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide (Cpd 401)
  • A mixture of (E)-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide Cpd 364 (0.020 g, 0.045 mmol) and 10% palladium on charcoal (0.005 g, 0.0045 mmol) in 2 mL MeOH was hydrogenated under H2 gas (1 atm) for 1 hour. The catalyst was removed by filtration, the filtrate was concentrated to dryness, and the residue was purified by chromatography (silica gel, MeOH: CH2Cl2=10:1) to give the title compound as a white solid. 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J=1.2 and 7.6 Hz) 7.74-7.53 (m, 4H) 7.60-7.56 (m, 2H) 7.51-7.40 (m, 4H) 3.41 (m, 4H) MS (ESI, pos. ion) m/z: 446.5 (M+1).
  • Using the procedures described in Example 22 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared from the corresponding vinyl derivatives:
  • Cpd Name and Data
    129 2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, 1.2 and 8.0 Hz)
    7.65-7.54 (m, 4H) 7.44-7.31 (m, 4H) 7.20 (d, 2H, J = 8.8 Hz) 3.26-3.23 (m, 4H) MS (ESI,
    pos. ion) m/z: 462.4 (M + 1).
    130 2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.12 (dd, 1H, J = 1.2 and 8.4 Hz)
    7.64-7.51 (m, 6H) 7.42 (d, 2H, J = 8.0 Hz) 7.39 (dd, 1H, J = 1.2 and 7.6 Hz) 7.27 (dd,
    1H, J = 1.6 and 8.4 Hz) 3.24 (m, 4H) MS (ESI, pos. ion) m/z: 446.4 (M + 1).
    131 2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.15 (dd, 1H, J = 1.2 and 8.0 Hz) 8.02 (d,
    2H, J = 8.8 Hz) 7.70-7.55 (m, 7H) 7.42 (dd, 1H, J = 1.6 and 7.2 Hz) 7.36 (dd,
    1H, J = 1.6 and 8.4 Hz) 3.41-3.48 (m, 4H) MS (ESI, pos. ion) m/z: 510.2 (M + 1).
    139 2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzene
    sulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.12 (dd, 1H, 1.6 and 8.0 Hz)
    7.64-7.59 (m, 2H) 7.55-7.51 (m, 2H) 7.39 (dd, 1H, J = 0.8 and 7.6 Hz) 7.32-7.14 (m, 5H)
    3.20-3.13 (m, 4H) MS (ESI, pos. ion) m/z: 412.3 (M + 1).
    145 2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, 1.2 and 7.6 Hz) 7.87 (d, 2H,
    J = 8.4 Hz) 7.66-7.50 (m, 6H) 7.41 (dd, 1H, J = 1.2 and 8.0 Hz) 7.30 (dd, 1H, J = 1.6
    and 8.4 Hz) 3.10 (m, 4H) MS (ESI, pos. ion) m/z: 456.3 (M + 1).
    175 2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (dd, 1H, J = 1.2 and 7.6 Hz)
    7.70-7.48 (m, 8H) 7.44 (dd, 1H, J = 1.6 and 8.0 Hz) 7.39 (dd, 1H, J = 1.2 and 7.2 Hz)
    3.40-3.30 (m, 4H) MS (ESI, pos. ion) m/z: 446.4 (M + 1).
    383 2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.02 (dd, 1H, J = 1.2 and 8.0 Hz)
    7.52-7.49 (m, 2H) 7.45-7.41 (m, 4H) 7.31-7.26 (m, 1H) 7.18 (dd, 1H, J = 1.2 and 8.0 Hz)
    7.13 (t, 1H, J = 7.2 Hz) 3.20-3.15 (m, 4H) MS (ESI, pos. ion) m/z:
    446.4 (M + 1).
    384 2-{2-[2-(2,3,4-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 8.0 Hz)
    7.66-7.53 (m, 4H) 7.42 (dd, 1H, J = 1.6 and 7.6 Hz) 7.29 (dd, 1H, J = 1.6 and 8.4 Hz)
    7.04-6.99 (m, 2H) 3.24 (m, 4H) MS (ESI, pos. ion) m/z: 432.5 (M + 1).
    385 2-{2-[2-(2,4,5-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 8.4 Hz)
    7.67-7.53 (m, 4H) 7.42 (dd, 1H, J = 1.2 and 7.6 Hz) 7.30 (dd, 1H, J = 1.6 and 8.4 Hz)
    7.26-7.10 (m, 2H) 3.23-3.20 (m, 4H) MS (ESI, pos. ion) m/z: 432.3 (M + 1).
    386 2-{2-[2-(2,6-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 8.0 Hz)
    7.67-7.53 (m, 4H) 7.42 (dd, 1H, J = 1.2 and 7.6 Hz) 7.31-7.25 (m, 2H) 6.97-6.93 (m,
    2H) 3.26-3.19 (m, 4H) MS (ESI, pos. ion) m/z: 414.3 (M + 1).
    387 2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.12 (dd, 1H, 1.6 and 8.0 Hz) 7.92 (dd,
    1H, 1.2 and 8.4 Hz) 7.80 (s, 1H) 7.64-7.51 (m, 4H) 7.40-7.33 (m, 2H) 7.28 (dd,
    1H, J = 1.6 and 8.0 Hz) 3.38-3.25 (m, 4H) MS (ESI, pos. ion) m/z: 514.4 (M + 1).
    388 2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.15 (dd, 1H, J = 1.2 and 7.6 Hz) 7.94 (d,
    1H, J = 8.0 Hz) 7.76-7.72 (m, 2H) 7.67-7.54 (m, 4H) 7.42 (dd, 1H, J = 1.2 and
    7.6 Hz) 7.33 (dd, 1H, J = 1.6 and 8.4 Hz) 3.50-3.45 (m, 2H) 3.31-3.26 (m, 2H)
    MS (ESI, pos. ion) m/z: 514.5 (M + 1).
    390 2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.12 (dd, 1H, 1.6 and 8.0 Hz)
    7.54-7.60 (m, 3H) 7.54 (dd, 1H, J = 1.2 and 8.0 Hz) 7.52-7.48 (m, 2H) 7.43 (dd, 1H, J = 2.0
    and 8.4 Hz) 7.39 (dd, 1H, J = 1.6 and 7.2 Hz) 7.27 (d, 1H, J = 8.0 Hz)
    3.23 (m, 4H) MS (ESI, pos. ion) m/z: 480.4 (M + 1).
    391 2-{2-[2-(3-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.15 (dd, 1H, 1.2 and 8.0 Hz)
    7.65-7.54 (m, 4H) 7.43-7.37 (m, 2H) 7.33 (dd, 1H, J = 2.0 and 8.0 Hz) 7.26 (d, 1H, J = 8.8 Hz)
    7.17 (s, 1H) 7.13 (d, 1H, J = 9.6 Hz) 3.26 (m, 4H) MS (ESI, pos. ion) m/z:
    462.4 (M + 1).
    392 2-{2-[2-(2,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.15 (dd, 1H, 1.6 and 6.4 Hz)
    7.67-7.53 (m, 4H) 7.42 (dd, 1H, 1.6 and 8.0 Hz) 7.30 (dd, 1H, J = 1.2 and 6.8 Hz)
    7.28-7.23 (m, 1H) 6.96-6.85 (m, 2H) 3.22 (m, 4H) MS (ESI, pos. ion) m/z:
    414.2 (M + 1).
    393 2-{2-[2-(3,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.15 (dd, 1H, 1.2 and 7.6 Hz)
    7.65-7.53 (m, 4H) 7.42 (dd, 1H, 1.2 and 7.2 Hz) 7.32 (dd, 1H, J = 1.2 and 8.4 Hz)
    7.22-7.13 (m, 2H) 7.04-7.01 (m, 1H) 3.22 (m, 4H) MS (ESI, pos. ion) m/z:
    414.4 (M + 1).
    394 2-{2-[2-(2,3-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, 1.6 and 8.0 Hz)
    7.68-7.53 (m, 4H) 7.42 (dd, 1H, 1.6 and 7.6 Hz) 7.32 (dd, 1H, J = 1.6 and 8.0 Hz)
    7.15-7.01 (m, 3H) 3.28 (m, 4H) MS (ESI, pos. ion) m/z: 414.3 (M + 1).
    395 2-{2-[2-(2,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.15 (dd, 1H, 2.4 and 7.6 Hz)
    7.67-7.53 (m, 4H) 7.43-7.39 (m, 1H) 7.33-7.29 (m, 1H) 7.12-6.94 (m, 3H) 3.26 (m, 4H) MS
    (ESI, pos. ion) m/z: 414.4 (M + 1).
    396 2-{2-[2-(3,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzene
    sulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.15 (dd, 1H, 2.0 and 8.0 Hz)
    7.67-7.54 (m, 4H) 7.42 (dd, 1H, 1.6 and 7.6 Hz) 7.36 (dd, 1H, 1.6 and 8.4 Hz)
    6.91-6.77 (m, 3H) 3.26-3.20 (m, 4H) MS (ESI, pos. ion) m/z: 414.6 (M + 1).
    397 2-(2-phenethyl-1H-benzimidazol-5-yl)-benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, 1.6 and 7.6 Hz)
    7.67-7.54 (m, 4H) 7.42 (dd, 1H, 1.6 and 7.6 Hz) 7.30-7.17 (m, 7H) 3.25-3.06 (m, 4H) MS
    (ESI, pos. ion) m/z: 378.3 (M + 1).
    399 N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-
    yl}-benzenesulfonamide
    The title compound was prepared by hydrogenation using Compound 398.
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.07 (dd, 1H, J = 1.2 and 8.0 Hz) 7.65 (dt,
    1H, J = 1.6 and 8.2 Hz) 7.58-7.53 (m, 5H) 7.41-7.38 (m, 3H) 7.20 (dd, 1H, J = 1.6
    and 8.4 Hz) 3.25 (m, 4H) 2.27 (s, 6H) MS (ESI, pos. ion) m/z: 474.4 (M + 1).
    402 2-{2-[2-(2-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.12 (d, 1H) 7.64-7.52 (m, 4H)
    7.41-7.38 (m, 2H) 7.26-7.19 (m, 4H) 3.22-3.18 (m, 4H) MS (ESI, pos. ion) m/z:
    412.3 (M + 1).
    404 2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.12 (dd, 1H, J = 1.6 and 8.0 Hz)
    7.64-7.60 (m, 2H) 7.56-7.51 (m, 2H) 7.46-7.38 (m, 3H) 7.30-7.27 (m, 2H)
    3.33-3.30 (m, 2H) 3.35-3.32 (m, 2H) MS (ESI, pos. ion) m/z: 464.4 (M + 1).
    405 2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.15 (dd, 1H, J = 1.2 and 8.0 Hz)
    7.66-7.62 (m, 2H) 7.59-7.50 (m, 4H) 7.41 (dd, 1H, J = 1.2 and 7.6 Hz) 7.31 (dd, 1H, J = 1.6
    and 8.0 Hz) 7.26-7.21 (m, 1H) 3.26 (m, 4H) MS (ESI, pos. ion) m/z:
    464.3 (M + 1).
    419 2-{2-[2-(2-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzene
    sulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (d, J = 8.0 Hz, 1H), 7.71 (s, 1H),
    7.68-7.64 (m, 2H), 7.60-7.57 (m, 1H), 7.40 (d, J = 8.0 Hz, 1H), 7.48 (d, J = 8.0 Hz, 1H),
    7.29-7.24 (m, 2H), 7.12-7.06 (m, 2H), 3.41 (t, J = 8.0 Hz, 2H), 3.28 (t, J = 8.0 Hz,
    2H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C21H18FN3O2S: 396.1 (M + H),
    Found 396.3.
    420 2-{2-[2-(4-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, J = 1.6, 8.0 Hz, 1H), 7.73 (s, 1H),
    7.69 (d, J = 8.0 Hz, 1H), 7.65 (dd, J = 1.6, 8.0 Hz, 1H), 7.58 (dt, J = 1.6, 8.0 Hz,
    1H), 7.51 (d, J = 1.6, 8.0 Hz, 1H), 7.40 (dd, J = 1.2, 7.2 Hz, 1H), 7.27-7.24 (m, 2H),
    7.04-7.00 (m, 2H), 3.42 (t, J = 8.0 Hz, 2H), 3.23 (t, J = 8.0 Hz, 2H). Mass
    Spectrum (LCMS, ESI pos.) Calcd. For C21H18FN3O2S: 396.1 (M + H), Found
    396.3.
    421 2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.12 (d, J = 8.0 Hz, 1H), 7.64-7.60 (m, 2H),
    7.56-7.51 (m, 2H), 7.40-7.36 (m, 2H), 7.32-7.29 (m, 3H), 3.27-3.25 (m, 4H).
    Mass Spectrum (LCMS, ESI pos.) Calcd. For C22H17F4N3O2S: 464.1 (M + H),
    Found 464.3.
    442 2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.12 (dd, J = 1.6, 8 Hz, 1H), 8.01 (d, J = 1.6,
    8 Hz, 1H), 7.65-7.60 (m, 3H), 7.58-7.53 (m, 3H), 7.48-7.44 (m, 1H), 7.40 (dd,
    J = 1.6, 8 Hz, 1H), 7.33 (dd, J = 1.6, 8 Hz, 1H), 3.13 (m, 1H), 2.86 (t, J = 7.6 Hz,
    2H), 2.83 (t, J = 7.6 Hz, 2H), 1.21 (d, J = 7.6 Hz, 6H). Mass Spectrum (LCMS, ESI
    pos.) Calcd. For C24H25N3O2S: 420.5 (M + H), Found 420.4.
    445 4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-
    benzimidazol-5-yl}-benzenesulfonamide
    The title compound was prepared by hydrogenation using Compound 444.
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.33 (d, J = 8 Hz, 1H), 7.83 (dd, J = 2, 8 Hz,
    1H), 7.63 (d, J = 8 Hz, 2H), 7.58-7.54 (m, 3H), 7.42 (d, J = 8 Hz, 2H), 7.29 (dd,
    J = 2, 8 Hz, 1H), 3.28-3.24 (m, 4H). Mass Spectrum (LCMS, ESI pos.) Calcd.
    For C23H17F6N3O2S: 514.5 (M + H), Found 514.3.
    447 4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-
    benzimidazol-5-yl}-benzenesulfonamide
    The title compound was prepared by hydrogenation using Compound 446.
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.42 (s, 1H), 7.94 (d, J = 8 Hz, 1H),
    7.63-7.56 (m, 5H), 7.42 (d, J = 8 Hz, 2H), 7.29 (d, J = 1.6, 8 Hz, 1H), 3.27-3.25 (m, 4H).
    Mass Spectrum (LCMS, ESI pos.) Calcd. For C23H17F6N3O2S: 514.1 (M + H),
    Found 514.2.
    • Example 23 N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide (Cpd 400)
  • Using the procedure of Example 18, the title compound was prepared from Compound 18c and 4-trifluoromethylphenyl propionic acid. 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.04 (dd, 1H, J=1.2 and 8.0 Hz) 7.66-7.53 (m, 6H) 7.42-7.38 (m, 3H) 7.29 (dd, 1H, J=1.6 and 8.4 Hz) 3.27 (m, 4H) MS (ESI, pos. ion) m/z: 460.4 (M+1).
    • Example 24 N-methyl-2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide (Cpd 350)
  • Using the procedure of Example 18, the title compound was prepared from Compound 18c and 3-trifluoromethylphenyl propionic acid. 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.05 (dd, 1H, J=1.2 and 7.6 Hz) 7.64 (td, 1H, 1.2 and 8.2 Hz) 7.58-7.53 (m, 4H) 7.50-7.44 (m, 3H) 7.40 (dd, 1H, J=1.2 and 7.2 Hz) 7.25 (dd, 1H, J=1.6 and 8.0 Hz) 3.26-3.22 (m, 4H) MS (ESI, pos. ion) m/z: 460.4 (M+1).
    • Example 25 2-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Cpd 464)
  • Using the procedure of Example 10, the title Compound 464 (0.013 g) was prepared from 5-bromo-2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazole Compound 25a (0.048 g, 0.13 mmol) and Compound 10e (0.032 g, 0.20 mmol).
  • 1H-NMR (400 MHz, DMSO d6) δ (ppm) 7.71 (dd, J=1.26, 8.08 Hz, 1H) 7.45 (d, J=7.8 Hz, 2H) 7.37 (d, J=8.34 Hz, 1H) 7.31 (d, J=8.08 Hz, 2H) 7.20-7.26 (m, 2H) 7.10 (ddd, J=1.51, 7.33, 7.58 Hz, 1H) 6.93-7.20 (m, 2H) 3.14 (m, 4H) 1.21 (s, 6H).
  • MS (ESI, pos. ion) m/z: 425.1 (M+1).
  • Using the procedures described in Example 25 and Compound 25a, and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared from the corresponding vinyl derivatives:
  • Cpd Name and Data
    457 N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-
    yl}-phenyl)-acetamide
    1H-NMR (400 MHz, CD3OD) δ (ppm): 7.50-7.60 (m, 5H)
    7.32-7.44 (m, 5H) 7.22-7.26 (d, J = 8.6 Hz, 1H) 3.24-3.30 (s, 4H)
    1.96 (s, 3H). MS (ESI, pos. ion) m/z: 424.2 (M + 1).
    • Prophetic Example 26
  • Using the procedures of Examples 22, 23, 24 or 25, and reagents, starting materials and conditions known to those skilled in the art, the following prophetic compounds representative of the present invention may be prepared.
  • Cpd Name and Data
    133 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    134 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    135 1-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanone,
    136 1-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
    137 N-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    138 2-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
    140 N-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-
    trifluoro-methanesulfonamide,
    141 1-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanone,
    142 1-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanol,
    143 N-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    144 2-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    146 C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    147 1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-
    benzimidazol-5-yl)-phenyl]-ethanone,
    148 1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-
    benzimidazol-5-yl)-phenyl]-ethanol,
    149 N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-
    benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    150 2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-
    benzimidazol-5-yl)-phenyl]-propan-2-ol,
    151 2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-
    benzimidazol-5-yl)-benzenesulfonamide,
    152 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-
    phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    153 1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-
    phenyl]-ethanone,
    154 1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-
    phenyl]-ethanol,
    155 N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-
    phenyl]-methanesulfonamide,
    156 2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-
    phenyl]-propan-2-ol,
    157 2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-
    benzenesulfonamide,
    158 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-
    benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    159 1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-
    benzimidazol-5-yl)-phenyl]-ethanone,
    160 1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-
    benzimidazol-5-yl)-phenyl]-ethanol,
    161 N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-
    benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    162 2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-
    benzimidazol-5-yl)-phenyl]-propan-2-ol,
    163 2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-
    benzimidazol-5-yl)-benzenesulfonamide,
    164 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-
    ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    165 1-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanone,
    166 1-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
    167 N-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    168 2-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-
    2-ol,
    169 2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    170 N-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-
    trifluoro-methanesulfonamide,
    171 1-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanone,
    172 1-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanol,
    173 N-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    174 2-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-
    propan-2-ol,
    176 C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    177 N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)-
    methanesulfonamide,
    178 N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-ethyl)-
    phenyl]-methanesulfonamide,
    179 N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-
    yl}-phenyl)-methanesulfonamide,
    180 N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-
    ethyl)-phenyl]-methanesulfonamide,
    181 2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    182 C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    183 N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)-C,C,C-
    trifluoro-methanesulfonamide,
    184 C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-
    2-yl}-ethyl)-phenyl]-methanesulfonamide,
    185 C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H-
    benzimidazol-2-yl]-ethyl}-phenyl)-methanesulfonamide,
    186 C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-
    benzimidazol-2-yl}-ethyl)-phenyl]-methanesulfonamide,
    187 2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-
    5-yl}-benzenesulfonamide, and
    188 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-
    ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide.
    • Example 27 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide (Cpd 190) Step A. 2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid methyl ester
  • To a solution of trimethylsulfonium iodide (0.53 g, 2.39 mmol) in 8 mL of DMSO was added sodium hydride (0.06 g, 2.39 mmol) at 25° C. After stirring for one hour, a solution of methyl 4-trifluoromethylcinnamate (0.50 g, 2.17 mmol) in 4 mL DMSO was added. The reaction mixture was stirred for six hours, when it was quenched by sat'd NH4Cl solution. The resulting mixture was extracted with CH2Cl2, the organic layer was dried over Na2SO4, filtered and the filtrate was concentrated. The residue was purified by chromatography (silica gel, hexanes: EtOAc, 2:1) to provide the title Compound 27a as a solid.
    • Step B. 2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid
  • A solution of Compound 27a in 10 mL MeOH and 4 mL of 1N LiOH (aq) was heated at 70° C. for 4 h. The mixture was then acidified by 4N HCl (aq) and extracted with EtOAc. The organic layer was washed with brine, dried over Na2SO4, filtered, and filtrate was concentrated to provide the title Compound 27b. 1H-NMR (400 MHz, CD3OD) δ (ppm): 7.56 (d, 2H) 7.25 (d, 2H) 2.39 (m, 1H) 1.80 (m, 1H) 1.47 (m, 1H) 1.18 (m, 1H).
    • Step C. 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide
  • To a solution of Compound 16c (0.140 g, 0.438 mmol) and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride Compound 27c (0.060 g, 0.313 mmol) in 4 mL acetonitrile at rt was slowly added a solution of Compound 27b (0.072 g, 0.313 mmol) in 2 mL of acetonitrile. After stirring for 2 hours, the mixture was passed through a short column (silica gel, hexanes: EtOAc, 2:1). The collected eluent was concentrated, and the residue was dissolved in AcOH. The reaction was heated at 80° C. for 3 h. The reaction was concentrated and the residue was purified by chromatography (silica gel, hexanes: EtOAc, 2:1). This material was dissolved in TFA, and the mixture was heated at 60° C. for 2 h. The reaction was concentrated, and the residue was purified by chromatography (silica gel, hexanes: EtOAc, 1:1) to provide the title Compound 190 as a solid. 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J=1.2 and 7.6 Hz) 7.74-7.63 (m, 6H) 7.60-7.47 (m, 5H) 7.40 (dd, 1H, J=1.6 and 7.2 Hz) 2.97-2.92 (m, 1H) 2.76-2.71 (m, 1H) 2.12-2.00 (m, 2H) MS (ESI, pos. ion) m/z: 458.3 (M+1).
    • Example 28 2-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Cpd 471) Step A. N-methoxy-N-methyl-3-(4-trifluoromethyl-phenyl)-acrylamide
  • To a solution of 4-trifluoromethyl cinnamic acid (3.6 g, 16.7 mmol) in anhydrous methylene chloride (40 mL) was slowly added oxalyl chloride (1.7 mL, 19.5 mmol). To the solution was added anhydrous dimethylformamide (10 μL) and the reaction was stirred at room temperature under an argon atmosphere. After 18 h, the reaction was concentrated. A solution of the residue Compound 10b (16.7 mmol) in methylene chloride (40 mL) was added dropwise to a solution of N,N-dimethylhydroxylamine hydrochloride (1.6 g, 16.7 mmol) and triethylamine (5.8 mL, 41.7 mmol) in methylene chloride (40 mL) at 0° C. The reaction mixture was stirred at 0° C. for 30 min, then warmed to room temperature. After 6 h, the reaction was successively washed with sodium carbonate (10% in water), water and brine. The organic fraction was dried over magnesium sulfate, filtered and the filtrate was concentrated. The compound was purified by chromatography (silica, EtOAc: hexanes, 1:1) to provide the title Compound 28a (2.2 g, 50% over two steps) 1H-NMR (400 MHz, DMSO d6) δ (ppm) 7.96 (d, J=8.3 Hz, 2H) 7.78 (d, J=8.08 Hz, 2H) 7.64 (d, J=15.9 Hz, 1H) 7.24 (d, J=15.9 Hz, 1H) 3.77 (s, 3H) 3.23 (s, 3H).
    • Step B. 2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid methoxy-methyl-amide
  • Anhydrous dimethylsulfoxide (8 mL) was added dropwise under an argon atmosphere to a mixture of sodium hydride (60% suspension in oil, 0.369 g, 9.2 mmol) and trimethylsulfoxonium iodide (2 g, 9.1 mmol). To the solution was added dropwise Compound 28a (1.2 g, 4.6 mmol) in DMSO (8 mL). The reaction mixture was stirred at room temperature for 18 h. The reaction was poured into ethyl ether:water (1:1, 50 mL). The organic layer was separated and washed successively with water and brine. The organic fraction was dried over magnesium sulfate, filtered and the filtrate was concentrated to provide the title Compound 28b (1.9 g, 90%). 1H-NMR (400 MHz, CDCl3) δ (ppm) 7.55 (d, J=8.08 Hz, 2H) 7.25 (d, J=8.3 Hz, 2H) 3.72 (s, 3H) 3.26 (s, 3H) 2.54-2.59 (m, 1H) 2.43-2.52 (m, 1H) 1.68-1.74 (m, 1H) 1.33-1.38 (m, 1H).
    • Step C. 2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid
  • To a solution of Compound 28b (3.6 g, 13.2 mmol) in tetrahydrofuran (45 mL) was added a solution of potassium-t-butoxide (1M in tetrahydrofuran, 50 mL, 50 mmol). To the reaction was added water (1.5 mL, 83.3 mmol), and the reaction was stirred at room temperature under an argon atmosphere. After 18 h, ice was added to the reaction until it became homogeneous. To the solution was added ethyl ether, and the layers were separated. The aqueous layer was cooled and acidified with 1 M HCl until the pH was 4. The aqueous layer was extracted with ethyl acetate. The ethyl acetate layer was washed successively with water and brine. The organic layer was dried over magnesium sulfate, filtered and the filtrate was concentrated to provide the title Compound 28c (2.2 g, 73%). 1H-NMR (400 MHz, DMSO d6) δ (ppm) 12.4 (s, 1H) 7.62 (d, J=8.08 Hz, 2H) 7.40 (d, J=8.08 Hz, 2H) 2.46-2.54 (m, 1H) 1.88-1.96 (m, 1H) 1.46-1.52 (m, 1H) 1.38-1.44 (m, 1H).
    • Step D. 5-bromo-2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazole
  • Using the procedure of Example 1, the title Compound 28d was prepared from Compound 28c and 4-bromobenzene-1,2-diamine. 1H-NMR (400 MHz, DMSO d6) δ (ppm) 7.96 (s, 1H) 7.68-7.75 (m, 3H) 7.60-7.64 (dd, J=1.5, 8.6 Hz, 1H) 7.46-7.56 (m, 4H) 7.10-7.14 (d, J=8.4 Hz, 2H) 2.96-3.02 (m, 1H) 2.70-2.78 (m, 1H) 2.10-2.16 (m, 1H) 2.00-2.08 (m, 1H).
    • Step E. 2-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol
  • Using the procedure of Example 10, the title Compound 471 was prepared from Compound 28d and Compound 10e. 1H-NMR (400 MHz, CD3OD) δ (ppm) 12.4 (s, 0.5H) 12.32 (s, 0.5H) 7.88 (m, 1H) 7.65 (d, 2H, J=8.084 Hz) 7.46 (m, 2H) 7.35 (m, 2H) 7.20 (m, 1H) 6.95 (m, 2H) 4.85 (s, 1H) 2.70 (m, 1H) 2.46 (m, 1H) 1.90 (m, 1H) 1.70 (m, 1H) 1.20 (d, 6H). MS (ESI, pos. ion) m/z: 437.2 (M+1).
  • Using the procedures described in Example 28 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared from the corresponding vinyl derivatives:
  • Cpd Name and Data
    198 2-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    1H-NMR (400 MHz, CD3OD) δ (ppm) 7.83-7.86 (m, 1H) 7.44-7.49 (bs, 1H)
    7.31-7.36 (m, 4H) 7.21-7.26 (m, 3H) 7.055-7.13 (m, 2H) 2.60-2.65 (m, 1H)
    2.40-2.44 (m, 1H) 1.84-1.90 (m, 1H) 1.62-1.70 (m, 1H) 1.32 (s, 6H). MS (ESI,
    pos. ion) m/z: 403.2 (M + 1).
    234 2-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-
    yl}-phenyl)-propan-2-ol
    1H-NMR (400 MHz, CD3OD) δ (ppm) 7.71-7.74 (dd, J = 1.01, 8.08 Hz, 1H)
    7.40-7.45 (m, 4H) 7.33-7.38 (d, J = 8.34 Hz) 7.21-7.26 (m, 2H) 7.08-7.13 (ddd,
    J = 1.52, 7.58 Hz, 1H) 6.99-7.02 (dd, J = 1.52, 8.34 Hz) 6.93-6.97 (dd, J = 1.52,
    7.58 Hz, 1H) 2.60-2.66 (m, 1H) 2.37-2.42 (m, 1H) 1.78-1.84 (m, 1H)
    1.59-1.65 (m, 1H) 1.22 (s, 6H). MS (ESI, pos. ion) m/z: 437.3 (M + 1).
    467 N-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-
    yl}-phenyl)-methanesulfonamide
    1H-NMR (400 MHz, CD3OD) δ (ppm) 7.52-7.62 (m, 5H) 7.33-7.41 (m, 4H)
    7.24-7.32 (m, 2H) 2.70 (m, 4H) 2.48-2.53 (m, 1H) 1.90-1.96 (m, 1H)
    1.69-1.75 (m, 1H). MS (ESI, pos. ion) m/z: 472.2 (M + 1),
    472 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenol
    1H-NMR (400 MHz, CD3OD) δ (ppm) 7.70 (bs, 1H) 7.61 (d, 2H,
    J = 8.34 Hz) 7.51 (m, 3H) 7.42 (m, 3H) 7.30 (m, 1H) 7.15 (m, 1H) 6.93 (m, 2H)
    2.72 (m, 1H) 2.50 (m, 1H) 1.93 (m, 1H) 1.74 (m, 1H). MS (ESI, pos. ion) m/z:
    395.2 (M + 1),
    474 (2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanol
    1H-NMR (400 MHz, CD3OD) δ (ppm) 7.62 (m, 3H)7.50 (m, 4H) 7.35 (m, 3H)
    7.20 (m, 1H) 4.50 (s, 2H) 2.73 (m, 1H) 2.52 (m, 1H) 1.95 (m, 1H) 1.78 (m,
    1H). MS (ESI, pos. ion) m/z: 409.1 (M + 1).
    494 2-(2-{2-[2-(4-methoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol
    1H-NMR (400 MHz, CD3OD) δ (ppm) 7.83-7.86 (m, 1H) 7.44-7.49 (d,
    J = 8.08 Hz, 1H) 7.34-7.40 (m, 2H) 7.14-7.28 (m, 3H) 7.12-7.18 (m, 2H) 3.80 (s,
    3H) 2.60-2.65 (m, 1H) 2.31-2.35 (m, 1H) 1.78-1.82 (m, 1H) 1.62-1.70 (m, 1H)
    1.34 (s, 6H). MS (ESI, pos. ion) m/z: 399.1 (M + 1).
    497 2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-
    yl}-phenyl)-propan-2-ol
    1H-NMR (400 MHz, DMSO d6) δ (ppm) 12.30-12.40 (d, 1H) 7.84-7.87 (d,
    J = 7.83 Hz, 1H) 7.45-7.48 (d, J = 7.83 Hz, 1H) 7.29-7.40 (m, 6H) 7.17-7.23 (m,
    1H) 6.96-7.10 (m, 2H) 2.60-2.67 (m, 1H) 2.38-2.43 (m, 1H) 1.81-1.86 (m, 1H)
    1.62-1.68 (m, 1H) 1.20 (s, 6H). MS (ESI, pos. ion) m/z: 453.3 (M + 1).
    498 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    benzamide
    1H-NMR (400 MHz, DMSO d6) δ (ppm) 12.5 (bs, 1H) 7.68-7.72 (d, J = 8.08 Hz,
    2H) 7.40-7.60 (m, 7H) 7.28 (s, 1H) 7.21-7.25 (dd, J = 1.77, 8.34 Hz, 1H)
    2.70-2.78 (m, 1H) 2.44-2.53 (m, 1H) 1.90-1.99 (m, 1H) 1.70-1.80 (m, 1H). MS
    (ESI, pos. ion) m/z: 422.2 (M + 1).
    499 N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-
    benzimidazol-5-yl}-benzenesulfonamide
    1H-NMR (400 MHz, DMSO d6) δ (ppm) 12.40 (s, 1H) 8.2-8.3 (d, J = 9.34 Hz,
    1H) 7.30-7.70 (m, 9H) 7.10-7.15 (m, 1H) 6.28-6.32 (m, 1H) 2.64-2.72 (m, 1H)
    1.90-1.94 (m, 1H) 1.70-1.75 (m, 1H) 0.90 (s, 9H). MS (ESI, pos. ion) m/z:
    514.2 (M + 1).
    500 5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-
    cyclopropyl]-1H-benzimidazole
    1H-NMR (400 MHz, DMSO d6) δ (ppm) 8.12-8.15 (dd, J = 1.26, 7.83 Hz, 1H)
    7.70-7.83 (m, 6H) 7.53-7.57 (d, J = 8.08 Hz, 2H) 7.42-7.47 (ddd, J = 1.26,
    7.32 Hz, 2H) 2.93-3.00 (m, 1H) 2.66-2.74 (m, 1H) 2.06-2.13 (m, 1H)
    1.97-2.03 (m, 1H). MS (ESI, pos. ion) m/z: 457.1 (M + 1).
    • Prophetic Example 29
  • Using the procedures of Examples 27 or 28, and reagents, starting materials and conditions known to those skilled in the art, the following prophetic compounds representative of the present invention may be prepared.
  • Cpd Name and Data
    189 2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    191 2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-
    5-yl}-benzenesulfonamide,
    192 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    193 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    194 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-
    cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    195 1-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanone,
    196 1-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanol,
    197 N-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    199 2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    200 N-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-
    C,C,C-trifluoro-methanesulfonamide,
    201 1-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-
    yl}-phenyl)-ethanone,
    202 1-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-
    yl}-phenyl)-ethanol,
    203 N-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-
    yl}-phenyl)-methanesulfonamide,
    204 2-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-
    yl}-phenyl)-propan-2-ol,
    205 2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    206 C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    207 1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-
    1H-benzimidazol-5-yl)-phenyl]-ethanone,
    208 1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-
    1H-benzimidazol-5-yl)-phenyl]-ethanol,
    209 N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-
    cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    210 2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-
    1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
    211 2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-
    1H-benzimidazol-5-yl)-benzenesulfonamide,
    212 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-
    phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    213 1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-
    benzimidazol-5-yl)-phenyl]-ethanone,
    214 1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-
    benzimidazol-5-yl)-phenyl]-ethanol,
    215 N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-
    benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    216 2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-
    benzimidazol-5-yl)-phenyl]-propan-2-ol,
    217 2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-
    yl)-benzenesulfonamide,
    218 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-
    1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    219 1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-
    benzimidazol-5-yl)-phenyl]-ethanone,
    220 1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-
    benzimidazol-5-yl)-phenyl]-ethanol,
    221 N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-
    benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    222 2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-
    benzimidazol-5-yl)-phenyl]-propan-2-ol,
    223 2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-
    benzimidazol-5-yl)-benzenesulfonamide,
    224 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-
    cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
    225 1-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanone,
    226 1-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-
    ethanol,
    227 N-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-
    methanesulfonamide,
    228 2-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-
    propan-2-ol,
    229 2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    230 N-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-
    C,C,C-trifluoro-methanesulfonamide,
    231 1-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanone,
    232 1-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanol,
    233 N-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    235 2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    236 C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    237 N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)-
    methanesulfonamide,
    238 N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-
    cyclopropyl)-phenyl]-methanesulfonamide,
    239 N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    240 N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-
    cyclopropyl)-phenyl]-methanesulfonamide,
    241 2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-
    5-yl}-benzenesulfonamide,
    242 C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-
    1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    243 N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)-
    C,C,C-trifluoro-methanesulfonamide,
    244 C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-
    2-yl}-cyclopropyl)-phenyl]-methanesulfonamide,
    245 C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H-
    benzimidazol-2-yl]-cyclopropyl}-phenyl)-methanesulfonamide,
    246 C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-
    benzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide,
    247 2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-cyclopropyl]-1H-
    benzimidazol-5-yl}-benzenesulfonamide, and
    248 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-
    cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide.
    • Example 30 2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol (Cpd 489) Step A. (E)-5-bromo-2-(2-chloro-2-phenyl-vinyl)-1H-benzimidazole
  • A mixture of 4-bromo-benzene-1,2-diamine dihydrochloride (1.3 g, 5 mmol), phenylpropiolic acid (0.73 g, 5 mmol) in 4 mL of ethylene glycol was heated to reflux for 5 h. The mixture was cooled to rt and poured into water. The mixture was neutralized with 2N sodium hydroxide and filtered. The solid was suspended in water and extracted with ethyl acetate. The organic layers were combined, dried with anhydrous sodium sulfate, and filtered. The filtrate was concentrated to yield a red oil. The residue was purified using preparative TLC plates twice (silica gel, 20×20 cm, 2000 microns, EtOAc: hexanes 3:7 and silica gel, 20×20 cm, 2000 microns, EtOAc: dichloromethane 3:97) to provide a mixture of cis and trans isomers of the title Compound 30a (0.345 g). 1H NMR (400 MHz, DMSO-d6) δ (ppm): 12.59 (m, 1H), 7.86-7.78 (m, 3H), 7.64-7.56 (m, 1H), 7.54-7.49 (m, 3H), 7.46 (s, 1H), 7.40-7.34 (m, 1H). Mass Spectrum (LCMS, APCI pos.) Calcd. For C16H10BrClN2: 333.0 (M+H), Found 333.1.
    • Step B. 2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol
  • A mixture of Compound 30a (25 mg, 0.075 mmol), Compound 10e (18 mg, 0.113 mmol) and Pd(dppf)Cl2CH2Cl2 (12 mg, 0.015 mmol) in 3 mL of DME and sodium carbonate solution (1.0 M, 0.6 mL) was heated at 150° C. for 1 h in a Biotage Initiator™ microwave synthesizer. The mixture was filtered through a pad of silica gel. The reaction was repeated total three times. The residues were combined and purified using preparative TLC plates twice (silica gel, 20×20 cm, 2000 microns, EtOAc: hexanes 3:7 and then silica gel, 20×20 cm, 2000 microns, EtOAc: hexanes: methanol 2:8:1) to provide the title Compound 489 (8.4 mg). 1H NMR (400 MHz, CD3OD) δ (ppm): 7.78 (dd, 1H, J=8.1, 1.1 Hz, 1H), 7.62-7.60 (m, 2H), 7.52 (d, 1H, J=8.3 Hz), 7.46-7.38 (m, 4H), 7.31 (dt, 1H, J=1.5, 8.0 Hz), 7.21-7.17 (m, 2H), 7.02 (dd, J=7.5, 1.3 Hz, 1H), 1.30 (s, 6H). Mass Spectrum (LCMS, APCI pos.) Calcd. For C24H20N2O: 353.2 (M+H), Found 353.3.
    • Example 31 2-(2-phenylethynyl-1H-benzimidazol-5-yl)-benzenesulfonamide (Cpd 490) Step A. N-tert-butyl-2-(2-phenylethynyl-1H-benzimidazol-5-yl)-benzenesulfonamide
  • A mixture of Compound 30a (25 mg, 0.075 mmol), 2-(tert-butylamino)sulfonylphenyl boronic acid (29 mg, 0.113 mmol), and Pd(dppf)Cl2.CH2Cl2 (12 mg, 0.015 mmol) in 3 mL of DME and sodium carbonate solution (1.0 M, 0.6 mL) was heated at 150° C. for 1 h in a Biotage Initiator™ microwave synthesizer. The mixture was filtered through a pad silica gel. The residue was purified by preparative TLC (silica gel, 20×20 cm, 2000 microns, EtOAc: hexanes 3:7) to provide the title Compound 31a (12.8 mg). Mass Spectrum (LCMS, APCI pos.) Calcd. For C25H23N3O2S: 430.2 (M+H), Found 430.3.
    • Step B. 2-(2-phenylethynyl-1H-benzimidazol-5-yl)-benzenesulfonamide
  • A mixture of Compound 31a (14.9 mg, 0.034 mmol) in trifluoroacetic acid and 1,2-dichloroethane (2 mL, 1:1) was heated at 90° C. for 3 h. The reaction was cooled to rt, and concentrated under reduced pressure. The residue was dissolved in dichloromethane, and washed with saturated sodium bicarbonate solution. The aqueous layer was extracted twice with ethyl acetate. The organic layers were combined, dried with anhydrous magnesium sulfate, filtered, and the filtrate was removed under reduced pressure. The residue was purified using preparative TLC plates (silica gel, 20×20 cm, 2000 microns, EtOAc: hexanes: methanol 5:5:1) to provide the title Compound 490 (12.1 mg). 1H NMR (400 MHz, CD3OD) δ (ppm): 8.11 (dd, 1H, J=8.0, 1.2 Hz), 7.67-7.56 (m, 5H), 7.52 (ddd, 1H, J=7.6, 6.4, 1.4 Hz), 7.48-7.33 (m, 5H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C21H15N3O2S: 374.1 (M+H), Found 374.2.
  • Using the procedures described in Examples 30 and 31, and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared from the corresponding vinyl derivatives:
  • Cpd Name and Data
    250 2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-
    benzenesulfonamide
    1H NMR (400 MHz, CD3OD) δ (ppm): 8.04 (dd, 1H, J = 8.0, 1.2 Hz), 7.76 (d, J2H, = 8.2 Hz),
    7.69 (d, 2H, J = 8.2 Hz), 7.58-7.53 (m, 2H), 7.54 (dt, 1H, J = 1.4, 7.5 Hz),
    7.46 (dt, 1H, J = 1.4, 7.7 Hz), 7.31 (dd, 1H, J = 7.5, 1.3 Hz), 7.30 (dd, 1H, J = 8.4,
    0.9 Hz). Mass Spectrum (LCMS, ESI pos.) Calcd. For C22H14F3N3O2S:
    442.1 (M + H), Found 442.2.
    294 2-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-
    propan-2-ol
    1H NMR (400 MHz, CD3OD) δ (ppm): 7.94 (s, 1H), 7.89 (d, 1H, J = 7.7 Hz),
    7.80-7.74 (m, 2H), 7.66 (t, 1H, J = 7.8 Hz, 1H), 7.60-7.39 (m, 2H), 7.33 (m, 1H),
    7.28-7.18 (m, 2H), 7.04 (dd, 1H, J = 7.5, 1.4 Hz, 1H), 1.32 (s, 6H). Mass
    Spectrum (LCMS, ESI pos.) Calcd. For C25H19F3N2O: 421.1 (M + H), Found
    421.3.
    295 2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-
    benzenesulfonamide
    1H NMR (400 MHz, CD3OD δ (ppm): 8.11 (dd, 1H, J = 8.0, 1.2 Hz), 7.94 (s, 1H),
    7.89 (dm, 1H, J = 7.6 Hz), 7.77 (dm, 1H, J = 7.9 Hz), 7.67-7.58 (m, 4H),
    7.52 (m, 1H), 7.38 (dd, J = 7.5, 1.3 Hz, 1H), 7.37 (br s, 1H). Mass Spectrum (LCMS,
    ESI pos.) Calcd. For C22H14F3N3O2S: 442.1 (M + H), Found 442.2
    492 2-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-
    propan-2-ol
    1H NMR (400 MHz, CD3OD) δ (ppm): 7.83 (d, 2H, J = 8.2 Hz), 7.79 (dd, 1H, J = 8.2
    1.1 Hz, 1H), 7.76 (d, 2H, J = 8.3 Hz), 7.64-7.37 (m, 2H), 7.33 (m, 1H),
    7.22 (br d, 1H, J = 7.2 Hz), 7.20 (dt, 1H, J = 1.3, 7.4 Hz), 7.04 (dd, 1H, J = 7.5, 1.4 Hz),
    1.32 (s, 6H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C25H19F3N2O:
    421.1 (M + H), Found 421.3.
    Preparation of (4-trifluoromethylphenyl)propynoic acid. To a solution of 4-
    ethynyl-α,α,α-trifluorotoluene (5 g, 29 mmol) in anhydrous THF (25 mL), was
    slowly added n-butyllithium 2.6M in hexanes (14.5 mL, 47 mmol). The mixture
    was stirred at −78° C. for 30 min and then at 0° C. for an additional 30 min. The
    mixture was cooled to −78° C. and transferred via a cannula to a saturated
    solution of carbon dioxide in anhydrous THF (25 mL) at −78° C. The mixture
    was stirred and allowed to warm to rt over 18 h. The mixture was quenched
    with saturated sodium chloride solution, and the two layers were separated.
    The aqueous layer was washed with hexanes and then acidified with 2N
    hydrochloric acid. The aqueous layer was extracted twice with ethyl acetate.
    The organic layers were combined and dried with anhydrous sodium sulfate and
    magnesium sulfate. The mixture was filtered and the filtrate was concentrated
    under reduced pressure to yield the title Compound 31b as a white solid (5.4 g,
    87%). 1H NMR (400 MHz, DMSO-d6) δ (ppm): 7.81 (s, 4H). Compound 31b was
    carried forward using the procedure of Example 31 to provide the title
    Compound 492.
    • Prophetic Example 32
  • Using the procedures of Examples 30 or 31, the corresponding bromobenzimidazole and, when not commercially available, the arylacetylenic acid precursors prepared as described in Reaction Scheme KK and reagents, starting materials and conditions known to those skilled in the art, the following prophetic compounds representative of the present invention may be prepared. Alternatively, the following compounds may be prepared from their corresponding vinyl compounds by hydrogenation:
  • Cpd Name and Data
    249 2-[2-(4-trifluoromethoxy-phenylethynyl)-1H-benzimidazol-5-yl]-
    benzenesulfonamide,
    251 2-[2-(4-trifluoromethanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-
    benzenesulfonamide,
    252 C,C,C-trifluoro-N-{2-[2-(4-trifluoromethoxy-phenylethynyl)-1H-
    benzimidazol-5-yl]-phenyl}-methanesulfonamide,
    253 C,C,C-trifluoro-N-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-
    5-yl]-phenyl}-methanesulfonamide,
    254 C,C,C-trifluoro-N-{2-[2-(4-trifluoromethanesulfonyl-phenylethynyl)-1H-
    benzimidazol-5-yl]-phenyl}-methanesulfonamide,
    255 1-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone,
    256 1-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol,
    257 N-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-
    methanesulfonamide,
    258 2-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-
    ol,
    259 2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-
    benzenesulfonamide,
    260 N-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-C,C,C-
    trifluoro-methanesulfonamide,
    261 1-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-
    ethanone,
    262 1-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-
    ethanol,
    263 N-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-
    phenyl}-methanesulfonamide,
    264 2-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-
    propan-2-ol,
    265 2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-
    benzenesulfonamide,
    266 C,C,C-trifluoro-N-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-
    benzimidazol-5-yl]-phenyl}-methanesulfonamide,
    267 1-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-
    benzimidazol-5-yl}-phenyl)-ethanone,
    268 1-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-
    benzimidazol-5-yl}-phenyl)-ethanol,
    269 N-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    270 2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-
    benzimidazol-5-yl}-phenyl)-propan-2-ol,
    271 2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-
    benzimidazol-5-yl}-benzenesulfonamide,
    272 C,C,C-trifluoro-N-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-
    phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    273 1-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanone,
    274 1-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-
    phenyl)-ethanol,
    275 N-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-
    phenyl)-methanesulfonamide,
    276 2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-
    phenyl)-propan-2-ol,
    277 2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-
    benzenesulfonamide,
    278 C,C,C-trifluoro-N-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    279 1-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-
    benzimidazol-5-yl}-phenyl)-ethanone,
    280 1-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-
    benzimidazol-5-yl}-phenyl)-ethanol,
    281 N-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-
    benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    282 2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-
    benzimidazol-5-yl}-phenyl)-propan-2-ol,
    283 2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-
    5-yl}-benzenesulfonamide,
    284 C,C,C-trifluoro-N-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-
    1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
    285 1-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone,
    286 2-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-
    ol,
    287 N-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-
    methanesulfonamide,
    288 1-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol,
    289 2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-
    benzenesulfonamide,
    290 N-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-C,C,C-
    trifluoro-methanesulfonamide,
    291 1-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-
    ethanone,
    292 1-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-
    ethanol,
    293 N-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-
    methanesulfonamide,
    296 C,C,C-trifluoro-N-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-
    5-yl]-phenyl}-methanesulfonamide,
    297 N-{4-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}-
    methanesulfonamide,
    298 N-(4-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl}-
    phenyl)-methanesulfonamide,
    299 N-{2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-
    phenyl}-methanesulfonamide,
    300 N-(4-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl-
    ethynyl}-phenyl)-methanesulfonamide,
    301 2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-
    benzenesulfonamide,
    302 C,C,C-trifluoro-N-{2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-
    benzimidazol-5-yl]-phenyl}-methanesulfonamide,
    303 N-{4-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}-C,C,C-
    trifluoro-methanesulfonamide,
    304 C,C,C-trifluoro-N-(4-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl-
    ethynyl}-phenyl)-methanesulfonamide,
    305 C,C,C-trifluoro-N-{4-[5-(2-methanesulfonylamino-phenyl)-1H-
    benzimidazol-2-yl-ethynyl]-phenyl}-methanesulfonamide,
    306 C,C,C-trifluoro-N-(4-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-
    benzimidazol-2-yl-ethynyl}-phenyl)-methanesulfonamide,
    307 2-[2-(4-trifluoromethanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-
    yl]-benzenesulfonamide, and
    308 C,C,C-trifluoro-N-{2-[2-(4-trifluoromethanesulfonylamino-phenylethynyl)-
    1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide.
    • Example 33 (E)-2-{2-[2-(2-quinolin-6-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol (Cpd. 449) Step A. 5-bromo-2-chloromethyl-1H-benzimidazole
  • A mixture of 4-bromo-benzene-1,2-diamine (200 mg, 1.07 mmol) and 2-chloroacetimidic acid ethyl ester hydrochloride salt (168 mg, 1.07 mmol; prepared according to the procedure described in J. Med. Chem. 1986, 29, 2280) in anhydrous ethanol (200 proof, 5 mL) was stirred at room temperature for 4 h. The reaction mixture was concentrated under reduced pressure and extracted with ethyl acetate and water. The organic layer was dried over Na2SO4, filtered, and the filtrate was concentrated in vacuo to provide the title Compound 33a as an off-white solid (240 mg, 92% yield). 1H NMR (400 MHz, CDCl3) δ (ppm): 7.75 (d, 1H, J=1.4 Hz), 7.47 (d, 1H, J=8.6 Hz), 7.42 (dd, 1H, J=8.6 Hz, J=1.3 Hz), 4.84 (s, 2H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C18H20ClN3O2S: 247.50 (M+H), Found 247.0.
    • Step B. (5-bromo-1H-benzimidazol-2-ylmethyl)-triphenyl-phosphonium chloride
  • A mixture of Compound 33a (240 mg, 0.98 mmol) and triphenylphosphine (385 mg, 1.47 mmol), in 1,2-dichloroethane (10 mL) was heated at 140° C. for 1 h. The reaction mixture was concentrated under reduced pressure to provide the title Compound 33b, which was used in the next step without further purification.
    • Step C. (E)-6-[2-(5-bromo-1H-benzimidazol-2-yl)-vinyl]-quinoline
  • A mixture of Compound 33b (100 mg, 0.204 mmol), 6-quinolinecarboxaldehyde (32 mg, 0.29 mmol) and DBU (39.6 uL, 0.265 mmol) in ethanol:tetrahydrofuran (1:1, 2 mL) was stirred at room temperature for 12 h. The reaction mixture was concentrated under reduced pressure, and the residue was purified by reverse phase preparative HPLC (10-100% gradient acetonitrile/water over 10 min) to provide the title Compound 33c as an off-white solid (50 mg, 72 yield). Calcd. For C18H12BrN3: 350.21 (M+H), Found 350.2.
    • Step D. (E)-2-{2-[2-(2-quinolin-6-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol
  • A mixture of Compound 33c (50.0 mg, 0.143 mmol), Compound 10e (46 mg, 0.29 mmol), PdCl2(dppf) (23.4 mg, 0.029 mmol) and 1M sodium bicarbonate solution (1.15 mL, 1.15 mmol) in 1,2-dimethoxyethane (1 mL) was heated at reflux for 12 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography (silica, EtOAc) to provide the title Compound 449 as an off-white solid (11.8 mg, 20% yield). 1H NMR (400 MHz, CD3OD) δ (ppm): 9.01 (br s, 1H), 8.68 (d, 1H, J=8.1 Hz), 8.35 (m, 2H), 8.12-8.21 (m, 2H), 7.76 (m, 3H), 7.67 (s, 1H), 7.53 (m, 2H), 7.38-7.43 (m, 1H), 7.28 (m, 1H), 7.09 (m, 1H), 1.42 (s, 6H). Calcd. For C27H23N3O: 406.5 (M+H), Found 406.3.
  • Using the procedures described in Example 33 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:
  • Cpd Name and Data
    448 (E)-1-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-
    yl}-vinyl)-phenyl]-ethanone
    The title compound was prepared from Compound 33b (100 mg, 0.204 mmol)
    and 4-acetylbenzaldehyde (30.2 mg, 0.204 mmol) as an off-white solid (3.75 mg,
    10% yield). 1H NMR (400 MHz, CD3OD) δ (ppm): 8.06 (d, 1H, J = 8.8 Hz),
    7.96 (m, 1H), 7.80 (m, 3H), 7.68 (m, 1H), 7.55 (m, 1H), 7.43 (m, 1H), 7.34 (m,
    2H), 7.17-7.24 (m, 2H), 7.07 (m, 1H), 2.63 (s, 3H), 1.35 (s, 6H). Mass Spectrum
    (LCMS, ESI pos.) Calcd. For C26H24N2O2: 397.5 (M + H), Found 397.3.
    450 (E)-N-isopropyl-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-
    yl]-vinyl}-benzamide
    The title compound was prepared from [5-(2-methylsulfamoyl-phenyl)-1H-
    benzimidazol-2-ylmethyl]-triphenyl-phosphonium chloride Compound 33c (90 mg,
    0.15 mmol) and 4-carboxyaldehyde-N-isopropylbenzamide (24.3 mg, 0.15 mmol)
    as an off-white solid (10.5 mg, 15% yield). 1H NMR (400 MHz, CD3OD) δ
    (ppm): 8.06 (dd, 1H, J = 8.1, Hz, J = 1.5 Hz), 7.87 (m, 2H), 7.55-7.74 (m, 7H),
    7.43 (dd, 1H, J = 8.1 Hz, J = 1.5 Hz), 7.29 (m, 2H), 4.22 (m, 1H), 2.37 (s, 3H),
    1.26 (s, 6H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C26H26N4O3S: 475.5 (M + H),
    Found 475.2.
    451 (E)-2-{2-[2-(4-cyano-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide
    The title compound was prepared from Compound 33c (90 mg, 0.15 mmol) and
    4-cyanobenzaldehyde (19.6 mg, 0.15 mmol) as an off-white solid (7.4 mg, 12%
    yield). 1H NMR (400 MHz, CD3OD) δ (ppm): 8.07 (dd, 1H, J = 8.0 Hz, J = 1.0 Hz),
    7.49-7.69 (m. 8H), 7.37 (m, 2H), 7.20 (m, 2H), 2.32 (s, 3H). Mass Spectrum
    (LCMS, ESI pos.) Calcd. For C23H18N4O2S: 415.5 (M + H), Found 415.2.
    452 (E)-N-(4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-
    phenyl)-acetamide
    The title compound was prepared from Compound 33c (90 mg, 0.15 mmol) and
    4-acetamidobenzaldehyde (24.3 mg, 0.15 mmol) as an off-white solid (11.3 mg,
    17% yield). 1H NMR (400 MHz, CD3OD) δ (ppm): 8.04 (dd, 1H, J = 8.0 Hz,
    J = 1.3 Hz), 7.63 (td, 1H, J = 7.4 Hz, J = 1.4 Hz), 7.55 (m, 5H), 7.26-7.39 (m, 5H),
    7.19 (dd, 1H, J = 8.1 Hz, J = 1.5 Hz), 2.22 (s, 3H), 2.03 (s, 3H). Mass Spectrum
    (LCMS, ESI pos.) Calcd. For C24H22N4O3S: 447.5 (M + H), Found 447.2.
    453 (E)-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-
    benzoic acid
    The title compound was prepared from Compound 33c (90 mg, 0.15 mmol) and
    4-carboxybenzaldehyde (22.4 mg, 0.15 mmol) as an off-white solid (3.4 mg, 5%
    yield). 1H NMR (400 MHz, CD3OD) δ (ppm): 8.02 (m, 2H), 7.53-7.77 (m, 6H),
    7.18-7.45 (m, 5H), 2.36 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For
    C23H19N3O4S: 434.5 (M + H), Found 434.2.
    454 (E)-2-{2-[2-(1H-indol-6-yl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide
    The title compound was prepared from Compound 33c (90 mg, 0.15 mmol) and
    indole-6-carboxaldehyde (21.6 mg, 0.15 mmol) as an off-white solid (6.5 mg,
    10% yield). 1H NMR (400 MHz, CD3OD) δ (ppm): 8.06 (m, 1H), 7.05-7.73 (m,
    11H), 6.48 (m, 2H), 2.36 (m, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For
    C24H20N4O2S: 429.5 (M + H), Found 429.2.
    455 (E)-2-{2-[2-(2,4-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-
    methyl-benzenesulfonamide
    The title compound was prepared from Compound 33c (90 mg, 0.15 mmol) and
    2,4-bis(trifluoromethyl)benzaldehyde (24.4 uL, 0.15 mmol) as an off-white solid
    (8.62 mg, 11% yield). 1H NMR (400 MHz, CD3OD) δ (ppm): 7.14-8.17 (m, 12H),
    2.44 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C24H17F6N3O2S:
    526.5 (M + H), Found 526.3.
    456 (E)-2-{2-[2-(4-acetyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-
    benzenesulfonamide
    The title compound was prepared from Compound 33c (90 mg, 0.15 mmol) and
    4-acetylbenzaldehyde (22.1 mg, 0.15 mmol) as an off-white solid (8.32 mg, 13%
    yield). 1H NMR (400 MHz, CD3OD) δ (ppm): 8.06 (m, 3H), 7.56-7.79 (m, 9H),
    7.44 (m, 1H), 2.62 (s, 3H), 2.37 (s, 3H). Mass Spectrum (LCMS, ESI pos.)
    Calcd. For C24H21N3O3S: 432.5 (M + H), Found 432.2.
    • Example 34 2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzylamine (Cpd 486) Step A. (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzonitrile
  • A mixture of Compound 10c (52 mg, 0.14 mmol), 2-cyanophenylboronic acid (38 mg, 0.26 mmol), Pd(dppf)Cl2CH2Cl2 (36 mg, 0.044 mmol), tetrabutylammonium bromide (55 mg, 0.17 mmol), and sodium carbonate (1 mL, 1.0 M) in DME (5 mL) was heated at 90° C. for 18 h. The mixture was cooled to rt, filtered through a pad of Celite and concentrated under reduced pressure. The residue was purified using preparative TLC plates (silica gel, 20×20 cm, 2000 microns, EtOAc:hexanes 1:1 and hexanes: dichloromethane: methanol 6:14:1) to provide the title Compound 34a (20 mg, 37%). 1H NMR (400 MHz, CD3OD+CDCl3) δ (ppm): 7.72-7.47 (m, 10H), 7.40-7.30 (m, 3H), 7.14 (d, 1H, J=16.55 Hz). Mass Spectrum (LCMS, APCI pos.) Calcd. For C23H14F3N3:.390.1 (M+H), Found 390.3.
    • Step B. 2-{2-[2-(4-Trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzylamine
  • A mixture of Compound 34a (20 mg, 0.051 mmol), Raney®-Nickel, ammonium hydroxide (0.1 mL) in ethanol was hydrogenated under 50 psi for 18 h. The mixture was filtered through a pad of Celite and washed with ethanol. The filtrate was concentrated under reduced pressure. The residue was purified using preparative TLC plates (silica gel, 20×20 cm, 2000 microns, NH3 in methanol: EtOAc 1:9) to provide the title Compound 486 (6.3 mg, 31%). 1H NMR (400 MHz, CD3OD) δ (ppm): 7.57-7.52 (m, 4H), 7.46-7.34 (m, 6H), 7.14 (dd, J=8.2, 1.5 Hz, 1H), 4.05 (s, 2H), 3.24 (s, 4H). Mass Spectrum (LCMS, APCI pos.) Calcd. For C23H20F3N3: 396.2 (M+H), Found 396.2.
    • Example 35 (Z)-2-(2-{2-[2-(4-Trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Cpd 469)
  • A solution of Compound 18 (0.030 g, 0.07 mmol) in DMSO (5 mL) was stirred at room temperature for 5 days under a 60 W light bulb. The reaction was then applied to a 2000 micron prep TLC plate (20×20 cm) and developed using ethyl acetate:hexanes 4:6. The desired band was extracted with MeOH, filtered and concentrated to provide the title Compound 469 (0.001 g). 1H-NMR (400 MHz, DMSO d6) δ (ppm) 7.71 (dd, J=1.01, 8.34 Hz, 1H) 7.53 (s, 4H) 7.37-7.41 (m, 1H) 7.21-7.28 (m, 2H) 7.11 (dt, J=1.26, 7.33 Hz, 1H) 7.05 (dd, J=1.52, 8.34 Hz, 1H), 6.94-7.10 (m, 4H) 6.67 (d, 12.6 Hz, 1H) 1.23 (s, 6H). MS (ESI, pos. ion) m/z: 423.2 (M+1).
    • Example 36 (E)-N-(2-{3-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-3H-benzimidazol-5-yl}-phenyl)-methanesulfonamide (Cpd 443) (E)-N-(2-{1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide (Cpd 477) Step A. (E)-5-bromo-1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole and (E)-6-bromo-1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole
  • To a solution of sodium hydride (60% suspension in oil, 0.131 g, 3.2 mmol) in anhydrous tetrahydrofuran (10 mL) was added Compound 10c (1 g, 2.7 mmol). The solution was stirred at room temperature under an argon atmosphere. After five minutes methyl iodide was added (0.205 mL, 3.2 mmol), and the solution was stirred at room temperature for 3 h. The reaction mixture was partitioned between ethyl acetate (10 mL) and ice water (20 mL). The organic fraction was washed with brine, dried over magnesium sulfate, then filtered and concentrated to give a 1:1 mixture of the title Compound 36a and 36b (0.38 g).
    • Step B. (E)-N-(2-{3-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-3H-benzimidazol-5-yl}-phenyl)-methanesulfonamide and (E)-N-(2-{1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide
  • Using the procedure of Example 1, Step B, the title compounds were prepared from a mixture of (E)-5-bromo-1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole and (E)-6-bromo-1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole and 2-methylsulfonylaminophenyl boronic acid.
  • Cpd 443: 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.82-7.80 (m, 3H) 7.75 (d, J=8.1 Hz, 3H) 7.52-7.62 (m, 3H) 7.34-7.42 (m, 4H) 4.00 (s, 3H) 2.76 (s, 3H). MS (ESI, pos. ion) m/z: 472.1 (M+1).
  • Cpd 477: 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.88-7.95 (m, 3H) 7.72-7.77 (m, 3H) 7.56-7.67 (m, 4H) 7.40-7.44 (m, 3H) 4.10 (s, 3H) 2.73 (s, 3H). MS (ESI, pos. ion) m/z: 472.1 (M+1).
    • Example 37 (E)-2-hydroxy-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone (Cpd 311) Step A. (E)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-5-[2-(1-trimethylsilanyloxy-vinyl)-phenyl]-1H-benzimidazole
  • To a solution of Compound 15 (0.20 g, 0.492 mmol) in 16 mL 1,2-dichloroethane was added TBSOTf (0.19 mL, 1.08 mmol) and Et3N (0.27 mL, 1.97 mmol) at 0° C. After 5 min., the mixture was warmed to 25° C. and stirred for 8 hours. The reaction was concentrated and the residue was purified by chromatography (silica gel, hexanes: EtOAc, 4:1) to provide the title Compound 37a as a colorless oil.
    • Step B. (E)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-5-[2-(2-trimethylsilanyloxy-oxiranyl)-phenyl]-1H-benzimidazole
  • A mixture of Compound 37a (0.124 g, 0.238 mmol) and mCPBA (0.053 g, 0.238 mmol) in 10 mL CH2Cl2 was stirred for two hours. The reaction was concentrated and the residue was purified by chromatography (silica gel, hexanes: EtOAc, 4:1) to provide the title Compound 37b as a yellow oil.
    • Step C. (E)-2-hydroxy-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone
  • A mixture of Compound 37b (0.026 g, 0.048 mmol) and p-toluenesulfonic acid monohydrate (p-TsOHH2O, 0.018 g, 0.0968 mmol) in 4 mL THF was stirred for four hours. The reaction was concentrated and the residue was purified by chromatography (silica gel, hexanes: EtOAc, 1:2) to provide the title Compound 311 as a brown solid. 1H-NMR (400 MHz, CD3OD) δ (ppm): 7.85 (d, 2H, J=8.8 Hz) 7.74 (d, 2H, J=7.6 Hz) 7.71 (d, 1H, J=16.4 Hz) 7.63-7.47 (m, 6H) 7.33 (d, 1H, J=16.0 Hz) 7.25 (dd, 1H, J=1.6 and 8.4 Hz) 4.08 (s, 2H) MS (ESI, pos. ion) m/z: 423.3 (M+1).
    • Example 38 2-(2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Cpd 501) Step A. (1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid ethyl ester
  • To a suspension of copper(I) trifluoromethanesulfonate toluene complex (31.0 mg, 0.12 mmol) in anhydrous CHCl3 (3.0 mL) was added a solution of 2,2-bis-[(4S)-(1,1-dimethylethyl)-1,3-oxazolin-2-yl]propane (35 mg, 0.12 mmol) in chloroform (1.2 mL). After stirring at ambient temperature for 1 h, the resulting green solution was filtered through glass wool under argon atmosphere into a flask previously charged with a solution of 4-(trifluoromethyl)-styrene (0.887 mL, 6.00 mmol) in chloroform (0.9 mL). To this solution was added a solution of ethyl diazoacetate (1.56 mL, 15.0 mmol) in chloroform (12.0 mL) at ambient temperature through a dropping funnel over a period of 6 h. The resulting mixture was stirred for 24 h, concentrated to dryness, and purified by flash chromatography on a silica gel column (45 mm×140 mm silica gel), eluting with ethyl acetate/hexane (1, 1.5, 2%) to provide the title Compound 38a (892 mg, 58% yield, 98% ee) as a colorless liquid, and cis isomer (1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid ethyl ester Compound 38b (128 mg, 5% yield calculated based on 34 wt % contamination of ethyl fumarate as analyzed by 1 NMR). The enantiomeric excess of the product was determined as described in Step E below.
  • 1H-NMR of Compound 38a (400 MHz, CDCl3) δ (ppm): 7.53 (d, 2H, J=8.3 Hz), 7.23 (d, 2H, J=8.1 Hz), 4.18 (q, 2H, J=7.1 Hz), 2.55 (dd, 1H, J=2.6, 4.3, & 6.6 Hz), 1.94 (ddd, 1H, J=4.3, 5.6, & 9.6 Hz), 1.68-1.53 (m, 1H), 1.34 (1H, ddd, 4.8, 6.7, & 1.1 Hz), 1.29 (t, 2H, J=7.0 Hz).
  • 1H-NMR of Compound 38b (400 MHz, CDCl3) δ (ppm): 7.51 (d, 2H, J=7.9 Hz), 7.37 (d, 2H, J=7.8 Hz), 3.92-3.86 (m, 2H), 2.62-2.56 (m, 1H), 2.14 (ddd, 1H, J=5.8, 8.1 & 9.3 Hz), 1.73 (td, 1H, J=5.3 & 7.6 Hz), 1.39 (ddd, 1H, J=5.1, 7.8 & 8.6 Hz), 0.99 (t, 3H, J=7.1 Hz).
    • Step B. (1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid
  • To a solution of Compound 38a (750 mg, 2.91 mmol) in ethanol (7.27 mL) was added a 1M aqueous solution of NaOH (7.27 mL). The resulting mixture was stirred at ambient temperature for 16 h, concentrated to about 4 g, acidified with 2M HCl to pH 3, and extracted with ethyl acetate (15 mL×2). The extracts were combined, washed with brine, dried over Na2SO4, concentrated to provide the title Compound 38c (611 mg, 91% yield) as a white solid. 1H-NMR (400 MHz, CDCl3 with a drop of CD3OD) δ (ppm): 7.51 (d, 2H, J=8.3 Hz), 7.18 (d, 2H, J=8.1 Hz), 2.57 (ddd, 1H, J=4.2, 6.6, & 10.3 Hz), 1.90 (ddd, 1H, J=4.0, 5.3, & 8.3 Hz), 1.65 (dt, 1H, J=4.9 & 9.3 Hz), 1.35 (ddd, 1H, J=4.9, 6.4, & 11.1 Hz).
    • Step C: 2-(2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol
  • Using the procedure of Example 10, Steps B and E, the title Compound 501 was prepared from Compound 38c. 1H-NMR (400 MHz, DMSO-d6) δ (ppm): 12.40 (s, 0.5 H), 12.32 (s, 0.5 H), 7.87-7.84 (m, 1H), 7.66 (d, 2H, J=8.0 Hz), 7.49-7.17 (m, 6H), 7.00-6.96 (m, 2H), 4.84 (s, 1H), 2.72-2.67 (m, 1H), 2.50-2.46 (m, 1H), 1.92-1.86 (m, 1H), 1.74-1.68 (m, 1H), 1.19 (s, 3H), 1.18 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd for C26H24F3N2O: 437.2. Found 437.3.
    • Step D: (1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid methoxy-methyl-amide
  • To a mixture of Compound 38c (50 mg, 0.216 mmol), N,O-dimethylhydroxylamine hydrochloride (30 mg, 0.30 mmol), BOP (134 mg, 0.30 mmol), and DMF (0.4 mL) was added DIEA (0.15 mL). The resulting mixture was stirred at ambient temperature for 48 h, concentrated to dryness, and partitioned between saturated NaHCO3 (2 mL) and ethyl acetate (4 mL). The ethyl acetate layer was separated, and the aqueous layer was extracted with ethyl acetate (5 mL×2). All ethyl acetate layers were combined, washed with brine, dried over Na2SO4, concentrated, and purified by prep-TLC, developed with 10% ethyl acetate/DCM to provide Compound 38d (46 mg, 78% yield) as a white solid. 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.52 (d, 2H, J=8.4 Hz), 7.23 (d, 2H, J=8.1 Hz), 3.70 (s, 3H), 3.24 (s, 3H), 2.56-2.52 (m, 1H), 2.45 (bs, 1H), 2.17-1.67 (m, 1H), 1.34 (ddd, 1H, J=4.6, 6.3, & 8.7 Hz).
    • Step E: Determination of ee
  • To a solution of Compound 38d (0.8 mg) in CDCl3 (0.6 mL) was added (R)-(−)-2,2,2-trifluoro-1-(9-anthryl)ethanol portion-wise and the amount of addition was monitored by 1HNMR until base line resolution of the resulting methoxy singlets was achieved. Thus, the enantiomer methoxy singlets were around 3.47 and 3.45 ppm. The integration of these singlets was 99 and 1, respectively; thus providing an ee value of 99%.
  • Using the procedure described in Example 38 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:
  • Cpd Name and Data
    502 2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-
    5-yl}-benzenesulfonamide
    Using the procedure of Example 38, the title compound was prepared from
    Compound 38c and 2-(t-butylamino)sulfonylphenyl boronic acid.
    1H-NMR (400 MHz, CDCl3) δ (ppm): 12.42 (s, 0.5H), 12.40 (s, 0.5H), 8.04 (dd,
    1H, J = 1.3 & 7.8 Hz), 7.66 (d, 2H, J = 8.3 Hz), 7.63-7.34 (m, 7H), 7.17-7.11 (m,
    1H), 7.06 (s, 1H), 7.03 (s, 1H), 2.71-2.65 (m, 1H), 2.50-2.46 (m, 1H),
    1.92-1.87 (m, 1H), 1.75-1.70 (m, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd for
    C23H19F3N3O2S: 458.1 (M + 1). Found 458.2.
    503 2-(2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-
    benzimidazol-5-yl}-phenyl)-propan-2-ol monosodium salt
    Using the procedure of Example 38, the title compound was prepared from 2,2-
    bis-[(4R)-(1,1-dimethylethyl)-1,3-oxazolin-2-yl]propane and 4-(trifluoromethyl)-
    styrene.
    To a suspension of N,N′-bis-[(2R)-3,3-dimethyl-1-hydroxybutyl]-2,2-dimethyl-
    1,3-propanediamide (83 mg, 0.25 mmol, prepared according to the procedure
    described in J. Am. Chem. Soc. 1991, 113, 726) in DCM (2.5 mL) was added
    (diethylamino)sulfur trifluoride (0.066 mL, 0.50 mmol, as described in J. Org.
    Chem. 2002, 67, 8566 for the formation of oxazoline from hydroxyamide)
    dropwise at ambient temperature. The resulting mixture was stirred at ambient
    temperature for 16 h, and poured into saturated NaHCO3 (4.0 mL). The mixture
    was extracted with DCM (3 × 5 mL). The extracts were combined and dried
    over Na2SO4, then concentrated and flash chromatographed with ethyl acetate/
    DCM (0, 5, 10, and 20%) to provide 2,2-bis-[2-((4R)-(1,1-dimethylethyl)-1,3-
    oxazolinyl)]propane (53 mg, 72% yield) as a white solid. 1H-NMR was identical
    to the literature as reported by Evans.
    1H-NMR (400 MHz, DMSO-d6) δ (ppm): 7.82 (dd, 1H, J = 1.5 & 8.1 Hz),
    7.61 (d, 2H, J = 8.1 Hz), 7.37 (d, 2H, J = 8.1 Hz), 7.24 (dt, 1H, J = 1.8 & 7.3 Hz),
    7.15-7.11 (m, 2H), 7.00 (d, 1H, J = 1.5 Hz), 6.98 (dd, 1H, J = 1.5 & 7.3 Hz),
    6.52 (d, 1H, J = 7.8 Hz), 4.63 (bs, 1H), 2.52-2.47 (m, 1H), 2.33 (ddd, 1H, J = 4.1, 5.8
    & 8.8 Hz), 1.75 (ddd, 1H, J = 3.7, 5.8, & 8.8 Hz), 1.45-1.40 (m, 1H), 1.22 (s, 6H).
    Mass Spectrum (LCMS, ESI pos.) Calcd for C26H24F3N2O: 437.2. Found 437.2.
    Analogous to Example 38, step A, both the trans isomer (1S,2S)-2-(4-
    trifluoromethyl-phenyl)-cyclopropanecarboxylic acid ethyl ester Compound 38e
    and the cis isomer (1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic
    acid ethyl ester Compound 38f were isolated.
    504 2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-
    5-yl}-benzenesulfonamide
    Using the procedure described for Compound 503, the title compound was
    prepared from Compound 38e, 4-(trifluoromethyl)-styrene and 2-(t-
    butylamino)sulfonylphenyl boronic acid.
    1H-NMR (400 MHz, DMSO-d6) δ (ppm): 12.41 (s, 0.5H), 12.40 (s, 0.5H),
    8.04 (dd, 1H, J = 1.3 & 7.8 Hz), 7.66 (d, 2H, J = 8.3 Hz), 7.63-7.34 (m, 7H),
    7.17-7.11 (m, 1H), 7.06 (s, 1H), 7.03 (s, 1H), 2.71-2.65 (m, 1H), 2.50-2.46 (m, 1H),
    1.92-1.87 (m, 1H), 1.75-1.70 (m, 1H). MS (ESI, pos. ion) m/z: 458.2 (M + 1). Mass
    Spectrum (LCMS, ESI pos.) Calcd for C23H19F3N3O2S: 458.1 (M + 1). Found
    458.2.
    505 2-(2-{2-[(1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-
    benzimidazol-5-yl}-phenyl)-propan-2-ol
    Using the procedure described for Compound 503, the title compound was
    prepared from Compound 38f.
    1H-NMR (400 MHz, CD3OD) δ (ppm): 7.79 (dd, 1H, J = 1.0 & 8.1 Hz),
    7.36-7.15 (m, 8H), 7.01 (t, 1H, J = 1.5 Hz), 6.99 (d, 1H, J = 1.5 Hz), 2.83-2.73 (m, 2H),
    2.08-2.03 (m, 1H), 1.71 (td, 1H, J = 8.6 & 5.6 Hz), 1.23 (s, 3H), 1.22 (s, 3H).
    Mass Spectrum (LCMS, ESI pos.) Calcd for C26H24F3N2O: 437.2. Found 437.3.
    Determination of ee: To a mixture of (1S,2R)-2-(4-trifluoromethyl-phenyl)-
    cyclopropanecarboxylic acid (14 mg, 0.0.061 mmol), (S)-(−)-α-
    methylbenzylamine (10.0 mg, 0.0609 mmol), BOP (27 mg, 0.0609 mmol), and
    DMF (0.2 mL) was added DIEA (0.023 mL, 0.13 mmol). The resulting solution
    was stirred at room temperature for 48 h, concentrated to dryness, and
    partitioned between saturated NaHCO3 (1 mL) and ethyl acetate (3 mL). Ethyl
    acetate layer was separated, and aqueous was extracted with ethyl acetate (5 mL × 2).
    All ethyl acetate layers were combined, washed with brine, dried over
    Na2SO4, concentrated, and purified by prep-TLC, developed with 10% ethyl
    acetate/DCM to give the title compound (10.1 mg, 70% yield) as a white solid.
    1H-NMR (400 MHz, C6D6) δ (ppm): 7.26 (d, 2H, J = 8.1 Hz), 7.03-6.95 (m, 5H),
    6.68-6.65 (m, 2H), 4.96-4.89 (m, 1H), 4.79 (bd, 1H, J = 7.6 Hz), 1.80-1.73 (m,
    2H), 1.23-1.17 (m, 1H), 1.00 (d, 3H, J = 6.8 Hz), 0.82-0.79 (m, 1H).). In the
    1H-NMR doublet of the Me in (1R, 2S, 1′S)-N-(1′-phenethyl)-2-(4-trifluoromethyl-
    phenyl)-cyclopropanecarboxamide appeared at 0.85 ppm. Integration of this
    methyl doublet and that of the title compound was 2.5 and 97.5, respectively.
    506 2-{2-[(1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-
    5-yl}-benzenesulfonamide
    Using the procedure of Example 38, the title compound was prepared from
    Compound 38b and 2-(t-butylamino)sulfonylphenyl boronic acid.
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.09 (dd, 1H, J = 1.3 & 7.9 Hz), 7.59 (dt,
    1H, J = 1.6 & 7.6 Hz), 7.51 (dt, 1H, J = 1.5 & 7.8 Hz), 7.47 (bs, 1H),
    7.42-7.29 (m, 6H), 7.19 (dd, 1H, J = 1.7 & 8.3 Hz), 2.84-2.74 (m, 2H), 2.05 (q, 1H, J = 6.3 Hz),
    1.72 (td, 1H, J = 8.5 & 5.7 Hz). Mass Spectrum (LCMS, ESI pos.) Calcd for
    C23H19F3N3O2S: 458.1 (M + 1). Found 458.2.
    507 2-(2-{2-[(1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-
    benzimidazol-5-yl}-phenyl)-propan-2-ol
    Using the procedure of Example 38, the title compound was prepared using
    Compound 38b.
    1H-NMR (400 MHz, CD3OD) δ (ppm): 7.79 (dd, 1H, J = 1.0 & 8.1 Hz),
    7.36-7.15 (m, 8H), 7.01 (t, 1H, J = 1.5 Hz), 6.99 (d, 1H, J = 1.5 Hz), 2.83-2.73 (m, 2H),
    2.08-2.03 (m, 1H), 1.71 (td, 1H, J = 8.6 & 5.6 Hz), 1.23 (s, 3H), 1.22 (s, 3H).
    Mass Spectrum (LCMS, ESI pos.) Calcd for C26H24F3N2O: 437.2. Found 437.3.
    Determination of ee: Using the procedure described for Compound 506, the
    amide intermediate of Compound 507 was prepared from (1R,2S)-2-(4-
    trifluoromethyl-phenyl)-cyclopropanecarboxylic acid Compound 38 g and (S)-(−)-
    α-methylbenzylamine.
    1H-NMR (400 MHz, C6D6) δ (ppm): 7.37 (d, 2H, J = 8.1 Hz), 7.35-7.02 (m, 5H),
    6.97-6.95 (m, 2H), 4.95-4.88 (m, 1H), 4.82 (bd, 1H, J = 7.8 Hz), 1.81-1.75 (m,
    1H), 1.70 (ddd, 1H, J = 4.8, 5.8 & 7.3 Hz), 1.14 (ddd, 1H, J = 5.6, 7.8 & 9.0 Hz),
    0.85 (d, 3H, J = 6.6 Hz), 0.80-0.75 (m, 1H).
    In the 1H-NMR doublet of the Me in (1S, 2R, 1′S)-N-(1′-phenethyl)-2-(4-
    trifluoromethyl-phenyl)-cyclopropanecarboxamide appeared at 1.00 ppm.
    Integration of this methyl doublet and that of the title compound was 3 and 97,
    respectively.
    508 2-{2-[(1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-
    5-yl}-benzenesulfonamide
    Using the procedure described for Compound 503, the title compound was
    prepared from Compound 38f and 2-(t-butylamino)sulfonylphenyl boronic acid.
    1H-NMR (400 MHz, CD3OD) δ (ppm): 8.09 (dd, 1H, J = 1.3 & 7.9 Hz), 7.59 (dt,
    1H, J = 1.6 & 7.6 Hz), 7.51 (dt, 1H, J = 1.5 & 7.8 Hz), 7.47 (bs, 1H),
    7.42-7.29 (m, 6H), 7.19 (dd, 1H, J = 1.7 & 8.3 Hz), 2.84-2.74 (m, 2H), 2.05 (q, 1H, J = 6.3 Hz),
    1.72 (td, 1H, J = 8.5 & 5.7 Hz). Mass Spectrum (LCMS, ESI pos.) Calcd for
    C23H19F3N3O2S: 458.1 (M + 1). Found 458.2.
    • BIOLOGICAL EXAMPLES Example 1 Human VR1 (hVR1) Binding Assay
  • Compounds of the present invention were tested for their ability to inhibit the binding of [3H] RTX to hVR1 receptors in a [3H] RTX binding assay as previously described (Zhang, Sui-Po. Improved ligand binding assays for vanilloid receptors. PCT Int. Appl. (2002), WO 0233411 A1 20020425 AN 2002:315209, and Elfrida G. R. et al., J. Pharmacol. Exp. Ther., 2002, 300(1): 9-17.)
  • HEK293 cells were transfected with hVR1 vanilloid receptors and washed with Hank's balanced Salt Solution, dissociated with cell dissociation buffer (Sigma), and then centrifuged at 1000×g for 5 min. Cell pellets were homogenized in cold 20 mM HEPES buffer (pH=7.4), containing 5.8 mM NaCl, 320 mM sucrose, 2 mM MgCl2, 0.75 CaCl2 and 5 mM KCl and centrifuged at 1000×g for 15 min. The resultant supernatant was then centrifuged at 40,000×g for 15 min. The pelleted membranes were stored in a freezer at −80° C.
  • Approximately 120 μg protein/ml from membranes were incubated with indicated concentrations of [3H]RTX in 0.5 ml of the HEPES buffer (pH 7.4) containing 0.25 mg/mL fatty acid-free bovine serum albumin at 37° C. for 60 min. The reaction mixture was then cooled to 4° C., and 0.1 mg of a, acid glycoprotein was added to each sample, which was then incubated at 4° C. for 15 min. The samples were centrifuged at 18,500×g for 15 min. The tip of the microcentrifuge tube containing the pellet was cut off. Bound radioactivity was quantified by scintillation counting. Non-specific binding was measured in the presence of 200 nM unlabeled RTX.
  • Data were calculated according to the equation:

  • % inhibition=100%×[(total binding-binding)/(total binding-non specific binding)]
  • Ki values were calculated using a Prism program.
  • TABLE 1
    Cpd Ki (nM)
    1 9.7
    3 20
    4 31
    5 17
    9 0.9
    14 380
    15 41
    17 8.7
    18 6.5
    27 1800
    32 100
    36 820
    40 81
    50 16
    51 6.4
    56 120
    69 6
    70 8.6
    71 22
    78 6.4
    79 18
    310 10
    312 19
    319 6
    407 5.7
    434 39
    • Example 2 Human VR1 (hVR1) Functional Assay
  • The functional activity of the test compounds was determined by measuring changes in intracellular calcium concentration using a Ca++-sensitive fluorescent dye and FLIPR™ technology. Increases in Ca++ concentration were readily detected upon challenge with capsaicin.
  • HEK293 cells expressing hVR1 were grown on poly-D-lysine coated 384 well black-walled plates (BD 354663) and 1 day later loaded with Calcium 3 Dye for 35 min at 37° C., 5% CO2 and then for 25 min at room temperature, and subsequently tested for agonist-induced increases in intracellular Ca2+ levels using FLIPR™ technology. Cells were challenged with test compounds (at varying concentrations) and intracellular Ca2+ was measured for 5 min prior to the addition of capsaicin to all wells to achieve a final concentration of 0.030 μM eliciting about 80% maximal response. IC50 values were determined from concentration-response studies, which were generated using the average of quadruplicate wells for each data point.
  • For those compounds tested, an IC50 (nM) value and percent inhibition value is shown in Table 2. Except where indicated, the percent inhibition values were obtained at a test concentration of 1 μM; otherwise: (1)the test concentration was 5 μM. The percent inhibition value is provided for those compounds where an IC50 value was not obtained. The term “NA” means that the data is “not available” because it was not obtained for a particular compound.
  • TABLE 2
    Cpd % Inh IC50
    1 100 27
    2 100 12
    3 NA 140
    4 78 400
    5 100 71
    6 12 NA
    7 10 NA
    8 10 NA
    9 99 2
    10 94 280
    11 100 210
    12 100 10
    13 82 310
    14 49 1000
    15 100 120
    16 100 45
    17 100 8
    18 100 4
    19 32 NA
    20 NA 320
    22 NA 18
    24 8 NA
    25 4 NA
    26 6 NA
    27 100 260
    28 96 250
    29 6 NA
    30 10 NA
    31 NA 13
    32 77 380
    33 NA 1700
    34 (1)75 NA
    35 100 41
    36 44 NA
    37 18 NA
    38 89 270
    39 98 200
    40 99 54
    41 90 280
    42 100 22
    43 58 890
    44 95 300
    45 100 16
    46 100 46
    47 100 20
    48 33 NA
    49 16 NA
    50 100 100
    51 100 66
    52 28 NA
    53 98 47
    54 20 NA
    55 14 NA
    56 100 110
    57 15 NA
    58 87 95
    59 80 440
    60 7 NA
    61 100 75
    62 100 200
    63 97 260
    64 41 NA
    65 0 NA
    66 98 48
    67 98 130
    68 NA 329
    69 98 6
    70 100 7
    71 99 22
    77 100 76
    78 99 5
    79 100 7
    83 NA >500
    84 100 40
    85 16 NA
    95 81 301
    101 NA >500
    113 48 NA
    114 99 3
    129 96 34
    130 100 6
    131 96 31
    139 98 31
    145 19 NA
    175 100 16
    190 94 38
    198 95 10
    234 7 NA
    250 98 19
    294 101 9.1
    295 100 16
    309 73 NA
    310 100 6
    311 99 54
    312 100 6
    314 100 18
    315 100 11
    316 101 12
    317 101 11
    318 100 50
    319 100 10
    320 100 13
    321 100 18
    322 101 14
    323 97 40
    324 98 33
    325 73 NA
    326 89 157
    327 77 343
    328 99 35
    329 98 27
    330 85 131
    331 97 43
    332 98 49
    333 98 27
    334 94 178
    335 100 47
    336 89 240
    337 96 14
    338 96 104
    339 99 27
    340 98 62
    341 99 6
    342 98 24
    343 82 243
    344 101 24
    345 101 13
    346 87 264
    347 100 44
    348 86 162
    349 99 59
    350 100 33
    351 NA >500
    357 100 8
    358 99 9
    359 98 24
    360 98 46
    361 97 27
    362 99 8
    363 98 12
    364 97 65
    365 99 17
    366 99 35
    367 98 53
    368 99 15
    369 99 8
    370 98 13
    371 98 18
    372 97 71
    373 99 20
    374 99 34
    375 97 139
    376 100 28
    378 100 12
    379 99 40
    380 99 12
    383 96 11
    384 98 7
    385 97 21
    386 96 43
    387 98 41
    388 99 54
    389 23 NA
    390 96 7
    391 95 8
    392 97 10
    393 98 10
    394 98 6
    395 99 15
    396 99 13
    397 99 23
    398 97 3
    399 97 3
    402 93 38
    404 94 47
    405 95 20
    406 97 170
    407 96 9
    408 64 NA
    409 43 NA
    410 91 156
    411 85 350
    412 86 190
    413 82 240
    414 98 140
    415 95 150
    416 96 120
    417 100 11
    418 100 18
    419 93 32
    420 93 15
    421 95 10
    422 98 7
    423 99 11
    424 99 11
    425 2 NA
    426 99 22
    427 98 13
    428 100 7
    429 98 6
    430 100 9
    431 97 35
    432 98 15
    433 98 10
    434 98 7
    435 97 20
    436 96 10
    437 97 24
    438 96 71
    439 97 23
    440 98 40
    441 40 NA
    442 96 4
    444 98 28
    445 96 20
    446 97 76
    447 98 44
    448 99 17
    449 100 9
    450 27 NA
    451 101 28
    452 5 NA
    453 22 NA
    454 36 NA
    455 100 17
    456 100 45
    457 22 NA
    458 15 NA
    459 0 NA
    460 21 NA
    461 99 5
    462 98 97
    463 100 14
    464 100 3
    465 75 363
    466 98 71
    467 86 182
    468 97 8
    469 99 7
    470 97 45
    471 100 10
    472 NA >500
    473 NA >500
    474 NA >500
    475 NA 77
    476 NA 68
    477 44 NA
    478 NA >500
    479 12 NA
    480 NA >500
    481 42 NA
    482 100 13
    483 21 NA
    484 NA >500
    485 NA >500
    486 NA >500
    487 20 NA
    488 4 NA
    489 96 2
    490 99 26
    491 NA 77
    492 99 5
    494 93 52
    497 94 39
    498 100 19
    499 7 NA
    500 97 19
    501 99 85
    502 82 190
    503 93 10
    504 95 22
    • Example 3 Chemically-Induced Models of Inflammatory Pain
  • Compounds of the present invention were tested in animal models of inflammation and inflammatory pain. To assess the ability of test compounds to reverse thermal hyperalgesia, baseline response latencies on a radiant heat (RH) paw stimulator were obtained before an intraplantar injection of 100 μL (1 μg/μL) CFA (1:1 CFA:saline) in male Sprague-Dawley rats. Only withdrawal responses that were quick hind paw movements (with or without licking of the hind paw) were recorded. Paw movements associated with locomotion or a shifting of weight were not considered a withdrawal response. The stimulus intensity that produced 10-15 sec baseline withdrawal latencies was used and a maximum cutoff of 20 sec was imposed. Hypersensitivity was evaluated 24 hr after CFA. Only rats that exhibited at least a 25% reduction in response latency from baseline (i.e. hyperalgesia) were included in further analysis.
  • Following the post-inflammogen latency assessment, rats were orally dosed (2.5 mL/kg) with test compound (10 mg/kg) or vehicle (20% hydroxypropyl beta cyclodextran). To determine the time of peak effect, latencies were redetermined 30, 60, 100, 180 and 300 min after compound administration.
  • Data are presented as the maximal percent reversal of hypersensitivity obtained during the 300 min test, which was calculated for each animal according to the formula:

  • % reversal=100%×(treatment response−post-inflammogen response)/(pre-inflammogen response−post-inflammogen response)
  • TABLE 3
    Cpd % Reversal
    17 104
    18 133
    22 18
    23 31
    31 72
    47 58
    70 76
    78 19
    114 56
    310 23
    464 65
    • Example 4 Incision-Induced Model of Postoperative Surgery
  • Compounds of the present invention were tested in animal models of postoperative surgery, as previously described (Brennan, T. J. et al., Pain, 1996, 64: 493-501). Male Sprague-Dawley rats were anaesthetized with 2-3 isoflurane and the plantar surface of the hindpaw was sterilized using three alternating betadine and alcohol scrubs. A 1 cm longitudinal incision through the skin of the plantar paw was made using a number 10 scalpel beginning 0.5 cm from the proximal heel and extending toward the toes. The plantaris muscle was excised using a forcep and incised longitudinally. The skin was then sutured in two locations using 5-0 silk. The wound site was then covered with antibiotic ointment and the animals were returned to their individual home cages. Changes in thermal sensitivity were evaluated before surgery and 24 hr after surgery. Vehicle (20% HPβCD) or test compound was orally administered and thermal sensitivity was re-assessed 30, 60, 100, 180 and 300 min later.
  • Data are presented as the maximal percent reversal of hypersensitivity obtained during the 300 min test, which was calculated for each animal according to the formula:

  • % reversal=100% (treatment response−post-inflammogen response)/(pre-inflammogen response−post-inflammogen response)
  • TABLE 4
    Cpd % Reversal
    18 132
  • While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the usual variations, adaptations and/or modifications as come within the scope of the following claims and their equivalents.
  • All publications disclosed in the above specification are hereby incorporated by reference in full.

Claims (5)

1-14. (canceled)
15. A method for treating a VR1 ion channel mediated disease in a subject in need thereof comprising administering to the subject an effective amount of the compound of claim Formula (I):
Figure US20110190364A1-20110804-C00210
and a salt, stereoisomer, tautomer or ester thereof, wherein:
the dashed lines between positions 1, 2 and 3 in Formula (I) indicate the positions of a tautomeric double bond,
wherein when a double bond is formed between positions 1 and 2, then R3b is present, and
wherein, when a double bond is formed between postions 2 and 3, then R3a is present;
p is 1 or 2;
q is 0 or 1;
r is 0, 1, 2 or 3;
L is C1-3alkyl, C2-3alkenyl, C2-3alkynyl or cyclopropyl;
A1 is selected from the group consisting of phenyl, biphenyl, naphthyl, pyridinyl, quinolinyl and indole;
R1 is each selected from the group consisting of hydroxy, cyano, halogen, formyl, carboxy, C1-6alkyl, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, C1-6alkylcarbonyl, C1-6alkoxycarbonyl, C1-6alkylthio, C1-6alkylsulfonyl, C3-8cycloalkyl, C3-8cycloalkyl-C1-4alkyl, C3-8cycloalkyl-C1-4alkoxy, C3-8cycloalkyl-oxy, amino, (C1-6alkyl)1-2-amino, (C3-8cycloalkyl)1-2-amino, (C3-8cycloalkyl-C1-4alkyl)1-2-amino, aminocarbonyl, (C1-6alkyl)1-2-aminocarbonyl, C1-6alkylcarbonylamino, C1-6alkoxycarbonylamino, aminocarbonylamino, (C1-6alkyl)1-2-aminocarbonylamino, C1-6alkylsulfonylamino, C1-6alkylsulfinylamino, aminosulfonyl, (C1-4alkyl)1-2-aminosulfonyl, aminosulfonylamino and (C1-6alkyl)1-2-aminosulfonylamino,
wherein alkyl is optionally substituted with C1-8alkoxy, amino, (C1-4alkyl)1-2-amino, C1-6alkylcarbonylamino, C1-6alkoxycarbonylamino, aminocarbonylamino, (C1-6alkyl)1-2-aminocarbonylamino, C1-6alkylsulfonylamino, aminosulfonylamino, (C1-6alkyl)1-2-aminosulfonylamino hydroxy and phenyl,
wherein phenyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halogen, cyano, nitro, C1-6alkyl, C1-6alkoxy, C1-6alkylthio and C1-6alkylsulfonyl, and
wherein, each instance of alkyl and alkoxy is optionally perfluorinated;
R2 is selected from the group consisting of halogen, C1-4alkyl, C1-4alkoxy, C1-4alkylsulfonyl, nitro, amino, (C1-4alkyl)1-2-amino and cyano,
wherein each instance of alkyl and alkoxy is optionally perfluorinated;
R3a and R3b are each selected from the group consisting of hydrogen and optionally perfluorinated C1-4alkyl; and
R4 is each selected from the group consisting of halogen, nitro, cyano, carboxy, C1-6alkyl, C1-6alkoxy, haloC1-6alkyl, haloC1-6alkoxy, C1-6alkoxy-C1-6alkyl, C1-6alkylcarbonyl, C1-6alkylthio, haloC1-6alkylthio, C1-6alkylsulfonyl, haloC1-6alkylsulfonyl, C3-8cycloalkyl, C3-8cycloalkyl-C1-4alkyl, C3-8cycloalkyl-C1-4alkoxy, C3-8cycloalkyl-oxy, amino, (C1-6alkyl)1-2-amino, (C3-8cycloalkyl)1-2-amino, (C3-8cycloalkyl-C1-4alkyl)1-2-amino, aminocarbonyl, (C1-6alkyl)1-2-aminocarbonyl, C1-6alkylcarbonylamino, C1-6alkoxycarbonylamino, aminocarbonylamino, (C1-6alkyl)1-2-aminocarbonylamino, C1-6alkylsulfonylamino, haloC1-6alkylsulfonylamino, C1-6alkylsulfinylamino, aminosulfonyl and (C1-4alkyl)1-2-aminosulfonyl,
wherein each instance of alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of C1-8alkoxy, amino, (C1-4alkyl)1-2-amino, C1-6alkylcarbonylamino, C1-6alkoxycarbonylamino, aminocarbonylamino, (C1-6alkyl)1-2-aminocarbonylamino, C1-6alkylsulfonylamino, oxo and hydroxy, and
wherein, each instance of alkyl and alkoxy is optionally perfluorinated.
16. The method of claim 15, wherein the VR1 ion channel mediated disease is chronic or acute pain due to disease that causes inflammatory pain, burning pain or post-operative pain.
17. The method of claim 15, wherein the effective amount of the compound of claim 1 is in a range of from about 0.001 mg/kg/day to about 300 mg/kg/day.
18-20. (canceled)
US13/084,718 2006-05-03 2011-04-12 Benzimidazole modulators of vr1 Abandoned US20110190364A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/084,718 US20110190364A1 (en) 2006-05-03 2011-04-12 Benzimidazole modulators of vr1

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79750406P 2006-05-03 2006-05-03
US11/734,984 US7951829B2 (en) 2006-05-03 2007-04-13 Benzimidazole modulators of VR1
US13/084,718 US20110190364A1 (en) 2006-05-03 2011-04-12 Benzimidazole modulators of vr1

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/734,984 Division US7951829B2 (en) 2006-05-03 2007-04-13 Benzimidazole modulators of VR1

Publications (1)

Publication Number Publication Date
US20110190364A1 true US20110190364A1 (en) 2011-08-04

Family

ID=38566108

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/734,984 Active 2028-12-02 US7951829B2 (en) 2006-05-03 2007-04-13 Benzimidazole modulators of VR1
US13/084,705 Abandoned US20110190344A1 (en) 2006-05-03 2011-04-12 Benzimidazole modulators of vr1
US13/084,718 Abandoned US20110190364A1 (en) 2006-05-03 2011-04-12 Benzimidazole modulators of vr1

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US11/734,984 Active 2028-12-02 US7951829B2 (en) 2006-05-03 2007-04-13 Benzimidazole modulators of VR1
US13/084,705 Abandoned US20110190344A1 (en) 2006-05-03 2011-04-12 Benzimidazole modulators of vr1

Country Status (37)

Country Link
US (3) US7951829B2 (en)
EP (1) EP2021330B1 (en)
JP (1) JP5302884B2 (en)
KR (1) KR101434883B1 (en)
CN (1) CN101511797B (en)
AR (1) AR060840A1 (en)
AT (1) ATE482201T1 (en)
AU (1) AU2007248341C1 (en)
BR (1) BRPI0709803B8 (en)
CA (1) CA2651128C (en)
CO (1) CO6160329A2 (en)
CR (1) CR10479A (en)
CY (1) CY1111269T1 (en)
DE (1) DE602007009378D1 (en)
DK (1) DK2021330T3 (en)
EA (1) EA019386B1 (en)
EC (1) ECSP088854A (en)
ES (1) ES2350959T3 (en)
HK (1) HK1131971A1 (en)
HR (1) HRP20100700T1 (en)
IL (1) IL194916A (en)
JO (1) JO3602B1 (en)
MX (1) MX2008014108A (en)
MY (1) MY154595A (en)
NI (1) NI200800290A (en)
NO (1) NO341965B1 (en)
NZ (1) NZ572251A (en)
PE (1) PE20080065A1 (en)
PL (1) PL2021330T3 (en)
PT (1) PT2021330E (en)
RS (1) RS51473B (en)
SI (1) SI2021330T1 (en)
TW (1) TWI419882B (en)
UA (1) UA94749C2 (en)
UY (1) UY30322A1 (en)
WO (1) WO2007130780A2 (en)
ZA (1) ZA200810234B (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9457027B2 (en) * 2011-05-16 2016-10-04 Cellceutix Corporation Compounds for use in treatment of mucostis
US10166232B2 (en) 2006-12-29 2019-01-01 Innovation Pharmaceuticals Inc. Arylamide compounds and compositions and uses thereof
WO2019213470A1 (en) * 2018-05-03 2019-11-07 Eternity Bioscience Inc. Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (rorϒ) and pharmaceutical uses thereof
CN112745268A (en) * 2019-10-31 2021-05-04 江苏恒瑞医药股份有限公司 Crystal form of benzimidazole derivative and preparation method thereof
RU2789059C2 (en) * 2018-05-03 2023-01-27 Цзянсу Хэнжуй Медицин Ко., Лтд. BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (RORγ) AND THEIR PHARMACEUTICAL USE
US11771694B2 (en) 2020-06-05 2023-10-03 Innovation Pharmaceuticals Inc. Arylamide compounds for treatment and prevention of viral infections

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ598485A (en) * 2006-12-15 2013-08-30 Janssen Pharmaceutica Nv Benzimidazole trpv1 inhibitors
PE20091102A1 (en) * 2007-12-17 2009-07-25 Janssen Pharmaceutica Nv IMIDAZOLO-, OXAZOLO-, AND THIAZOLOPYRIMIDINE MODULATORS OF TRPV1
WO2009079000A1 (en) * 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Imidazolopyrimidine modulators of trpv1
CA2719515C (en) * 2008-04-18 2013-11-05 Daewoong Pharmaceutical Co., Ltd. A novel benzoxazine benzimidazole derivative, a pharmaceutical composition comprising the same, and a use thereof
US8232409B2 (en) 2008-10-15 2012-07-31 Janssen Pharmaceutica N.V. Heterocyclic benzimidazoles as TRPM8 modulators
US8217060B2 (en) * 2009-05-15 2012-07-10 Janssen Pharmaceutica, Nv Benzimidazole derivatives useful as TRP M8 receptor modulators
US8323805B2 (en) * 2009-06-04 2012-12-04 Nitto Denko Corporation Emissive aryl-heteroaryl acetylenes
CN102002010A (en) * 2009-08-31 2011-04-06 住友化学株式会社 Method for refining bioxazoline alkane compound
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
WO2014143638A1 (en) 2013-03-14 2014-09-18 Novartis Ag 2-(1h-indol-4-ylmethyl)-3h-imidazo[4,5-b]pyridine-6-carbonitrile derivatives as complement factor b inhibitors useful for the treatment of ophthalmic diseases
CN105517999B (en) 2013-07-11 2019-06-28 百时美施贵宝公司 IDO inhibitor
US9676728B2 (en) 2013-10-30 2017-06-13 Novartis Ag 2-benzyl-benzimidazole complement factor B inhibitors and uses thereof
CN108026071A (en) * 2015-09-08 2018-05-11 住友化学株式会社 The method for preparing triazole compounds
EP3534888B1 (en) * 2016-11-01 2022-04-06 Merck Sharp & Dohme Corp. Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors
CN108997398B (en) * 2018-07-23 2020-12-15 被忽略疾病药物研发组织 Preparation method of 3, 3-dimethylbenzo [ C ] [1,2] oxapentaborane-1 (3H) -alcohol
CA3156332A1 (en) * 2019-10-31 2021-05-06 Jiangsu Hengrui Medicine Co., Ltd. Acid addition salt of ror.gamma. regulator

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
US6299796B1 (en) 1997-12-18 2001-10-09 Fuji Photo Film Co., Ltd. Styryl compound, method for the preparation thereof and electroluminescent element employing the same
US6748803B1 (en) * 2000-02-22 2004-06-15 Simmonds Precison Products, Inc. Liquid measurement system and shared interface apparatus for use therein
JP2006505570A (en) * 2002-10-17 2006-02-16 アムジエン・インコーポレーテツド Benzimidazole derivatives and their use as vanilloid receptor ligands
TW200418806A (en) * 2003-01-13 2004-10-01 Fujisawa Pharmaceutical Co HDAC inhibitor
SG130192A1 (en) * 2003-07-28 2007-03-20 Janssen Pharmaceutica Nv Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators
CA2543918A1 (en) * 2003-10-28 2005-05-12 Dean Wilson Benzimidazoles useful as modulators of ion channels
WO2006058338A2 (en) * 2004-11-29 2006-06-01 Janssen Pharmaceutica N.V. 4 - piperidinecarboxamide derivatives as modulators of vanilloid vr1 receptor
SI2081572T1 (en) * 2006-07-04 2010-06-30 Janssen Pharmaceutica Nv Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group
NZ598485A (en) * 2006-12-15 2013-08-30 Janssen Pharmaceutica Nv Benzimidazole trpv1 inhibitors

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10166232B2 (en) 2006-12-29 2019-01-01 Innovation Pharmaceuticals Inc. Arylamide compounds and compositions and uses thereof
US9457027B2 (en) * 2011-05-16 2016-10-04 Cellceutix Corporation Compounds for use in treatment of mucostis
US9795575B2 (en) 2011-05-16 2017-10-24 Innovation Pharmaceuticals Inc. Compounds for use in treatment of mucositis
US10206894B2 (en) 2011-05-16 2019-02-19 Innovation Pharmaceuticals Inc. Compounds for use in treatment of mucositis
US10603294B2 (en) 2011-05-16 2020-03-31 Innovation Pharmaceuticals Inc. Compounds for use in treatment of mucositis
WO2019213470A1 (en) * 2018-05-03 2019-11-07 Eternity Bioscience Inc. Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (rorϒ) and pharmaceutical uses thereof
CN112135611A (en) * 2018-05-03 2020-12-25 江苏恒瑞医药股份有限公司 Benzimidazole derivatives as modulators of retinoic acid-related orphan receptor gamma (ROR γ) and pharmaceutical uses thereof
US11512055B2 (en) * 2018-05-03 2022-11-29 Jiangsu Hengrui Medicine Co., Ltd. Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical uses thereof
RU2789059C2 (en) * 2018-05-03 2023-01-27 Цзянсу Хэнжуй Медицин Ко., Лтд. BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (RORγ) AND THEIR PHARMACEUTICAL USE
TWI818985B (en) * 2018-05-03 2023-10-21 中國大陸商江蘇恒瑞醫藥股份有限公司 BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (RORγ) AND PHARMACEUTICAL USES THEREOF
CN112745268A (en) * 2019-10-31 2021-05-04 江苏恒瑞医药股份有限公司 Crystal form of benzimidazole derivative and preparation method thereof
US11771694B2 (en) 2020-06-05 2023-10-03 Innovation Pharmaceuticals Inc. Arylamide compounds for treatment and prevention of viral infections

Also Published As

Publication number Publication date
EP2021330B1 (en) 2010-09-22
CN101511797B (en) 2013-01-02
EP2021330A2 (en) 2009-02-11
CA2651128C (en) 2014-09-02
BRPI0709803B1 (en) 2019-12-10
BRPI0709803A2 (en) 2011-07-26
HRP20100700T1 (en) 2011-02-28
BRPI0709803B8 (en) 2021-05-25
UY30322A1 (en) 2007-08-31
PT2021330E (en) 2010-12-03
CY1111269T1 (en) 2015-08-05
JP5302884B2 (en) 2013-10-02
ATE482201T1 (en) 2010-10-15
MY154595A (en) 2015-06-30
AR060840A1 (en) 2008-07-16
TW200808738A (en) 2008-02-16
NO20085031L (en) 2009-01-06
CR10479A (en) 2009-03-31
WO2007130780A3 (en) 2008-02-14
JP2009535414A (en) 2009-10-01
AU2007248341C1 (en) 2013-01-17
EA200870497A1 (en) 2009-06-30
US20070259936A1 (en) 2007-11-08
US7951829B2 (en) 2011-05-31
UA94749C2 (en) 2011-06-10
CN101511797A (en) 2009-08-19
TWI419882B (en) 2013-12-21
MX2008014108A (en) 2008-11-14
IL194916A (en) 2013-01-31
PE20080065A1 (en) 2008-02-25
SI2021330T1 (en) 2011-01-31
EA019386B1 (en) 2014-03-31
DE602007009378D1 (en) 2010-11-04
ES2350959T3 (en) 2011-01-28
NI200800290A (en) 2012-01-30
RS51473B (en) 2011-04-30
NO341965B1 (en) 2018-03-05
US20110190344A1 (en) 2011-08-04
CA2651128A1 (en) 2007-11-15
ECSP088854A (en) 2008-11-27
IL194916A0 (en) 2009-08-03
AU2007248341B2 (en) 2011-12-08
KR20090008428A (en) 2009-01-21
NZ572251A (en) 2010-08-27
ZA200810234B (en) 2010-02-24
CO6160329A2 (en) 2010-05-20
KR101434883B1 (en) 2014-08-27
JO3602B1 (en) 2020-07-05
PL2021330T3 (en) 2011-03-31
AU2007248341A1 (en) 2007-11-15
DK2021330T3 (en) 2010-12-06
WO2007130780A2 (en) 2007-11-15
HK1131971A1 (en) 2010-02-12

Similar Documents

Publication Publication Date Title
US7951829B2 (en) Benzimidazole modulators of VR1
EP2493862B1 (en) Imidazole derivatives as ido inhibitors
JP4445262B2 (en) Imidazole derivatives as anti-inflammatory agents
US8598355B2 (en) Amide compound
US20110034441A1 (en) Indazoles as wnt/b-catenin signaling pathway inhibitors and therapeutic uses thereof
EP0544821B1 (en) Indole derivatives as antiallergy and antiinflammatory agents
US20110105509A1 (en) Indole based receptor crth2 antagonists
JP2000509719A (en) Substituted azabicyclo compounds and their use as inhibitors of TNF and cyclic AMP phosphodiesterase production
US20070185184A1 (en) Carbazole derivatives
TW201341370A (en) Chemical compounds
KR20060079190A (en) Substituted arylalkanoic acid derivative and use thereof
JP5746471B2 (en) Benzimidazole TRPV1 inhibitor
CA2930584A1 (en) Ebna1 inhibitors and their method of use
WO2008142550A2 (en) Spirocyclic derivatives
US20170071910A1 (en) Dihydropyrazoles
EP1908752A1 (en) Novel 2-quinolone derivative
KR19990087130A (en) (1, 4-diazepan-1-yl) -2- ( Aryl) butyl) benzamide
EP2323991B1 (en) Chymase inhibitors

Legal Events

Date Code Title Description
AS Assignment

Owner name: JANSSEN PHARMACEUTICA N.V., BELGIUM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PLAYER, MARK R.;DAX, SCOTT L.;PARSONS, WILLIAM H.;AND OTHERS;SIGNING DATES FROM 20070507 TO 20070707;REEL/FRAME:026117/0105

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION